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Abstract 
Growing evidence has shown that peripheral inflammation can trigger a central nervous 
system response, sometimes worsening pre-existing neurological conditions, breaking down 
the concept of brain as an immune-privileged organ.  
Understanding which components contribute to periphery-to-brain communication may 
help identify molecules exploitable for therapeutic intervention. Usually, inflammation is 
followed by resolution: one of the main effectors in this process during peripheral 
inflammation is Annexin A1, while its implications in the CNS are still unclear. This thesis 
provides evidence for a new face for the molecule: we observed a well-defined expression 
at blood brain barrier (BBB) at endothelial level and we detected, in vivo, significantly higher 
BBB permeability in the AnxA1 null mice due to disrupted inter-endothelial cell tight 
junctions, essentially as a consequence to changes in the actin cytoskeleton. Such changes 
are reminiscent of early MS pathology, a relationship confirmed by detecting a selective loss 
of ANXA1 in the plasma and cerebrovascular endothelium of MS patients. 
Under peripheral inflammatory conditions (i.p. lipopolysaccharide, LPS), in vivo data 
suggested an inherent sex difference in BBB response, while in vitro studies confirmed the 
protective action of sex hormone 17β-Estradiol on the endothelium through ANXA1 
modulation.  
Within the CNS, we detected a constitutively higher microglial density and pro-inflammatory 
environment in the Anxa1 null mouse, which worsened upon peripheral inflammation. In a 
neurodegeneration model (6-hydroxydopamine), genotype-related differences in microglial 
invasion occurred, while subsequent peripheral inflammatory challenges synergised and 
caused worse dopaminergic neuronal loss only in the knock-out model.   
These original data unveil a novel functional paradigm for ANXA1 as a “translator” between 
peripheral immune system and CNS through novel pathways compared to its well-
characterized peripheral role. In addition, this study opens up a novel path to find 
therapeutic applications against disorders characterized by central and peripheral 
inflammation. 
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1.1 General aspects of inflammation 
Inflammation is a primordial, highly evolutionary-conserved active response mounted by the 
innate immune system in response to injury, xenobiotics exposure and infections in order to 
promote recovery. The final goal of inflammation is not only to clear the environment from 
harmful agents but mainly to restore tissue homeostasis and to stimulate healing processes 
where necessary (Janeway and Medzhitov, 2002). In its absence, injuries and infections 
would never be tackled, with unrelenting deterioration of the affected tissue and 
consequent risks for the entire organism. The typical signs of inflammation were first 
described by the roman doctor Celsus in the 1
st
 century AD as: rubor, tumor, calor, dolor 
(redness, swelling, heat and pain, respectively) while function lesa (loss of function) was 
added more recently; remarkably, they do not always appear together and simultaneously 
during an inflammatory event.  
There are several possible triggers for an inflammatory reaction, usually classified as 
physical, chemical and biological causes. The latter are by far the most common ones, 
including microbial infections (bacteria, fungi, viruses, protozoa, parasites).  
Inflammation can be 
classified in acute and 
chronic.  
Acute inflammation is the 
initial intense response 
that the organism activates 
to remove the harmful 
problem, which can 
originate from the outside 
or from inside the host. In 
the case of an acute 
reaction not being able to 
restore the homeostasis of the injured site in a limited amount of time due to the 
persistence of the harmful stimulus or to inefficiencies of the defensive process itself, 
inflammation undergoes a strategic change becoming chronic.  
Figure 1.1 Inflammation cascade. Overview of typical sequential 
vascular and cellular events occurring during an inflammatory 
reaction (Janeway and Medzhitov, 2002) 
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Chronic inflammation is characterized by a progressive shift in the type of cells which are 
recruited to the site of the reaction (mainly monocytes, lymphocytes and plasma cells) and 
is characterized by simultaneous active inflammatory events, tissue destruction and 
inefficient repairing by fibrotic tissue deposition. An inflammatory response is a highly 
harmonized process where several phenomena happen in a defined schedule, prompted to 
rapidly and effectively overcome the harmful agent in a multi-tasking fashion. Auto-immune 
diseases, aging and prolonged exposure to toxic compounds are the main causes that trigger 
a shift towards chronicity (Johnson, 2006). When such a response is not maintained, as in 
the case of insufficient, excessively sustained or inappropriate inflammation, the final 
outcome is undoubtedly different, indeed causing pathological disorders like allergies, 
atherosclerosis, autoimmune diseases, and participating in many others like cancer and 
cardio-vascular pathologies. It is not surprising that the inflammatory response, normally 
protective, has been nicknamed “the silent killer”.  
 
1.1.1 Cellular and molecular mediators of inflammation 
Inflammation often generates a wide sequence of events, known as the acute phase 
response; this represents a potent host defensive process aimed at limiting proliferation and 
diffusion of the insulting agent. It includes generalised processes like activation of the 
sympathetic nervous system, changes in cardiovascular functions, in the neuroendocrine 
balance (i.e. activation of the hypothalamic pituitary adrenal axis) and behavioural changes 
(Lucas et al., 2006). Triggering all these systemic processes requires a highly organised 
cascade of molecular and cellular events. If we have to describe a typical inflammatory 
reaction, numerous components participating in this complex process should be mentioned, 
which contribute to promptly trigger a quick and highly hierarchical signalling cascade, as 
depicted in Figure 1.1. 
In terms of cellular participants, the major ones are the granulocytes, mainly the 
neutrophils, the mast cells and the mononuclear phagocytes, monocytes and macrophages.   
A typical acute inflammatory reaction is started by the prompt activation of the resident 
defensive cells, the macrophages (although others should also be included, like mast cells 
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and dendritic cells), which sense a dangerous stimulus (microbial agents, necrotic tissue, 
toxic substances, etc.) through their numerous membrane receptors and start battling 
against it, while requiring for more support from other compartments. As a consequence of 
these rapid events, a quick (in the range of minutes) and progressive recruitment of the 
granulocyte neutrophils occurs; this cell type possesses important phagocytic properties 
towards bacteria and external physical insults. Their activation through several mediators 
inside the inflamed tissue is followed by an intense release of proteolytic enzymes and toxic 
mediators aimed at tackling the insult. Usually, a typical acute reaction is characterised by 
the progressive substitution in the type of cells recruited: the neutrophils are short-lived 
cells (around 1 day), so after 4 hours from the inflammatory initiation, monocytes are 
recruited instead by switching the type of mediators released from the injured site. Inside 
the tissue, monocytes differentiate into macrophages, which present longer life span and a 
dedicated defensive plethora of functions (chemotaxis, enzymes and toxic products release, 
phagocytosis).  
During inflammation, a great number of chemical mediators is involved, a condition 
necessary to sustain the recruitment and the activation of the correct type of leukocytes 
only in the injured tissue. The release of inflammatory signals like histamine, serotonin and 
prostaglandins (derivatives of the arachidonic acid metabolism) is in charge to trigger 
dramatic vascular alterations (vascular tone, expression of adhesion molecules, changes in 
paracellular permeability) which result in the invasion of the target tissue by blood-derived 
proteins as those of the complement system, responsible for the lysis and opsonisation of 
microbial and exogenous agents, and the coagulation system, which contributes to further 
increase the vascular permeability. The contemporary release of chemotactic molecules like 
chemokines, the lipoxygenase products like leukotriene B4, and some complement proteins 
themselves, along with pro-inflammatory activating signals like cytokines (TNF-α, IL-1 and in 
part IL-6) is required for the intense blood-born cells recruitment by acting on the 
endothelium or directly on the cells to be recruited; in this way, the cells are able to be 
directed towards the source of the insult and thanks to their activated state they will fight 
against it. Lysosomial enzymes (proteases, nucleases, lipases, etc.), production of reactive 
oxygen species (ROS) and reactive nitrogen species (RNS) are the major candidates for the 
elimination of the insulting agent, along with the damaged surrounding tissue.  
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Since the inflammatory response is tightly linked with the resolution/repair phase, anti-
inflammatory mediators (mainly cytokines like TGF-β and IL-10, arachidonic acid anti-
inflammatory metabolites as some lipoxins, and other peptides) and signals aimed to 
stimulate the regeneration of the injured parenchyma (by cell substitutes 
recruitment/regeneration or fibrotic tissue deposition by fibroblasts) are normally released 
when the original cause of the reaction is close to be eliminated (Norling and Serhan, 2010; 
Norling et al., 2012).  
Cooperation between the innate and adaptive immune responses is critical to enable the 
correct tackling of the trigger. Distinct types of effector T lymphocytes are involved in 
bridging the innate inflammatory response towards the development of a more injury-
specific adaptive reaction. For example, certain sub-types of T cells, once entered in the 
injured site, play important roles in the control of intracellular pathogens by activating 
macrophages, cytotoxic T lymphocytes and by producing IFN-γ. As an example, TH17 cells 
are fundamental to potentiate the inflammatory response mediated by neutrophils and 
monocytes. In this concerted action, the innate immunity should be able to limit the 
problem until antigen-specific adaptive immune responses are established (Koyasu and 
Moro, 2012).  
Inflammation is substantially a protective response, aimed to be positive for the host, 
therefore it should not be regarded as a form of disease, but as a powerful non-specific 
reaction against the initial cause of the insult and its consequences. When control of one or 
more of the phases is lost, detrimental consequences can definitely occur, as noticed in 
several pathologies with a chronic inflammatory component, where the destructive power 
of inflammation overtakes the positive outcomes of the reaction.  
 
1.2 Inflammation in the central nervous system 
All the structural and functional districts of human body can be injured by inflammation, 
including the central nervous system (CNS). The healthy brain was once regarded as an 
“immune privileged” organ, protected from immune responses (Lucas et al., 2006; 
Ransohoff and Brown, 2012): this concept arose due to the protection offered by the blood 
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brain barrier (BBB) but also because of the almost complete absence of the classical antigen 
presenting cells, the dendritic cells, therefore stating the apparent inability to sustain the 
maturation of an adaptive immune reaction de novo. Moreover, the fact that some of the 
most evident features of a typical inflammatory reaction (like oedema formation, or 
leukocyte recruitment) seemed to be absent or limited, reinforced this simplistic concept. 
The brain can definitely be subjected to immune reactions like inflammation but the 
concept of “neuro-inflammation” should not be taken sensu stricto as inflammatory 
reactions in the nervous system do not show all the 5 typical hallmarks, but they do 
resemble the molecular and cellular features of a typical inflammatory event of peripheral 
tissues, despite not showing evident changes. In the CNS are evident prompt increase in 
expression of typical inflammatory markers, production of cytokines (such as TNF-α, IFN-γ or 
IL-17) and acute inflammatory messengers and other key features of all inflammatory 
reactions as well as the characteristic intensity and efficacy, which all guarantee an effective 
tackling of the injurious stimulus. More in detail, activation of all the glial resident 
population is the hallmark of CNS inflammatory reactions; astrocytes and oligodendrocytes 
are able to respond and to release inflammatory mediators like cytokines and reactive 
oxygen species (Allan and Rothwell, 2001; Lucas et al., 2006; Mena and Garcia de Yebenes, 
2008; Allen and Barres, 2009; Glass et al., 2010), supporting the development of an 
inflammatory reaction. More importantly, the quick activation of the resident population of 
myeloid-lineage immune cells (as in the peripheral system with macrophages) plays an 
essential role in starting and orchestrating the innate response and, eventually, directing the 
following adaptive immunity. Pericytes, the perivascular macrophages (both involved in the 
complex functional composition of the microvasculature), the mast cells (Ransohoff and 
Brown, 2012) and, above all, the microglia (Guillemin and Brew, 2004) are the main 
protagonists of the CNS innate immune response.  
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1.2.1 Microglia: the good and the bad of central inflammatory responses 
Microglia are by far the most studied and preeminent type of specialised macrophages 
adapted to the neural environment (Garden and Moller, 2006; Ransohoff and Perry, 2009). 
Described for the first time by Pio del Rio Hortega in 1919 (McGeer and McGeer, 2011), 
these spidery small cells were found to constitute around 5-15% of the total cell CNS 
population and to be the principal CNS resident cell type in charge of recognizing harmful 
stimuli and mounting a consequent reaction (Czeh et al., 2011).  
Their developmental origin has been source of a huge debate in the scientific community: 
recent studies have dismissed the hypothesis that these cells have a neuro-ectodermal 
origin like astrocytes and oligodendrocytes (Ransohoff and Perry, 2009), supporting instead 
the derivation from mesodermal progenitors distinct from the ones that generate future 
peripheral macrophages and circulating monocytes (Chan et al., 2007; Ginhoux et al., 2010). 
More in detail, microglia progenitors appear to populate the nervous system during two 
very short and defined temporal windows of the fetal and postnatal development: first, 
mesodermal progenitors (sometimes called amoeboid microglia) from the yolk sac or 
another hematopoietic organ of the developing embryo enter and seed the forming nervous 
system mainly through meninges, ventricles and choroid plexus; later in the second phase, 
this happens through the blood vessel walls (Czeh et al., 2011). 
Once CNS has been populated, microglia progenitors adapt to the neural environment and 
take part directly in the development of the nervous system, by removing apoptotic cells, 
regulating axon formation and length, stimulating angiogenesis and releasing neurotrophic 
factors. So formed resident microglia represent the life-long population, which is able to 
sustain its self-renewal through slow local cell division (Perry et al., 2010) and only in small 
part (perivascular microglia and few specific parenchymal regions) by peripheral circulating 
cells contribution (Chan et al., 2007; von Bernhardi et al., 2010). On the other hand, a more 
intense turnover from circulating monocytes occurs under pathological conditions (Hanisch 
and Kettenmann, 2007; D'Mello et al., 2009; Ajami et al., 2011; Mizutani et al., 2012), with 
infiltrating cells differentiating into microglia with a stronger expression of functional 
molecules and better phagocytic functions and antigen presenting-cell properties (Czeh et 
al., 2011).  
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Exploring microglial activity and biology has not been an easy task indeed, due to absence of 
specific microglial markers able to discriminate microglia from those peripheral monocytes 
assuming microglia-like features during disease (Gao and Hong, 2008). 
Initially, it was believed that 
microglia exist in only two 
functional and 
morphological forms, the 
resting and the activated. 
This view has proved to be 
highly limited (Garden and 
Moller, 2006; Hanisch and 
Kettenmann, 2007) to 
describe the complex and 
variable physiology of this 
multifaceted cell type. The 
present knowledge about 
microglial activation lays on the existence of three distinct phenotypes known as amoeboid, 
ramified-resting/surveying and reactive-activated microglia which may exploit different 
functions. As previously described, the amoeboid microglia are associated with 
development of CNS, synaptic remodelling and plasticity (Chan et al., 2007; Hanisch and 
Kettenmann, 2007). The ramified-resting/surveying form represents the type of microglia 
associated with a healthy CNS: it exhibits a branched morphology and low expression of 
surface antigens. This is not a real resting phenotype but more correctly an activity state, 
since cells are constantly monitoring the brain parenchyma through their highly motile 
processes (Nimmerjahn et al., 2005), sensing any change in physiological conditions and 
cleansing the extracellular fluid in order to maintain central homeostasis. Disturbance of 
brain homeostasis causes a prompt shift towards the reactive-activated form: the 
complexity of this phenotype depends on the fact that we can distinguish between an 
“alerted” subtype, characterized by a local, transient and subtle activation (often not 
recognizable) of specific functions, and a “reactive” subtype, represented by more evident 
Figure 1.2 Microglia activity phenotypes: Reactive-activated 
microglia can be divided in numerous sub-phenotypes.                        
From Garden and Moller 2006. 
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functional and morphological changes (Hanisch and Kettenmann, 2007; Perry et al., 2010). 
As a general description, fully activated microglia exhibit changes in morphology, up-
regulation and synthesis de novo of specific membrane molecules, like the Toll-like 
receptors (TLR) family [able to recognise pathogen-associated molecular patterns or PAMPs 
and danger-associated molecular patterns, or DAMPs (Rivest, 2009; Ransohoff and Brown, 
2012)], chemotaxis and consequent migration to the site of interest, phagocytic properties, 
antigen presentation, rapid proliferation and secretion of numerous inflammation 
mediators like cytokines, chemokines, eicosanoids, reactive oxygen species (ROS) (Aloisi, 
2001; Lucas et al., 2006; Gao and Hong, 2008).  
It is important to emphasise that changes in morphology, expression of certain molecules or 
fulfilment of certain functions are not simple guides to define the reactivity of these cells. 
What defines which level of activation will be generated is not clear, but it seems that most 
hinges on the intensity, on the nature and on the sequence of the triggering stimulus/i, as 
happens for peripheral macrophages and the supposed M1 (classically activated phenotype) 
and M2 (alternatively activated) dichotomy (Hanisch and Kettenmann, 2007; Perry et al., 
2010). On this behalf, some scientists (Hanisch and Kettenmann, 2007; Ransohoff and Perry, 
2009; Perry et al., 2010) sub-divide the reactive-fully activated form in two main further 
classes, the phagocytic one [amoeboid-shaped, able to invade inflamed lesions and to 
phagocytize foreign materials and dying cells, therefore with a potentially anti-
inflammatory/pro-resolving role as we and others have already demonstrated (McArthur et 
al., 2010; Czeh et al., 2011)] and the non-phagocytic one (highly proliferative and secreting 
pro-inflammatory cytokines, truly the intermediary between the phagocytic and the 
ramified-resting forms); more phenotypes could actually exist, making a real strict 
classification rather limiting and not representative of the multi-faceted ability to sense the 
precise nature of the stimuli, resulting in different activation patterns, as seen in Figure 1.2.  
Importantly, microglia acts in concert with astrocytes and oligodendrocytes, either when in 
a “surveying” state or when activated and committed to quickly restore brain welfare: 
during neuroinflammation, these cells collaborate to promote clearance of any insulting 
factor to favour regeneration of the affected tissue, also through release of neurotrophic 
factors (Perry, 2004; Gao and Hong, 2008).  
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1.2.1.1 Contributions of microglia in neurological disorders 
Inflammation has always to be considered a protective response aimed at removing the 
harmful stimuli and to initiate a healing/repairing process, which should rebalance the 
homeostasis as close as it was before the insult occurred. The same stands for CNS: without 
neuroinflammation, restoring the normal functionality and structural harmony of the tissue, 
such an essential working unit, would be practically impossible. Microglia should always be 
considered first as a beneficial cell type if we consider the numerous positive actions that 
can exert, like scavenging toxic compounds, phagocytising and inactivating infectious 
organisms, releasing trophic factors promoting neuronal survival like the nerve growth 
factor (NGF), stimulating astrocytes to promote axonal growth, etc. However, due to the 
high susceptibility of the nervous system to stress factors and strength of the defensive 
responses and to the contained nature of this compartment, excessive microglial activation 
could become destructive with consequent damage in healthy regions, explaining why 
microglial reactions are more tightly regulated in time and space when compared to 
macrophages of other tissues (Gao and Hong, 2008; Lucin and Wyss-Coray, 2009). As an 
example of potential damaging role of this potent reaction, it is important to note how 
strikingly neuroinflammation is related with many diseases affecting the CNS, like stroke 
(Lucas et al., 2006) and aging-related neurodegenerative disorders as Alzheimer’s disease 
(von Bernhardi et al., 2010), Parkinson’s disease (Frank-Cannon et al., 2009), amyotrophic 
lateral sclerosis, prion disease (Cunningham et al., 2005) and multiple sclerosis (Stolp and 
Dziegielewska, 2009). Microglial reactions are normally self-limiting, resolving once 
eradication of the initial insult has occurred. However, functional impairment and loss of 
regulation can occur in response to non-successfully eradicated persistent trigger/s (that 
may or may not be the initial cause of the degenerative event, or may have been 
accumulated during the cells life-span) as demonstrated in the aforementioned disorders 
(Perry, 2004; Tansey et al., 2007; Frank-Cannon et al., 2008; Gao and Hong, 2008; Rivest, 
2009). Over time, such conditions may lead to the switch from the protective role of 
microglia to detrimental effects of its actions on the CNS environment and cellular 
components, worsening the actual pathological state, creating a vicious self-propagating 
loop (over-activated microglia causing neuronal death, which in turn triggers subsequent 
microglial activation; as depicted in Figure 1.3) negatively contributing to the outcome of 
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the disease. In the case of Parkinson’s disease, for example, microglia could be activated by 
infectious events, traumatic brain injury or extracellular α-synuclein (Glass et al., 2010), 
resulting in microgliosis (accumulation of activated microglial cells) with subsequent 
increase in inflammatory (release of cytokines, prostaglandins, lytic enzymes) and oxidative  
stress inside the challenged area (Knott et al., 2000). This can play a very harmful effect 
towards the delicate and vulnerable dopaminergic neuronal networks lost in Parkinsonian 
patients, as thoroughly reviewed by Tansey et al. (Tansey et al., 2007). In the case of 
Alzheimer’s disease, instead, a decreased ability by microglia to clear toxic β-amyloid, and 
an immoderate pro-inflammatory/cytotoxic behaviour by microglia, are shown to play an 
essential role in the pathophysiology of the disease (Rivest, 2009).  
Microglia show, therefore, a double-sword role: on one hand they definitely exert a 
neuroprotective role, supporting the development of the neuronal tissue and forming the 
first line of defence in the CNS, readily committed to respond to any insulting stimulus and 
promoting a prompt resolution; from the other side, it can result in neurodegenerative 
consequences, when its power becomes excessive for the goal that must be achieved. 
Understanding these two opposite roles of microglia behaviour will allow minimizing the 
harmful and capitalizing the beneficial effects.  
 
1.3 Effect of peripheral inflammation 
Increasing experimental and clinical evidence indicates that CNS not only is characterised by 
the ability to develop inflammatory reactions within the nervous tissues, but also can be 
strongly affected by peripheral inflammation (Perry, 2004; Cunningham et al., 2005; Perry et 
al., 2007; Perry, 2010). We all are aware that peripheral/systemic inflammatory reactions 
communicate with the brain as it can be easily seen in normal life by the appearance of a 
clearly brain-driven response, the so called “sickness behaviour”, characterised by general 
malaise, including lethargy, fever, reduced activity, energy saving mechanisms, and so on 
(Dantzer, 2004). Interestingly, the events triggered by a peripheral inflammatory reaction 
within the central nervous system are quick and can have a high impact on the homeostasis 
of the tissue, involving molecular (cytokines) and cellular components similar to those 
activated contemporarily in the periphery (Qin et al., 2007). 
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Figure 1.3 Inflammation determines the progression and outcome of neurodegenerative diseases. 
Insults to the CNS driving to neuronal death cause activation of surrounding microglia, which 
promptly start to release an array of inflammatory mediators aimed at eradicating the initial insult. 
Normally, self-controlling innate immune mechanisms maintain tight control of neuro-inflammatory 
events, restoring the CNS homeostasis as soon as the traumatic event has been solved. However, a 
self-perpetuating vicious cycle between neuronal damage and inflammatory response could lead to 
an escape from the regulatory system, therefore the immune response becoming chronically 
destructive. Adapted from Block et al., 2007. 
  
Consequences of these peripheral events could play a role in worsening, or even triggering, 
neuroinflammation correlated with neurological diseases by causing microglial chronic over-
activation and the consequent onset of detrimental effects overcoming the beneficial ones 
in the pathology (Aloisi, 2001; Gao and Hong, 2008). However, it should be emphasised that 
in healthy young individuals, symptoms and consequences of systemic inflammation are 
usually transient, short-lived and leave no long-term consequences, thanks to the tight 
regulatory system (Perry, 2010).  
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The major impact seems to occur in aged individuals or those with on-going 
neurodegeneration, seemingly mediated by microglia and by their long-lived nature, which 
attributes them an intrinsic innate immunity memory. Hugh Perry’s group in the University 
of Southampton proposed that existing chronic neuroinflammation and aging are able to 
induce microglia to acquire a particular form of activated phenotype, that has been called 
“primed”; chronic exposure to the same stimulus over time could be the primary cause of 
this state, which is characterized by morphological changes (typical of an activated state), 
high levels of transcription of inflammatory cytokines (like TNF-α and IL-1β) with minimal 
translation and a consequent inefficient response, resulting in the failure to completely 
effect clearance and induce restoration of homeostasis. Intriguingly, they also suggest the 
possibility that aging of the brain could be another factor leading to “microglial priming”, 
with all the changes and stimuli received by the CNS during the course of life (Perry, 2010; 
von Bernhardi et al., 2010). As Perry and his collaborators, as well as others groups, recently 
demonstrated in a number of neurodegenerative models (Cunningham et al., 2005; 
Godbout et al., 2005; Pott Godoy et al., 2008), the concomitant occurrence of a peripheral 
insult in an already injured brain is able to induce a more rapid and intense over-activation 
of microglia, whose beneficial roles get completely overtaken by the strong pro-
inflammatory cytokines and reactive (Pott Godoy et al., 2008) mediators release, 
accelerating neural death and cognitive alterations.  
From a physiopathological point of view, multiple sclerosis represents a good example of 
multi-factorial disease with a strong participation of inflammation in the CNS. Many of the 
relapses experienced by patients are tightly linked with infection and inflammatory events 
(Perry, 2004), which confirms the impact of peripheral inflammation in a injured brain, most 
likely populated by “primed” microglia. Also, it is well known that systemic infections in 
aged people may also result in cognitive disturbances like delirium, while several 
Alzheimer’s disease patients die as a consequence of systemic infections impacting on the 
injured brain.  
 
Chapter 1 – General introduction 
Enrico Cristante – PhD degree thesis                    Page | 15  
 
1.3.1 How peripheral events communicate into the brain 
Understanding the routes of communication between peripheral immune responses and the 
brain has not been an easy challenge (Dantzer, 2004; Perry et al., 2007). There are several 
potential routes by which systemic events are passed to the brain, which can be divided in 
neural, humoral and cellular pathways (Ferrari and Tarelli, 2011). First, on-going peripheral 
reactions occurring in the thoracic-peritoneal cavity can be sensed and transmitted to 
specific brain regions via neural afferent pathways, mainly through the vagus nerve 
(Dantzer, 2004). Also those events occurring in the oral cavity (for example during 
periodontal diseases) can be signalled into the CNS. On the other hand, peripherally-arising 
signals (mainly pro-inflammatory cytokines like IL-1β, TNF-α and IL-6) and even PAMPs (for 
example the lipopolysaccharide (LPS), the main cell-wall component of gram-negative 
bacteria) can access the nervous system through brain sites that lack a proper blood brain 
barrier, known as circumventricular organs, through fenestrated capillaries or through 
vascular regions with a damaged or more permeable BBB due to pre-existing pathological 
conditions (Perry et al., 2007; Machado et al., 2011). The BBB itself, through its numerous 
cellular components like endothelial cells (Singh and Jiang, 2004; Murray et al., 2011), 
perivascular macrophages (Garden and Moller, 2006) and astrocytic feet can sense and or 
actively transport circulating signals and respond to them, affecting the behaviour of 
neurons, astrocytes but especially of resident microglia population (Dantzer, 2004; Perry, 
2004). The peripheral signals can also increase the BBB permeability or even temporarily 
damage its peculiar tightness, therefore allowing an easier access of molecules and immune 
cells into the brain parenchyma. Recently, growing evidence has shown the longer-term 
entry of activated peripheral immune cells during systemic inflammatory diseases (mainly 
monocytes, bone marrow derived microglia-like cells and lymphocytes) from the inflamed 
periphery into the brain (D'Mello et al., 2009), where these cells can directly release pro-
inflammatory cytokines. Interestingly, the communication between the brain and the 
periphery is not a one-way road, but it is actually characterised by a more complex 
relationship, where signals not only go from the periphery to the brain, but also they can 
travel in the opposite direction, as happens, for instance, during acute brain injuries, which 
induce early hepatic expression of chemokines and cytokines able to trigger mobilisation of 
leukocytes and  recruitment in the injured tissue (Ferrari and Tarelli, 2011). 
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With all this in mind, it’s clear that understanding the routes and especially the mechanisms 
of the communication “periphery-to-central” is extremely important to limit the phenotypic 
switch seen in microglia cells of neurodegenerating or aged brains, counteracting the 
consequences of systemic inflammation on the brain of a population which is living longer 
(Perry et al., 2007).  
 
1.4 Resolution of inflammation 
As it has been described previously, the power of inflammation is given by potent signals 
which regulate the quick amplification and events cascade; their control is of paramount 
importance, in order to maximize the benefit of the response, minimize unwanted side 
effects that lead to chronicity and are on the basis of all the chronic inflammatory disorders. 
Limitation and suppression of inflammation have been one of the leading therapeutic 
approaches studies in pre-clinical and clinical research, with non-steroidal anti-inflammatory 
drugs (NSAIDs) being an excellent example. However, it should not be forgotten that the 
initiation of an inflammatory response also triggers a set of resolution pathways, the so 
called “resolution phase”, which is an active phenomenon brought about by endogenous 
anti-inflammatory agonists triggering a series of events aimed to restore tissue homeostasis, 
integrity and functionality (Serhan, 2007; Serhan et al., 2007; Perretti and Dalli, 2009). 
Resolution is something more than anti-inflammation: the latter, represented by certain 
cytokines like IL-4, IL-6, IL-10, TGF-β, cytokines inhibitors and soluble receptors (Opal and 
DePalo, 2000), is mainly based on suppressing the release and the action of the various pro-
inflammatory mediators which maintain the whole process “switched-on”; resolution, 
instead, goes beyond, directly down-regulating the recruitment of inflammatory cells like 
PMNs, restoring vascular component homeostasis, contributing to clear death cells left on 
the battle-field, therefore releasing factors aimed at supporting not only the extinguishing 
of the reaction but especially the restoration of tissue structural and functional homeostasis 
as close to normality as possible.  
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This complex phase of inflammatory reactions is characteristic of every tissue, therefore also 
of the brain, where the typical mechanisms and mediators of resolution have been also 
detected (Knott et al., 2000; Lukiw et al., 2005; Biber et al., 2007; Serhan, 2007; Gao and 
Hong, 2008).  
Recently, limitation of inflammation along with homeostasis and integrity restoration 
through exploitation of endogenously produced molecules have been regarded as a smarter 
move compared to the simplistic blockage of the reaction (and of its beneficial 
consequences) and it has become a principal therapeutic target against the side effects of 
the defensive response (Perretti and Dalli, 2009): interventions aimed at regulating the 
expression and efficacy of pro-resolution factors or mimicking their effects are promising, 
but a complete knowledge of these factors and of their biology is needed before their 
therapeutic potential can be addressed. Several local endogenous resolution autacoids are 
involved, their synthesis being mediated directly by the initial pro-inflammatory stimuli that 
triggers the reaction itself.  In particular, lipidic mediators such as lipoxins, resolvins and 
protectins have acquired lately great importance and interest due to their potent resolutive 
action and to the fact that they derive from the “pro-inflammation to resolution” class 
switch of the same synthetic pathways of pro-inflammatory lipidic mediators like 
leukotrienes and prostaglandins (Serhan, 2007; Serhan et al., 2007), which is based on the 
essential polyunsaturated fatty acids (PUFAs) pathways such as the eicosapentaenoic acid 
(EPA) and the docosahexaenoic acid (DHA).  
Glucocorticoids (GCs) are another important class of molecular mediators of the resolution: 
these cholesterol-derived hormones have a wide range of actions (see below), which are 
exerted both through genomic and non-genomic mechanisms. The anti-inflammatory 
protein Annexin A1 (ANXA1 for the human form; Anxa1 for the rodent form) has been 
discovered as the main “second messenger” of the mechanisms of actions of the 
glucocorticoids (Flower and Blackwell, 1979; Blackwell et al., 1980), therefore it represents 
an important endogenous contributor to resolution of inflammation.  
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1.4.1 The Annexin protein family: generalities 
Previously known as macrocortin or lipocortin-1, ANXA1 belongs to the Annexins super-
family (Parente and Solito, 2004; Solito et al., 2008). More than 100 proteins of annexins in 
more than 45 eukaryotic species are known, which all conserved a high homology 
throughout evolution. In humans, the Annexins super-family consist of 12 members, which 
are thought to have evolved and differentiated from an ancestral Anxa13 gene (Iglesias et 
al., 2002). Each protein contains a highly conserved C-terminal core formed by several 
(usually four) repeat sequences (60-70 amino acids each) that are involved in binding 
negatively charged (acidic) phospholipids in a Ca2+- dependent manner, and a more variable 
(and unique for each member of the family) N-terminal region that gives the functional 
peculiarity to each member of this family (Gerke et al., 2005). The name Annexins was 
chosen due to the ability of the first identified members to “annex” or hold together calcium 
and negatively charged phospholipids. Annexins are mainly localized in the cytosol whether 
in a soluble form or associated with other cellular components (proteins or lipids), but can 
also be identified associated to the cell surface or released in the surrounding micro-
environment (Solito et al., 2006). Changes in cellular localisation occur promptly in presence 
of specific stimuli, along with changes in tissue expression (Perretti and Dalli, 2009). 
Although no known disease has been linked so far with a direct dysfunction of a particular 
annexin (for example, no genetic disorders involving annexin genes are known), the term 
annexinopathies has been coined to refer to those diseases where a strong correlation 
between the condition and the Annexin expression dysregulation has been identified. These 
proteins have been defined as disease modifiers (Fatimathas and Moss, 2010) in conditions 
such as cancer, diabetes and disorders of circulatory system.  
 
1.4.1.1 Annexin A1 
1.4.1.1.1 Annexin A1: molecular properties 
Annexin A1 is a monomeric amphipathic protein composed of 346 amino acids weighting 
38714 Da. The gene encoding for this protein is 18637 bp long and it is located on the 
human chromosome 9, region 9q11-9q22, showing a high degree of homology between 
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different mammalian and avian species. Annexin A1 is characterised by an N-terminal 
unique domain (amino acids 1-40) which contains the entire biological activity; several post-
translational (phosphorylation, myristoilation, trans-glutamination, glycosylation) 
modifications sites are also present and may affect functionality and localisation of the 
molecule. Also, proteolysis can occur at specific sites and profoundly affect the potency of 
the biological responses (Vong et al., 2007). The C-terminal domain, consists in 4 
homologous repeats each one formed by five α-helices, as shown in Figure 1.4.  
The molecule presents a 
concave shape, with two calcium 
binding sites expressed on the 
outer side. The N-terminal 
domain integrates into repeat 3 
of the folded core domain in the 
Ca
2+
-free protein. Upon Ca
2+ 
binding, the N-terminal α helix is 
expelled from the protein core 
and becomes accessible for 
other interactions (Rosengarth 
and Luecke, 2003). In the Ca
2+
-bound conformation, the annexins can attach to membranes 
through the core domain, with the Ca
2+ 
ions serving a bridging function.  
 
1.4.1.1.2 Distribution of Annexin A1 in the periphery 
ANXA1 location varies between tissue and cell types and it is often found in discrete 
populations of differentiated cells. This mediator is widely distributed in the body: in fact, it 
is found in white blood cells, stromal cells of the lung, bone marrow, intestine and biological 
fluids (Perretti and Dalli, 2009). In circulation, granulocytes like neutrophils and mast cells 
present a great cellular amount of ANXA1, predominantly at the level of intracellular 
granules; also monocytes express a lot of it in the cytoplasm or associated to the membrane 
depending on the level of activation, and macrophages show a huge increase due to full cell 
differentiation/specialisation [up to 4% of the total protein content (Lim and Pervaiz, 2007)]. 
Figure 1.4 Molecular structure of Annexin A1. Ribbon 
presentation of the three-dimensional structure of AnxA1. 
Adapted from Rescher and Gerke, 2004. 
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Lymphocytes show a modest expression of it, while B cells and platelets interestingly show 
undetectable levels of ANXA1 expression.  
Past and recent studies have shown the ability of this protein to respond promptly to certain 
anti-inflammatory stimuli like glucocorticoids or pro-inflammatory stimuli as LPS (Solito et 
al., 2003; Solito et al., 2006; Skrahina et al., 2008), by undergoing post-translational 
modifications (Solito et al., 2006; McArthur et al., 2009; Yazid et al., 2009) which lead to 
translocation from inside the cell body to the cell surface where it is readily available for its 
functions. So far, the mode of secretion of the protein has been an unsolved topic: since 
ANXA1 lacks a signal peptide for externalisation, it cannot be secreted through a classical 
pathway. Granule extrusion upon activation is the main explanation but it is valid only for 
certain type of cells (granulocytes and  mast-cells mainly); in other cell types, non-classical 
pathway have been proposed, like through the ABC-A1 transporter system (Omer et al., 
2006) or via microparticle release (Dalli et al., 2008).  
 
1.4.1.1.3 The Annexin A1 receptors: a complex topic 
Once on the cell surface or in the surrounding of the cell, Annexin A1 can act through an 
autocrine or paracrine fashion and exert its vast plethora of potent functions. The possibility 
for AnxA1 to play certain roles intracellularly has been confirmed in recent studies (Solito et 
al., 2006) but since initial studies demonstrated the presence of ANXA1 saturable binding 
sites on the cell surface of human and rodent peripheral blood leukocytes (Perretti et al., 
1993; Goulding et al., 1996), the autocrine/paracrine pathways has been the main research 
direction taken to understand the molecular mechanisms triggered by this mediator. Recent 
studies, although not always conclusive and extensively reviewed elsewhere (Walther et al., 
2000; Le et al., 2002; Perretti, 2003; Migeotte et al., 2006; Perretti and Dalli, 2009), have 
suggested that this protein interacts with receptors of the seven transmembrane G-protein 
coupled formyl peptide receptor (FPR) family (Figure 1.5).  
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Initially identified on the surface of the neutrophils as the receptors for the strong 
chemoattractant N-formylated peptides (arising from bacterial and host cell-derived 
mitochondrial protein degradation), these receptors have a wide range of ligands, including 
endogenous acute phase response molecules like serum Amyloid A (SAA), endogenous 
(Resolvin D1, Lipoxin A4) and synthetic (Humanin) anti-inflammatory molecules and 
pathological peptides like β-Amyloid (Le et al., 2002; Perretti, 2003). So far, 3 subtypes have 
been identified in humans: FPR1, FPR2 (also known as FPR Like 1 or FPRL-1, recently 
renamed as the Lipoxin A4 (LXA4) receptor, ALXR) and FPR3 (FPRL-2), all of them with a wide 
variety of endogenous and exogenous ligands, which bind the three receptors with very 
different affinities (Perretti, 2003; Migeotte et al., 2006). These molecules are expressed in a 
very wide range of cell types, which include mainly immunity-related cells like, besides 
neutrophils, monocytes/macrophages, dendritic cells, endothelial cells, fibroblasts and 
stromal cells. In the central nervous system, the situation is still not clear (Solito et al., 2008) 
but all the three members have been detected either in microglia or astrocytes or in both 
(FPR1 and FPR2), while some recent evidence has been reported for expression at the level 
of microvascular endothelium (Mou et al., 2012).  
Figure 1.5 Structure and intracellular signalling pathways activated on agonist binding of FPRs. It is 
evident that increase in Ca2+ is the main signal triggered to induce cellular responses.                 
Modified from Le, Murphy et al. 2002. 
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1.4.1.2 Annexin A1 functions in acute inflammation and beyond 
Annexin A1 shows involvement in a wide array of functions, like cell-growth regulation (Ang 
et al., 2009), tumorigenesis (de Coupade et al., 2000), cell differentiation, neuroendocrine 
activity regulation (McArthur et al., 2009). However, the most prominent studies have been 
focusing on the anti-inflammatory role of ANXA1 in the periphery, especially thanks to the 
exploitation of the Anxa1 null mouse (Roviezzo et al., 2002; Hannon et al., 2003), which 
interestingly exhibits exaggerated responses in many of the inflammatory pathways. In 
particular, as mentioned before, Annexin A1 has been deeply studied for its mediating role 
in the anti-inflammatory action of glucocorticoids; in fact, it has been observed its high 
ability to independently mimic many if not all the effects brought about by GCs (Blackwell et 
al., 1980; Goulding et al., 1996) in several inflammatory models as well as its GC-inducible 
nature (Solito et al., 1994).  
During inflammatory reactions, this effector, along with its proteolysis-derived peptides 
such as the N-terminal fraction named Ac2-26 (Perretti and Dalli, 2009), is up-regulated and 
translocated from the cytosol to the cell membrane and the surrounding environment. 
Here, it primarily prevents the phosphorylation/activation of phospholipase A2 (PLA2), which 
is the enzyme responsible for the release of arachidonic acid from cell membrane 
phospholipids, the consequence of which is the suppression of eicosanoid synthesis (Flower 
and Blackwell, 1979; Parente and Solito, 2004). These findings were produced in vitro and 
confirmed in vivo, thanks to the useful Annexin A1 null mouse, which showed exacerbated 
inflammation, increased PLA2 expression and activity and a consequent resistance to GCs 
treatment (Hannon et al., 2003). Past experiments have shown other enzymes to be targets 
of Annexin A1 action in controlling inflammation, like inducible cyclo-oxygenase-2 (COX-2; 
another important enzyme for conversion of arachidonic acid into pro-inflammatory 
mediators like prostaglandins) and inducible nitric oxide synthase (iNOS; involved in the 
production of nitric oxide, which is a free radical involved in tackling pathogenic infections) 
(Parente and Solito, 2004).  Production and release of other potent inflammatory mediators, 
like pro-inflammatory cytokines, histamine (on mast-cells) and ROS, are also negatively 
affected, both directly and indirectly by ANXA1, at the level of innate immune cells (Parente 
and Solito, 2004; Perretti and D'Acquisto, 2009).  
Chapter 1 – General introduction 
Enrico Cristante – PhD degree thesis                    Page | 23  
 
The most important action of Annexin A1, though, remains the halting effect on leukocyte 
migration and invasion of the inflamed tissue as well as their viability; this links perfectly if 
we consider that this is also one of the major anti-inflammatory properties of 
glucocorticoids. Circulating neutrophils first, and monocytes later on, extravasate into an 
inflamed area through a multistep process in which the endothelium activated by cytokines 
derived from the injured site sustains rolling of the white blood cells, their firm adhesion 
through interactions between a class of proteins on the leukocytes (called selectins and 
integrins) and their endothelial cognate partners (adhesion molecules), and final migration 
through the endothelium (Janeway and Medzhitov, 2002). The whole process is Annexin A1 
sensitive. In fact, this protein has been shown to be mobilized upon leukocyte-endothelium 
adhesion and then to inhibit neutrophil inflammatory function as well as monocytes 
recruitment (Parente and Solito, 2004). The mechanism is not fully clear yet, but it seems to 
involve L-selectin shedding from leukocyte membranes, influence of cytoskeletal 
organisation of the attached cells, blockage of firm-adhesion binding sites on the 
endothelium [α4β1 integrin; (Solito et al., 2000)] and probably by down-regulation of 
chemoattractant receptors (Walther et al., 2000; Perretti, 2003). This role explains the anti-
inflammatory impact of the protein in several ischemia-reperfusion injury models, both at 
the level of the myocardium (La et al., 2001) and of the brain (Gavins et al., 2007).  
Interestingly, much evidence suggest Annexin A1 to be involved also in apoptosis, by 
activating caspase-3 signalling pathway (Solito et al., 2001). Since controlled cell death is 
one of the mechanisms in place to maintain a tight regulation of inflammatory cells present 
on the battle field, this ANXA1 function could be easily explained as part of the anti-
inflammatory/resolution machinery. On this regard, we should also mention its ability to 
serve as a “eat-me” or “find-me” signal on apoptotic cells, which are rich in negatively 
charged phospholipids like phosphatidylserine on the outer membrane (Parente and Solito, 
2004; McArthur et al., 2010), promoting chemotaxis of macrophages and clearance of the 
injured site from potential signals able to perpetrate the inflammatory reaction over time. 
Stimulation of anti-inflammatory cytokines like IL-10 and TGF-β1 (Ferlazzo et al., 2003), 
along with the whole array of resolutive functions described above, well represents how 
ANXA1 plays a central role in dampening inflammatory responses and contributing to 
restoration.  
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Recently, roles of ANXA1 in the adaptive immunity have been proposed according to first 
experimental evidences of T lymphocytes expression (D'Acquisto, 2009; Perretti and 
D'Acquisto, 2009): interestingly, it seems that ANXA1 shows a pro-adaptive immunity 
phenotype (shifting the balance towards TH1 and cell-mediated responses, strengthening T 
cell receptor signalling) and a completely opposite responsiveness to glucocorticoids.  
Most, if not all, of the studies cited in this paragraph justify ANXA1 functions through its 
ability to bind and activate one or more of the three members of the FPR receptor family. 
Full length AnxA1 protein is able to bind either FPR1 or FPR2, while N-terminal peptides 
seem to be able to bind and activate only FPR2 (Hayhoe et al., 2006; Migeotte et al., 2006). 
The current view supports the concept of FPR2 being a conveyer of proper anti-
inflammatory signals (Perretti, 2003; Perretti and Dalli, 2009), while FPR1 seems to have a 
more heterogeneous nature probably due to its ability to bind either pro-inflammatory or 
anti-inflammatory/pro-resolution mediators, as previously described. 
Figure 1.6 The principal biological actions of Annexin A1. The anti-inflammatory/pro-resolution 
mediator Annexin A1 has been found to be involved in 1) negatively regulating leukocytes 
extravasation 2) inhibiting cytosolic PLA2 3) and 3’) inducing apoptosis in certain cell-types, at 
certain doses and through multiple pathways 4) representing an “eat-me” signal for apoptotic cells 
and consequently mediating phagocytosis of these by professional phagocytes.            
Adapted from Lim and Pervaiz, 2007. 
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Being a constitutive protein, there have been several suggestions about ANXA1 being 
involved in several human disorders, primarily with an inflammatory component, even 
though it has been never reported to be the primary cause of a disease. For example, 
Annexin A1 undergoes an abnormal metabolism in cystic fibrosis and other lung disorders 
(Smith et al., 1995), while auto-antibodies were detected in a number of conditions, maybe 
explaining the glucocorticoid resistance observed (Podgorski et al., 1992). Also, it has been 
proposed as a marker for autoimmune diseases like systemic lupus erythematosus and 
Crohn’s disease or for certain tumours (Goulding et al., 1989; Stevens et al., 1993). 
  
1.4.1.3 Annexin A1 role in the brain 
In contrast to the extensive knowledge of the peripheral activation of Annexin A1, no clear 
understanding exists about the mechanism of action in the brain, where it has also been 
identified (Knott et al., 2000; Solito et al., 2008). Extensive studies have also shown the 
strong involvement of ANXA1 in HPA axis regulation (Woods et al., 1990; Buckingham et al., 
2006), where it plays a significant role in mediating the negative feedback actions of 
glucocorticoids on various steroid-releasing hormones: since this neuro-endocrine system is 
the principal source of stimulation and production of glucocorticoids, it is interesting to note 
how tightly these molecules are functionally bound to the anti-inflammatory mediator. As 
for the rest of the brain, protein expression has been detected in several central cellular 
components, such as the ependymal cells, glial cells such as microglia and astrocytes 
(McKanna, 1993), large and small gauge blood vessels and restricted neuronal populations, 
as extensively reviewed by Solito et al. (Solito et al., 2008). Interestingly, ANXA1 is expressed 
in the cells of the innate immune system of the brain, posing the question whether its role is 
the same as in the peripheral immune system or if there are special peculiarities. To that 
extent, growing evidence suggests that this protein does take part into the resolution of 
inflammation: in fact, Annexin A1 has been shown to prevent in vitro COX-2 and iNOS 
activation in microglia, and to mediate other glucocorticoids-linked actions that limit 
stressing conditions for the delicate cerebral environment (Minghetti et al., 1999). Annexin 
A1 expression was seen to directly correlate with neurodegenerative disorders like multiple 
sclerosis [MS; (Elderfield et al., 1992)], in particular at the level of active lesions and sclerotic 
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plaques; also, severity of the symptoms in a rodent model of MS, the experimental 
autoimmune encephalomyelitis [EAE; (Huitinga et al., 1998)], was seen to be reduced by 
ANXA1 N-terminal intracerebral administration, while the same model set on the Anxa1 null 
mouse developed a less severe pathology, indicating an apparent contradiction which may 
be explained with the multi-faceted roles of ANXA1 between innate and adaptive immunity 
(Paschalidis et al., 2009). Other positive effects by the protein were detected in 
neurodegenerative models cause by cerebral ischemia or N-methyl-D-aspartate (NMDA) 
excitotoxicity (Relton et al., 1991; Black et al., 1992). Also, evidence for an increase in 
ANXA1 expression was reported (Knott et al., 2000) on activated microglia cells present in 
the degenerating substantia nigra pars compacta (SNpc) of post-mortem tissue of PD 
patients. In recent years, several mechanisms of actions have been proposed for its 
supposed neuroprotective action, spanning from being an endogenous controller of 
microglia over-activation or a direct fail-safe signal acting on neurons, determining their fate 
on the basis of the level of damage undergone (Solito et al., 2008). We recently 
demonstrated ANXA1 to be important for microglia-driven clearance of apoptotic neurons 
(McArthur et al., 2010), which is an essential requirement to avoid secondary necrosis and 
perpetuation of central inflammation (Tansey et al., 2007). Neuroprotective roles of ANXA1 
were also shown in acute neurodegenerative events like the middle cerebral artery 
occlusion and reperfusion model of stroke (Rothwell and Relton, 1993; Gavins et al., 2007): 
infarct volume, along with neurological damage/clinical score, leukocyte adhesion and 
inflammatory markers, were negatively altered in the Anxa1 null mouse but could be 
improved by intravenous administration of recombinant ANXA1. 
Anti-inflammatory/pro-resolution therapies have been proposed as a potential approach in 
chronic neurodegenerative diseases. Long term treatment with non-steroidal anti-
inflammatory drugs (NSAIDs) seems to offer some protection in AD and PD, likely by 
targeting the inflammatory arsenal of the innate immune cells of the brain (Minghetti et al., 
1999) and it is interesting to parallel the role of some of the mediators released upon 
NSAIDs stimulation [like aspirin-triggered lipoxins; (Perretti et al., 2002)] with ANXA1 
functions.  
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Also, treatment with glucocorticoids, that are the main triggers for ANXA1 expression, have 
been tested as potential therapy for diseases with neuroinflammatory participation (Lucas 
et al., 2006). All these evidences and considerations clearly elevate Annexin A1 as a “hot” 
potential therapeutic molecule, whose role seem to be key, although yet far to be clear, also 
in the central nervous system.   
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2.1 Hypothesis and aims 
Exaggerated central inflammatory responses appear to exacerbate neuronal loss in existing 
degenerative conditions (Block et al., 2007) and systemic inflammation has arisen to be one 
of the primary factors that clinically lead to worsening existing neuroinflammation (Perry, 
2004; Perry et al., 2007).  
A means to control the communication of peripheral inflammatory events into the damaged 
CNS would certainly represent a powerful tool to ameliorate the overall outcome of the 
disease. Studying endogenously produced mediators of anti-inflammation and inflammatory 
resolution and adapting them to specific clinical conditions could generate novel insights for 
the discovery of new therapeutic tools able to tackle more “naturally” the problem (Dufton 
and Perretti, 2010). In the peripheral system, Annexin A1 has represented for years a 
candidate for resolution: for instance, it is up-regulated in peripheral inflammatory cells and 
in the liver in response to pro-inflammatory stimuli, promoting a shift towards a more anti-
inflammatory phenotype and resolution by driving to inflammatory cell apoptosis and 
phagocytosis by professional macrophages (Parente and Solito, 2004; Perretti and Solito, 
2004).  
Overall, this broad study aimed at improving the understanding of communication occurring 
between peripheral immune events and CNS and about how an important biological 
component as annexin A1 takes part in this process.  
Preliminary unpublished data, reviewed in Figure 2.1 and Figure 2.2, showed the presence 
of a specific temporal and spatial pattern of Anxa1 expression in critical anatomical and 
functional regions both under basal conditions or peripheral inflammatory challenge; in 
particular, a periphery/central interface as the microvascular bed was Anxa1 positive as well 
as the substantia nigra pars compacta (SNpc), the area of the brain undergoing 
neurodegeneration in PD.  
We hypothesized that ANXA1 may be a key molecule regulating the transfer of systemic 
inflammatory reactions into an intact or injured brain, controlling the consequent response 
mounted by the brain, ultimately limiting neurotoxicity. Therefore, it may represent an 
endogenous anti-inflammatory effector not only in the periphery, but also in the CNS.  
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In particular, we proposed Annexin A1 to play a neuroprotective role at various levels, 
regulating the behaviour of BBB as well as limiting microglial hyper-activation in response to 
a) peripheral inflammation, b) on-going degenerative conditions or c) both, thereby 
beneficially controlling neuroinflammation, pre-existing neurodegeneration and 
pathological outcomes. 
Using an integrative in vivo/in vitro approach, our aims included: 
• understanding if and how ANXA1 participates in regulating BBB integrity and 
responsiveness in basal conditions and under systemic inflammatory events; 
• a comprehensive characterisation of the temporal and spatial pattern of ANXA1 
expression in the normal brain in response to peripheral inflammation, in order to 
define a functional link for the protein in regulating cerebral immune homeostasis;  
• the evaluation of the effects brought by  peripheral inflammation  in worsening the 
neuronal damage under neurodegenerative conditions, using experimental PD 
model based on 6-hydroxydopamine-induced lesion [6-OHDA; (Gillies and McArthur, 
2010)] of the nigro-striatal dopaminergic pathway (NSDA), depicting microglia 
involvement and the impact of ANXA1 on the neurodegenerative outcome. 
 
The overall goal of this thesis was thus to investigate the relevance of central ANXA1 as an 
essential “communication bridge”, able to sense, decode and translate events occurring in 
the rest of the organism into the CNS, with the ultimate aim to maintain the general 
homeostasis, without limiting the physiological periphery-to-brain communication, but 
instead regulating it in case of excesses.  
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Figure 2.1 Anxa1 basal expression in various brain regions. Sections are from healthy untreated 
animals and suggest the presence of basal Anxa1 in numerous cell types and functionally relevant 
brain regions. Sections from wild-type C57Bl/6 mice were stained by immunofluorescence for Anxa1, 
while those from Anxa1 null mice were probed for β-galactosidase activity through X-gal staining; 
this was possible because exons 2-4 of the Anxa1 murine gene were replaced with β-galactosidase 
coding sequence (LacZ) as reviewed (Hannon et al., 2003). For technical details please refer to 
General methods. Scale bars: 800 µm. TH: tyrosine hydroxylase positive neurons; Anxa1: Annexin A1.  
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Figure 2.2 Activation of Anxa1 promoter under LPS challenge in midbrain, hypothalamus, striatum 
and meninges. X-gal staining in Anxa1 null mice brain slices was performed according to an 
established method. Big-headed arrows in D|, E| and F| indicate neuron-like cells while small-
headed arrows point to small glia-like cells. Results for 2 hours LPS administration are not presented 
since very similar to 24 hours. Pictures produced by Dr. S. McArthur and used for grant application.
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3.1 Materials 
Reagent description and composition of solutions used in the various methods described 
below can be found in Chapter 10, the Appendix, Section 10.1. For antibodies and primer 
details refer to sections 10.2 and 10.3, respectively.  
 
3.2 Methods 
In this section, methods that have been used extensively throughout the project are 
described. For methods relevant for only one specific part of the thesis, please refer to the 
specific result chapter. 
 
3.2.1 In vivo methods 
All animal experiments were performed in accordance with the UK Animals Scientific 
Procedures) Act 1986, under project licence (PPL 70/7082), and personal licence (PIL 
70/21936). In vivo experiments were carried out on 2-4 month-old male or female mice as 
stipulated. All mice were group-housed in the facilities at the Hammersmith Campus of 
Imperial College London with sawdust and paper-wool nesting material provided. A 12:12 
hour light/dark cycle at 22°C was used. Food pellets and water were available ad libitum. 
Wild-type animals were from the C57BL/6 strain and were purchased from Charles-River 
(UK). After arrival, animals were allowed to acclimatize to their new surroundings for at 
least a week. Annexin A1 null mice (Anxa1-/-) were bred in-house (Hannon et al., 2003). All 
Anxa1-/- mice used for experiments were genotyped by polymerase chain reaction (PCR) 
according to standard procedures [as described in (Hannon et al., 2003)] prior to use, using 
plasmids bearing the murine coding sequence for Anxa1 or β-galactosidase as controls. 
 
3.2.1.1 LPS time-response in wild-type and Anxa1 null mice 
Wild-type and Anxa1 null male mice (2/3 months old; n=4/group) were weighed before 
treatment and then received a single intraperitoneal (i.p.) dose of 3 mg/kg LPS in 100 μl 
saline or 100 μl 0.9% saline for control animals (2 hours, 24 hours and 7 days as time points).  
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Group of animals were sacrificed at the scheduled time points (2 hours, 24 hours and 7 days 
after LPS injection), perfused, fixed and brain tissues collected as explained in the following 
paragraph. 
 
3.2.1.2 Perfusion, fixation and collection of brain tissue 
Animals were deeply anesthetised by i.p. injection of 100 μl sodium pentobarbitone (60 
mg/ml). Once fully anesthetised, an incision was made through the peritoneal cavity, 
revealing the diaphragm. The heart was then revealed by cutting through both sides of the 
rib cage and the diaphragm. Blood samples were collected by cardiac puncture of the right 
ventricle and the right atrium was cut to allow release of blood. Blood was washed out of 
the body by perfusion through the left ventricle with approximately 15 ml of filtered saline 
at 4°C, followed by fixation by perfusion with approximately 20 ml of filtered 2% PFA 
(paraformaldehyde) in PBS (Phosphate buffered saline) 0.01 M at 4°C. Brains were rapidly 
removed and post-fixed in 2% PFA overnight at 4°C, cryoprotected in 30% sucrose solution 
for 2 days at 4°C and frozen on dry ice, for long-term storage at -80°C. In some cases, 
samples were not exposed to formaldehyde, but were snap-frozen in isopentane cooled on 
dry ice and subsequently frozen at -80°C. 
 
3.2.1.3 In vivo administration of Evans Blue 
Evans blue dye extravasation was chosen to detect changes in permeability in vivo. This 
technique is based on the small molecule Evans blue; once in the blood stream, most of it 
binds to albumin and serum proteins, while a small portion remains uncoupled. In normal 
conditions, non-significant amounts are able to cross the blood brain barrier and leak into 
the brain parenchyma, while under certain stimuli the leakage increases mainly via the non-
specific vesicular-mediated or the paracellular pathways (Pardridge et al., 1985; Greenwood 
et al., 1988). Male and female animals (2 months old) were purchased from Charles-River or 
obtained from our running colony of Anxa1-/- mice and divided in treatment groups (n=4-
5/group). Before the LPS/saline administration, animals were weighed in order to work out 
the LPS dosage.  
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Those belonging to different time point groups (4 hours, 24 hours and 7 days) were injected 
i.p. with a single dose of 3 mg/kg LPS in 100 μl 0.9% saline solution or 100 μl 0.9% saline 
solution for the control animals (24 hours as unique time point). Animals were placed under 
warming lamp for 5 minutes to facilitate tail vein visualization and 100 μl of filtered 2% 
Evans blue solution were injected intravenously. After allowing 1 hour for the dye to diffuse 
from the circulation into the tissues, a sample of blood was collected and mice were 
perfused with 15 ml cold saline to remove Evans Blue from the circulatory system. Brains 
were rapidly removed and sliced in the two hemisphere by cutting through the midline 
using a scalpel; one half was post-fixed (in 4% PFA) overnight at 4°C and then cryoprotected 
in sucrose, while the other half was used for the spectrophotometric assay described in the 
next section. 
 
3.2.1.4 Evans Blue detection in brain homogenates and serum samples 
The following protocol was adapted from published methods (Morrey et al., 2008; 
Manaenko et al., 2011). Brain tissue was collected as described in section 3.2.1.2 and 
dissected along the cerebral midline. One half was placed in 4% PFA in PBS 0.01 M and the 
other half in 3 ml PBS 0.01 M and placed on ice. The hemisphere was mechanically 
homogenised and 2.5 ml of 60% trichloroacetic acid (TCA) was added; samples were mixed 
for 10 seconds and left on ice for 30 minutes. Tubes were then centrifuged at 1000xg for 30 
minutes and 200 µl of the supernatant were spectrophotometrically assayed at 620 nm 
alongside a standard curve ranging from 20 µg/ml to 2 ng/ml of Evans Blue dye.  
Blood samples obtained by cardiac puncture were allowed to clot at 37°C for 10 minutes 
and then centrifuged at 1200xg RPM for 30 minutes at 4°C; the resulting supernatant 
(serum) was collected in a fresh tube. Serum samples were analysed 1:40 in a final 200 µl 
volume. Final values were normalized to tissue weight and expressed as percentage of 
serum dye content, as reported (Morrey et al., 2008): 
(μg	of	dye	in	brain) ⁄ (mg	of	tissue)
(μg	of	dye	in	serum)
× 100 
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3.2.2 In vitro methods 
3.2.2.1 Cell culture 
3.2.2.1.1 Origin of hCMEC/D3 cell line 
The hCMEC/D3 (human cerebrovascular endothelial cell line/clone D3) cell line was 
obtained by Dr I. Romero, Professor O. Couraud and Professor B. Weksler (Cornell 
University, NY, USA) under a signed material transfer agreement (MTA). This cell line was 
originally established as described in Weksler et al., 2005 (Weksler et al., 2005). Briefly, 
isolation of primary endothelial cells was undergone on a surgical excision of cerebral tissue 
from an epilepsy female patient (surgery performed at Kings College Hospital), following the 
protocol established at King’s College London for rat brain endothelial cells isolation and 
reported in the literature (Abbott et al., 1992). Purified endothelial cells were immortalized 
by sequential lentiviral transduction of human telomerase reverse transcriptase (hTERT), a 
ribonucleoprotein which maintains the telomere ends of chromosome, therefore preserving 
the genetic information present in the genome and the ability to replicate safely, and of 
Simian virus 40 (SV40) large T antigen, which is a viral proto-oncogene driving the host cell 
cycle towards the S phase (DNA replication) and G2 phase (cell division). 
Clonal selection was performed according to several parameters, like morphology, 
proliferating capacity, and stable expression of typical endothelial phenotype markers 
(Weksler et al., 2005). 
 
3.2.2.1.2 Routine cell culture of hCMEC/D3 cell line 
hCMEC/D3 cell line was maintained in EGM-2 MV (Lonza, CH) provided with all the growth 
factors (see Appendix, section 10.1.3) as indicated by the authors (Weksler et al., 2005) and 
in the original datasheet. Cells have been used until passage 35, since this has been defined 
as the limit after which cells start losing their microvascular endothelial phenotype. T-75 
growth flasks (VWR, UK) were routinely used to expand the number, while 10-cm dishes, 6-, 
12-, 24-well plates (Corning Inc., Sigma, UK), labtek devices and transwells (see below) were 
used to run the functional experiments.  
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Before plating, growth surface was coated with rat tail collagen (BD Biosciences, UK) for 1h, 
37°C or overnight at room temperature (RT). Working volumes were chosen to be between 
0.2 and 0.5 ml/cm2. Cells were passaged during their log-phase of division (approximately 
when they reached 70-80% of confluence). First, they were washed twice with DPBS 
(Dulbecco-modified phosphate buffered saline) without Ca2+/Mg2+, then incubated with 
enough volume of Trypsin-EDTA (Lonza, CH) at 37°C; enzymatic activity was stopped with 
fresh growth medium and cells were counted by using a disposable haemocytometer (Kova 
Glasstic slide 10; Hycor biomedical Inc., US); the required number of cells (calculated 
knowing that the optimal plating concentration should be 25000 cells/cm2) were 
subsequently harvested at 1200 x g (centrifuge model: Harrier 15/80; MSE, UK) at RT for 5 
minutes and the pellet was resuspended in fresh medium and transferred into the plate. 
 
3.2.2.1.3 Cryopreservation of hCMEC/D3 cell line 
Frozen stocks were regularly produced by detaching the cells through trypsinisation, 
resuspending around 4·106 of them in freezing medium (see Appendix 10.1.3) and storing 
them in cryovials (containing 1 ml of the cell suspension; cryovials from Nalgene, Sybron 
Int., US), which were then frozen down at approximately 1°C per minute in a -80°C freezer 
using a freezing device filled with isopropanol (as specified in the datasheet; Nalgene, 
Sybron Int., US). After 24 hours, samples were transferred to the -196°C liquid nitrogen 
general stock. 
 
3.2.2.1.4 Thawing hCMEC/D3 cell line 
A frozen stock vial was removed from the liquid nitrogen tank and placed immediately 
inside the incubator (37°C). Once the cell suspension had completely thawed (within 2 
minutes maximum), cells were transferred into a 15 ml Falcon tube and 5-10 ml of pre-
warmed EGM-2 MV medium was added drop-by-drop to dilute the toxic effect of DMSO. 
Cells were then sedimented by centrifugation, supernatant was aspirated and fresh medium 
was added to resuspend the pellet. The volume was finally transferred into a new T-75 flask 
and fresh medium was replaced 24 hours after thawing.  
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3.2.2.1.5 Cell transfection of hCMEC/D3 cell line 
Following the manufacturer’s instructions, HiFect (Lonza, CH) was employed to transfect 
hCMEC/D3 cells. Cells were seeded in 10 cm dishes or 12-well plates and transfected when 
they reached 60/80% of confluence after replacing the medium with fresh 2/3 hours before 
the transfection, to induce cell division and consequent higher accessibility of the 
transfected DNA into the cell nuclei. 
24 hours later, cells were washed with DPBS without Ca2+/Mg2+ and medium changed with 
fresh one. Cells were harvested or put under selective agent (Geneticin G418®; for stable 
transfected clones selection) after further 24 hours of growth. 
 
3.2.2.1.6 Paracellular permeability assessment 
The permeability of hCMEC/D3 cell monolayers to molecules of different sizes was 
measured, as described [(Dehouck et al., 1992; Weksler et al., 2005; Forster et al., 2008)] 
and represented in Figure 3.1, on 12-well plate transwell polycarbonate inserts (surface: 1.1 
cm2; pore size: 0.4 µm; Sigma-Aldrich, UK) coated as following: 1h RT with 1:20 calf-skin 
collagen solution in HBSS without Ca2+/Mg2+; 1h RT with 1:100 fibronectin solution in HBSS 
without Ca2+/Mg2+. 1.8x105 cells were seeded on the filters in complete EGM-2 MV medium. 
When cells reached 100% confluence, they were quickly washed in HBSS without Ca2+/Mg2+ 
and medium was switched to EGM-2MV provided with all the growth factors but VEGF for 
96 hours, to limit over-growth and support the formation of a tight monolayer. Certain 
stimuli were added during the incubation without VEGF (long incubation with 17-β Estradiol; 
see experimental plans) while others (TNFα and IFNγ) were added in the last 24 hours. At 
the end of the stimulation, the experiments were performed using FITC-labelled dextran 
(molecular weight 70 kDa; Sigma-Aldrich, UK) dissolved to 3 mg/ml in transport buffer (2% 
Fetal calf serum (FCS) DMEM without phenol-red) and added (500 µl) carefully on top (the 
upper chamber) of the cells. One insert (empty filter) was treated exactly as described 
above but no cells were plated; this served to measure the resistance of the plastic surface 
itself. The various transwell filters were carefully moved to the first row of wells of 12-well 
plates where 1.5 ml of transport buffer was added for each well. At 10 minute intervals, 
insert were moved to the next row of wells, for a total of 60 minutes.  
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The fluorescent content of the wells was sampled for fluorescence emission using a 
fluorescence multiwell plate reader (VersaMax, Molecular Probes) with the following 
parameters: excitation wavelength: 485 nm; emission wavelength: 520 nm. To define a 
concentration-dependent transport parameter, the clearance principle was used. Cleared 
volume for each time interval was calculated following this equation:  
Vcl	 =
×
[]
	  
[C]u represents the fluorophore concentration on the upper chamber, while [V]l and [C]l the 
volume and the fluorophore concentration in the lower chamber, respectively. 
Concentration values of the lower chamber were calculated by plotting a standard curve of 
known amounts of FITC-dextran. An increment of cleared volumes was plotted against time 
of measurement (60 minutes); the slope of the linear curve proportionally represents the 
permeability properties of the monolayer and defines PS, the permeability surface area, 
which indicates the resistance opposed to the clearance: 
PS	TOT	 = slope 
The total resistance opposed to the passage of the dye is the sum of the resistance offered 
by the monolayer and the one offered by the filter itself; so: 
PS	TOT = PS	endo + PS	filter 
Therefore, Ps endo can be calculated by subtracting PS filter from PS TOT.                         
Since the permeability coefficient (in physics also called conductance) is defined as the 
inverse of the resistance, the permeability coefficient of the endothelium (Pe) can be 
calculated as follows: 
Pe	 = P	TOT	-	P	filter	 = 	
1
PS	TOT
	- 	
1
PS	filter
 
Endothelial permeability coefficient (Pe) was calculated in unitary value (cm min ) as 
described (Dehouck et al., 1992). Each single experimental repeat was performed in 
duplicate and at least 3 independent repeats were performed for each set of treatments. 
Values usually are reported as relative percentage of the control. Average control/untreated 
Pe value is: 5x10-5 cm/min.  
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Figure 3.1 Procedure and principles of the in vitro paracellular permeability assay. A) Visual 
description of the transwell system and temporal procedure used to measure paracellular 
permeability on hCMEC/D3 monolayers. B) Principle of the cleared volume by which permeability 
coefficient is calculated; slopes of the lines are indicated in the equation and in the x/y graph (as the 
angular coefficient). See section above for detailed description. 
 
3.2.2.1.7 Electrical resistance measurement 
Another way of assessing the tightness of cellular monolayers was by calculating the 
resistance offered by the monolayer to ions passage/electric currents, defined 
transendothelial electrical resistance (TEER). 100% confluent cultures underwent TEER 
measurements using a two-electrodes Millicell-ERS apparatus (Millipore, UK). TEER were 
expressed as Ohms·cm
2
 (Ω·cm
2
) and values obtained from collagen-coated cell-free inserts 
were subtracted from the resistance values of the cultures to yield the resistance values due 
to the cells only. In some cases, after empty filter subtraction, values have been reported as 
relative percentage of the untreated control. Average control value obtained for cell 
cultures was 44.88 ± 1.44 Ω·cm
2
 while for primary cultures was 100 ± 4.15 Ω·cm
2
. 
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3.2.3 Immunoassays: Enzyme-linked immunosorbent assay (ELISA) 
3.2.3.1 Principles 
Enzyme-linked immunosorbent assay (ELISA) is an immunoassay used to detect and quantify 
analytes by using antibodies specific for that antigen. The most widely used type of ELISA for 
antigen quantification is the sandwich ELISA, so called because the molecule of interest is 
bound between two antibodies (Lequin, 2005). First, a primary antibody (called capture 
antibody) is incubated in a 96 well plate in order to tightly bind to the plastic, which is 
specifically treated for this application. After occupying the free sites with a blocking 
solution, to avoid unspecific further binding, samples containing the analyte are incubated 
and this step is then followed by several washes, to remove unbound molecules. The second 
antibody, called detecting antibody, is then added to each well. Therefore, this technique is 
possible only if two antibodies specific for two different epitopes of the antigen of interest 
and from different species origin exist. The final step involves the use of a conjugated 
tertiary antibody produced against the isotype and species, which the detecting antibody 
belongs to. Conjugation of the tertiary antibody with an enzyme like horseradish peroxydase 
(HRP) or alkaline phosphatase (AP) and incubation with a substrate like 3,3’,5,5’ 
Tetramethylbenzidine (TMB), which can be converted to a coloured product, allows the 
amplification of the signal and detection of even small quantities of antigen. Absorbance at 
specific wavelength will be directly proportional to the amount of antigen captured into the 
wells. 
 
3.2.3.2 Quantification of Annexin A1 protein by ELISA 
Total human Annexin A1 in cell cultures samples was measured by ELISA, following a 
protocol developed at William Harvey Research Institute, Queen Mary University London 
(Goulding et al., 1990).  
At each step, 100 µl of the different solutions was the volume chosen per well. Mouse 
monoclonal antibody (called m1B, produced in-house through hybridoma formation) was 
used as capture antibody at 10 µg/ml concentration in bicarbonate buffer and absorbed on 
ELISA-treated plates (Nunc MaxiSorp, ThermoScientific, UK) overnight at 4°C.  
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Plates were then washed 3 times with bicarbonate buffer and blocked with PBS without 
Ca2+/Mg2+ 1% bovine serum albumin (BSA) for 1 hour at 37°C. During the incubation, ANXA1 
standards were prepared (500, 250, 125, 62.5, 31.25, 15.62, 7.8, 3.9, 1.95, 0.98, 0.49 and 0 
ng/ml) in assay diluent (PBS without Ca2+/Mg2+ 1% Triton-X-100). Unknown samples were 
treated as follows: cell medium samples were loaded neat, cells lysate samples were diluted 
1:5; human and rodent serum samples were loaded neat. Samples were loaded and 
incubated for 1 hour at 37°C. Plates were washed 5 times with 0.9% NaCl 1% Triton-X-100 
and incubated with 1 µg/ml of detecting antibody (Rabbit polyclonal anti-ANXA1; Invitrogen, 
UK) for 1 hour at 37°C. After 5 washes, immune-complexes were detected by adding the 
tertiary goat-anti-rabbit IgG antibody, which is conjugated to alkaline phosphatase. After 5 
final washes, reaction was triggered by incubation with a solution of p-Nitrophenyl 
phosphate (tablets from Sigma, UK) in bicarbonate buffer and plates were left in the dark 
for 10-20 minutes, until a clear yellow colour was formed, paying attention to avoid 
saturation of highest standard points and of more concentrated samples. Plate wells were 
finally measured for their absorbance at 405 nm and corrected at 540 nm as reference 
wavelength, using a spectrofluorimeter (Tecan Infinite M200 Pro, Tecan, Austria). 
 
3.2.4 Protein isolation and analysis: immunoblotting 
3.2.4.1 Protein extraction from tissue 
For tissue protein analysis, two protocols were adopted, the first one for total protein 
extraction, the second one for soluble and insoluble protein fractionation. Animals were 
transcardially perfused with filter-sterilized saline (0.9% NaCl) and brains were excised and 
subsequently snap-frozen in isopentane cooled in liquid nitrogen and stored at -80°C. A 
portion of the frontal cortex was obtained by using a scalpel, weighted and homogenised in 
radioimmunoprecipitation assay (RIPA) lysis buffer (5 µl/mg tissue) through a homogenizer 
(Omni Int., US) at 4°C for total protein extraction. The homogenate was left at 4°C for 30 
minutes under agitation and subsequently centrifuged (bench centrifuge model: Biofuge 
Fresco, Heraeus, Thermo Scientific, UK) at 14000xg for 30 minutes at 4°C. Supernatant was 
kept while pellet was discarded. 
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For soluble/insoluble extraction, the tissue portion was homogenised in Triton X-100 
extraction buffer (5 µl/mg tissue), left at 4°C for 30 minutes under agitation and 
subsequently centrifugated at 14000xg for 30 minutes at 4°C. Supernatant was then 
transferred to a separate tube and labelled as the soluble fraction. 150 µl of the same lysis 
buffer supplemented with 1% sodium dodecyl sulfate (SDS) was added to the pellet, 
subsequently disrupted with an ultrasonic crusher (Ultrasonic processor; Jencons, US with 
the following parameters: 30% duty cycle, output control 2; 3 strokes/10 sec each with 15 
seconds on ice between each stroke), left under agitation at 4°C for 15 minutes and 
centrifugated at 14000xg for 20 minutes at 4°C. The supernatant was collected and labelled 
as the insoluble fraction.  
 
3.2.4.2 Protein extraction from cells 
For cell-line analysis, cells were trypsinised, collected and the pellet frozen at -80°C. RIPA 
lysis buffer (100 µl/0.5x106 cells) was added and cells were homogenised through 3 cycles of 
freeze and thawing. If the lysate was too viscous, it was passed through a syringe needle 
(30G) to shear DNA and make it easier to handle. Samples were then centrifuged at 14000xg 
for 30 minutes at 4°C and the supernatant transferred in a separate tube.  
In the case of soluble and insoluble fraction isolation, 1% Triton X-100 DPBS with Ca2+/Mg2+ 
solution was first used to extract all the soluble proteins for 5 minutes on cell monolayers; 
this was saved as the soluble fraction. Subsequently, after 2 quick washes in DPBS without 
Ca2+ and Mg2+, a new buffer was added (Insoluble β-actin extraction buffer) and cells were 
scraped, passed through a fine 30G needle, sonicated as described above in case the 
viscosity of the material (mainly due to sheared DNA) remained too high (Cramer et al., 
2002). Both fractions were centrifuged at 14000xg for 20 minutes at 4°C, and supernatants 
transferred to fresh tubes (soluble and insoluble fractions). Please refer to Chapter 4 for 
more details.  
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3.2.4.3 Protein content estimation 
Protein concentration of the samples was calculated through Bicinchoninic Acid Assay (BCA; 
Thermo Fisher Scientific, UK). Briefly, this assay is based on two reactions: first, the 
reduction of copper cations (Cu2+) derived from the component cupric sulphate to Cu+ by 
peptide bonds, a reaction proportional to the amount of proteins present; second, the 
chelation of the Cu2+ ions by bicinchoninic acid molecules, which results in the formation of 
a purple product with high light absorbance at 562 nm wavelength (Smith, Krohn et al. 
1985). 96 well plates were used and each sample was analysed in triplicate. Dilutions of the 
samples were prepared using the lysis buffer as diluent; a standard curve was produced 
using BSA as the standard (0; 0.2 mg/ml; 0.4 mg/ml; 0.6 mg/ml; 0.8 mg/ml; 1 mg/ml; 1.5 
mg/ml; 2 mg/ml points). All wells received 200 µl of a solution formed by mixing 50 parts of 
solution A (which contains bicinchoninic acid and sodium tartrate in an alkaline - pH 11.2 - 
buffer) and 1 part of solution B (4% cupric sulphate pentahydrate solution) as described in 
the manufacturer’s protocol. Plates were incubated at 37°C for 30 minutes and then read at 
562 nm with a spectrophotometer. Interpolation of absorbance and standard known 
concentration was used to calculate the sample protein content.  
 
3.2.4.4 Electrophoresis and immunoblotting 
Equal amounts (10-50 µg of tissue lysates; 5-15 µg of cell lysates) of extracted proteins were 
separated by SDS-polyacrylamide gel electrophoresis, based on the principles described by 
Laemmli in his pioneering work (Laemmli, 1970); reducing conditions and usage of SDS as 
anionic detergent determine the separation of the different protein entities according only 
to their molecular weight. For tight- and adherence junctions detection, pre-casted 4-20% 
gradient poly-acrylamide gels (Tris-Glycine Novex; Invitrogen, USA) were used, while for the 
other molecules studied gels were cast in house. To accomplish that, glasses for gel 
electrophoresis were mounted by using 1.5 mm spacers and the relative support (Biorad, 
UK); resolving gels were prepared at 10 or 12% of poly-acrylamide content, pH 8.8, poured 
into the gap between the outer and the inner glass and left to polymerise for 15-20 minutes 
at RT. A thin layer of water or absolute alcohol was added right after layering the solution to 
avoid any reaction between air and the solidifying gel.  
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The resolving gel acrylamide concentration was chosen according to the size of the proteins 
to be studied. After polymerisation occurred, the liquid added on top was discarded and the 
resolving gel was overlaid with 4% polyacrylamide stacking gels, pH 6.8.  
Samples were prepared in loading buffer (see Appendix; section 10.1.8) and subsequently 
boiled at 95°C for 5 minutes to denature the proteins. After loading the samples and pre-
stained standards (Page Ruler Plus; Thermo Scientific, UK) into the wells, gels were mounted 
into the running apparatus (Biorad, UK) and run at 30 mA/gel for stacking, then 50 mA/gel 
for resolution in running buffer. Resolved proteins were transferred to nitrocellulose 
membrane (Hybond®, Amersham Biosciences, UK): a gel sandwich was prepared in a 
cassette (Bio-Rad, UK) by layering fibre pad, filter paper, gel, membrane, filter paper and 
fibre pad. The cassette was placed in the appropriate module and tank, filled with chilled 
transfer buffer and connected to the power pack for 1 h at 400 mA, 100 V. Membranes were 
then blocked in 3% BSA in Tris-buffered saline 0.1% Tween-20 (TBS-T) for 45 minutes-1 hour 
to block non-specific antibodies binding. Membranes were then washed briefly in TBS-T 
before incubation with primary antibody at the desired dilution (prepared in 3% BSA TBS-T) 
overnight at 4°C. Membranes were then washed in TBS-T once for 30 minutes and twice for 
15 minutes to ensure removal of unbound antibody, incubated with the host-specific HRP-
conjugated secondary antibody for 1-2 hours at RT and washed again as above.  
Immune-reactive bands were visualised by enhanced chemiluminescence (ECL) reaction: 
this is based on the hydrogen peroxide-dependent oxidative activity of HRP on luminol, 
which results in the subsequent emission of light; the intensity is proportional to the 
quantity of the enzyme (so to the quantity of the bound protein of interest) and can be 
captured on an autoradiographic film. The ECL commercial kit by Thermo Scientific, UK was 
chosen and consisted in preparing a working solution by mixing equal volumes of reagents A 
and B. Membranes were submerged in this mix for 1 minute; the excess of liquid was then 
removed, immunoblots were wrapped in plastic film prior to exposure to X-ray films (GE 
Healthcare; Amersham Biosciences, UK and Santa Cruz Biotech; US), which occurred for 10 
seconds – 10 minutes under dark conditions. Films were developed by using an automatic 
developer and fixer machine.  
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To re-probe the membranes with different antibodies, these were stripped in stripping 
buffer (Restore Western Blot; ThermoScientific, UK) under gentle agitation for 15 minutes at 
RT, then washed in TBS-T and re-blotted for β-actin or GAPDH as internal controls that 
ensured similar loading for all the samples/wells. 
X-Ray films were scanned at high resolution and band intensities were detected through 
Image J software densitometry application, normalising the values against the internal 
loading controls of each sample. Results of the repeats of the same condition were averaged 
as well as results from different independent blotting repetitions. 
 
3.2.5 Molecular biology 
3.2.5.1 RNA extraction 
Total RNA was extracted from cell pellets according to the manufactures instruction, using 
the RNAeasy Qiagen kit (Qiagen Ltd, UK). All steps were performed quickly at room 
temperature using RNAse-free filtered-pipette tips to avoid contamination. Briefly, lysis 
buffer RLT (provided with the kit) was added to the cell pellet previously collected (350 µl is 
recommended as enough for 106 cells). The mixture was quickly mixed by pipetting up and 
down and transferred into QIAshredder columns (Qiagen Ltd., UK) and centrifuged for 2 
minutes at 12000xg to shear genomic DNA. An equal volume of 70% (v/v) ethanol was 
added to the eluate and mixed by pipetting. Samples were then transferred to an RNAeasy 
mini spin column which was centrifuged for 1 minute at 10000xg. Buffer RPE was then 
added into the column and centrifugation (1 minute, 10000xg) was repeated; this washing 
step was repeated twice. 40 µl RNAse-free water was added on the silica-membrane of the 
column, which was left to stand for around 1 minute, after which columns were centrifuged 
at maximum speed for 1 minute. Samples were analysed for RNA concentration and nucleic 
acid purity by spectrophotometry, using a NanoDrop (Thermo Scientific, UK) and following 
manufacturer instructions. Samples were kept at -20°C until further use.  
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3.2.5.2 Reverse transcription polymerase chain reaction (RT-PCR) 
For the first strand cDNA synthesis, 3 µg of total extracted RNA were used. These were 
denatured with 3 µl oligo (dT)15 (Promega, UK) for 5 minutes at 65°C, followed by reverse 
transcription at 42°C for 2 hours using 0.6 mM dNTP solution (Invitrogen, UK) 1 U/ml 
RNAsine® ribonucleases inhibitor (Promega, UK), 50 U/reaction of Moloney murine 
leukaemia virus reverse transcriptase (M-MLV RT; Promega, UK).  
10 µl of the reverse transcription reaction were used for PCR reactions, together with 1.5 
mM MgCl2 final concentration, 0.5 mM dNTP, 1 µl Taq polymerase and PCR buffer mix, all 
from Invitrogen, UK. The cycling parameters consisted of a denaturing step for 5 minutes at 
95°C, followed by 40 cycles of denaturation for 1 minute at 95°C, primer specific annealing 
for 1 minute (see Appendix; section 10.3), extension step for 1 minute at 72°C. A final 
extension stage was also included for 15 minutes at 72°C.  
 
3.2.5.3 Scale-up amplification of plasmids through QIAGEN MAXI prep Kit 
Plasmids were amplified in order to obtain large quantities of them for further applications 
(lentiviral particle production and transfections). Maxi-prep plasmid DNA purification kit 
(Qiagen, UK) was chosen as it gives endotoxin-free purified DNA, an important aspect 
considering future cell culture use. Starter cultures (5 ml Luria Bertani (LB) broth 
supplemented with 100 µg/ml ampicillin) were prepared from colonies bearing the correct 
plasmids or from glycerol stocks. These were allowed to grow with vigorous shaking (~300 
rpm) at 37°C for 8 hours. Subsequently, 200 ml of LB broth (supplemented with ampicillin) 
in a capable flask were inoculated with 400 µl of the starter culture (1:500 dilution) and 
incubated at 37°C with vigorous shaking for 12-16 hours. Afterwards, bacteria were 
collected through centrifugation (4000xg for 20 minutes, 4°C) and pellet was frozen; a 
sample from the suspension was taken and DNA was extracted to assess the identity of the 
plasmid. Pellets were allowed thawing and treated exactly as indicated in the provided 
protocol. The DNA obtained was finally diluted in a suitable volume of Tris-EDTA (TE) buffer 
(provided with the Qiagen kit) in order to achieve a final concentration of around 1 μg/μl, as 
measured using NanoDrop 1000 spectrophotometer (Thermo Scientific, UK).  
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3.2.5.4 Checking the identity of the constructs through restriction enzymes 
Identity and possible recombination in original vectors and ligation products was checked 
through at least 3 different restriction enzymes and via sequencing with specific primers to 
check the correct insertion, frame and identity of the insert. Restriction pattern 
identification was performed using Webcutter 2.0 (Yale University, USA), Vector NTI 10.30 
(Invitrogen, UK) and by using the plasmid sequences provided by the manufacturer or the 
authors of the original vectors. Every restriction reaction was performed on DNA samples 
from colonies picked-up from selective agar plates and purified by MINI prep plasmid DNA 
purification Kit (Qiagen, UK) according to the supplier’s instructions. When correct colonies 
were identified, stocks were prepared (15% glycerol; 75% bacterial suspension) and stored 
at -80°C. 
 
3.2.5.5 Agarose gel electrophoresis 
10 µl samples of PCR reactions or restriction reactions were mixed with 10X gel loading 
buffer to reach a final concentration of 1X, loaded and run, each of them in separate wells, 
along with 6 μl of 1 Kb ladder (Invitrogen, UK) in agarose gels, prepared using 1X Tris-
Acetate-EDTA (TAE) buffer as solvent, stained with Ethidium Bromide (0.02% v/v) or the 
safer GelRed® (Invitrogen, UK; 1:10000 (v/v) as recommended by the manufacturer)  and 
run at 80-100V (if regular-sized gels) or 70-90V (if mini-gels) in order to assure 5-8V/cm max. 
Gels were soaked into 1X TAE running buffer. Concentration of the gels was decided 
according to the band pattern expected (briefly: 0.7% to separate species with length 
around or longer than 3 Kb; 0.8% to separate species with length around 1 Kb; 1% to 
separate species less than 1 Kb long; 1.5% to separate species shorter than 500 bp long; 2% 
to separate species shorter than 200 bp long). Gels were observed under UV rays through 
Gene Genius luminometer (Syngen, USA) and images were acquired and modified to avoid 
saturated signals using the provided software (Syngen, USA). 
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3.2.5.5.1 Agarose gel densitometric analysis 
Analysis of the RT-PCR products were performed under ultraviolet light using a specific gel-
docking system (MultiGenius; Syngene, UK). The provided software was used to adjust 
exposition and background in order to clearly visualise the bands.  
 
3.2.6 Immunophenotyping of tissue and cells 
3.2.6.1 Immunofluorescence on tissue slices 
Frozen mouse brains, fixed for 24 h in 4% PFA in 0.01 M PBS at 4°C, were sliced into 15 µm-
thick sections on a freezing microtome (Bright Instruments Ltd, UK) and stored at -20°C in 
anti-freeze solution. Sections were washed 2 times (5 minutes/wash; RT) with TBS 1X and 
permeabilized for 10 minutes in 0.5% Triton X-100 in TBS 1X under agitation, at RT. To limit 
auto-fluorescence, sections were incubated for 5 minutes in Sudan Black solution, washed 
twice in tap water under agitation (3 minutes/wash; RT), blocked for 30 minutes at RT in 
blocking solution to limit non-specific secondary antibody binding. Primary antibodies 
(diluted as detailed in Appendix, Section 10.2) incubation was performed overnight at room 
temperature (unless otherwise stated in the Results) in antibody buffer. The following day, 
sections were rinsed 3 times in antibody buffer and then incubated for 1-2 h at RT with 
specific secondary antibodies in antibody buffer. Finally, sections were rinsed 3 times in TBS 
1X and manually mounted on gelatine-coated slides, allowed to air-dry and cover-slipped 
under mounting solution with or without 4',6-diamidino-2-phenylindole (DAPI) (Prolong 
Gold Antifade mountant with DAPI; Invitrogen, UK). 
Digital images of the immunostained tissue sections were captured using a system 
consisting of a Hamamatsu C4742-95 CCD camera (Hamamatsu Photonics UK Ltd, UK) 
attached to a Nikon TE2000U inverted microscope (Nikon UK Ltd, UK).  
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3.2.6.2 Immunofluorescence on cells 
Cells were cultured on Labtek multiwell glass slides (Invitrogen, UK) or on glass coverslips 
treated with specific agents to increase attachment of the cells (rat tail type I collagen for 
hCMEC/D3), growth up to 100% confluent and treated with the different stimuli. After a 
quick wash in warm DPBS without Ca2+/Mg2+, cells were fixed in different ways according to 
the past experience and literature: with 4% PFA for 10 minutes at RT (ANXA1 (McArthur, 
Cristante et al. 2010); Zonula Occludens-1; VE-Cadherin), with 100% methanol at 4°C 
followed by cold absolute acetone for 3 minutes at RT (Furuse et al., 1994) and personal 
communication from Dr AM Lopez-Ramirez [Open University, UK; (Lopez-Ramirez et al., 
2012) for Occludin, Claudin 5], with 4% PFA in cytoskeleton preserving buffer for 30 minutes 
at RT  for Fibrillar Actin (Cramer et al., 2002). After fixation, cells were washed twice in DPBS 
with Ca2+/Mg2+ (~ 1 min/wash, RT), permeabilized for 5 minutes, then blocked in blocking 
buffer for 30 minutes at RT. Primary antibodies were diluted at the desired concentration 
(see Appendix; section 10.2) in antibody buffer and enough volume was layered onto the 
cells, which were incubated overnight (tight- and adherence-junctions) under agitation at 
RT, or for 1 hour at RT (ANXA1). Rhodamine-conjugated or Alexa-488-conjugated phalloidin 
was incubated at room temperature for 15-20 minutes under agitation. After washing 3 
times in DPBS with Ca2+/Mg2+ 1% FCS, 0.1% BSA (10 minutes/wash at RT, to ensure major 
removal of unbound primary antibody), fluorophore-conjugated secondary antibodies were 
diluted in antibody buffer and applied for 1 h in the dark at RT. Finally, samples have been 
washed 3 times in DPBS with Ca2+/Mg2+ (10 minutes/wash, RT) and once in DPBS with 
Ca2+/Mg2+ 0.1% Triton X-100 (10 minutes, RT) air-dried and mounted using Mowiol or 
Prolong Gold Antifade with DAPI.  
Digital images of the immunostained tissue sections were captured using the same system 
described for tissue samples. Alternatively, confocal microscopy [TCS SP5 (Leica, UK) 
equipped with: Argon-UV (351 nm) laser, Diode 405 (405 nm) laser, Argon (488 nm) laser, 
Helium-Neon (543 nm) laser, DPSS 561 (561 nm) laser; 10X (HCX PL APO CS dry; 0.4 
numerical aperture), 20X (HCX PL APO CS dry; 0.7 numerical aperture), 40X (HCX PL APO dry; 
0.85 numerical aperture), 63X (HCX PL APO water-immersion; 1.2 numerical aperture) 
objectives) was conducted along with Z-stack analysis to increase detail depiction, using 
Leica Application Suite software provided.  
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3.2.6.3 β-galactosidase staining on tissue slices 
Blood was washed out of the body by perfusion through the left ventricle with 
approximately 15 ml of filtered saline at 4°C. Brains were rapidly removed and divided 
coronally in 2 mm slices; these were fixed in fresh 4% PFA for 1 hour at 4°C. After rinsing 
them 3 times (30 minutes each) in rinse buffer, brain chunks were incubated overnight at 
room temperature with staining buffer. The following day, they were rinsed three times in 
PBS 0.01M, post-fixed in 4% PFA for 2 hours at room temperature or overnight at 4°C. 15-
µm sections were produced by cryostat cutting. After having let them dry, sections were 
counterstained with eosin Y (0.1% w/v) for 15 seconds, rinsed once in tap water (5 minutes), 
dehydrated in 95% ethanol for 2 minutes, cleared in xylene for 10 seconds and mounted 
with Di-N-Butylephthalate in xylene (DPX; VWR, UK).  
 
3.2.6.4 Flow cytometry  
Cells were washed once with DPBS without Ca2+/Mg2+ and quickly trypsinised before fixation 
in 2% PFA for 15 minutes at RT. Cells were then pelleted and washed with DPBS with 
Ca2+/Mg2+ twice and incubated for half hour at room temperature in blocking buffer with or 
without permeabilisation (represented by 0.025-0.1% (v/v) saponin). 
Cells were then washed twice with wash buffer with or without saponin and then incubated 
with primary antibodies diluted in antibody buffer for 1 hour at room temperature. Next, 
cells were washed twice before incubation for 1 h at RT in the dark with fluorophore-
conjugated secondary antibodies, washed twice and finally re-suspended in 300 μl of DPBS 
with Ca2+/Mg2+. 
Analysis by flow cytometry was performed within 1 h using a FACScan II analyzer (Becton 
Dickinson, UK), with 15 mW argon ion laser (488 nm) and Consort 32 computer running 
CellQuest software (Becton Dickinson, UK). Log10(mean intensity of fluorescence) 
histograms (256-channels) were obtained from approximately 10000 cells from a gate set-
up according to Forward Scatter (FSC) and Side Scatter (SSC) parameters (representing  
cellular dimensions and granularity). FlowJo (Tree Star, USA) was used to assess differences 
in fluorescence intensity.  
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3.2.7 Statistical analysis 
Number of repeats and experiments is reported in the figure legends. Normally distributed 
data are presented as mean ± standard error of means (SEM) of n samples per group.  
Data have been analysed using Excel, GraphPad Prism 5 or SPSS; two-tailed Student’s t-test 
has been chosen for comparisons between two previously assessed normally distributed 
populations while one-, two- or three-way ANOVA and Bonferroni’s, Tukey’s or Dunnett’s 
(comparison to a reference control group) multiple comparison post-hoc test for more than 
two groups, depending on the number of variables of the study. A p value lower than 0.05 
was considered statistically significant. 
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4.1 Overview and aim of the chapter 
In this chapter, I will present the most significant data obtained about the mechanistic 
involvement of ANXA1 at the level of the endothelium forming the BBB. Using a 
comprehensive approach, which included a comparative in vivo permeability assessment 
between the Anxa1 null mouse and the wild-type counterpart, primary isolation of 
microvascular endothelial cells and in vitro extensive exploitation of a human cell line, we 
were able to pinpoint ANXA1 to be a critical component for the barrier integrity of BMECs.  
 
4.2 Protection of the central nervous system: the need for barriers 
Undoubtedly, the brain is the most complex organ of the body. Evolution has provided the 
CNS tissues with protective bony formations, connective ensheathing membranous 
structures (the meninges) and a fluid cushion (the cerebrospinal fluid). These properties 
define a physically confined and protected environment, though unable to undergo major 
changes in response to external stimuli. Brain energy requirements are very intense [around 
20% of the total oxygen consumption (Clark & Sokoloff, 1999) and 25% of glucose utilization 
(Attwell and Laughlin, 2001)] due to the high number of operations that it has to constantly 
process, while tight ionic homeostasis at synaptic levels appear to be fundamental for the 
correct CNS activity (Abbott, 2005); therefore, the brain strongly depends on the constant 
maintenance of a controlled internal environment. Every tissue of the body is able to adapt 
to small fluctuations in the concentration of hormones, ions and nutrients, which occur 
typically after eating or exercising; the central nervous system cannot sustain this type of 
sharp changes, since these would result in uncontrolled neuronal activity (some ions and 
amino-acids are involved in neurotransmission) and in irreversible damage of the circuitry 
and delicate brain parenchyma. The evolutionary pressure for structures able to control the 
CNS homeostasis has brought the development of specialised barriers able to separate the 
central tissues from the periphery and to regulate the molecular traffic between the two 
compartments. These structures can also control pathogenic agents and microorganism 
invasion, as well as uncontrolled cellular invasion from the blood stream, which would all 
result in serious consequences for this delicate environment.  
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Thus, a great variety of highly specialised barriers have evolved in different areas of the 
CNS-blood interfaces (Neuwelt et al., 2011): the blood-cerebrospinal fluid barrier (BCSFB), 
the blood-retinal barrier (BRB), the blood-nerve barrier, the blood-labyrinth barrier, the 
ventricular ependyma (although there is no complete agreement in including this structure 
among the specialised barriers array) and the blood-brain barrier (BBB), which is the focus 
of this and of the following two chapters.  
 
4.3 Peculiarities and commonalities of the different barriers 
Brain barriers exert similar functions but each one shows particular properties. Structural 
isolation is permitted thanks to specific features of each barrier, but all of them have an 
important point in common: the presence of a specialised endothelium or epithelium as an 
essential component. The characteristics of this vary in the different barriers. In the case of 
the blood-retina barrier, a highly restricted layer of epithelial cells (the retinal pigment 
epithelium) and a tight vascular endothelium contribute to its characteristic limited 
permeability; a similarly tight endothelium is also peculiar to the blood brain barrier.  
In the brain, there are, however, structures that lack an endothelial BBB and are 
characterised instead by fenestrated leaky capillaries: these are known as circumventricular 
organs (CVOs), which are present at the level of specific regions containing neurons 
specialised in neurosecretory and chemosensitive functions; thanks to the permissive 
barrier structure (glial coverage offers only a partial hindrance), these areas of the brain are 
able to sense signals from the periphery (Engelhardt and Sorokin, 2009). Similarly, BCSFB is 
formed by a dense tangle of leaky capillaries, the choroid plexuses (which are present at the 
level of the lateral, third and fourth ventricles), surrounded by tightly organised epithelial 
cells: here, the nourishing and protecting cerebrospinal fluid is produced and distributed 
through the CNS. 
Bearing in mind these examples, we now know that the properties of the barriers cannot be 
reduced simplistically to the status of tightness of its endothelium.  
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4.4 The blood-brain barrier (BBB) in physiological conditions 
Among all the specialised brain barriers, the blood brain barrier (BBB) covers the largest 
surface area, therefore representing the site where most of the peripheral stimuli impact, 
inducing central responses. The BBB has the fundamental role of tightly checking the 
movement of molecules and inflammatory cells from the circulating blood, protecting the 
CNS from potentially harmful compounds (microorganisms, toxins and, in physiological 
conditions, certain immune cells) and regulating the passage of nutrients, signals waste and 
other molecules to the brain tissue (Abbott et al., 2006; Abbott et al., 2012).  
 
4.4.1 Historical background 
The existence of brain barriers, and more specifically of a BBB, was firstly investigated by the 
German physiologist and Nobel laureate Paul Ehrlich in the late XIX century. He observed 
that the administration of intravenous or sub-cutaneous dyes in experimental animals 
resulted in heavy staining of all the organs except the brain and the spinal cord. Initially, the 
conclusions drawn were wrongly attributed to supposed tissue- and organ-specific affinities 
of the dyes (Engelhardt and Sorokin, 2009). Further work from Ehrlich’s student, Edwin 
Goldman, shed more light on these observations: by directly injecting brains with the same 
dyes, clear staining of the nervous system was observed, while peripheral tissue remained 
unstained. The explanation was the existence of a physiological barrier between the CNS 
and the rest of the body, able to hold back and control the movement of certain molecules. 
Due to light microscopy limitations, a definite anatomical and functional demonstration of 
the existence of the BBB came only in the 1950s (Dempsey & Wislocki, 1955), thanks to the 
exploitation of the newly developed transmission electron microscopy. Through these 
techniques, it was possible to correlate the localisation of the BBB with the microvascular 
endothelial cells. The existence of a complex arrangement of different cell types and 
molecular structures became clear; since then, this has been the basis of the peculiar barrier 
properties of the microvasculature of the brain parenchyma when compared to their 
peripheral equivalents. 
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4.4.2 Development of the blood-brain barrier 
The CNS vasculature develops similarly to the peripheral one: embryonic precursors cells 
(EPCs; also known as angioblasts) are formed in the yolk-sac mesoderm and invade the head 
region tissues in early phases of embryogenesis, differentiating into endothelial cells and 
defining a vascular plexus that runs around the entire surface of the neural tube (Mehta and 
Malik, 2006; Abbott et al., 2010; Neuwelt et al., 2011). From here, further vascularisation 
processes occur in the developing brain: capillaries can sprout from the plexus by stimuli 
linked to the metabolic demands of the expanding neuroectoderm and invade the forming 
parenchyma. While forming, the brain vasculature is further stabilized by the recruitment of 
other supporting cells and by the deposition of the extracellular matrix, which represents a 
strong signal towards maturation and against further proliferation/migration (Abbott, 2005); 
these steps are all finely tuned by the surrounding environment with its important cues 
coming from neighbouring cells. In this way, the complexity of the brain barriers can be 
sequentially achieved, along with their full functionality.  
Since a certain degree of isolation of the CNS from the rest of the forming organism is 
required also during development, functionally effective barrier molecular structures, like 
tight junctions complexes between endothelial cells and specific transporters, are present 
shortly after the microvasculature starts to invade the CNS tissue (in the mouse this occurs 
between E11 and E17), although BBB maturation (like astrocytes generation and end-feet 
extension) continues in later stages as well as during the first post-natal days (Liebner et al., 
2008; Abbott et al., 2010; Daneman et al., 2010).  
Interestingly, the ependyma lining the cerebral ventricles of the developing brain (called 
neuroependyma) constitutes a proper tight barrier during embryogenesis but not at later 
times, when the adult ependyma is a more permeable interface (Neuwelt et al., 2011).  
 
4.4.3 The neurovascular unit 
The definition of the anatomy and localisation of the BBB are constantly receiving novel 
inputs from the discovery of new interactions and participations (Neuwelt et al., 2011). 
While initially neurobiology research was mainly driven by a unique interest in the neurons, 
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in recent years scientists have discovered that a neuro-centric focus is not sufficient but 
instead simplistic, therefore emphasizing the fact that all cell types in the brain including 
neuronal, glial and vascular components, must be examined in an integrated context both 
under physiological and the pathological conditions. Not only the neurons but also the BBB 
strongly depends on the inputs received from the microenvironment (Lok et al., 2007) and 
the current tendency is to cluster the BBB cellular and molecular components into the wider 
concept of the neurovascular unit (NVU), which also includes microglia, neurons and 
oligodendrocytes (Neuwelt et al., 2011). Nerve terminals sheathe brain capillaries, 
potentially providing a source of molecules (neurotransmitters) able to modulate 
microvascular permeability (Abbott, 2002). Circulating blood cells (in particular the 
polymorphonuclear cells, the lymphocytes and the monocytes) and their inflammatory 
mediators (cytokines) should also be included into an “extended” concept of NVU (Neuwelt 
et al., 2011), because they have been shown to be important mediators of CNS 
pathophysiology and directly interact with the BBB vasculature. Initial evidence has been 
produced in support of this novel concept (Joice et al., 2009; Cowan and Easton, 2010).  
Increasing evidence is showing that the interactions occurring between these cellular 
components are essential to maintain homeostasis of the entire CNS, as well as to respond 
to inflammation and disease. Since the definition of the existence of a NVU, novel concepts 
have arisen: the hemodynamic neurovascular coupling between blood flow and brain 
activity; the importance of cellular inputs derived from neuronal cells that contribute to 
evoke the BBB phenotype; the parallelism underling both neurogenesis and angiogenesis in 
the CNS; the potential exchange of trophic factors that may link neuronal, glial and vascular 
homeostasis. These and other phenomena appear to rely on the existence of a tripartite 
synapse (Perea et al. 2009), established between endothelium, astrocytes and neurons. It is 
therefore essential to understand and expand the knowledge of the regulatory mechanisms 
not only in each NVU component, but also between different players; only in this way it will 
be possible to fully explain how the structural integrity of the barrier is achieved and 
modulated (and could eventually be restored under pathological conditions). 
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4.4.4 Composition of the blood-brain barrier 
Historically, BBB has been recognised to be formed mainly by the highly specialised 
microvascular endothelial cells, the glial/supportive cells astrocytes, the pericytes, the 
perivascular macrophages/antigen-presenting cells and the cellular basal membrane 
(Abbott et al., 2006; Engelhardt and Sorokin, 2009). The major components are represented 
in Figure 4.1. 
 
Figure 4.1 Principal components of the blood brain barrier. The main components of the blood-
brain barrier are depicted. Neurons, microglia and other components have not been represented for 
clarity purposes but their role in the neurovascular unit has been extensively described in the text. 
Figure modified with permission of Dr CP Watson; original picture based on Cecchelli, Berezowski et 
al. 2007. 
 
4.4.4.1 The BBB endothelium 
The main component of the BBB, and the one that provides the core of this complex 
structure, is the brain microvascular endothelial cells (BMECs). Compared to peripheral 
capillary endothelial cells, BMECs show a tightly sealed phenotype: blood cells and 
substances cannot cross the endothelium layer easily as no fenestrations are present.  
A reduced constitutive non-specific transcytosis (pinocytosis) means that hydrophilic 
molecules can only cross the BBB and enter the brain parenchyma from the blood stream 
only almost exclusively through specific transporters and receptor mediated transcytosis. 
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Such specialised tightness is allowed by the presence of complex cell-cell junction 
complexes (described more in detail in Figure 4.4), which show a higher degree of 
complexity compared to those of peripheral capillaries (Engelhardt and Sorokin, 2009) and 
this is reflected in the differential expression patterns of cell junctions genes (Wolburg and 
Lippoldt, 2002). Thus, cerebral endothelial cells are much less permeable even to small ions 
like Na+ and Cl- than their peripheral counterparts, as represented by the much higher 
transendothelial electrical resistance (TEER) measurable in the brain capillaries [in the 
magnitude of 1500 Ω·cm2 as reported (Deli et al., 2005; Abbott et al., 2006)]. 
The BBB endothelium shows other special properties, such as a higher number of 
mitochondria, necessary to produce the energy (i.e. ATP) required by the highly numerous 
and specialised influx and efflux pumps (Wolburg and Lippoldt, 2002). In addition, these 
cells show a very low basal expression of leukocyte-adhesion molecules like ICAM-1, VCAM-
1, and leukocyte-rolling molecules like P- and E-selectins, but they can be promptly up-
regulated by specific inflammatory signals (Whalen et al., 1998; Dobbie et al., 1999).  
 
4.4.4.1.1 Annexin A1 in the endothelium 
While several reports concerning other annexins and their endothelial localisation and 
involvement exist, the role of Annexin A1 in the endothelium is practically an unexplored 
area. Only a few scattered studies have investigated why this protein is present at this level 
and how it affects endothelial functions. In particular, two early reports (Patte and Blanquet, 
1992a, b) observed ANXA1 to be associated with the membrane of HUVEC cells (the most 
widely used model of peripheral endothelial cells) and to affect the cell cycle. In 
inflammation, a cleaved form of ANXA1 produced and released by activated neutrophils has 
been shown to re-organize adhesion molecules on the same cell line, inducing a more 
intense leukocyte extravasation (Williams et al., 2010). No reports so far have investigated 
the role of ANXA1 at the level of the microvascular endothelium and of the BBB. As it 
occurred for the peripheral system, the attention has been focused exclusively on the blood 
cells, since ANXA1 is historically recognised for its anti-inflammatory role played at this level. 
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4.4.4.2 The astrocytes and the astrocytic end-feet 
Astrocytes are a type of glial cell and one of the most numerous cell types in the CNS. They 
play several roles in tissue homeostasis (glia comes from the Greek word for “glue”, which 
semantically indicates their supportive role), which span from regulation of metabolism (as 
glycogen and lactate reserve), regulation of ionic concentrations and pH in neuron-rich 
regions, buffering and release of neurotransmitters, immunity regulation (as potential 
antigen-presenting cells) and players in nervous system repair (Abbott et al., 2006; Allen and 
Barres, 2009). Importantly for the purpose of our interest, astrocytes are able to extend 
their end-feet so that they stay in close contact with the vascular unit (98% of the cerebral 
micro-vascular tree is ensheathed by astrocytic end-feet lamellae), defining the so-called 
glia limitans perivascularis (Engelhardt and Coisne, 2011), which not only represents a 
physical barrier for molecules and cell passage but also shows several specialized features 
such as up-regulation of specific transporters and receptors on the endothelial cells, 
modulation of vascular tone and blood flow (Abbott et al., 2006; Engelhardt and Sorokin, 
2009; Neuwelt et al., 2011), contributing to the BBB-specific features. The glia limitans and 
the vasculature also define a perivascular space important for antigen presentation and 
immune-surveillance (Engelhardt and Coisne, 2011).  
Astrocytes are very important for the correct development of the blood-brain barrier: 
temporal and spatial characterisation has shown their regulatory role (Liebner et al., 2008; 
Alvarez et al., 2011). In particular, soluble factors released by astrocytes (for example 
transforming growth factor-β (TGF-β), glial derived neurotrophic factor (GDNF) and steroids 
such as hydrocortisone) as well as direct contact with BMECs are essential aspects for the 
correct induction of their peculiar BBB properties (Abbott, 2002). Also, astrocytes have 
proved to be very important for the definition of quick changes in BMECs tightness, for 
example when a higher metabolic support is required by the neurons (Abbott, 2002). 
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4.4.4.3 The basement membranes 
Generally, the basement membranes (BMs, also known as basal lamina) are considered as 
part of the extracellular matrix and are composed of several structural molecules such as 
collagen type IV isoforms, nidogens, fibronectin, laminin, perlecan and other proteoglycans 
(Mehta and Malik, 2006; Engelhardt and Sorokin, 2009). Endothelial cells are able to 
synthesize and secrete these constituents on the abluminal/parenchymal surface during 
angiogenesis and vasculogenesis, which represent a supportive/anchoring structure for their 
correct functioning. More in detail, two distinct BBB basement membranes can be 
distinguished: one originating from the endothelium and one from the astrocytes, which 
underlie the endothelium and cover the astrocytic end feet, respectively (Engelhardt and 
Sorokin, 2009). Interestingly, these two distinct structures are clearly distinguishable at the 
level of post-capillaries venules, while they are fused to form one single basement 
membrane at the level of brain capillaries. 
The BM of the capillaries play an essential role in modulating and remodelling the 
endothelium; not only it serves as an anchoring support for the endothelium, which 
expresses several BM receptors [the integrins; (Engelhardt and Sorokin, 2009)], but it also 
has been observed that inflammatory stimuli can stimulate BM-disruptive enzymes which 
denude regions of the endothelial lining. Cell adhesion can also be modulated at the level of 
the BM, therefore indicating an overall role in barrier function and integrity (Mehta and 
Malik, 2006; Engelhardt and Sorokin, 2009).  
 
4.4.4.4 The glycocalyx 
The glycocalyx is a negatively charged surface made of proteoglycans, glycosaminoglycans 
and plasma proteins, which is secreted on the luminal (blood-stream) side of the endothelial 
monolayer. At the level of the BBB, its role is still not fully clarified (Neuhaus et al., 2009) 
but initial evidence supports similar roles as those served in the peripheral vascular system, 
where this structure limits leukocyte attachment to the endothelial surface and potentially 
the passage of macromolecules (Mehta and Malik, 2006).  
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4.4.4.5 The pericytes 
Pericytes represent a “hot-topic” in terms of identification of their role as BBB components. 
Previously known as adventitial cells, pericapillary cells, intramural cells or Rouget’s cells, 
these are small contractile and phagocytic cells that surround the endothelial cells 
monolayer with secondary cellular branches and are also enclosed by the endothelial BM. 
Embryonically, they have a mesodermal origin: they migrate as general macrophages into 
the tissue during the late stages of vascularization, developing the specialised pericyte 
phenotype thanks to stimuli from the vascular microenvironment (Guillemin and Brew, 
2004). They are ubiquitously present in every microvascular bed of most tissues but 
especially at the level of the BBB and of the BRB. Originally, they were thought to 
structurally support the vascular endothelium and to regulate local blood flow of small-
calibre vessels devoid of smooth muscle cells (Thomas, 1999), since they were found to 
express receptors for vasoactive mediators (Healy and Wilk, 1993). While a role in 
coagulation pathway has been also proposed, pericytes are now included among the central 
players of the immune response of the brain (Thomas, 1999): in fact, pericytes are not only 
able to increase paracellular permeability during inflammatory reactions by contraction, but 
are also to act as antigen-presenting cells (APCs) and since the perivascular space of 
microvessels is now regarded as an important site for the development of adaptive immune 
reactions, these cells have been gaining even more interest and importance. Recently, two 
important reports (Armulik et al., 2010; Daneman et al., 2010) shed more light on the topic: 
by using pericyte-deficient murine models, both works indicated a direct involvement of this 
cell-type during BBB embryological development, as well as in the regulation of the BBB 
permeability to low- and high-molecular-mass tracers by affecting transcytosis. Such effects 
seem to be mediated by maintaining the correct astrocytic end-feet polarity along the 
cerebral microvasculature and by regulating the correct BBB-specific gene expression in the 
endothelial cells (Armulik et al., 2010).  
The direct involvement of these cells in several neurological disorders like Alzheimer’s 
disease, diabetic retinopathy and those with an inflammatory component indicate how 
crucial this cell type appears to be at the interface between the peripheral system and CNS.  
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4.4.4.6 The perivascular macrophages 
Perivascular macrophages (PVMs) are considered a subset of brain-resident macrophages, 
whose role has just started to become clearer. This cell type resides in the perivascular 
space created between the BBB endothelium and the glia limitans perivascularis, where 
they act as sentinels for peripheral harmful stimuli plus they convey information about the 
CNS health status to the peripheral cells that enter this space. It has been difficult to 
distinguish them from pericytes (Guillemin and Brew, 2004): based on their morphology and 
on developmental studies, PVMs were shown to be derived from migration of bone marrow 
precursors that populate the brain in early postnatal life and turn over slowly during life 
(Serrats et al., 2010), therefore they are different from resident histiocytes present in 
peripheral capillaries already during vasculature development (Guillemin and Brew, 2004). 
PVMs do not show proliferative ability (differently from microglia and pericytes) but 
together with pericytes they can serve as APCs, representing important implications since 
the CNS lacks proper professional antigen-presenting cells (therefore proposing a potential 
role of PVMs in pathologies like multiple sclerosis). In this way, immune surveillance of the 
nervous brain parenchyma as well as of the peripheral system [by monitoring the blood 
stream composition (Serrats et al., 2010)] appear possible. 
 
4.4.5 Vascular localisation of the blood-brain barrier 
One of the most important questions lately posed by scientists is which parts of the 
microvascular tree possess the real and fully-developed BBB phenotype. Every organ 
possesses a microvasculature network composed of arterioles, capillaries and venules to 
meet the local energy requirements of the underlying tissue. As every organ has defined 
specialisations, so does the endothelium, which shows structural and functional differences 
among different organs (fenestrated kidney glomerular capillaries compared to brain 
microvasculature are good examples) but also within the same microvascular tree. Recent 
(Macdonald et al., 2010) and less recent (Ge et al., 2005) reviews indicate the existence of 
important heterogeneity in endothelial cells of the cerebral microvasculature. By analysing 
gene expression differences, Macdonald et al. (Macdonald et al., 2010) observed that both 
capillaries and venules presented a basal expression of basic BBB-associated genes, like 
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those involved in formation of cell-cell junctions, transporters and metabolic enzymes, but 
capillaries showed a higher enrichment and specialisation towards a full blood-brain barrier 
phenotype. These findings are confirmed by protein expression (Ge et al., 2005), which 
included also arterioles in their analysis. A potential explanation for this heterogeneity is 
that special vascular functions can be divided in this way along the length of the 
microvasculature tree, with the capillaries being the most specialised in finely tuning the 
passage of small molecules, while the larger arterioles and especially venules are involved in 
the passage of bigger molecules and peripheral cells into the CNS. The reason for these 
differential properties could reside on the effect that shear stress can have at different 
levels of the vascular tree, as well as on the influence of neighbouring cellular components 
like pericytes and astrocytes; however, a proper explanation is still lacking (Ge et al., 2005; 
Macdonald et al., 2010). 
These findings have important consequences for BBB endothelium in vitro models, since 
venular endothelial cells showed less complex cell-cell junctions formation and transporters 
presence, which is paralleled by a less tight phenotype.  
Interestingly, some evidence is beginning to arise on regional heterogeneity, i.e. differences 
between the same portions of the microvasculature (e.g. capillaries) present in different 
regions of the same organ; in fact, BBB properties of different brain lobes at various ages 
(for example the hippocampus), or between white and grey matter, show a certain degree 
of difference (Pelegri et al., 2007; Zeevi et al., 2010). 
 
4.5 Functions of the blood-brain barrier 
Since the BBB represents the largest CNS-blood/periphery interface in humans (it represents 
an area of 12 to 18 m2 per adult human brain on average), it shows a predominant role in 
regulating the cerebral environment (Abbott et al., 2010).  
As already mentioned, the BBB protects the brain from fluctuations in ionic concentration 
that could play a detrimental role on synaptic and axonal action potentials. Also, it physically 
limits neurotoxic interferences that could occur if peripheral neuroactive molecules (for 
example excitatory amino acids like glutamate) could freely penetrate into the CNS.  
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In addition, the BBB controls the passage of many plasma proteins as those involved in the 
coagulation cascade (fibrinogen, thrombin, etc.) or the complement components which 
have a high index of neurotoxicity, along with some endogenous metabolites, xenobiotics 
from the diet or certain nutrients at high concentrations. Overall, the blood-brain barrier 
functions as a physical, a metabolic and a transport highly specialized barrier, as described 
in Figure 4.2.  
 
 
Figure 4.2 The three main BBB functions. BBB presents a distinctive phenotype which is 
characterized by three types of barrier function. These are: a physical barrier, formed by tight- (TJ) 
and adherens-junctions (AJ) components, that hampers the paracellular flow of molecules; a 
transport barrier, which is able to regulate the traffic of hydrophilic substances between peripheral 
blood and CNS through transmembrane proteins as the P-glycoprotein (P-gp), the multi-drug 
resistance associated proteins (MRPs), the amino acid transporters (AATs), glucose transporters; a 
metabolic barrier, which consists in drug catabolic enzymes like cytochrome P450s (P450s) ones. 
Some bigger molecules can cross the BBB by receptor specific and non-specific transcytosis.               
Figure based on Cecchelli et al., 2007.  
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4.5.1 The transport barrier 
Lipophilic molecules are theoretically able to cross the BBB simply by passive diffusion 
through the cellular membranes. Small non-polar gaseous molecules like O2 are able to 
freely diffuse through the lipid membranes, in a similar way to other small lipophilic 
molecules such as ethanol (Abbott et al., 2006; Abbott et al., 2010).  
On the other hand, the passage of water-soluble molecules is severely restricted by the 
physical tight properties of the endothelium, as explained in Section 4.5.3. This 
phenomenon virtually isolates the brain from essential nutrients like sugars and amino 
acids; since the level of non-specific/non-receptor mediated endocytosis is extremely low 
when compared to other tissue endothelial cells, evolution has led to a complex system of 
highly substrate-specific transporters that are a peculiarity of the BBB. Some of these 
selective transporters are expressed only at the luminal side (facing the blood stream) of the 
endothelium, some others only at the abluminal side (towards the brain parenchyma), 
others on both sides. Therefore, the localisation of these transporters determines also the 
preferred directionality of the specific molecules - i.e. towards the CNS (absorption), or 
towards the blood stream (excretion).  
Several reviews have extensively described the BBB transporters system (Abbott et al., 
2010) and the main classes have been depicted in Figure 4.3. We should remember the 
important transport system of glucose and amino acids, present on the BBB endothelium, 
where tightly regulates the amount of energetic molecules and potential neurotransmitter 
entering the brain; another important example is the ATP-binding cassette (ABC) 
transporter family (P-glycoprotein, also known as MDR-1, is one of the most relevant 
members), which mainly contribute to the efflux of potentially toxic catabolites (Abbott et 
al., 2010; Neuwelt et al., 2011). To transport molecules with a considerable molecular 
weight as cytokines, immunoglobulins and other proteins, receptor-mediated transcytosis is 
the only feasible pathway that can be used at BBB level. This is mediated mainly by 
caveolae-based vesicle formation which promptly forms upon receptor(s) engagement. The 
transcellular pathway is also the main one used by certain leukocytes when entering the 
CNS for patrolling and pathological implications, as it will be described more extensively. 
Figure 4.3 reviews the main transporter pathways at the level of the BBB.  
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Figure 4.3 Transport systems at the level of the BBB. A| Lipophilic molecules are able to passively 
diffuse through the cell membrane and to cross the endothelium. For water-soluble molecules, 
highly specialised transports play a key role in the whole process. B| Active efflux carriers (ABC 
transporters) are able to pump out of the CNS all those molecules with intrinsic toxicity. C| Solute 
carriers (SLCs) are another form of specialized transporters, which actively transport small essential 
nutrients as glucose, amino acids and nucleotides. The direction of net transport is fundamental and 
depends on the cellular (luminal vs. abluminal) localisation of the transporters. D| The paracellular 
diffusion of water-soluble small molecules is strongly limited by the presence of healthy cell-cell 
junctions and it only involves ions and water, while E| receptor-mediated transcytosis is acquiring 
more and more evidence and consideration across the BBB endothelium. Non-receptor mediated 
transcytosis is very limited at this level. F| Leukocytes cross the BBB either by a process of diapedesis 
through the endothelial cells (penetrating close to the tight junctional regions), or via modifications 
of the tight junctions. Figure based on Abbott et al., 2010 (Abbott et al., 2010). 
 
4.5.2 The metabolic barrier 
Drug metabolism is exerted mostly by the liver, highly specialised in modifying a vast array 
of molecules. Since the nervous tissue is so extremely vulnerable to toxic molecules, either 
endogenous products or exogenously derived through the diet, the BBB offers a long list of 
metabolizing enzymes that promptly act to inactivate potential toxicity or to modify their 
bioavailability. This is mostly true for molecules such as drugs, which may have wanted and 
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unwanted effects at the level of the CNS. Phase I enzymes (like cytochrome P450s) and 
phase II enzymes (UDP-glucuronosyltransferase, glutathione S-transferase, etc.) have been 
identified at the level of the human BBB endothelium, strongly affecting the impact and the 
duration of action for numerous pharmacological molecules (Strazielle and Ghersi-Egea, 
2005).  
 
4.5.3 The physical barrier 
The primary and fundamental extreme tightness of the blood-brain barrier is given by the 
fact that BMECs are sealed together in a way that is only present at this anatomical level. 
Consequently, endothelial paracellular (i.e. between the cells) permeability to small solutes 
is dramatically limited compared to most types of endothelia and has to occur through the 
transporter system; also, the filtration coefficient for water is extremely low. This peculiar 
feature can be achieved thanks to specialized junctional complexes, the adherens junctions 
(AJs) and the tight junctions (TJs), as described in Figure 4.4, Panel A. Gap junctions (GJs) 
represent structures connecting the cytoplasm of neighbouring cells, therefore promoting 
molecular exchanges and perpetuation of signalling waves along the vascular tree; however, 
these structures are almost absent from most of the brain microvasculature and do little 
towards the maintenance of the structural integrity, therefore they won’t be further 
described (Sato et al., 2002).  
 
4.5.3.1 The adherens junctions 
AJs play a fundamental role in the development and further maintenance of the endothelial 
sealed phenotype. These membrane-associated molecular complexes are mainly present at 
the basolateral level of the endothelial cells. The main component of this family is VE-
cadherin, a Ca2+-regulated protein that mediates cell-cell adhesion via interactions of the 
extracellular domains of proteins expressed in adjacent cells (Brown and Davis, 2002). The 
cytoplasmic portion of VE-cadherin is directly or indirectly linked to the actin cytoskeleton 
(see below) by the scaffolding proteins α-, β-, γ-catenin (also included in the family) and 
members of the p120 family, like plakoglobin (Engelhardt and Sorokin, 2009; Abbott et al., 
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2010; Komarova and Malik, 2010). In this way, the cytoskeleton of neighbouring cells is 
tightly connected in order to allow mechanical cell-cell communication. VE-cadherin, and 
other members of the family, has been shown to be benefit from phosphorylation, since its 
interaction with β-catenin is potentiated (Komarova and Malik, 2010).  
VE-cadherin has been shown to be fundamental for the correct close apposition of cell 
membranes and overall the formation of the zipper-like structures that characterise BMECs 
and capillary beds in general. Deletion of this protein, in fact, is embryonically lethal due to 
immature vascular development and exaggerated leakage in the forming CNS (Carmeliet et 
al., 1999). In some old studies this class of proteins has been considered as less relevant for 
the regulation of the BBB permeability (Breier et al., 1996), but more recent findings have 
confirmed that a proper establishment of adherens junctions is required for the expression 
and correct placement of the major tight-junction components such as claudin-5 (Taddei et 
al., 2008) while disruption of AJs leads to barrier disruption (Wolburg and Lippoldt, 2002). 
Recently, the new concept of discontinuous adherens junctions has been coined, which 
involves the direct physical connection of VE-cadherin and other AJs components to some 
actin cytoskeleton filaments (e.g. the stress fibres) mediating the response of the 
endothelium to certain stimuli, such as pro-inflammatory cytokines (Millan et al., 2010).  
 
4.5.3.2 The tight junctions 
Tight junctions (TJs) were found in the 1960s by electron microscopy as points where the 
outer leaflets of the membranes between adjacent endothelial cells were fused in the so-
called “kissing” points (Farquhar and Palade, 1963; Brightman and Reese, 1969; Wolburg 
and Lippoldt, 2002), as illustrated in Figure 4.4, Panel B. Their composition varies greatly 
depending on the location and the role of the endothelium. As already mentioned, post-
capillary venules are characterised by not-complex and poor tight-junctions, to allow rapid 
blood-tissue exchanges in these compartments. On the other side, BMECs show the most 
complex and restrictive composition of tight junctions of the entire body, which results in 
the effective limitation in the passage of small polar solutes and even ions (Liebner et al., 
2008). This results in a high in vivo electrical resistance of around 2000 Ω·cm2 (Abbott et al., 
2010). The inter-endothelial tight junctions are formed by an array of transmembrane 
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(claudins, occludin, junctional adhesion molecules) and cytoplasmic (zonula occludens, 
cingulin) molecules ultimately linked to the actin cytoskeleton (Wolburg and Lippoldt, 2002).  
Occludin was the first transmembrane junctional molecule to be studied at the cerebral 
endothelial cell level (Mehta and Malik, 2006). With a molecular weight of 65 kDa, it is 
found at the level of every branch of the vascular bed throughout the body, but it is 
expressed at the highest levels in endothelial cells of the CNS (Furuse et al., 1993). It 
consists in four transmembrane domains and two extracellular loops, the latter being able 
to form homotypic bonds with counterparts present on adjacent cells. In the cytosol, 
occludin binds indirectly to the actin cytoskeleton through another tight junction 
component, zonula occludens-1 (ZO-1; see below), which is important to structurally 
stabilize the tight junctions. Interestingly, mice carrying a null mutation on the occludin gene 
are viable, do not show gross changes in tight junction morphology or relevant alterations in 
paracellular permeability, indicating, therefore, that this component is not essential for cell-
cell junction formation but it is more an accessory molecule that maintains and regulates 
the tight endothelium; this role is achieved by modulation of the phosphorylated and 
ubiquitinated state of the protein (Papadopoulos et al., 2004), which normally is linked to 
dissociation from the membrane, internalization and consequent increased paracellular 
permeability. Stress factors like small GTPases (see below), oxidative stress and angiogenic 
inducers (e.g. VEGF) have an effect on barrier permeability by promoting the regulatory 
modifications that show a negative effect on the protein functionality (Coisne and 
Engelhardt, 2011). 
Claudins are a family of proteins crucial for the formation of barrier properties (Wolburg 
and Lippoldt, 2002). More than 24 members are known in humans, some of which are also 
expressed in non-endothelial cells; all are formed by four transmembrane domains and two 
extracellular domains, similarly to occludin, although not showing sequence homology. In 
BMECs, only claudin-1, -3, -5 and -12 are present (although this presents some controversy 
due to cross-reactivity of antibodies and high sequence homology), with claudin-5 being 
highly endothelial cell-specific (Engelhardt and Sorokin, 2009). Claudins have been shown to 
be sufficient to form fully functional tight junctions and to be fundamental for the correct 
establishment of the BBB properties (actually, they are considered the major contributors of 
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barrier functionality); in fact, claudin 5 knock-out (KO) mice die shortly after birth due to 
excessive leakage at the BBB level (Gavard and Gutkind, 2008).  
The immunoglobulin supergene family members (JAMs; 3 members have been discovered 
so far, JAM-1, -2 and -3) are single-pass membrane proteins with a long extracellular domain 
(Nasdala et al., 2002), while endothelial cell-selective adhesion molecule (ESAM)-1 has just 
become object of study. Both classes of protein have been shown to be part of the tight 
junctions of the blood-brain barrier: their role in paracellular permeability regulation is still 
disputed but its known that JAMs, besides their roles in cell adhesion and leukocyte 
transmigration, can increase cellular resistance by forming homodimers between 
neighbouring membranes in cells that do not normally form tight junctions (Williams et al., 
1999), plus it is able to drive occludin localisation at the intercellular junctions level (Del 
Maschio et al., 1999). Finally, the Ig-superfamily member platelet endothelial cell adhesion 
molecule-1 (PECAM-1) was found to be localized at the basolateral level and to be involved 
in cell-cell junctions, including at the BBB level (Graesser et al., 2002).  
All these integral TJ membrane proteins, along with some AJs, are linked inside the cells 
through an important class of cytoplasmic peripheral membrane proteins, members of the 
membrane-associated guanylate kinases (MAGUKs), namely the zonula occludens (ZO) 
proteins, (ZO-1, ZO-2 and ZO-3), which anchor the transmembrane structure to the cellular 
actin cytoskeleton and give overall stability to the entire structure (Mehta and Malik, 2006). 
Also, some old evidence (Fanning et al., 1998) supports a potential role of ZOs in serving as 
chaperones for the correct maturation and localisation of the other TJs components.  
 
4.5.3.2.1 Tight junctions and cell polarity 
It is worth mentioning that another important role of TJs (and indirectly of AJs, for their 
influence on correct TJs formation) is to contribute to the definition of the molecular 
polarity of the cells, defining specialised luminal and abluminal membrane compartments 
(Dejana 2004). By acting as limiting factors towards the free diffusion of transmembrane 
molecules and lipid rafts on the lateral cell membranes, the TJs maintain a specific polarized 
organization in terms of transporters, channels, enzymatic proteins, etc. which determines 
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the differential functionality of different regions of the cellular membrane. The 
establishment of cell polarity also requires cell growth and motility inhibition, which are 
strongly affected by TJs and AJs, important mediators of growth factors and signals as 
vascular endothelial growth factor (VEGF) and others (Dejana 2004; Shin, Fogg et al. 2006). 
 
4.5.3.3 Endothelial cell-basal lamina interactions 
Endothelial cells express transmembrane molecules called integrins, which are heteromeric 
molecules involved in anchoring the cellular structure on the sub-endothelial basal 
lamina/extracellular matrix (Mehta and Malik, 2006). Integrins localize in specific abluminal 
cellular sites called “focal adhesions” or “focal contacts” (see Figure 4.4), which are tightly 
connected to the actin cytoskeleton and together with TJs and AJs are very important for 
paracellular permeability definition. In fact, blocking integrins and focal adhesions with 
neutralizing antibodies resulted in increased passage of molecules through the endothelium 
(Dejana et al., 1993).   
 
4.5.4 The importance of maintaining low paracellular permeability 
The contribution of the CNS barriers in controlling the exchanges from the peripheral 
compartments is essentially dual, involving both a passive role in limiting vascular leakage of 
blood-derived molecules and an active role in guiding inflammatory cell migration.  
Maintenance of extremely low paracellular permeability at the level of the BBB depends on 
several factors. Tight junction formation between endothelial cells is strongly affected by 
astrocytes and astrocyte-derived soluble factors, as demonstrated by several studies where 
in vitro BBB models have been improved by using astrocyte-conditioned medium (Abbott et 
al., 2006; Abbott et al., 2012). Also, the pericytes are increasingly considered as important 
modulators for the proper definition of low permeability coefficients; overall, all the NVU 
components may influence the homeostasis of the cell-cell endothelial junctions (Neuwelt 
et al., 2011). Generally, maintaining a healthy tight BBB is of fundamental importance for 
the homeostasis of the entire CNS. While normal passage of small and big solutes is carefully 
regulated by the BBB transporter system, in the case of paracellular permeability this tight 
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control can be partially or totally lost: blood-derived ions, proteins, nutrients, circulating 
signalling molecules and even cells can more easily access the brain in high concentrations 
through newly-formed gaps, immediately starting to cause damage (Abbott et al., 2006; 
Abbott et al., 2010; Simpson et al., 2010).  
 
 
 
Figure 4.4 Cell-cell junction composition. A| At tight junctions level, cell adhesion is maintained by 
claudins, occludin, JAMs and ESAM-1. B| Transmission-electron microscopy image of “kiss” cell-cell 
fusion between adjacent cells. C| Freeze-fracture electron microscopy, showing the continuous and 
complex morphology of the tight junctions at the level of BMECs. Figure A adapted from Abbott et 
al., 2010. Electron microscopy images taken from Stevenson and Keon, 1998 & Tsukita et al., 2001.  
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It is now clear that many permeability-increasing agents have an action on the paracellular 
permeability. Most of these factors, like platelet-activating factor (PAF), VEGF, histamine, 
inflammatory cytokines, cytochalasin B and D, etc. trigger a series of molecular events that 
are reflected in changes in cell shape, like cell-rounding, therefore on the cellular 
cytoskeleton, which result in gap formation between endothelial cells due to loss of the 
highly organized inter-cellular junctions. To understand this, we should analyse the 
importance of the cytoskeleton, and its strong relationship with all the molecular 
components of the physical barrier.  
 
4.5.4.1  The actin cytoskeleton in the endothelium 
The cytoskeleton is the cellular skeleton, contributing to an enormous array of events like 
cell locomotion, definition of cellular shape and polarity, emission of cell protrusions 
(philopodia, lamellipodia, etc.), intracellular trafficking, structural cell support, cell-cell 
contact definition, basal lamina anchorage and focal adhesion formation (Hall, 1998; Lai et 
al., 2005; Prasain and Stevens, 2009). All these functions are the net result of centrifugal and 
centripetal tensions generated by the various cytoskeletal components (Mehta and Malik, 
2006). This shows how important is the cytoskeleton in defining properties of the various 
cell types, constituting the base for others to form, such as endothelial cell junctions. 
 
4.5.4.1.1 Generalities 
The cytoskeleton is essentially formed by microfilaments, microtubules and intermediate 
filaments. Microtubules represent thick (diameter around 23 nm) polymers of α- and β-
tubulin, that could be coarsely defined as supportive beams of the cells due to their 
property of resisting compression; they do not appear to be directly involved in the 
regulation of paracellular permeability (Mehta and Malik, 2006) but their disruption has 
been shown to impair endothelial barrier (Prasain and Stevens, 2009). Intermediate 
filaments and microfilaments are instead the “cables” of the structure, being thinner 
(diameter between 6 and 10 nm) and involved in generating tension. Intermediate filaments 
are relatively stable structures that primarily maintain cell shape and structure; they are 
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formed by several molecules such vimentins, lamin, keratin, and others depending on the 
location. Microfilaments are thin, long filaments formed by polymerized monomers of actin, 
which is one of the most highly conserved and abundant proteins in eukaryotes (Firat-
Karalar and Welch, 2011). Several studies have confirmed the primary role played by these 
three cytoskeletal components, in constant and intimate communication with each other to 
maintain numerous cell functions (Prasain and Stevens, 2009). In particular, actin 
microfilaments appear to be the most dynamic structures, therefore most studies have 
focused their attention on these.   
 
4.5.4.1.1.1 Actin organisation 
The polymerisation of actin is a phenomenon involved in almost every aspect of cell 
physiology, including membrane structure and function maintenance, cytokinesis, 
migration, endocytosis, exocytosis. 
Actin is a globular ATP-binding protein normally present in two conformations: globular (G-) 
actin, which indicates monomers of the molecule, and fibrillar (F-) actin, which indicates 
polarized filaments of many actin molecules upon ATP binding. At the level of the 
endothelium, actin constitutes around the 10% of the entire protein content (Prasain and 
Stevens, 2009); therefore, the actin cytoskeleton is by far the most important modulator, 
representing a quickly responding structure.  
The dynamics of the entire actin cytoskeleton are reflected in the transition between G- and 
F-actin, a phenomenon directly linked to ATP binding and hydrolysis (Prasain and Stevens, 
2009; Lee and Dominguez, 2010). Through two complex processes called nucleation and 
elongation, F-actin quickly forms and grows unidirectionally (the so called “actin 
treadmilling”, depicted in Figure 4.5, Panel D). The balance between polymerisation and 
depolymerisation is defined by several modulators, whose mechanisms started to be 
elucidated only recently.  
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These are mainly involved in providing or sequestering G-actin monomers from the growing 
filaments (actin-binding proteins (ABP) such as cofilin and profilin), or in forming the pro-
nucleation complexes that direct formation of a stable multimer of G-actin monomer, 
chemically unstable, thus representing the true rate-limiting step in F-actin formation. A 
more detailed molecular explanation of the polymerisation of actin can be found in some 
recent reviews (Prasain and Stevens, 2009; Lee and Dominguez, 2010).  
 
4.5.4.1.1.1.1 Annexin A1 and actin 
Several reports support the role of ANXA1 as an actin-binding protein, or at least as an inner 
regulator of the actin cytoskeleton. Due to their calcium-binding nature, annexins are 
regarded as important factors mediating responses to changes in this ion levels, for example 
membrane structure and function regulation (Gerke et al., 2005). They have been observed 
to interact with G- and F-actin in cell-free in vitro models, while this has been difficult to 
prove in vivo and in cell models. In particular, Annexin A2 was the first one shown to bind 
actin filaments in a Ca2+-dependent manner (Hayes et al., 2004). Annexin A1 was also shown 
to co-localise with F-actin during phagosome formation (Patel et al., 2011) and to directly 
impact on actin polymerisation by interacting with profilin, which is an important actin-
binding protein able to catalyse ADP-ATP conversion of actin and to stimulate F-actin 
formation (Alvarez-Martinez et al., 1996; Alvarez-Martinez et al., 1997). Some evidence also 
supports the participation of ANXA1 and ANXA2 in complexes which are involved in the 
actin cytoskeleton formation, like Arp2/3 complex (Ghitescu et al., 2001; Hayes et al., 2004; 
Prasain and Stevens, 2009). 
Actin and annexins show concomitant re-distribution in response to certain stimuli, which 
may suggest close parallelisms between these molecules. Notably, all these findings have 
been only demonstrated in vitro; they suggest the relevance of this class of proteins in actin 
physiology and dynamics, but they should be confirmed in cell models and in vivo before 
definite conclusions can be drafted.  
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4.5.4.1.1.2 Cytoskeletal structures 
In general, F-actin organizes mainly into three distinct cytoskeletal structures (Prasain and 
Stevens, 2009). The first is the membrane skeleton, which is formed by short F-actin 
filaments (yellow structures, Figure 4.5, Panel A) that are distributed right underneath the 
cell membrane, where it acts as a scaffolding structure for the membrane itself, affecting its 
ability to distend, affecting the overall cell shape.  
 
 
Figure 4.5 Actin cytoskeleton structures and F-actin formation. A| The membrane skeleton 
determines membrane architecture and enables for membrane distensibility. It is formed by short F-
actin filaments (yellow structures), interconnected by spectrin molecules (brown structures). B| The 
cortical actin rim is intimately associated with cell-cell and cell-matrix adhesion complexes. C| Stress 
fibres run through the cytosol and interact with focal adhesion complexes. D| Structural differences 
between ATP-bound and ADP-bound actin monomers and schematic definition of the actin thread-
milling model determining F-actin unilateral formation. Panels A, B and C have been modified from 
Prasain and Stevens, 2009, while panel D was taken from Lee and Dominguez, 2010.  
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The second one is the cortical actin rim (Figure 4.5, Panel B), which is a fundamental 
structure, running along the cell membrane and lying underneath the membrane skeleton 
with which it is intimately interacting. The cortical actin is formed by a dense tangle of long 
F-actin fibres, linked to the endothelial junctional components as ZO-1, α- and β-catenin, 
and a large plethora of accessory proteins, which have the role to maintain the correct 
location and actin state of this structural formation, limiting the generation of excessive F-
actin, which would result in the stress fibres. The latter is the third actin formation present 
in cells (Figure 4.5, Panel C): stress fibres are bundles running throughout the cytosol, which 
are able to generate intense contraction within the cell body. They are formed by short 
polymerised actin fibres, myosin filaments, some actin-binding proteins and are anchored to 
the membrane; specific contractile molecules (myosin motor proteins) run along the F-actin 
fibres generating centripetal (inward) tension, which counteracts the centrifugal (outward) 
tension established by the cortical actin rim. Stress fibres are also very important for focal 
adhesion formation, since they directly interact with the cytoplasmic tail of the integrins. 
 
4.5.4.1.2 Modulation of actin polymerisation and effect on intercellular 
junctions 
Early studies by Madara et al. (Madara et al., 1986; Madara et al., 1987), although not in the 
brain vascular endothelium, produced the first evidence for an association of tight junctions 
with actin cytoskeleton; moreover, they observed a strong correlation between the 
perturbation of intercellular junctions, structural disorganisation of the cytoskeleton and 
concurrent alteration of the barrier function. 
A precise mechanism by which actin exerts its influence on TJs is currently not clear (Lai et 
al., 2005): structurally, the cortical actin rim is essential to anchor all the intercellular 
junctions and to sustain the molecular connection with adjacent cells, therefore, it is clear 
that stress fibres show a negative effect on the formation and on the maintenance of the 
cellular junctions, since they generate forces that are opposite to the one contributing to 
junctional complexes maintenance. However, the precise relationship between these 
opposing forces is not completely understood yet and new mechanisms have also been 
proposed, linking actin remodelling to secondary messengers like Ca2+, which can mediate 
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the activity of certain enzymes that have been shown to modify and negatively modulate 
the expression and the distribution of TJs and AJs. Nevertheless, it is clear that one of the 
primary roles of the contractile apparatus is to regulate endothelial barrier properties: while 
stress fibres constitute a negative factor towards paracellular permeability, the thickening of 
the cortical actin rim coincided with reduction of the permeability (Crawford et al., 1996), 
therefore the whole process should be tightly controlled. The cytoskeleton can be 
modulated by an enormous variety of intracellular mechanisms, which all converge on 
affecting the degree of actin polymerisation, the F-actin intracellular localisation and the 
contractility that is subsequently generated (Mehta and Malik, 2006). Among these 
mechanisms we should mention the serine-threonine phosphatases (regulation of the 
activity state of some contractile molecules), the Ca2+ channels (a molecular cascade can be 
triggered by high concentrations of the cation, with consequent effects at the level of the 
contractile apparatus), the actin-binding proteins and their action towards F-actin 
formation, the adenylyl cyclases and the small guanosine triphosphate (GTP) binding 
proteins (Prasain and Stevens, 2009). This last class of modulators is definitely the most 
important, responsive and tightly controlled system existing to control actin cytoskeleton 
dynamics, therefore it deserves a detailed description.  
 
4.5.4.1.2.1 The role of small GTP binding proteins 
The Rho family of monomeric small GTPases has been shown to play an important role in 
the regulation and modulation of the endothelial barrier function by directly affecting the 
actin cytoskeleton. Being GTPases, they cycle between an active, GTP-bound state and an 
inactive, GDP-bound state (Beckers et al., 2010). Guanine nucleotide exchange factors 
(GEFs) catalyse the exchange of GDP for GTP, therefore mediating the activation of the 
molecule; GTPase-activating proteins (GAP) instead catalyse the inactivation of the enzymes 
by promoting the hydrolysis of GTP. The first member of the family was identified in 1985 
(Wojciak-Stothard and Ridley, 2003) and was RhoA; so far, 21 members have been 
identified, with Rho (A, B, C, D, G), Rac (1, 2, 3), Cdc42 (Hs/G25K, TC10, Tc1) being the most 
prominent sub-classes. In particular, RhoA, Rac1 and Cdc42 are the best characterized ones.  
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RhoA has been reported to stimulate formation of stress fibres and focal adhesions; 
therefore it has always been regarded as effector acting against endothelial tightness and 
towards increase of permeability. Through its downstream mediator, Rho-associated 
protein kinase (ROCK), active RhoA inhibit, by phosphorylation, the activity of the myosin 
light chain phosphatase (MLCP). Such event causes a net increase in myosin light chain 
(MLC) phosphorylated form, which is the one that interacts with actin and slide along actin 
filaments causing contraction (Wojciak-Stothard and Ridley, 2003; Mehta and Malik, 2006; 
Beckers et al., 2010). Active RhoA induces actin polymerization and stress fibre formation by 
inhibiting (through phosphorylation) the actin-binding protein cofilin, which has a role in 
depolymerising F-actin and moving the balance towards G-actin (Maciver and Hussey, 
2002). Several vasoactive mediators like thrombin, LPS, lysophosphatidic acid (LPA), 
histamine and VEGF induce quick activation of RhoA, subsequently resulting in the 
generation of cytoskeletal tension and hyper-permeability. Since attachment and 
extravasation of leukocytes through endothelium have been shown to cause stress fibre 
formation and endothelial contractility, there is evidence that this is at least partially RhoA-
mediated, which can be activated by signals triggered from adhesion molecules as VCAM-1 
and E-selectin (Wojciak-Stothard et al., 1999). In addition, RhoA is also able to negatively 
influence permeability through an actin-independent mechanism:  being a protein kinase, it 
has the ability to phosphorylate occludin and claudins, reducing their membrane association 
and overall the strength of cell-cell junctions (Persidsky et al., 2006). Therefore, RhoA is 
usually regarded as a tightness-disruptive molecule and not as a mediator involved in 
junctional maintenance (Beckers et al., 2010).  In fact, it has been observed that in resting 
conditions RhoA is usually inactivated by other small GTPases. However, one recent work 
(van Nieuw Amerongen et al., 2007) reported complete opposite results, indicating that 
basal RhoA activity in resting conditions was fundamental to generate a higher affinity 
between cortical actin and junction proteins (VE-cadherin), adding more complexity to the 
topic (Wojciak-Stothard et al., 2001).  
Stress fibre formation and actin polymerisation are not always followed by an increase in 
paracellular permeability. As explained in section 4.5.4.1.1.2, the cortical actin rim is a 
fundamental scaffolding structure to support and mechanically sustain the cell-cell 
junctions, therefore its potentiation brings definitely an improvement in terms of tightness 
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(Crawford et al., 1996). Rac1 appears to be the Rho family member in charge of enhancing 
the endothelial barrier function: in the absence of vasoactive stimuli, this molecule tends to 
show always a basal level of activity, reinforcing its importance in maintaining cell-cell 
junctions. On the other hand, Rac1 is down-regulated upon stimulation with permeability-
enhancing factors, like thrombin (Wojciak-Stothard et al., 2001), indicating its opposing 
effects to RhoA. Noteworthy, Rac1 may also show barrier disturbing functions, in particular 
under oxidative stress conditions (Beckers et al., 2010). Cdc42 plays a more limited role in 
the maintenance of basal paracellular permeability and tightness properties, while being 
more active during cell mobility and migration [generation of filopodia (Ridley, 1999)], which 
governs angiogenesis events.  
 
Figure 4.6 Overall view of the signalling mechanisms regulating endothelial permeability. This 
image describes the main signalling pathways triggered by RhoA and Rac1. Please note that some 
pathways have not been depicted for space constraints reasons. RhoA tends to cause a phenotype 
towards increase of barrier permeability; Rac1 instead shows an overall influence towards the 
reinforcement of the barrier properties. Exceptions to these concepts exist; please refer to the text 
for further details. Image taken and modified from Wojciak-Stothard et al., 2001.   
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However, it is induced in a delayed fashion upon stimulation with certain vasoactive 
stimulants like thrombin, possibly paralleling the endothelial barrier recovering after the 
initial, prompt RhoA-mediated effects (Wojciak-Stothard and Ridley, 2003; Mehta and 
Malik, 2006; Beckers et al., 2010) and it may represent a negative-feedback mechanism 
towards AJs-reassembly after an insult, therefore rescuing the permeability. Overall, the 
main members of the Rho GTPases family are deeply involved in the regulation of the actin 
cytoskeleton and consequently into the modulation of cell-cell junctions: very complex 
signalling pathways can be triggered both in basal/resting conditions and upon stimulation 
by a vast plethora of vasoactive agents, as illustrated in Figure 4.6.  
 
4.5.5 Modelling the blood brain barrier 
Increased interest in deciphering the physiological and pathological mechanisms of the BBB 
has led to the development of numerous ways of investigation (Chen et al., 2003; Wee 
Yong, 2010). In the clinic, brain imaging (e.g. MRI), biomarker identification and histology 
are the current techniques of choice to detect alterations and BBB-related damage; for in 
vivo animal models, intravital microscopy represents the technique of choice to study 
leukocyte-endothelium interactions, but it can only reach superficial blood vessels, which 
tend to lack a fully developed BBB phenotype. Moreover, these techniques do not reach a 
degree of detail sufficient to describe the various cellular and molecular mechanisms. These 
and other limitations have pushed the development of numerous in vitro models, each 
characterised by its own advantages and disadvantages. Modelling such a complex structure 
ex-situ has proved to be a difficult task, in particular reproducing the characteristic low 
paracellular permeability, the complex transport system and the peculiar apical-basolateral 
polarisation. Since most of these properties are centred on the BBB endothelium, the 
greatest interest has been focused on that. Initially, epithelial cells with similar features to 
brain endothelial cells (i.e. Madin-Darby canine kidney cells; MDCK) were used as BBB 
model, as well as human umbilical endothelial cells (HUVECs), which bore the advantage of 
being human. An ambiguous model used for several years has been the ECV304, initially 
claimed to derive from transformed endothelial cells but recently found to be closer to 
epithelial than endothelial cells (Cabrita et al., 2006).  
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Although it may be possible that certain cellular mechanisms can overlap between 
endothelial and epithelial cells, scientists are in the process of abandoning them for more 
reliable models. The establishment of successful and reproducible protocols for brain 
capillary isolation (Hatherell et al., 2011), along with the ability of selectively culturing the 
endothelial cells without causing loss of the cellular phenotype, represented an essential 
step forward in modelling the BBB in a more reliable fashion. The most widely used primary 
cultures have always been those from rodent, due to the high availability of transgenic 
animals and pathological models, as well as reagents necessary for the studies, like 
antibodies and expression vectors. The small size limits the yield, plus some properties 
typical of higher mammalians cannot be reproduced faithfully; therefore, some efforts has 
been dedicated at optimising brain capillary extraction from bovine and porcine specimens 
sometimes with optimal results (Patabendige et al., 2012), as well as from human surgical 
material, which cannot be considered healthy and physiological though. The establishment 
and optimisation of static endothelial cell monocultures on transwell filter devices allowed 
to mimic more closely the bipartite in vivo environment and to induce the peculiar 
membrane polarisation (Grant et al., 1998). 
The necessity to develop high throughput assays to test drugs and specific conditions does 
not find in primary cultures a sufficient means to meet the high requirements of cells, 
leading to the development of immortalized cell lines, easy to culture and possibly able to 
retain their differentiating properties even after repetitive passages, reducing labour and 
costs usually linked with primary isolation. One of the best characterised brain endothelial 
cell lines is RBE4, obtained from rat brain microvascular endothelial cells (Lippmann et al., 
2012) as well as GP8, also of rat origin (Galati and Di Giovanni, 2010). Amongst the most 
widely used, the murine cell lines bEND.3 (Cavegn and d'Ydewalle, 1996) and bEND.5 
(Hamberger et al., 2009) represent a good means to study molecular signalling pathways 
and permeability regulation. Some bovine immortalized cell lines also exist, although much 
less characterised and used.  
One of the main limitations of primary cultures and cell lines of non-human origin has 
always been the inability to reproduce the same degree of expression and complexity of the 
human BBB and BMECs. Therefore, in the last decade most of the efforts has been thrown 
Chapter 4 – Annexin A1 physiological role at BBB level 
 
Page | 90   Enrico Cristante – PhD degree thesis    
 
into the development of cell lines of human origin. To date, the best characterised human 
cell line is the hCMEC/D3, which was obtained from a surgical excision from the temporal 
lobe of an adult female with epilepsy (Weksler et al., 2005). This cell line has now been used 
in more than 60 publications, especially for drug transport/efflux studies and to investigate 
permeability regulation. Recently, a new conditionally immortalized human microvascular 
endothelial cell line called TY08 was established (Sano et al., 2010), but it did not reach 
equal levels of reliability compared to hCMEC/D3. Currently, smart approaches are being 
developed to develop new BMEC lines from pluripotent stem cells (Lippmann et al., 2012), 
with promising results. 
All these monoculture models of endothelial cells represent easy and reproducible ways to 
study a number of aspects in the BMECs physiology, but they lack a number of critical 
features necessary for the correct full development of true BBB properties; absence of 
typical stimuli from the surrounding environment can also cause de-differentiation of the 
endothelial cells and loss of BBB-specific features. Nowadays, technical efforts are focused 
on co-cultures models with astrocytes and/or pericytes, which are fundamental to induce 
and maintain a properly formed BBB in vivo (Abbott et al., 2006; Armulik et al., 2010; 
Daneman et al., 2010). Considerably higher TEER and lower paracellular permeability values 
have been obtained with several co-cultures models (Descamps et al., 2003; Coisne et al., 
2005; Abbott et al., 2012), both growing endothelial cells in contact or not with the 
accessory cells, as well as by using conditioned medium. Triple co-culture models including 
endothelial cells, astrocytes and pericytes are currently being investigated (Hatherell et al., 
2011), while interest has been generated by the BBB phenotype-inductive role of neurons in 
cultured BMECs, as well as from the role of microglia cells and macrophage-related cells 
(Garden & Moller, 2006; Banerjee & Bhat, 2007). Finally, the role of shear-stress in inducing 
BBB-specific phenotype has received increasing evidence and has led to the development of 
dynamic in vitro flow models mimicking physiological conditions of brain capillaries (Cucullo 
et al., 2011; Naik & Cucullo, 2012). Shear-stress was able to improve the TEER values 
(Wilhelm et al., 2011) and to induce a resting a-mitotic phenotype more resembling the 
conditions found in vivo. Further investigation on this field is currently undertaken and will 
hopefully generate more information. 
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Some acellular and in silico models, aimed to study drug membrane penetration and CNS 
distribution, have been recently developed and have started to be used by pharmaceutical 
companies, although their applicability and reliability still have to be proved and  improved 
(Naik & Cucullo, 2012). Overall, the constant need to pre-screen and validate novel CNS 
therapeutics, as well as certain pathological toxins and disease conditions, is pushing to 
develop continuously new in vitro models, possibly able to reproduce a reliable BBB. The 
large number of different in vitro models suggests the absence of the perfect model and 
rather the necessity to find and use those more advantageous for the studied question, 
complementing them with the still informative in vivo and human studies.  
 
4.5.6 The blood brain barrier as a therapeutic target 
Since BBB damage appears to be present in several neurological disorders, it is not 
surprising to see many efforts thrown towards the development of potential therapies for 
these diseases that target the impairment of the barrier. Since BBB dysfunction can either 
be a causative phenomenon or a propagative/exacerbating event in the course of the 
disease, limiting its impairment would potentially reduce the severity of the pathology and 
facilitate recovery (Abbott et al., 2006; Vastag, 2010). As inflammation and inflammatory 
mediators are the primary cause for the negative effects at the barrier level, most of the 
attempts have been focused on halting the inflammatory reaction: glucocorticoids like 
dexamethasone have shown to improve (Romero et al., 2003; Cucullo et al., 2004; Bauer et 
al., 2005) the physical and transport barrier properties of the blood brain barrier, but their 
usefulness in MS patients decrease with time (Plumb et al., 2002).  
Therefore, other approaches are currently being tested, which mainly target either the 
strength of the intercellular junctions or the expression of adhesion molecules on the 
endothelial cells. For example,  the potential use of flavonoids has generate interest; 
normally used with success as a treatment of some venous insufficiency pathologies, these 
molecules have given promising results in the EAE model of MS (Simka, 2009).  
Equal interest has generated the possibility to deliberately increase basal permeability to 
improve administration of therapeutic molecules into the brain. This is a topic still at its 
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infancy and brings a lot of complications: in fact, the therapeutic opening needs to be tightly 
controlled and as brief as possible, to limit the impact of oedema and extravasation of 
peripheral molecules into the tissue. Some novel studies, mainly targeting tight junction 
expression, have started to provide some promising results (Farkas et al., 2005; Campbell et 
al., 2011). Noteworthy is the “Trojan horse-like approach” which has been developed by 
William Pardridge to deliver therapeutic molecules into the brain by coupling them to 
molecular portions that allow to cross the barrier by exploiting a natural occurring 
transcytosis mechanism (Vastag, 2010). 
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4.6 Methods 
Please refer to Chapter 3 (General methods) for general in vivo and in vitro procedures. Here 
I will provide more details about certain technical aspects and describe those procedures 
specifically used for the purpose of only this chapter. Please refer to the Appendix (Chapter 
10) for solutions composition. 
 
4.6.1 Magnetic resonance imaging (MRI) 
MR imaging of anaesthetised wild-type and Anxa1 null mice was performed using a 9.4T 
Varian Direct Drive system and quadrature volume head RF coil. The MRI protocol consisted 
of dynamic contrast acquisitions with a multi-slice T1 weighted gradient echo with a fixed 
30° flip angle (repetition time 132ms,  echo time 2.77ms,  field of view 20x20mm, matrix 
size 128x96, 24 contiguous transverse slices of 0.6mm covering the whole brain). A total of 
50 volumes were acquired, with 100µl 0.5mM dimeglumine gadopentetate (Magnevist, 
Schering Health Care Ltd, UK) administered intravenously after the 14th volume at a rate of 
3.3µl/s (average of 0.02 mmol/kg of body weight, resulting in a total dose of 0.5 mmol per 
animal). TOPPCAT software (Barboriak et al., 2004; Barboriak et al., 2008) was used to create 
quantitative maps of fractional volume. Kind help and support for the technical procedure 
and data interpretation was provided by Dr. J. Lopez-Tremoleda and Dr. M. Wylezinska-
Arridge (Biological Imaging Centre (BIC); Imperial College London, UK).  
 
4.6.2 Brain water content determination by wet-to-dry weight ratio 
The procedure followed published methods (Xiao et al., 2004; Yan et al., 2011). Animals 
were deeply anesthetised by i.p. injection of 100 μl sodium pentobarbitone (60 mg/ml). 
Once fully anesthetised, the heart was revealed by cutting through both sides of the rib cage 
and the diaphragm. Blood samples were collected by cardiac puncture of the right ventricle 
while the right atrium was cut to allow release of blood. Blood was washed out of the body 
by perfusion through the left ventricle with approximately 15 ml of filtered saline solution. 
Brains were rapidly removed, placed on microscope glass slides, weighed (WW, wet weight) 
and then placed in a laboratory oven (set at 100°C) for 24 h.  
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Samples were weighted again (DW, dry weight) and results were expressed as percentage of 
water content towards total wet weight, according to the following equation: 
WW-DW × 100
WW
 
 
4.6.3 Electron microscopy 
Processing and analysis of transmission electron microscopy (TEM) images were performed 
by Dr. Helen Christian (Oxford University, UK). Cells monolayers were grown in transwell 
inserts at the described conditions. Preparation occurred as described (McArthur et al., 
2009). Briefly, cells were fixed in 0.05% (w/v) glutaraldehyde in PBS 0.01M pH 7.4 for 20 
minutes at 4°C, washed briefly in PBS 0.01M, and transferred to a solution of 2.3 M sucrose 
in PBS at 4°C overnight.  
Cryoprotected cells were snap-frozen, freeze-substituted at −80°C in methanol for 48 h, and 
embedded at −20°C in LRGold acrylic resin (London Resin, Reading, UK) in a Reichert freeze-
substitution system (Reichert MM80E; Leica, UK). Ultrathin sections (50–80 nm) were 
stained for ANXA1 by immunogold labeling using a rabbit polyclonal anti-ANXA1 (Invitrogen, 
UK) for 2 hours at RT followed by 1 hour incubation with anti-rabbit IgG linked to 15 nm gold 
particles (British Biocell, Cardiff, UK). Sections were then mounted and examined 
morphologically with a JEOL 1010 transmission electron microscope (JEOL, Peabody, MA).  
 
4.6.4 hCMEC/D3 cell culture and stable transfection 
Human cell line hCMEC/D3 was maintained as described in Section 3.2.2.1.2. Transfection 
was performed as described in Section 3.2.2.1.5, using plasmids produced by Dr. Solito 
(Solito et al., 1998b) bearing either an antisense sequence directed against messenger RNA 
products of the ANXA1 gene or the full length coding sequence (coding DNA) of ANXA1 
itself, or an empty plasmid as control for transfection effects (pRc/CMV; Invitrogen, UK). 
Both plasmids contain the gene for the antibiotic Geneticin® resistance, which allowed 
selection of cells that stably incorporated the plasmid into their genome (initial 7 days: 400 
µg/ml; subsequently 200 µg/ml). Resistant clones were cultured until they achieved a good 
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size; then passaged by using replica disks into 24-well plates and expanded into more 
capacious culturing devices. When enough cells were obtained, they were grown until 
confluent and immunophenotyped for ANXA1 and for the major tight- and adherens-
junction components expression by flow-cytometry. For certain studies, only the best stable 
clones were used, which were “pRc/CMV-empty 3” (E3), “Antisense 4” (AS4) and “Full-
length 11” (FL11).  
 
4.6.5 Lentiviral vector production 
In order to achieve a more definite regulation of ANXA1 on hCMEC/D3 cell line, replication-
deficient lentiviral particles bearing either full length cDNA of ANXA1 or specific silencing 
sequences were produced, since this approach allowed for quicker, more efficient and more 
stable integration as reported (Vigna and Naldini, 2000).  
Production of lentiviral particles for stable expression of transgenes was conducted in 
collaboration with Dr. E. Pazarentzos (Imperial College London, UK), whose help and advice 
are fully acknowledged. For details on the production, refer to Appendix, section 10.4.  
 
4.6.5.1 Infection and selection of infected cells 
hCMEC/D3 cells were seeded on 12-well plates at low density. When 30-50% confluent, cells 
were transduced with 500 µl of virulent medium supplemented with 1 µg/ml of Polybrene® 
(Sigma-Aldrich, UK) for 6 hours. Fresh EGM-2 MV medium was added to the infection, 
diluting the existing infectious medium at least 3 fold. The next day, medium was changed 
to fresh one and cells were left to recover for 8 hours. Medium was again replaced with 
fresh EGM-2 MV supplemented with puromycin (16 µg/ml for pLKO.5-based viral infections; 
5 µg/ml for modified pLenti7.3-based viral infections) and selection occurred for 3-4 days 
before switching the medium to a reduced selection (5 µg/ml and 2 µg/ml respectively).  
Resistant cells were cultured until confluent and a fraction of them was assessed for 
expression of the transgene or shRNA-dependent down-regulation of the gene of interest by 
flow cytometry or western blotting. 
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4.6.6 Co-immunoprecipitation of proteins 
hCMEC/D3 cells were seeded and grown on 10-cm plates until confluent and left 24 hours in 
medium without VEGF to improve the formation of a full and tight monolayer. Cells were 
scraped and lysed in 1 ml/plate of RIPA buffer. More than 250 µg of total protein were 
resuspended in 1 ml of RIPA buffer and pre-cleared (removing any unspecific binding 
occuring between proteins and mouse or rabbit IgG) using 5 µl of naive mouse or rabbit 
serum (according to the source of the antibody used for the immunoprecipitation) and 30 µl 
of protein G sepharose-coated beads (Sigma, UK; in resuspension buffer) under rotation for 
1 hour, at 4°C. Samples were centrifuged at 13000 RPM for 1 minute and supernatant 
retained; this was incubated overnight at 4°C with the immunoprecipitation-specific dose of 
the antibody raised against the desired protein to pull-down. Specifically, 2 µg of an anti-
ANXA1 antibody raised in rabbit [called “Hortense”, home-raised by Dr. Solito (Solito et al., 
1998a)], 3 µg of monoclonal anti-β actin and 3 µg of the anti-tight and adherens-junctional 
proteins antibodies were incubated with 250 µg of total proteins. Negative controls were 
also included, consisting in incubating the total protein lysate with mouse or rabbit control 
IgG isotype. 80 µl of protein G sepharose-coated beads were added and rotated at 4°C for 4 
hours.  
Samples were centrifuged at 13000 RPM for 1 minute and supernatant was discarded. Pellet 
(i.e. beads and pulled-down proteins and complexes) was washed three times in low buffer 
and then twice in high buffer to remove any unspecific or weak interactions. Beads were 
then resuspended in 40 µl Tris.HCl, pH 7.4 with protease inhibitors. Reducing sample buffer 
was added, samples were boiled for 5 minutes at 95°C to denature proteins, separate them 
from each other and from the beads. After a final centrifugation the supernatant was 
separated by SDS-PAGE using 10% gels and immunoblotted using antibodies directed 
towards the molecule which had been pulled down and potential interacting targets. 
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4.6.7 Small GTPases pull-down assay 
hCMEC/D3 cells were grown on 6-cm Petri dishes until confluence and then incubated 
overnight in complete EGM-2 MV medium without VEGF before exposure to recombinant 
human ANXA1 (in-house stock (Lim et al., 1998) used at 20 µg/ml final concentration for 3 
hours) or thrombin (from Sigma, UK; used at 1 IU/ml final concentration for 8 minutes as a 
positive up-regulator of RhoA activity). Cells were then lysed and scraped off the plates in 
Cell Biolabs specific lysis buffer (5X lysis buffer, Cell Biolabs Inc, USA). The GTP-bound active 
form of RhoA was isolated as previously reported (Wojciak-Stothard et al., 2001): the whole 
lysate was incubated with 200 µl of GST-tagged recombinant Rhotekin bound to glutathione 
beads (a kind gift from Dr. B. Wojciak-Stothard), while the activity of Rac1 was measured by 
isolating the GTP-bound active form through GST-tagged p21-activated kinase binding 
domain (PAK1-PBD) bound to glutathione beads (Cell Biolabs Inc, USA). A control plate was 
also grown and lysate prepared as described above and loaded with guanosine-5’-O-γ-thio-
triphosphate (GTPγS) or GDP respectively to have a positive or negative internal control, as 
suggested (Cell Biolabs Inc, USA).  
Lysates and beads mixtures were rotated for 1 hour at 4°C and washed three times in lysis 
buffer. Affinity-precipitated active forms of RhoA and Rac1 proteins were resolved by SDS-
PAGE and detected by Western blotting. 10 µg of the total lysate were run in parallel to 
measure the total quantity of the small GTP-ases of interest along with loading control 
(GAPDH).  
 
4.6.8 Soluble and insoluble β-actin extraction 
Soluble vs. Insoluble β-actin extraction was conducted as described (Cramer et al., 2002) 
with slight modifications. Latrunculin treatment, a potent cytoskeletal actin depolimerizing 
agent (20 µM final concentration; Cayman Chemical, US) for 10-30 minutes was included as 
a positive control. hCMEC/D3 cells were seeded on 10-cm dishes and grown until confluent 
in complete EGM-2 MV medium. Medium was then changed to EGM-2 MV without VEGF for 
24 hours. Globular monomeric actin (G-actin) was extracted by washing cells briefly with 
DPBS without Ca2+/Mg2+ followed by 5 minutes incubation at RT with 1 ml of soluble actin 
extraction buffer, which contained 1 µg/ml unlabelled phalloidin (Sigma, UK) to stabilize the 
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cytoskeletal actin. The volume was removed and centrifuged at 1000xg for 5 minutes at 4°C 
to remove any detached cell; the supernatant was saved and stored at -80°C. Cells were 
washed quickly three times with DPBS without Ca2+/Mg2+; after that, fibrillar polymeric 
cytoskeletal actin (F-actin) was extracted by incubating with 1 ml of insoluble actin 
extraction buffer and by  scraping cells off the plate through a sterile tissue culture scraper. 
The lysate was sonicated for 10 seconds (30% duty cycle, output control 2; Ultrasonic 
processor, Jencons) and centrifuged at maximum speed at 4°C for 10 minutes. Supernatant 
was saved for further analysis. In parallel, total β-actin samples were prepared by growing 
and treating cells in the same way and by extracting the whole protein content by using 1 ml 
RIPA buffer, scraping off cells from the dish and briefly sonicating the lysate to ease the 
viscosity. Samples were quantified for their protein content and the following quantities 
were loaded and resolved on a SDS-PAGE: 3 µg for the total extraction, 6 µg for the soluble 
extraction, 2 µg for the insoluble extraction. These quantities were optimised so that the 
intensity of the bands obtained on the blots were not saturated, therefore allowing for 
detection of changes between treatments.  
 
4.6.9 Proximity ligation assay 
In order to detect points of interaction between ANXA1 and β-actin within hCMEC/D3 
monolayers, a proximity ligation assay (PLA; Duolink, Olink Bioscience) was used, able to 
detect points of close (40 nm) vicinity. The principle of this relatively new technology is 
based on two unique probes (provided with the commercial kit), which consist of a 
secondary antibody attached to a unique synthetic oligonucleotide. The proximity of the 
probes allows DNA ligation at the exact location where these probes are localised. The 
distance of the oligonucleotides permitting DNA hybridization and ligation is small (<40nm) 
so only proteins that interact can allow ligation. The ligated DNA can then be amplified by 
DNA polymerase and detected through labelled oligonucleotides complementary to the 
amplified sequence. This technique provides very high sensitivity as the ligated DNA is 
amplified several fold, resulting in enhancement of the initial ligation event.  
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As the spots can be counted, the PLA signal provides not only the exact spatial information 
(the location of the interaction events) but also an objective way of quantifying these 
events.  
Optimised protocols and technical support were kindly provided by Dr. E. Thymiakou and 
Prof. V. Episkopou (Imperial College London, UK) (Thymiakou and Episkopou, 2011), while 
procedure was performed together with Dr. S. McArthur. Briefly, wild-type hCMEC/D3 were 
grown on transwell filters until confluent as described; after fixation in 2% (w/v) PFA for 10 
minutes at RT and subsequent washes in DPBS with Ca2+/Mg2+, monolayers were 
permeabilized in 0.5% Triton X-100 in DPBS with Ca2+/Mg2+ for 5 minutes at RT and blocked 
for 1 hour at 37⁰C using Duolink II Blocking Solution (1X). Primary antibodies anti-ANXA1 and 
anti-β-actin were then diluted to the desired concentration (see Appendix; Section 10.2) in 
Duolink II Antibody Diluent (1X) and incubated for 1 hour at RT, under slow agitation. 
Meanwhile, the two PLA probes (Duolink II anti-Mouse MINUS and Duolink II anti-Rabbit 
PLUS) were prepared by 1:5 dilution in Antibody Diluent (1X). Filters were washed twice (5 
minutes/wash) with 1X Duolink II Wash Buffer A under agitation and at RT. After this step, 
PLA probes were added and samples were incubated in a pre-heated humidity chamber for 
1 h at 37°C. The Duolink II Ligation stock was prepared following the datasheet and the 
provided ligase was added (1:40) just before incubation with the samples, which were 
washed once (5 minutes/wash) before the ligation which lasted 30 minutes at 37°C in a pre-
heated humidity chamber. Then, Duolink II Amplification stock was prepared in and the 
provided DNA-polymerase was added (1:80) just before incubation with the samples, which 
were washed twice (2 minutes/wash) in Wash Buffer A before incubation for 2 h in a pre-
heated humidity chamber at 37°C. Finally, samples were incubated 2 times (10 
mins/incubation) in 1X Duolink II Wash Buffer B (containing fluorescently-labelled probes), 
then washed briefly in 0.1X Duolink II Wash Buffer B. To visualise F-actin, filters were 
incubated for further 20 minutes in Alexa 488-conjugated phalloidin (Invitrogen, UK) diluted 
1:40 in DPBS with Ca2+/Mg2+. Filter were mounted with Prolong anti-fade mounting medium 
(Invitrogen, UK) and visualized by confocal microscopy.  
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4.6.10 Murine primary microvascular endothelial cell isolation 
The following isolation protocol was kindly provided and explained by Dr. R. Brown (King's 
College London); it is based on those developed by Coisne et al. (Coisne et al., 2005) and on 
that used in the Professor NJ Abbott laboratory at King’s College London (Abbott et al., 
1992). Volumes and concentrations are optimised to be effective for 12 mouse brains. 
Solution composition is described in the Appendix, Section 10.1.  
Animals were quickly sacrificed by deep anaesthesia, decapitated and brains were extracted 
from the skull and placed into a 50 ml falcon filled with ice-cold DPBS with Ca2+/Mg2+.  
When all the animals had been culled and operated, brains were deprived of the 
cerebellum, sliced into hemispheres and transferred into ice-cold wash buffer and left to 
chill for 15 minutes. The following steps were all performed under a tissue culture laminar 
flow hood to guarantee sterile conditions and avoid contamination of the preparation. 
Each half brain was rolled on dry Kimberly tissue to remove meninges and surface blood 
vessels; after moving it to a Petri-dish, a sterile Q tip was used to remove remaining blood 
vessels identified under a dissecting microscope (Meiji, Japan). Striatum, choroid plexus and 
white matter were removed using sterile fine forceps. After these operations, cleaned 
halves were placed into a 50 ml falcon tube containing 25% BSA solution. When all the 
brains underwent the cleaning procedure, they were homogenised with 15 strokes in a 
Dounce glass homogenizer with a large (0.06-0.08 mm) clearance pestle. Small volumes 
were processed to guarantee a complete homogenisation. Homogenate was repeatedly 
triturated until smooth with a 10 ml plastic pipette. Tubes were centrifuged at 3000xg for 25 
minutes at 4⁰C. After the first spin, tubes were carefully turned on themselves to loosen the 
plug formed on the top of the volume (containing mainly myelin, astrocytes and other cell 
types not necessary for the preparation); volume and plug were quickly poured into a new 
sterile 50 ml Falcon tube and underwent trituration by repeated pipetting and a following 
centrifugation at 3000xg for 25 minutes at 4⁰C. The first tube was capped and left on ice 
upside down to remove any remaining myelin from the capillary pellet. Clean pellets from 
the two tubes were resuspended in wash buffer, joined together and applied to a 70 µm 
filter, meant to trap big vessels. The filter was washed with 10-15 ml of wash buffer.  
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The capillary-enriched filtrate was centrifuged at 1200xg for 7 minutes at 4⁰C and pellet was 
resuspended in enzyme cocktail solution (10 ml/preparation) and incubated at 37⁰C in 
shaking water bath. 
Tubes were centrifuged for 5 minutes at 1500xg at 4⁰C and pellets washed more than 3 
times with wash buffer. Capillaries were seeded in a small volume of primary endothelial 
cell medium (2 ml) in T25 flask (pre-coated for at least 3 hours with home-made rat tail type 
I collagen, kindly provided by Dr. Rachel Brown).  
Puromycin (4 µg/ml) was used for the first 3 days of culturing for maximal removal of 
contamination from non-resistant cell types. Primary cultures resulted in > 95% pure 
microvascular endothelial cells as assessed by endothelial markers phenotyping (tight and 
adherens junctions). Medium was changed every 4 days; when cultures were 70-80% 
confluent, cells were trypsinised and seeded on transwell inserts (Corning, Sigma-Aldrich, 
UK) coated in rat tail type I collagen at a density of 80000 cells/cm2. When cells reached 
confluence, medium only in the lower chamber was replaced to complete medium devoid of 
fetal bovine serum and cultures were left for 3 days to increase their tightness, as reported 
(Coisne et al., 2005). 
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4.7 Results 
The major aim of the thesis is to unravel the involvement of ANXA1 in the mechanisms of 
communication between peripheral immune system and CNS; therefore, we first focused on 
the potential role of this protein at BBB level, which represents the real and definite 
interface between the two compartments and an important check-point. Initial findings 
(Figure 2.1) led us to hypothesise for a physiological role of Annexin A1 at the level of the 
BMECs, where the fully-developed BBB is formed and functions (Macdonald et al., 2010). 
 
4.7.1 Anxa1 null mice show increased basal paracellular permeability 
Figure 4.7 clearly shows Annexin A1 to be well expressed at the level of the endothelium of 
the microvasculature, both in human (non-neurologic control post-mortem cortical excision; 
see Section 5.3.3 for tissue processing and staining methods) and murine tissues (Figure 4.7; 
panels A, B, C). Lack of Anxa1 caused increased basal Evans Blue intracerebral leakage 
(Figure 4.7; panel D), which was paralleled by an augmented serum IgG extravasation 
(Figure 4.7; panel F) in the brain parenchyma (see white arrows). In order to confirm the 
constitutive higher BBB endothelium-related permeability in vivo, we compared magnetic 
resonance imaging (MRI) signals from adult male C57Bl/6 wild-type and Anxa1 null mice 
following the dimeglumine gadopentetate administration. Considerable leakage of contrast 
medium was detected into the brain parenchyma of Anxa1 null mice, especially at the level 
of the midbrain, while no changes were detected in wild-type counterparts, as expected 
(Figure 4.7; Panel G). Interestingly, these results were not paralleled by changes in water 
content between the genotypes (Figure 4.7; panel E), indicating that the increased diffusion 
of substances is not accompanied by cerebral oedema formation.  
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4.7.2 The expression and distribution of tight and adherens junctions 
components are disrupted in Anxa1 null mice 
Such a strong evidence for an increased permeability in Anxa1 null animals led us to 
investigate further how Annexin A1 is mechanistically involved in the correct BBB 
functionality. As shown in Figure 4.8 (Panels A and B), we did not detect evident changes in 
major components of the BBB such as pericyte organisation, astrocytic end feet positioning 
and basal lamina formation, or the expression of the efflux pump p-glycoprotein (MDR-1), 
that could have suggested an alternative explanation to the changes observed. We then 
investigated the major components of TJs, namely claudin-5, ZO-1 and occludin, and the 
major AJ component VE-cadherin, responsible for the establishment of full BBB tightness. 
Interestingly, we observed, by confocal microscopy, a significant organizational disruption in 
Anxa1 null mice (Figure 4.8; Panel C) mainly for occludin and VE-cadherin. Further analysis 
by western blot revealed also a significant reduction in these components’ content in the 
insoluble/membrane associated fraction of cortical homogenates in Anxa1 null mice (Figure 
4.10). These observations were confirmed by confocal analysis of primary cerebral 
microvascular capillaries (Figure 4.8; Panel D). Notably, histological analysis of kidney cortex 
(Figure 4.9; Panel A), a tissue rich in tight junctions but functionally and anatomically 
unrelated to BBB, revealed no evident occludin disorganization in null mice compared to 
wild-type, supporting the high anatomical specificity for this phenotype. ANXA1 is a member 
of the large family of Annexins (see Chapter 1, Introduction) and compensatory effects have 
been detected in several tissues of the Anxa1 null mouse (Hannon et al., 2003). Therefore, 
we looked for differences in the expression of Anxa2, which has been reported to play a 
tight-junction protein-like role in the epithelial cells of the kidney (Lee et al., 2004) and of 
Anxa5, which has unrelated roles (van Engeland et al., 1998). 
Chapter 4 – Annexin A1 physiological role at BBB level 
 
Page | 104   Enrico Cristante – PhD degree thesis    
 
 
Figure 4.7 Annexin A1 is expressed in brain microvascular endothelium and Anxa1
-/-
 mice show 
constitutively elevated BBB permeability. A| Confocal microscopic analysis of ANXA1 expression on 
the endothelium of a human cortical capillary, immunofluorescently labelled for endothelial marker 
CD31 (green) and ANXA1 (red); scale bar is 10 µm. B| Confocal microscopic analysis of Anxa1 
expression on mouse capillary, immunofluorescently labelled for Anxa1 (red); scale bar is 20 µm. C| 
Microscopic analysis of Anxa1 null mouse capillary, histochemically stained for β-galactosidase 
activity and counterstained with eosin Y; scale bar is 20 µm. D| Basal permeability was assessed in 
untreated young adult animals (2-3 months old). Results are presented as means ± SEM (n=4) of the 
percentage of the serum dye content compared to the amoung (ng) of Evans Blue (EB) extravasated 
into the brain parenchyma/mg of total tissue. t-test between the two independent groups was 
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performed and p<0.05 was considered significant. *** p<0.001. E| Percentage of brain water 
content/total wet brain weight in male C57Bl/6 mice and Anxa1 null mice; results are presented as 
means ± SEM (n=4/genotype). Student’s t-test between the two independent groups was 
performed. F| Extravasation of IgG (red) into brain parenchyma in wild-type and Anxa1 null mice, 
tissue nuclei stained with DAPI (blue), laminin (green) to delineate basement membrane of 
capillaries; arrows indicate clear points of mouse IgG extravasation into brain parenchyma; scale bar 
is 10 µm. G| T1-weighted dynamic contrast MRI series of coronal cranial sections taken at various 
distances from bregma of wild-type and Anxa1 null mice. Brighter areas show increased 
dimeglumine gadopentetate leakage. Typical profile of n=5 mice/genotype are shown. Panels A, C, D 
& F produced with help from Dr. S McArthur. 
 
Although we did not detect any change in total expression in the whole cortical tissue 
extracts (data not shown), in contrast we detected an increase in Anxa2 expression in total 
homogenates from isolated Anxa1 null mouse brain capillaries (Section 3.2.4.1) compared to 
the wild-type counterpart (Figure 4.9; Panel B), which may suggest the presence of partial 
compensatory mechanisms in place of the cognate molecule.  
 
4.7.3 Annexin A1 regulates paracellular permeability in an in vitro model of 
BMECs 
Since the above described in vivo and ex vivo experiments indicated that Annexin A1 exerts 
its role on BBB permeability at the level of the cerebro-vascular endothelium, we looked at 
primary isolated and culture of microvascular capillaries from wild-type and AnxA1 null 
mice. Pure endothelial cell cultures were grown until 100% confluent. In vitro paracellular 
permeability indicated two-fold increase in leakiness of the barrier properties of the cellular 
Anxa1-/- monolayers (Figure 4.11; Panel A). In order to understand the mechanisms by which 
Annexin A1 affects the BBB permeability, we moved to an established in vitro model based 
on the line called hCMEC/D3 (Weksler et al., 2005). Firstly, we stably modified ANXA1 
expression of these cells and characterised their properties as depicted in Chapter 9, Section 
10.5. 
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Figure 4.8 Lack of Anxa1 results in disruption of tight- and adherens junctions. A| Confocal 
microscopic analysis of the typical BBB basement membrane proteins laminin and perlecan, the 
pericyte marker PDGF receptor, and bright field microscopic analysis of the astrocyte marker GFAP in 
wild-type and Anxa1-/- mice; typical examples from n=3 mice per genotype, scale bars are 10 µm. B| 
Total expression of p-glycoprotein transporter MDR-1α was assessed on total cortical lysates from 
wild-type and Anxa1 null mice. Histograms indicate densitometric analysis of blots normalized to β-
actin loading control and expressed as percentage of wild-type control (mean ± SEM; n=3 
independent experiments, each with n=4 male samples/genotype). Student’s t-test was performed 
showing no significant difference. C| Immunofluorescent analysis of claudin-5, ZO-1, occludin and 
VE-cadherin in cortex sections from wild-type and Anxa1 null mice reveal disordered localization of 
occludin and VE-cadherin but not evident disruption of Claudin-5 and ZO-1; typical images from n=6 
mice per genotype, scale bar is 10 µm. D| Confocal microscopic analysis of occludin and VE-cadherin 
expression in isolated cortical capillaries from wild-type and AnxA1-/- mice in vitro. Arrows indicated 
points of altered or absence expression of the correspondent junctional protein. Nuclei are labeled 
with DAPI, endothelial cells were identified by immunofluorescent detection of CD31 (green), 
occludin and VE-cadherin are immunofluorescently labelled in red; typical images from n=3 
independent preparations; scale bar is 10 µm. Panels A & D produced with help from Dr S. McArthur. 
 
 
Figure 4.9 Occludin expression in cortical kidney and compensatory over-expression of Anxa2. A| 
Confocal microscopic analysis of occludin expression in the kidney from wild-type (C57Bl/6) and 
Anxa1 null mice; typical examples from n=3 mice per genotype. Scale bar: 20 µm. B| Typical western 
blot analysis of annexin A2 (Anxa2; A) and annexin A5 (Anxa5; B) expression in extracts from isolated 
cerebral capillaries of wild-type and AnxA1 null mice, alongside GAPDH loading controls; n=3 
independent experiments, each with n=4 male samples/genotype. Histograms show densitometric 
analysis of 4 animals per genotype, expressed as mean ± SEM. Student’s t-test between the two 
independent groups was performed. * p<0.05 vs. C57Bl/6.  
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Using paracellular permeability in vitro assay, we showed (Figure 4.11; Panel B) that cells 
bearing an antisense sequence against ANXA1 had significantly greater trans-endothelial 
permeability than untransfected or pRc/CMV empty plasmid-transfected hCMEC/D3 cells, 
while cells stably expressing increased levels of the protein showed a lower transcellular 
permeability, indicating the formation of a tighter cellular monolayer. Furthermore, no 
significant endocytosis of the fluorescent dextran was detected, indicating that differences 
in the permeability coefficients were mainly due to changes in the paracellular passage of 
substances (See Chapter 10, Section 10.7) as in part it has been already indicated by others 
(Plateel et al., 1997). 
 
 
Figure 4.10 Lack of Anxa1 results in decreased expression of insoluble occludin and VE-cadherin. 
Typical western blot analysis of soluble and insoluble protein fractions from cortical extracts from 
wild-type and Anxa1 null mice. Analysis of the major tight-junctions components: A| occludin B| 
claudin-5 C| ZO-1 and one of the main adherens junctions D| VE-cadherin. Histograms indicate 
densitometric analysis of blots normalized to β-actin loading control and expressed as percentage of 
wild-type control (mean ± SEM; n=3 independent experiments, each with n=4 male 
samples/genotype). Student’s t-test between the two independent groups was performed. * p<0.05 
vs. wild-type control.   
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These findings were supported by studies showing a direct correlation between ANXA1 
expression and TEER (Figure 4.11; Panel C): antisense cells showed a significantly reduced 
TEER compared to the other cell lines analysed.  
To confirm the direct contribution of ANXA1 towards endothelial tightness, wild-type 
untransfected cells were incubated with a neutralizing monoclonal antibody against the 
protein (Pepinsky et al., 1990), which significantly enhanced paracellular permeability 
(Figure 4.11; Panel D) of the monolayers.  
Since paracellular permeability across the cerebral microvascular endothelium is affected by 
the correct arrangement and regulation of tight and adherens junction complexes, which we 
proved already to be disrupted in Anxa1 null mouse (Figure 4.9 and Figure 4.10), we first 
examined ANXA1 distribution on hCMEC/D3 cells polarized monolayers by electron 
microscopy. As evident from Figure 4.11, Panel F and also confirmed in Figure 4.12, ANXA1 
is mainly localized in proximity of cell membrane, mostly at points of close cell-cell contact 
[electron-rich “kiss-points”; (Stevenson and Keon, 1998)]. Since this is where the junctional 
complexes contribute to the extremely low paracellular permeability of BMECs, we 
examined the distribution of occludin and VE-cadherin (the two proteins which showed 
major disruption in the murine brain sections) on hCMEC/D3 cell monolayers. A clear loss in 
normal peripheral organisation of occludin and VE-cadherin was evident in the antisense 
cells when compared with either mock-transfected or full-length ANXA1 stable cells (Figure 
4.11; Panel E). Lower levels of expression for occludin, claudin-5 and VE-cadherin were also 
detected, as depicted by flow-cytometric analysis in Section 10.5 (Appendix), when stable 
clones were immunophenotyped. FL cells showed a stronger and more continuous staining, 
paralleled by increased levels of expression of the major adhesion molecules (Figure 10.2).  
Direct interactions between ANXA1 and the major two junctional components, whose 
expression and organisation were found to be altered, was assessed by co-
immunoprecipitation (Figure 4.11; Panel G). We could not detect direct interaction between 
ANXA1 and occludin, while we could detect some limited interaction with VE-cadherin, 
although the efficiency of the technique was not exceptional. This indicates that ANXA1 may 
affect junctional complexes by directly interacting with the most important component of 
the adherens junctions family (Wolburg and Lippoldt, 2002).   
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Figure 4.11 Annexin A1 modulates paracellular permeability ex vivo and in vitro. A| Paracellular 
permeability was conducted with 70 kDa FITC-dextran on primary cerebrovascular endothelial cells 
isolated from wild-type (C57Bl/6) and Anxa1 null mice (n=12/preparation) grown on transwells. 
Values are representative of four independent experiments, performed in duplicate, expressed as 
percentages of the wild-type control and represented as mean ± SEM. Student’s t-test was 
conducted between the two independent groups. * p<0.05 vs. wild-type control. B| Relative 
paracellular permeability coefficients and C| TEER measured in wild-type hCMEC/D3 human brain 
microvascular endothelial cells WT or stable hCMEC/D3 clones transfected with a pRc/CMV plasmid 
alone (Empty) or containing an antisense ANXA1 sequence (AS1, AS4, AS100B) or full-length ANXA1 
(FL5, FL11); data are representative of at least three independent experiments, performed in 
triplicate, expressed as mean ± SEM, * p<0.05 vs. WT clones. D| Paracellular permeability of wild-
type hCMEC/D3 monolayers following exposure to a neutralizing anti-ANXA1 antibody at 20 µg/ml 
for 3 hours, compared to exposure to an irrelevant mouse IgG isotype control (30 µg/ml); data are 
representative of at least three independent experiments, performed in triplicate, expressed as 
mean ± SEM, * p<0.05. E| Confocal microscopic analysis of VE-cadherin and occludin in polarized 
monolayers of WT, FL11 and AS4 hCMEC/D3 clones reveals marked disturbances in both proteins in 
AS clones; typical example from n=3 independent preparations, scale bar is 10 µm. F| Electron 
microscopic analysis of immunogold labelling for ANXA1 in wild-type hCMEC/D3 cells grown as a 
polarized monolayer on a transwell polycarbonate filter reveals a striking localization of the protein 
at points of cell-cell contact. Top panel is a transverse image through the cell monolayer, bottom 
panels are vertical images of cell contacts; scale bar is 200 nm. Images were produced and provided 
by collaborator Dr. H. Christian (Oxford University). G| Co-immunoprecipitation analysis of ANXA1 
and TJ and AJ interactions. Upper panel: 250 µg of total hCMEC/D3 cell extracts were immune-
precipitated with 3 µg of a polyclonal anti-VE cadherin or 5 µg of monoclonal anti-ANXA1 and 
western blot was performed with either anti-ANXA1 antibody or anti-VE cadherin antibody, 
respectively; bottom panel: 3 µg monoclonal anti-occludin antibody or 5 µg monoclonal anti-ANXA1 
was used to immune-precipitate complexes and western blot was performed with either anti-ANXA1 
or anti-occludin antibody, respectively.  
 
4.7.4 Annexin A1 profoundly affects the actin cytoskeleton 
The stability of both tight and adherens junctions within the intercellular connections is 
determined to a large extent by the actin cytoskeleton, and in particular by interactions 
between the actin cytoskeleton and the cell membrane (Wittchen et al., 1999). Since we 
have already shown that ANXA1 plays an important regulative role for hormone exocytosis 
at cytoskeletal level (McArthur et al., 2009), we looked for differences within capillaries 
isolated from wild-type and Anxa1 null mice (Figure 4.12; Panel A). 
Rhodamine-conjugated phalloidin staining revealed significant differences, as wild-type 
vessels were shown to possess dense bundles of longitudinally aligned actin fibres, in 
marked contrast to AnxA1-/- vessels, in which only sparse discontinuous actin fibres were 
evident. Moving to the in vitro model, we compared the phenotype of actin microfilaments 
within WT, FL and AS hCMEC/D3 cells.  
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Whilst wild-type and FL cells showed strong cortical actin staining, AS cells exhibited a 
distorted actin cytoskeleton, with a marked alteration in cell shape and an apparent loss in 
polarity (Figure 4.12; Panel B). Consequently, we concluded that ANXA1 must have a 
profound effect on the correct formation and organisation of the actin cytoskeleton.  
To investigate how this can be accomplished, we investigated the association between 
ANXA1 and the actin cytoskeleton. Initial co-immunoprecipitation experiments identified a 
clear biochemical interaction between ANXA1 and β-actin (Figure 4.12; Panel C); this 
evidence was supported by confocal microscopic analysis of points of ANXA1/β-actin 
interaction in wild-type hCMEC/D3 cells, using a proximity ligation assay (PLA) as shown in 
Figure 4.12; Panel D. Clear co-localization of ANXA1 and β-actin was shown through this 
technique, mostly in proximity of cortical F-actin fibres, supporting once again the idea that 
ANXA1 may play an important role in formation/stabilisation of the actin cytoskeleton 
fibres.  
In order to get a more definite up-regulation in ANXA1 expression, we produced lentiviral 
particles bearing the human ANXA1 coding sequence under the transcriptional control of 
the cytomegalovirus (CMV) promoter. These particles were used to infect exponentially 
growing hCMEC/D3 cells, which were further selected for puromycin resistance and for 
expression of ANXA1 by western blotting and flow cytometry analysis.   
Figure 4.12, Panel E shows the major differences in terms of F actin between mock-infected 
and full length ANXA1-infected cells (IgG2A isotype control treated): thicker cortical actin 
cytoskeleton was evident in the ANXA1-infected cells, along with a more elongated 
conformation and close association between neighbouring cells, indicating that a higher 
constitutive expression of the protein contributes significantly to the formation of a more 
continuous and stable cortical cytoskeleton as well as positively affecting the polarity of the 
cellular monolayer. The higher level of F-actin at the cortical level was paralleled by an 
increased F/G β-actin ratio which was detected biochemically, as represented in Figure 4.12, 
Panel E. Differently from mock-transfected cells, full length ANXA1-treated cells were able 
to show a detectable level of ANXA1 in the insoluble fraction, likely to be directly interacting 
with insoluble F-actin fibres.  
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Figure 4.12 ANXA1 directly affects the formation and location of cytoskeletal actin microfilaments. 
A| Rhodamine-phalloidin staining of F-actin in isolated brain capillaries from WT and AnxA1-/- mice, 
identified by staining nuclei with DAPI (blue) and F-actin with rhodamine-phalloidin (red); typical 
images from n=3 independent preparations, scale bar is 10 µm. B| Rhodamine-phalloidin staining 
was performed on WT, FL11 and AS4 hCMEC/D3 clones monolayers, revealing a disorganized 
cytoskeletal structure in AS4 cells; scale bar is 10 µm. C| Co-immunoprecipitation analysis of ANXA1 
and β-actin interaction. Top panel: 250 µg of total cell extracts were immuno-precipitated with 2 µg 
of an anti-ANXA1 antibody and western blot was performed with an anti-β-actin antibody. Bottom 
panel: 250 µg of total cell extracts were immune-precipitated with 5 µg of a monoclonal anti-β-actin 
antibody and western blot was performed with anti-ANXA1 antibody. D| Confocal microscopic 
analysis of ANXA1 and β-actin co-localization in WT hCMEC/D3 cell monolayers determined by use of 
the proximity ligation assay (PLA, red), and F-actin identified by Alexa 488-conjugated phalloidin 
staining (green) in WT hCMEC/D3 cells. Images are from a 400 nm optical section; scale bar is 5 µm. 
E| Confocal microscopic analysis of F-actin in mock transfected and full length ANXA1 infected 
hCMEC/D3 cell monolayers following exposure to a neutralizing anti-ANXA1 antibody at 20 µg/ml for 
3 hours, or to an irrelevant mouse IgG isotype control (30 µg/ml); data are representative of at least 
three independent experiments. Scale bars 5 µm, while inset scale bars 7.5 µm. F| Biochemical 
analysis of G (soluble) and F (insoluble) β-actin in hCMEC/D3 cells mock- or full length ANXA1-
infected. Histograms represent analysis of three different experiments, performed in triplicate; data 
are presented as mean ± SEM. Student’s t-test between the two independent groups was performed 
with * indicating p<0.05 vs. untreated. Panels A, B and D were produced together with Dr. S 
McArthur. 
 
Treating these cells with a monoclonal antibody anti-ANXA1 (the same one used in Figure 
4.11; Panel D) resulted in a loss of thickness at the cortical level, with the appearance of 
more disorganized stress fibres throughout the cytosol.  
Overall, these findings confirmed that ANXA1 may provide its role both through an 
endogenous and an exogenous role, as already suggested on Figure 4.11, Panel A-D by 
overexpressing total ANXA1 or blocking the action of the released molecule. 
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4.7.5 In vivo and in vitro BBB integrity restoration by recombinant ANXA1  
In previous reports we have shown the potential of recombinant human ANXA1 (rANXA1) in 
significantly rescuing aberrant phenotypes when given exogenously (Solito et al., 2000; 
McArthur et al., 2009). Therefore, we investigated whether a similar action of ANXA1 could 
be identified in the restoration of BBB function both in vivo and in vitro. Intravenous 
administration of rANXA1 (0.67 µg/kg body weight) to Anxa1 null mice was chosen on the 
basis of previous studies (de Coupade et al., 2001); we observed that 24 hours after the i.v. 
administration of ANXA1 and of Evans blue dye (1 hour prior assessment) significantly 
reduced the degree of tracer extravasation into the brain, effectively rescuing the enhanced 
BBB leakage (Figure 4.13; Panel A). This phenomenon was also reproduced by the treatment 
of AnxA1-/- mouse brain microvascular endothelial primary cultures and AS hCMEC/D3 
clones with human recombinant ANXA1 at 20 µg/ml, where the protein was able to 
significantly reduce paracellular permeability towards that of untransfected cells (Figure 
4.13; Panel B and C), closely correlating with our in vivo data. Interestingly, treatment of 
wild-type hCMEC/D3 cells with ANXA1 also produced a decrease in the basal permeability 
(Figure 4.13; Panel C), indicating that a potentiation of basal tightness is also possible. 
To further investigate the mechanism whereby rANXA1 could rescue the permeability deficit 
seen in AnxA1-/- mice or in AS clones when given exogenously, we analysed the role of the 
main formyl peptide receptor (FPR) family member, FPR2, which we, and others, have 
previously shown to mediate the actions of ANXA1 in different cellular contexts (Solito et al., 
2000; Perretti, 2003). First we confirmed that hCMEC/D3 cells expressed FPR2 (and FPR1) by 
using flow cytometry, although their expression at the endothelial levels has been already 
reported in different species (Mou et al., 2012); the results are shown in Figure 4.13, Panel 
E. To test FPR2 involvement we used WRW4 (used at 5 µM concentration), a very specific 
FPR2 antagonist. WRW4 had an effect when administered before ANXA1; two-way ANOVA 
identified significant (p<0.05) interaction between WRW4 and ANXA1. Overall, this may 
indicate that FPR2 is occupied by exogenously administered ANXA1, but also may be 
interested in the action brought by ANXA1 molecules constantly released by the cells, which 
therefore is able to mediate a basal autocrine/paracrine action and in this way to contribute 
to the basal paracellular permeability.  
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Considering that the levels of ANXA1 released by wild-type, AS and FL cell monolayers follow 
the intracellular relative expression (i.e. AS clones released less ANXA1 while FL more 
compared to WT; see Table 4.1), this may give another potential mechanism to explain the 
differences in terms of paracellular permeability that were observed between clones. 
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Figure 4.13 Exogenous ANXA1 restores BBB integrity in vivo and in vitro. A| Anxa1-/- mice (n=6) 
were pre-treated intravenously with 0.67 μg/kg body weight of rANXA1 in saline and after 3 or 24 
hours were further injected with 100 µl 2% Evans blue in saline. Data are expressed as mean ± SEM. 
One-way ANOVA was conducted and followed by Tukey’s range post-hoc test; * indicates p<0.05 vs. 
saline control and it was considered as significant. B| Administration of 20 µg/ml rANXA1 3 hours 
prior to analysis of significantly reduced permeability in primary brain endothelial cells isolated from 
Anxa1 null mice and littermate controls. One-way ANOVA was conducted and followed by Tukey’s 
range post-hoc test. Data are representative of at least three independent experiments, performed 
in triplicate, expressed as mean ± SEM. * p<0.05; # p<0.05 vs. untreated wild-type. C| Administration 
of 20 µg/ml human recombinant ANXA1 3 hours prior to analysis significantly reduced paracellular 
permeability in WT hCMEC/D3 cells, and significantly improved the permeability in AS clones 
towards WT; data are representative of at least three independent experiments, performed in 
triplicate, expressed as mean ± SEM. One-way ANOVA was conducted and followed by Tukey’s range 
post-hoc test. * p<0.05 vs. untreated wild-type and was considered as significant. D| Administration 
of the FPR2 antagonist WRW4 at 5 µM 10 minutes prior to treatment with 20 µg/ml ANXA1 for 3 
hours blocked the effect of ANXA1 on paracellular permeability. Data are representative of at least 
three independent experiments, performed in duplicate, expressed as mean ± SEM. Two-way 
ANOVA was performed and followed by Bonferroni post-hoc test, in which * indicates p<0.05 and 
was considered as significant. E| Expression of FPR1 and FPR2 in untransfected hCMEC/D3 cells. 
Representative example of flow cytometric analysis of FPR1 and FPR2 expression in untransfected 
hCMEC/D3 cells; at least 10000 events were analysed after proper gating; histograms represent one 
of 6 independent experiments.  
 
 
 
Table 4.1 hCMEC/D3 clones release different amounts of ANXA1 into the cell culture medium. 
Secreted ANXA1 was measured by ELISA on medium collected from 100% confluent monolayers 
incubated for 24 hours with fresh medium but without incubation with stimuli. One-way ANOVA was 
conducted and followed by Tukey’s range post-hoc test. Data are representative of at least three 
independent experiments, performed in triplicate, expressed as mean ± SEM. One-way ANOVA was 
performed and followed by Dunnett post-hoc test against a reference group (Untreated), in which * 
indicates p<0.05 and was considered as significant.  
 
 
 
 
 
Full length ANXA1 
FL11
4.422 ± 0.087 4.563 ± 0.095 3.33 ± 0.186 * 5.82 ± 0.427 *
ANXA1 in the medium
(ng/ml)
Untreated CMV-empty Antisense AS4
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Following the identification of endogenous ANXA1 as a stabilizer for both fibrillar actin and 
consequently cell polarity, we assessed the effects of exogenous hrANXA1 (20 µg/ml; 3 or 
24 hours treatment) on the actin cytoskeleton on wild-type hCMEC/D3 monolayers (Figure 
4.14). Interestingly, the cortical actin cytoskeleton showed increased thickness and number 
of fibrillar actin fibres, while the few stress fibres present throughout the cell body showed 
high polarity, following the longitudinal cell axis. Endogenous ANXA1 staining was identified 
throughout the entire cytosol, but particularly it defined a continuous sub-membranous ring 
that strongly co-localized with the cortical actin fibres (white arrows, Figure 4.14; Panel A).  
Interestingly, the microscopic results were paralleled by biochemical analysis of the F/G 
actin ratio in the hCMEC/D3 cells treated with hrANXA1 (Figure 4.14; Panel B): actin 
polymerization appeared to be improved by the exogenous stimulus, replicating findings 
that we have already reported in a different system (McArthur et al., 2009). 
Since exogenous hrANXA1 showed a direct effect on cortical actin fibres, we assessed the 
consequent effect on cell junction component expression after stimulation of wild-type 
hCMEC/D3. All the major tight- and adherens-junction proteins analysed (occludin, claudin-
5, ZO-1 and VE-cadherin) showed increased expression at membrane-associated level 
(insoluble fraction) as evident from , Panel C, which could be closely linked structurally to 
improved cortical F-actin driven by the treatment and functionally to the increased tightness 
observed in terms of paracellular permeability (Figure 4.12; Panel C).  
Taking into account the profound effects that exogenous ANXA1 showed at the level of the 
actin cytoskeleton, we hypothesised that the rescue effect shown on the Anxa1 null mice 
and on BBB endothelium may be also mediated by targeting actin. Primary wild-type 
endothelial cells stimulated with hrANXA1 for 3 hours (20 µg/ml) showed an improved 
cortical actin cytoskeleton, closely resembling the results obtained with the human cell line 
hCMEC/D3 (Figure 4.15; Panel A). Anxa1 null mice primary endothelial cells showed a 
disrupted actin cytoskeleton, rich in disorganised stress-fibres and devoid of continuous 
membrane-associated actin fibres. Treatment with hrANXA1 for 3 hours improved the 
disrupted phenotype, strongly reducing the presence of stress-fibres in favour of cortical F-
actin filaments. 
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Figure 4.14 Effects of ANXA1 on wild-type hCMEC/D3 on actin cytoskeleton polymerization and 
cell-cell junctions. A| Confocal microscopic analysis of ANXA1 and F-actin co-localization in WT 
hCMEC/D3 cell monolayers stimulated with human recombinant ANXA1 (20 µg/ml) for 3 hours and 
24 hours. ANXA1 was detected by incubation with a rabbit-polyclonal antibody and with Alexa 488-
conjugated anti-rabbit IgG secondary antibody, while F-actin was detected by rhodamine-phalloidin 
staining. White arrows indicate regions of clear co-localization. Scale bars are 5 µm. B| Biochemical 
analysis of G (soluble) and F (insoluble) β-actin in hCMEC/D3 cells treated with 20 µg/ml hrANXA1 for 
3 or 24 hours, or with 10 µM of the actin-depolymerizing agent latrunculin (as positive control for 
low F/G β-actin ratio) for 1 hour. Histograms represent analysis of three different experiments, 
performed in triplicate; data are presented as mean ± SEM. One-way ANOVA was performed and 
followed by Bonferroni post-hoc test, in which * indicates p<0.05 and was considered as significant. 
Student’s t-test between the two independent groups (untreated and latrunculin) was performed 
with # indicating p<0.05 vs. untreated. C| Administration of 20 µg/ml rANXA1 to wild-type 
hCMEC/D3 cells induces an upregulation of membrane associated (insoluble) occludin and VE-
cadherin expression as measured by western blot. Results are representative of three independent 
experiments.  
 
The direct effect of exogenous hrANXA1 on the actin cytoskeleton organisation was also 
confirmed on hCMEC/D3 cells with a constitutive lower expression of ANXA1. In order to 
obtain more definite reduction in the protein expression compared to what was achieved by 
stable transfection (Figure 4.11), we opted for shRNA technology, by producing lentiviral 
particles bearing a specific shRNA sequence directed towards a portion of the ANXA1 mRNA. 
We had the chance to test 5 different human ANXA1-specific shRNA (named 1257, 1258, 
1259, 1260 and 1261). We concluded that shRNA 1258 and 1259 did not produce a 
significant reduction in ANXA1 expression (data not shown), while the others did produce a 
considerable reduction, with the simultaneous infection with two different shRNA lentiviral 
particles producing the best results (Figure 4.15; Panel B). We then focused on hCMEC/D3 
cells infected stably with 1257+1261 and observed the effect of exogenous hrANXA1 on 
actin cytoskeleton (3 and 24 hours treatment; 20 µg/ml ANXA1). Similarly to what we 
observed in AS stably transfected cells (Figure 4.12), actin cytoskeleton is heavily disrupted 
along with cell polarity and correct juxtaposition with the neighbouring cells (Figure 4.15, 
Panel C). Treatment with hrANXA1 partially improves the phenotype in a time-dependent 
fashion, by increasing the amount of F-actin at the cortical level, reducing the amount of 
unorganised stress fibres present throughout the cytosol.  
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Figure 4.15 Effects of hrANXA1 on wild-type and Anxa1 null primary endothelial cultures and 
shRNA infected cells. A| Confocal microscopic analysis of ANXA1 and F-actin co-localization in 
primary endothelial monolayers derived from wild-type and Anxa1 null mice. The monolayers were 
stimulated with hrANXA1 (20 µg/ml) for 3 hours. ANXA1 was detected by incubation with a rabbit-
polyclonal antibody (Zymed; Invitrogen, UK) and with Alexa 594-conjugated anti-rabbit IgG 
secondary antibody, while F-actin was detected by Alexa 488-conjugated phalloidin staining. Scale 
bars are 5 µm. B| Evaluation of ANXA1 expression on hCMEC/D3 cells infected with different types 
and combinations of shRNA-bearing lentiviral particles and selected for stable genomic integration 
by culturing under puromycin selective agent. ANXA1 expression was evaluated by Western blotting. 
10 µg of total lysate extraction were loaded/lane and run as described in the general methods. 
Nitrocellulose membranes were probed for ANXA1 (in-house rabbit polyclonal anti-ANXA1) and 
subsequently stripped and re-probed for GAPDH as internal loading control. C| Confocal microscopic 
analysis of F-actin localization in hCMEC/D3 stably expressing 1257+1261 shRNA sequences directed 
towards ANXA1 messenger RNA. The cell monolayers were stimulated with human recombinant 
ANXA1 (20 µg/ml) for 3 and 24 hours. F-actin was detected by Alexa488-conjugated phalloidin 
staining. Scale bars are 5 µm and 7.5 µm (inset).  
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4.7.6 Mechanistic involvement of ANXA1 in regulating the actin cytoskeleton  
So far we have described the direct involvement of ANXA1 as a fundamental regulator of 
paracellular permeability. This role appears to be exerted both via an endogenous (direct 
interaction of the protein with β-actin and the cortical actin cytoskeleton) and an 
autocrine/paracrine mechanism (constitutive release of ANXA1 which signals through FPR2 
receptors, ultimately affecting the organisation of the actin microfilaments and overall their 
shape, polarity and location in regards to the neighbouring cells). At this stage, we sought to 
identify the molecular mechanism(s) whereby the two pathways could be reconciled. Firstly, 
we observed that treating wild-type hCMEC/D3 monolayers for 24 hours with 20 µg/ml 
hrANXA1 induced a marked increase in intracellular ANXA1 (Figure 4.16; Panel A), a result 
supported by previous studies identifying a similar effect of the bioactive N-terminal peptide 
towards total intracellular ANXA1 (Rescher et al., 2002).  This self-potentiating action of 
ANXA1 is important but not sufficient to explain the rescuing effect of exogenous hrANXA1 
seen in vivo and in vitro (Figure 4.13). Therefore, we investigated which signalling pathways 
could have been triggered by ANXA1 upon binding and activation of its main receptor FPR2. 
As extensively described (Section 4.5.4.1.2), small GTPases have an essential role in the 
control and regulation of the actin cytoskeleton, of the tight junctions formation and overall 
of the paracellular permeability; moreover, we have already shown that ANXA1 is able to 
regulate RhoA-dependent pathway in endocrine cells (McArthur et al., 2009). Therefore, we 
measured the activity of the major small GTPases proteins in the wild-type hCMEC/D3 cells 
and in ANXA1 antisense clones (Figure 4.16; Panels B and C). Interestingly, whilst levels of 
active RhoA were low in wild-type cells, activity was markedly increased in antisense clones. 
Importantly, this activity was significantly reduced by treatment with hrANXA1 (20 µg/ml, 3 
hours), indicating that the absence of endogenous ANXA1 permits excessive activity of 
RhoA, a factor known to trigger enhanced paracellular permeability via increased actin 
cytoskeleton instability (i.e. stress fibres formation and destabilization of the cortical F-actin 
ring). Moreover, we could also detect an increased level of basal Rac1 activity in WT 
hCMEC/D3 compared to AS cells, partially restored by ANXA1 treatment. Basal activity levels 
of Rac1 are well known to have a positive effect on paracellular permeability through an 
effect directed towards the cortical actin cytoskeleton, which sustains cell-cell junctions 
maintenance (Wojciak-Stothard et al., 2001; Komarova and Malik, 2010).  
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The third GTPase analysed, namely Cdc42, also showed a different level of activity in cells 
with lower endogenous ANXA1 levels; since its involvement in terms of BBB paracellular 
permeability definition and maintenance is less understood and most probably not as 
important as it is known for RhoA and Rac1, we did not investigate further. Therefore, the 
treatment of either AnxA1 null mice or ANXA1 antisense hCMEC/D3 clones with hrANXA1 
limits RhoA and improves Rac1 activities, stabilizing the actin cytoskeleton towards the 
formation of healthy tight junctions, which ensure appropriate BBB integrity. 
 
Figure 4.16 Exogenous ANXA1 both enhances endogenous ANXA1 and inhibits activity of the RhoA 
small GTPase in hCMEC/D3 cells. A| Treatment of wild-type hCMEC/D3 cells with 20 µg/ml hrANXA1 
for 3 or 24 hours induces upregulation in endogenous ANXA1 expression, as indicated in the 
representative Western blot (upper panel) and in the densitometric analysis (lower panel); data are 
representative of at least three different experiments, performed in duplicate, and are presented as 
mean ± SEM. One-way ANOVA was performed and followed by Bonferroni post-hoc test, in which * 
indicates p<0.05 vs. untreated. B| hCMEC/D3 cells transfected with an antisense sequence to ANXA1 
exhibit constitutively raised activity of the small GTPase RhoA, an effect that can be reversed by 
treatment with 20 µg/ml hrANXA1 for 3 hours. Thrombin (Thr; used 1 IU/ml in serum-free medium 
for 8 minutes) was used as positive control. Data are representative of n=3 independent 
experiments. C| hCMEC/D3 cells transfected with antisense sequence to ANXA1 exhibit 
constitutively decreased activity of Rac1 and Cdc42, an effect that can be reversed by the treatment 
with hrANXA1 for 3 hours. Separate cell lysates were loaded for 30 minutes at 37°C with either 
GTPγS or GDP (provided with the assay kit) in order to have positive and negative internal controls. 
These were run in parallel with the unknown samples for the isolation and detection steps and 
finally visualised to confirm successful procedure. GAPDH was chosen as loading internal control. 
Data for Rac1 are representative of at least three independent experiments, while Cdc42 has been 
studied only once, therefore these data should be defined as only preliminary. 
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4.8 Discussion 
The BBB plays a vital role in at the interface between the periphery and the CNS, acting as a 
physical barrier, interpreting and decoding the stimuli that travel through the blood, which 
indicate the overall state of the entire body. The physiological mechanisms regulating the 
BBB permeability are not fully clear yet; that is why there is increasing interest in defining 
and mechanistically explaining how the peculiar physiological properties of the BBB are 
maintained, so that the main protagonists in this process can be possibly exploited as 
therapeutic targets under pathological conditions (Komarova and Malik, 2010).  
 
4.8.1 Annexin A1 as a new player in the definition of BBB properties 
Our in vivo data showed that BBB permeability is significantly greater in Anxa1-/- mice than 
in wild-type controls; this defect in basal paracellular permeability could be reversed by 24 
hours intravenous treatment with human recombinant ANXA1. Interestingly, the 10-fold 
increase in paracellular permeability did not result in oedema formation (Figure 4.7, Panel 
D) or in any symptomatic manifestation, indicating that the mechanisms dedicated to drain 
the CSF back into the blood stream [like the arachnoid villi in the sagittal sinus of the dura 
mater (Yamashima 1986) or the aquaporins in the astrocytic end-feet (Filippidis et al., 2011)] 
are able to compensate the augmented fluid passage, protecting the entire brain from 
building noxious pressure. Importantly, the defect caused by the lack of Anxa1 seemed to 
affect only the endothelium of the BBB, without causing any morphological defect on the 
main other components of this complex structure (Figure 4.8).  
Complementary evidence obtained from the human cell line hCMEC/D3 showed ANXA1 to 
be distributed distinctively at the sub-membranous level (Figure 4.11, Panel F; Figure 4.14, 
Panel A).  ANXA1 expression was shown to inversely correlate with paracellular permeability 
to 70 kDa fluorescent dextran, since ANXA1 positively correlated with cell-to-cell junction 
proteins (Figure 4.11), in particular occludin and VE-cadherin, as already shown in our 
animal model. Having confirmed a strong ANXA1 expression in the choroid plexus epithelial 
cells (see Chapter 2 and Chapter 5) may contribute to support this novel idea, since they 
also exhibit highly organised tight junctions and may benefit from this novel ANXA1 role. 
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Overall, these novel findings propose ANXA1 as a new fundamental endogenous component 
of the system that regulates and maintains BBB permeability, and highlights its role in the 
physiology of cerebral microvasculature. Moreover, the ability to restore an altered 
phenotype shown by hrANXA1 both in vivo and in vitro intriguingly gives this protein high 
potential to be therapeutically exploited.  
The experiments performed to unravel this new role for ANXA1 at the BBB endothelium 
level all revealed the important effects on the stability of the actin cytoskeleton, which 
affects consequently the cellular polarity and tight and adherens junction 
formation/maintenance. We have identified a number of pathways through which ANXA1 is 
able to regulate the conformation of the cytoskeleton: endogenous ANXA1 is able to directly 
interact with β-actin, while released/exogenous ANXA1 influences the complex small 
GTPases signalling pathways involved in the cytoskeleton dynamics.  
 
4.8.1.1 Endogenous Annexin A1 targets the actin cytoskeleton 
The results presented in this chapter have stressed the importance of ANXA1-actin 
interaction to maintain BMECs peculiar tightness. The idea of ANXA1 directly interacting 
with actin and the cytoskeleton has been proposed for several years to explain many of the 
functions that ANXA1 mediates (Schlaepfer and Haigler, 1987; Alvarez-Martinez et al., 1996; 
Patel et al., 2011). However, evidence for ANXA1 and F- or G-actin interaction was almost 
exclusively obtained from cell-free in vitro biochemical assays, a factor that reduced the 
applicability and reliability of these findings.  
In this chapter, we were able to detect direct binding of ANXA1 and β-actin (Figure 4.12) in a 
human cell line model. Although Annexin A1 has been indicated as strong F-actin binding 
protein (Cote et al., 2010), in our model this interaction appeared mainly, but not 
exclusively, to involve cytosolic rather than fibrillar actin as demonstrated by several 
biochemical approaches and by microscopy. In fact, only a percentage of the points of co-
localisation visualised by the proximity ligation assay were also co-localising with actin 
microfilaments forming the cytoskeleton, while the majority seemed to be scattered 
throughout the cytosol, always in the vicinity of regions where the F-actin fibres were 
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abundant. Moreover, we were able to detect ANXA1 only in the soluble fraction of total 
protein extracts (Figure 4.12; Panel F), therefore indicating that the interaction with 
insoluble actin fibres was not normally detectable or it was not enough stable under 
physiological conditions. We could only detect ANXA1 in the insoluble fraction in hCMEC/D3 
overexpressing ANXA1 (Figure 4.12; Panel F), letting us speculate that only a considerable 
increase in protein expression can result in the protein being able to stably interact with the 
actin microfilaments, as already shown elsewhere in vitro. Given that ANXA1 appeared to 
bind predominantly to soluble G-actin, it was tempting to speculate on a potential role as an 
endogenous effector specialised in stabilizing actin monomers and oligomers prior to 
addition to the growing cytoskeleton (Lee and Dominguez, 2010). Currently, we know that 
the assembly of stable actin dimers or trimers is the rate limiting step in the formation of 
actin fibres, so to overcome the kinetic hurdle, cells are provided with a broad set of actin-
nucleating protein complexes called actin nucleators, which are formed by various 
components (nucleation promoting factors; NPFs) and present enzymatic and chaperone-
like activity favouring actin filaments formation (Firat-Karalar and Welch, 2011). 
Interestingly, ANXA2 has been shown to be an important nucleating protein for endosomal 
transport and trafficking (Morel et al., 2009); this may certainly reinforce the possibility that 
also ANXA1 may play a similar role at the level of the BBB endothelium. In support of the 
involvement of ANXA1 in the regulation of actin filaments formation, previous work showed 
this protein to directly interact with profilin, another member of the huge family of ABPs 
(Alvarez-Martinez et al., 1996; Alvarez-Martinez et al., 1997).  
Additionally, we should also remember that ANXA1 is a strong Ca2+-dependent binding 
protein of negatively charged phospholipids, which are abundant in the inner membrane 
leaflet of live cells and in the external one of apoptotic cells. Patel et al. (Patel et al., 2011) 
demonstrated that sub-membrane ANXA1 is able to link actin microfilaments to the plasma 
membrane in order to generate enough support and strength for membrane protrusions 
and phagocytic cup formation. We did identify ANXA1 to be present most prominently at 
the same sub-cellular level (Figure 4.11; Panel D), therefore it is highly possible that the 
endogenous population of the protein could also act as an anchor for the cytoskeleton, so 
that it can be linked and maintained at the sub-membranous level, where it serves as an 
important scaffolding structure for the cell-cell junctional components.  
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This statement is strongly supported by several findings here reported (in particular by 
Figure 4.11, Panel F and Figure 4.12, Panel D), in which the correlation between sub-
membranous ANXA1 and cortical F-actin is clearly evident.  
Finally, we also detected biochemical interaction between a limited quantity of VE-cadherin 
and ANXA1, as presented in Figure 4.11, Panel G. Considering the position of ANXA1 close to 
cell-cell junctions levels and cortical actin microfilaments, it is possible that the protein is 
part of a complex at the cell junctional level. We cannot exclude a potential role of ANXA1 
as linking factor between VE-cadherin and cortical F-actin, which represents an important 
interaction for junctional correct assembly and overall for tight junction assembly. However, 
the strong evidence obtained on ANXA1 role on actin cytoskeleton, along with the limited 
co-immunoprecipitation with VE-Cadherin, led us to conclude that this interaction, if real, 
could represent close proximity between the two proteins and a similar positioning inside 
the cells, more than a real physical interaction.  
In our model, we did observe a positive effect of ANXA1 in terms of cortical actin ring 
formation and towards cell polarity definition; we did also identify a limited number of 
stress fibres, which ran parallel to longitudinal cellular axis (Figure 4.12; Panel B). 
Considering this and the possible link between ANXA1 and VE-cadherin (both structural and 
functional), it is possible that this protein also influences the formation of discontinuous 
adherens junctions, suggested to occur in confluent endothelial monolayers and to be 
involved in regulation of junction formation and paracellular permeability, making the entire 
monolayer readily responding to certain stimuli (Millan et al., 2010).  
Although the scope of this part of the project was not to describe in detail the molecular 
involvement of endogenous ANXA1 in actin cytoskeleton dynamics, we could gather a 
strong evidence, along with other published work (Patel et al., 2011), placing ANXA1 as an 
endogenous regulator of actin microfilaments behaviour by taking part directly into the 
filaments formation and cytoskeleton localisation.  
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4.8.1.2 Annexin A1 also functions in an autocrine/paracrine fashion 
In a previous report (McArthur et al., 2009), we showed Annexin A1 to be linked with 
inhibition of hormone exocytosis through actin polymerization triggered via FPR receptor-
dependent stimulation of RhoA kinase (ROCK) activation. Here, in addition to the 
endogenous role of ANXA1, we observed a similar autocrine/paracrine action of ANXA1 
(Figure 4.12 and Figure 4.16), which resulted in increased F/G actin ratio, confirming 
previous evidence (Ikebuchi and Waisman, 1990), as well as in the potentiation of cortical 
actin ring. ANXA1 is constantly released by microvascular endothelial cells and we have 
observed that considerable levels of exogenous protein are able to trigger new synthesis of 
the protein itself, therefore reinforcing its endogenous role. Moreover, we showed that 
basal ANXA1 also serves to constitutively inhibit the small GTPase RhoA [as it normally 
happens at cell confluence (Beckers et al., 2010)] while guaranteeing a certain degree of 
Rac1 activity. RhoA is known to initiate a signalling pathway resulting in the formation of 
disorganised stress actin fibres generating centripetal forces, which destabilize cell junctions 
and paracellular permeability (Wojciak-Stothard et al., 2001; Zlokovic, 2005). Instead, Rac1 
has been shown to stabilize the endothelial junctions, favouring the formation of cortical 
fibrillar actin ring and reducing itself RhoA (Wojciak-Stothard and Ridley, 2003). 
Improvement of the endothelial barrier function can therefore be achieved by increasing 
the Rac1/Rho activity ratio by either inactivating Rho or activating Rac1, with exogenous 
ANXA1 seemingly involved in both pathways.  
We did not investigate post-translational modifications of tight and adherens junctions, 
which can be linked to small GTPases action (Wojciak-Stothard et al., 2001; Wolburg and 
Lippoldt, 2002; Wojciak-Stothard and Ridley, 2003), mainly because of the lack of specific 
antibodies for phosphorylated tight- and adherens-junctions components; therefore, we 
cannot exclude that the inhibitory ANXA1 action on RhoA does also involve blocking 
negative effects directly exerted on tight-junctions [occludin and claudins mainly (Wojciak-
Stothard and Ridley, 2002)], besides blocking those played on the cytoskeleton; moreover, 
we cannot exclude that augmented Rac1 directly phosphorylates VE-cadherin, which has a 
positive effect in terms of junctions formation, as reported (Seebach et al., 2007).  
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We did not make use of any specific antagonist or inhibitory molecule directed towards one 
of the members of this numerous family since they would have caused changes in terms of 
BBB permeability in the conditions in which we work (confluent monolayers, supposed 
quiescent state of the cells).  
As for the autocrine/paracrine action of ANXA1, significant reports have indicated FPR2 to 
be the major ANXA1 putative receptors (Perretti, 2003; Migeotte et al., 2006; Perretti and 
D'Acquisto, 2009). Interestingly, several reports have linked FPRs with activation of 
signalling pathways based on small GTPases, like Rac1 (Belisle and Abo, 2000), Cdc42 
(Glogauer et al., 2000) and Rho-based signalling (Simoes and Fierro, 2005). These works 
based their investigation on different models, while none has so far linked FPRs with 
RhoA/Rac1 in endothelium; however, they may indicate that the complex role of ANXA1 in 
reducing RhoA activity while guaranteeing basal Rac1 activity may be exerted through 
different receptors of the same family. The strong downstream implication of Protein Kinase 
C (PKC) in several FPRs ligands responses (Le et al., 2002) as well as in the activation of RhoA 
- by phosphorylation and inactivation of the inhibitory protein RhoGDI (Wojciak-Stothard et 
al., 2001; Wojciak-Stothard and Ridley, 2002) - definitely supports our idea.  
The autocrine/paracrine role produced by ANXA1 may be particularly important from a 
pharmacological point of view, as not only it supports the importance of the continuous 
release of protein outside the cell to contribute to the maintenance of BBB structure and 
function, but also it propose ANXA1 to be amenable for future therapeutic targeting in 
conditions associated with an impaired BBB. This point is further reinforced by our 
experiments with the Anxa1 null mouse, where, even in the absence of intracellular AnxA1, 
we could induce a significant phenotypic rescue through treatment with hrANXA1, again 
highlighting the central role of FPR2 and its potential for therapeutic exploitation. 
 
4.9 Limitations of the study 
Every model presents limitations; for example, we could consider limited the in vivo mouse 
model, since it presents BBB permeability values different if compared to humans. On the 
other side, in vitro cell line models are based on simplified conditions, which may limit the 
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impact of the findings. We tried to adopt a multi-targeting approach to complement our 
findings. Results derived from human samples represent a plus, not only because they offer 
more reliable mechanistic explanation, but also because they offer the possibility to test 
new potential treatments. Consequently, we chose the immortalised cell line hCMEC/D3 as 
in vitro model for brain cerebrovascular endothelium, since it proved to be easy to use and 
reliable in its phenotype, as many recent published studies certainly testify. When possible, 
we tried to rely on primary murine BMECs to confirm the major findings obtained in vivo 
and in the cell line; however, cost, time and handling constraints limited their extensive use.  
As with any in vitro cell line models, we had to face several constraints. In general, the 
isolation of primary cells from their natural environment causes the loss of some of their 
features and this is particularly true for CNS-derived endothelial cells. Immortalization with 
viral oncogenes (SV40 large T antigen, used with hCMEC/D3, is one of these) has possibly 
contributed to the alteration of the phenotype. A way to compensate for the lack of 
endogenous stimuli is to grow hCMEC/D3 in co-culture with those important components of 
the BBB known to be extremely important to induce the peculiar properties of BMECs, 
namely astrocytes (Abbott, 2002; Abbott et al., 2006; Wilhelm et al., 2011) and pericytes 
(Armulik et al., 2010). Soluble released factors (Alvarez et al., 2011) as well as direct contact 
between endothelial cells (Wilhelm et al., 2011) and other cells are fundamental to promote 
immune quiescence and limit the basal active phenotype usually visualized in cell lines. 
Some initial attempts have been described but have failed to show significant 
improvements (Hatherell et al., 2011), therefore further optimisation will be required to 
obtain reproducible and satisfying results. We did not test co-cultures for several reasons: 
first, we decided to simplify the model conditions and to focus on endothelial cells biology; 
second, we could not have access, at the time, to a good line of astrocytes or pericytes, 
possibly non tumorigenic; third, funds limitations placed these experiments beyond the 
primary scope of the study. This may seem a limitation, since all our studies have focused on 
permeability regulation, which depends on the correct expression and formation of 
junctional proteins and on the proper cellular and molecular polarisation. This is a likely 
reason for why hCMEC/D3 monolayers showed low TEER values compared to in vivo values 
(Crone and Olesen, 1982) or other mammalian primary cells, like rodent, porcine and  
bovine models (Deli et al., 2005; Abbott et al., 2012; Patabendige et al., 2012) or cell lines 
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(Silwedel and Forster, 2006). However, the values we were able to obtain - around 50 Ω·cm2 
- are among the best ones for this line. Despite these considerations, we were able to detect 
clear-cut differences linked to changes in Annexin A1 expression levels, as well as to give 
proof of concept for the putative mechanisms of action. Since we wanted to justify the 
pioneering results obtained in the Anxa1 null mouse through albumin-bound Evans Blue, we 
decided to use tracers with a significant molecular weight (FITC-conjugated dextran 70 kDa), 
likely not affected by the leakiness shown by hCMEC/D3 with ions (low TEER) and small 
tracers [FITC-conjugated dextran 4 kDa; (Wilhelm et al., 2011)].  
Shear-stress is another important and often not mentioned physiological stimulus that 
contributes to the peculiar specialisation of BMECs (Cucullo et al., 2011). The microvascular 
cerebral blood flow creates intense forces values that seem to contribute to the 
differentiation of the endothelium into the highly specialised BBB phenotype and to 
intervene in every functions of the barrier (paracellular permeability regulation, leukocyte 
migration, etc.). The reasons for the improvement offered by shear-stress are not fully clear, 
but seem to be linked to aerobic metabolism changes (Cucullo et al., 2011).  
Several other aspects of the complex structure of the NVU have not been taken directly into 
account; for example, the glycocalyx, i.e. the luminal layer of extracellular polymers, was not 
taken into consideration during the study despite its presence on vascular endothelial cells 
(Ebong et al., 2011) because we looked at the passage of molecular tracers from the luminal 
side to the abluminal, not at the uptake of these by endothelial cells. Also, growing evidence 
is currently supporting the importance of basal lamina (Engelhardt and Sorokin, 2009; 
Engelhardt and Coisne, 2011) and perivascular space in defining the barrier in its entirety 
but it seems to be more relevant for cellular transmigration than for the diffusion/passage 
of molecules. We cannot exclude a role of ANXA1 in other cellular components, like the 
astrocytes, which were shown to express the protein (Young et al., 1999; Knott et al., 2000; 
Probst-Cousin et al., 2002).  
Knowing the fundamental role played by these cells in determining the correct maturation 
of blood-brain barrier, such investigation will deserve future attention.  
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Gross ANXA1-linked changes in receptor-mediated or non-specific transcytosis have not 
been detected during our paracellular permeability studies (Appendix; Figure 10.3); these 
observations were only drawn from microscopic analysis of hCMEC/D3 monolayers without 
investigating for changes in the molecular pathways involved in this process, like caveolae 
formation (Nag et al., 2011). However, no reports linked ANXA1 to caveolae regulation.  
Finally, we did not consider the role of phosphorylated forms of tight junctions; first, 
because there is a shortage of specific antibodies able to recognized these post-
translationally modified forms; second, the relevance of these modification still needs to be 
confirmed, with some supporting a negative effect on the overall stability of the cellular 
junctional complex (Murakami et al., 2009) and others indicating a correlation with 
functional membrane localisation (Sakakibara et al., 1997; Wong, 1997).  
 
4.10 Future work 
Before moving on to investigate the therapeutic exploitability of this protein, the molecular 
pathways involved in ANXA1 exogenous pool mechanism should be elucidated in detail 
starting from the evidence we have already collected (FPR2 involvement; small GTPases).  
With this work, we have detailed the physiological ANXA1 implications in paracellular 
permeability, whose impact on the brain parenchyma should also be clarified. The interest 
now moves to the impact of the protein in terms of endothelium-leukocyte interactions, 
since this has great clinical implications. Indeed, recently we started to investigate the role 
of ANXA1 in the interactions between leukocytes and vasculature from the endothelium 
point of view, since all the previous studies have instead only considered its effects played 
on circulating cells (Perretti et al., 2002; Roviezzo et al., 2002; Yazid et al., 2010).  
Regulation of the adhesion molecules by different levels of ANXA1 expression, together with 
the implications on endothelium extravasation by patrolling circulating cells are aspects 
undergoing already deep investigation. 
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4.11 Summary and conclusions 
This chapter described the latest evidence for a direct implication of ANXA1 in contributing 
to the correct formation and assembly of the actin cytoskeleton, directly influencing the 
entire process of cell-cell junctions formation. This represents indeed a novel role, different 
from the classic immunological participation, which the protein has been historically linked 
to. We added more information to the scattered reports present in literature about the 
structural involvement of ANXA1 into cytoskeleton dynamics, by focusing our attention 
within the BBB endothelium, which was until now an unexplored field in terms of ANXA1 
functions. Interestingly, there seem to be two ways by which ANXA1 produces its 
physiological role, one by the endogenous pool and the other one by the released 
population of ANXA1 molecules. We propose that these two pathways act in concert to 
maintain tight junction formation, and through this they preserve efficient BBB function, as 
described in Figure 4.17.  
Our results showing that a reduction in ANXA1 expression in BMECs leads to a decrease in 
the formation of junctions and a loss of cellular polarity, with a consequent increase in 
paracellular permeability, may definitely provide important clinical implications for 
conditions where ANXA1 is reduced at this level; please refer to Chapter 5 for more details. 
In parallel, the enhanced junction formation obtained through increased ANXA1 expression 
and exogenous recombinant protein may also be therapeutically useful.  
Overall, it is not too speculative to propose Annexin A1 as a new endogenous mediator 
participating in endothelial barrier maintenance and limiting the response to permeability-
increasing mediators as it will be discussed more in detail in Chapter 6. This class of 
endogenous factors are normally present in blood plasma, enriched within the endothelium 
and are also concentrated in certain spots of the tissue interstitium to continuously provide 
support for the vascular integrity. Among these factors, we should mention fibroblast 
growth factor (FGF), which mediates the integrity of TJs and AJs or cyclic adenosine-
monophosphospate, which shows stabilization of microvascular barrier properties by 
positively regulating Rac1 activity and protecting against disruptive stimuli, like thrombin or 
bacterial inflammogens (Baumer et al., 2008). Annexin A1 could definitely be listed as one of 
these factors, specific for the blood brain barrier endothelium.  
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Figure 4.17 Schematic representation of potential mechanisms of action of ANXA1 in BBB integrity 
maintenance. Our experimental evidence demonstrated the existence of at least two mechanisms 
mediating the effects of ANXA1 on paracellular permeability. 1a| Endogenous ANXA1 binds to β-
actin, promoting cytoskeleton formation, and 1b| serving as an anchor linking it to the plasma 
membrane facilitating the establishment of tight junctions between endothelial cells. Released 
ANXA1 acting via FPR receptors 2a| inhibits the activity of RhoA and 2b| promotes the activity of 
Rac1, which can limit RhoA-dependent stress fibre formation as well as activating MLCP, therefore 
preventing the contraction of actin-myosin filaments; overall, this promotes cytoskeletal stability 
and enhances tight junction formation, hence contributing to BBB integrity. 3| Exogenous ANXA1 
appeared also to have a positive effect on the total ANXA1 content, therefore potentiating the 
endogenous mechanism of action.  
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5.1 Overview and aim of the chapter 
In this chapter, I will present some still-in-progress data on ANXA1 expression in the BBB 
under pathological conditions such as multiple sclerosis. The introductive section is not 
completely exhaustive of all the literature published; this is merely for the purpose of thesis 
scope and length. Therefore, I often refer to literature for more detailed information.  
These data offer novel clinical perception on ANXA1 role in disease and they correlate well 
with our previous findings (presented in Chapter 4) on the Anxa1-/- mouse, which defined 
the benchside of the project, underlining once more the central role played by the protein 
and the implications that a lack of it could mean in the pathophysiology of diseases like 
multiple sclerosis, as well as proposing a novel therapeutical target.  
 
5.2 Involvement of the BBB in pathology and aging 
The blood brain barrier is often regarded as a static, passive structure that merely serves as 
an impediment to molecular access (i.e. drug delivery) into the CNS (Carvey et al., 2009). 
The neuron-centred vision of central diseases often precluded consideration of a potential 
role of the vasculature in the disease pathogenesis, despite knowing how highly vascularized 
is the brain [400 miles of capillaries run within the human brain parenchyma; (Grammas et 
al., 2011)]. The reality is, instead, that in a number (if not in all) of CNS pathologies, BBB 
physiology is altered, negatively contributing to the outcome of the disease. It is not clear if 
changes in BBB physiology should be considered more as one of the causes of the disease, 
as part of the pathophysiological process, as a consequence of the disease or both (Carvey 
et al., 2009). Nonetheless, recent evidence supports the hypothesis of endothelial 
dysfunction as a link between neurological impairment and vascular disease and as a crucial 
sensitizing/worsening factor in the development of CNS disorders (see Figure 5.1).  
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Figure 5.1 Dysfunction of the blood-brain barrier during neurological diseases. Impairment of the 
barrier mediated by neuroinflammation leads to disruption of the physiological boundaries between 
the peripheral blood stream and the brain parenchyma. As a result, circulating factors as toxins, 
complement, ions and in certain cases even leukocytes can enter the brain and be sensed by the 
various components of the neurovascular unit. Chemokines, metabolites, neurotransmitters etc. 
may then leave the brain parenchyma and enter the blood stream. The uncontrolled mixing that can 
occur between compartments that are usually separated strongly contributes to determine a self-
sustaining process participating in the disease process. Adapted from Carvey et al., 2009. 
 
The concept of the BBB as a static structure is now old-fashioned and starts to be replaced 
with the idea of BBB being a dynamic interface not only responsive to signals coming from 
the periphery through the blood stream, but also derived from the brain parenchyma. 
Stroke and ischemic brain oedema, traumatic brain injury (TBI), multiple sclerosis (MS), 
human immunodeficiency virus (HIV) and other pathogenic infections, Alzheimer’s disease 
(AD), Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), inflammatory pain, 
epilepsy and brain tumours are only a small number of CNS disorders, with involvement of 
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the BBB (Engelhardt and Sorokin, 2009; Grammas et al., 2011; Neuwelt et al., 2011). The 
impairment in the regulation of exchange occurring towards the brain could allow many 
molecules, agents and even uncontrolled immune cells to access the nervous parenchyma 
(Coisne et al., 2005; Stolp and Dziegielewska, 2009; Zlokovic, 2005). The initial opening of 
the BBB can be seen as a potential attempt to recruit more defensive tools and to try to 
resolve the harmful insult, but in presence of an excessive phenomenon, it would seem that 
the inflammation becomes uncontrolled and detrimental, ultimately contributing to the 
neuronal death. Factors that are produced during neuroinflammation, like pro-inflammatory 
cytokines (mainly TNF-α, IL-1 and IL-6), reactive oxygen species (ROS), bradykinin and 
prostaglandins, lead to BBB opening (Deli et al., 2005). In support of this, much interest is 
now focused on anti-oxidant and anti-inflammatory therapies as modulatory approaches to 
treat inflammatory-mediated diseases and to limit the implications on the microvasculature 
(Coisne and Engelhardt, 2011).   
The level of BBB injury can be very different, but normally changes can be of two types: 
complete breakdown of barrier function (for example in stroke or in brain tumours) and 
subtle functional and structural barrier impairment without massive initial damage (for 
example in AD and PD) as reviewed (Wolburg and Lippoldt, 2002). Pathological conditions 
can, therefore, affect various features of the barrier. To cite only some recent evidence, it is 
becoming clearer the involvement of pericytes in certain metabolic-related pathologies of 
the BRB (Diffley et al., 2009), while astrocytic regulatory role can also be altered, with 
numerous molecules (aquaporins, TGF-β, proteolytic enzymes like metalloproteases that 
can affect basal lamina, etc.) showing altered expression (Abbott et al., 2006; Carvey et al., 
2009). Within the endothelium, oxidative stress and the generation of ROS has been 
detected as a consequence of initiating pathological factors like amyloid-beta in AD, 
mutated scavengers in ALS and certain products expressed by HIV. BMECs possess a great 
number of mitochondria, therefore being highly susceptible to oxidative challenges (de 
Castro et al., 2010; Grammas et al., 2011). Overall, all these alterations were shown to be 
mediated by inflammatory mediators released during the pathogenesis events (Abbott et 
al., 2006), which ultimately caused changes at the level of correct tight- and adherens-
junctions formation and functionality, as well as in the activation of the endothelium, which 
responds by increasing the expression of leukocyte adhesion molecules.  
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Therefore, the ultimate effect is the alteration of the controlled permeability to solutes and 
cells (Carvey et al., 2009; Coisne and Engelhardt, 2011; Grammas et al., 2011). These 
changes can either be intense and clearly evident, as during the manifestation of the 
disease, or more subtle (at the level of the signalling pathways regulating the barrier 
properties), detected during neurological disorder asymptomatic phases. Those changes 
might therefore be an early step on the way to develop further barrier damage, ultimately 
contributing to the disease appearance.  
In conclusion, the endothelium of the blood brain barrier is primarily involved in CNS 
disorders due to its high responsive nature and ability to sense even small alterations both 
within CNS and in the periphery. Inflammatory signals represent the link between the 
pathology and the vascular impairment, in both directions, as it is becoming clear for 
multiple sclerosis, which represents a good example of the complex signals and events 
occurring in neurological diseases with disruption of the BBB.  
 
5.2.1 BBB and multiple sclerosis 
5.2.1.1 Multiple sclerosis: generalities 
Multiple sclerosis is a heterogeneous and complex diseases characterised by inflammation, 
demyelination, scarring and axonal degeneration in the CNS, first described in 1868 by JM 
Charcot (Clanet 2008;Compston and Coles, 2008). MS represents truly a good example of 
multi-factorial disorder, since it arises after exposure to various, and mostly unknown, 
environmental trigger(s). The development of MS is thought to require a combination of 
factors acting on susceptible genetic traits, leading to a response targeting the myelin 
sheaths surrounding the nerves (Glass et al., 2010).  
The pathological mechanisms of the disease have lately become clearer: MS has an irregular 
temporal and spatial development throughout the neuraxis, with a predilection for optic 
nerves, periventricular white matter, brain stem and spinal cord. What characterise the 
disease is the classical MS lesion called plaque or scar (scleroses), an area where myelin 
degenerates and gets removed by macrophages and microglial cells, while axons remain 
relatively preserved in their morphology but functionally are deeply impaired. MS lesions 
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are also characterised by pronounced astrocytic gliosis and formation of glia scars, aiming to 
constrain the problem (Compston and Coles, 2008). 
The most common theory of MS pathogenesis is that it is an autoimmune inflammatory 
condition and it involves the role of activated leukocytes, mainly CD4+ lymphocytes, 
antibody-producing plasma cells and macrophages, penetrating the brain parenchyma and 
causing damage to the nervous tissue by attacking the myelin sheaths around axons of the 
brain and spinal cord. However, the aetiology of the disease is complex, not yet fully 
understood and controversial (Behan and Chaudhuri, 2010): in general, myelin shows 
metabolic abnormalities that may be caused by a combination of genetic predisposition, 
environmental factors, infectious factors and others listed as potential cumulative cues 
leading to the development of the disease (Marrie 2004). Viral and bacterial infections are 
thought to be strong candidates as factors able to initiate the disease, since they may 
activate the immune system against auto-antigens such as myelin, potentially through 
mechanisms as molecular mimicry (Sospedra and Martin, 2005; Ascherio and Munger, 
2007). Genetic factors are thought to play a role, since the risk of acquiring MS is higher in 
relatives of people diagnosed with the disease and various polymorphisms in T and B cells 
loci are reported to influence susceptibility to MS (Fugger et al., 2009), but the strength of 
familial influence is still a huge matter of debate (Compston and Coles, 2008). Both innate 
and adaptive immunity are involved in the pathology, with the former showing a prominent 
role in the initiation of the disease, in particular through the role of cells such as dendritic 
cells, macrophages and microglia (Bailey et al., 2007; Glass et al., 2010). Various 
environmental factors have received past and current attention as susceptibility triggers 
[the example of the role of sun and vitamin D being extremely significant (Ascherio et al., 
2010)]; however, their actual role and importance is still debated (Compston and Coles, 
2008). 
The huge debate on MS currently occurring testifies how unclear the definition of the 
pathological mechanisms is and how important this is to develop preventive and curative 
approaches. At present, there is no known cure for MS: current treatments attempt to 
return function after an attack, prevent new relapses and prevent permanent disability. One 
of the factors negatively affecting the success of therapies is the chronic presence of 
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inflammation, which is the basis for the vicious perpetuation and exacerbation of the 
disease. Moreover, pre-existing central inflammation has been proposed as one of the 
potential causes for the disease: in fact, one of the hypotheses is that neuroinflammation 
could lead to generation of ROS and other toxic reactive species, which attack the normal 
brain antigens, forming neo-antigens (Minagar and Alexander, 2003). These can either leave 
the brain for lymphoid tissues (Weller et al. 2009), inducing a classically-activated adaptive 
immune response or may be presented directly in situ to naïve lymphocytes by antigen-
presenting-like cells  such as microglia, perivascular macrophages, pericytes, BMECs and 
astrocytes (Hemmer et al., 2004; Minagar and Alexander, 2003).  
 
5.2.1.2 Brain barrier alterations in MS pathology 
Despite the aetiology of the disease still remaining unclear, it is widely accepted that BBB 
and BCSFB alterations are among the earliest abnormalities seen in MS, as testified by the 
clear vascular leakage of fibrinogen and other serum proteins described in post-mortem MS 
brains (Coisne and Engelhardt 2011), which plays an important role in the development and 
progression of the disease. While the BCSFB alterations in TJs have only been poorly 
characterised, despite the choroid plexus being one of the principal entry paths for immune 
cells into the inflamed CNS (Engelhardt and Wolburg 2004; Engelhardt and Sorokin 2009; 
Coisne and Engelhardt 2011), interest has mainly focused on alterations at the BBB level. In 
the interesting study by Plumb et al. (Plumb et al. 2002), around 40% of all the microvessels 
analysed in MS patients (either with a relapsing-remitting or chronic progressive disease) 
showed alterations (ZO-1 and occludin discontinuous staining, focal leakage of serum 
proteins, leukocyte capping), indicating how diffuse the implication of the vasculature can 
be.  
The fact that some vessels of the normal appearing white matter (NAWM) also showed 
some degree of alteration supports the idea of vascular changes occurring much earlier than 
the pathological events and symptoms, therefore lesion activity not being a prerequisite for 
barrier alterations. Moreover, this evidence led some scientists to propose this as a primary 
initiating event in the pathology of the disease (Stolp and Dziegielewska, 2009).  
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Two types of BBB disruption are known to occur in MS patients: first, phases of intense 
acute focal loss of barrier, characteristic of acute and chronic MS lesions; second, diffuse 
dysregulated BBB is seen in patients with a long-term, low-intensity pathology (Bennett et 
al. 2010).  
The mechanisms for the breakdown of the barriers are incompletely understood, but some 
recent evidence indicates inflammation and inflammatory mediators as the key cause in 
triggering all the vascular-related events seen during the course of the disease (Minagar and 
Alexander 2003). Activation of the endothelium (changes in paracellular permeability and 
adhesion molecules) alters the BBB properties and contributes to the progression of the 
pathology (Carvey et al. 2009; Coisne and Engelhardt 2011; Holman et al. 2011) through the 
recruitment of activated T-lymphocytes, which tend to focally accumulate in the 
perivascular space of the capillaries and post-capillary venules (between the endothelium, 
the basal lamina and the astrocytic end-feet), a phenomenon that has been named 
“perivascular cuffing” (Minagar and Alexander 2003; Engelhardt and Coisne, 2011). Here, 
leukocytes undergo a certain number of phases resulting in the invasion of the CNS and 
their detrimental action. Linked to these aspects, recent studies have also shown the 
relevant role played by meningeal barrier and subarachnoid space for inflammatory cell 
recruitment and pathology outcome (Howell et al., 2011; Choi et al., 2012). 
The experimental allergic encephalomyelitis (EAE) murine model shares several 
commonalities with the human disease, plus gives many indications about barriers 
disruption and how activated lymphocytes enter the intact CNS (Bennett et al. 2010; 
Grammas et al. 2011), since this model is not driven from central triggers (Engelhardt and 
Coisne, 2011; Huitinga et al., 1998). IFN-γ and TNF-α, among the cytokines elevated in MS, 
and free radicals have been shown to disrupt certain tight junctions and to reduce VE-
cadherin (Jy et al. 2004).  
Gross focal disruption of the BBB has been consistently demonstrated in vivo in acute 
relapsing and chronic progressive events; in parallel, subtle increase in vascular permeability 
has also be shown in early stages and during remission of the disease (Plumb et al. 2002), 
causing a consequent confined leakage of serum proteins into the brain parenchyma which 
may represent a sensitizing event (Simpson et al. 2010). Mouse models with impaired 
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junction molecules and subsequent enhanced paracellular permeability demonstrated that 
the disruption of the endothelial tightness favour the entry via the paracellular pathway of 
activated leukocytes (Engelhardt and Coisne, 2011). Not only lymphocyte extravasation is 
important for the pathogenesis of the MS, but also the invasion by neutrophils and 
monocytes has been shown to stand a role in this pathology (Bolton et al. 1998; Allport et 
al. 2000); these other leukocytes are well known to cross the endothelium by provoking a 
direct disruption of the junctional complexes, and the rate of migration increased in 
presence of already damaged junctions. The same considerations stand also for the BCSFB, 
which has a central role in lymphocytes invasion during multiple sclerosis (Engelhardt and 
Sorokin 2009).  
Nowadays, it is still unclear if the disassembly of the barriers is secondary to the 
characteristic inflammation of the disease, or alternatively if the weakening of the barriers 
actually precedes the inflammatory process, therefore supporting the theory of MS being 
also a hemodynamic vascular disorder, as a party of researchers, led by Zamboni and his 
colleagues, has been trying to propose (Zamboni et al. 2007; Simka 2009). Despite these 
recent innovative hypothesises have been strongly reshaped and debased by strong patient 
studies (Comi et al., 2013), this new enthusiasm around the question has posed the 
vasculature topic under the spotlight of the MS community. Today, subtle BBB leakage can 
be detected via perfusion magnetic resonance imaging (MRI), which has become an 
important diagnostic instrument (Abbott et al., 1999; Plumb et al. 2002) to detect new 
inflammatory lesions in relapsing-remitting or chronic progressive MS patients. 
 
5.2.2 BBB alterations with ageing 
Ageing has an important impact on the integrity of all tissues, including the blood-brain 
barrier. Constant daily stimulation, adaptation, reorganisation, etc. have a cumulative effect 
on this complex structure and compromise the fundamental role of the BBB. Several age-
related changes are evident in the BBB properties, both at an anatomical and a physiological 
level. For example, aged microvessels show a smaller diameter and an increased tortuosity, 
which can have consequences in terms of shear-stress (Cucullo et al. 2011); endothelial cells 
show fewer mitochondria, indicating therefore impairment from the transporters point of 
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view (Zeevi et al. 2010). Defects in transport of glucose, amino acids, hormones and other 
important molecules has also been shown giving higher risk of nutrient-deficient syndromes 
and cognitive decline. The specialized efflux pump system of the BBB also showed 
decreased activity (in particular P-gp), which could clearly explain some neurological 
conditions of the elderly like delirium and the adverse effect of certain medications 
(Toornvliet et al. 2006). No known aging-effects on tight-, adherens-junctions or surface 
adhesion molecules have been reported, although they seem to respond much more quickly 
and intensely after an insult. Interestingly, vascular regional heterogeneity has also been 
proposed for the ageing of the BBB: in fact, greater vascular impairment appears in certain 
brain regions of the old mouse (Pelegri et al. 2007). All these changes seem to occur 
gradually during life-time, and do not normally (Carvey et al. 2009) result in evident changes 
in the overall integrity [at least in human; some animal models showed controversial results 
(Campbell et al. 2007; DiNapoli et al. 2008)]; however, it is clear that the aged BBB is more 
prone to react to certain conditions, by responding with a more intense increase in 
paracellular permeability and loss of its main properties (Zeevi et al. 2010). Old individuals 
are often characterised by white-matter lesions (WML), which are a strong indication of the 
impairment in the microvasculature: in fact, local low serum protein extravasation has been 
indicated as a major factor in determining the activation of surrounding glial cells with the 
consequent damage of circumscribed areas of white matter (Simpson et al. 2010; Zeevi et 
al. 2010).  
The role of aging at the level of other components of the NVU (e.g. pericytes, astrocytes, 
basal lamina) has not been sufficiently investigated; however, it is becoming clearer why 
aging represents the most important risk factor for neurological disorders, and yet another 
important factor to take into account when investigating the central role of the BBB in 
neurological disorders. 
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5.3 Methods 
Please refer to Chapter 3 for the description of general in vitro procedures. More details 
about certain technical aspects of procedures specifically used for the purpose of only this 
chapter and about clinical details of the cases analysed will be here provided. Please refer to 
the Appendix (Chapter 10) for solution composition.  
 
5.3.1 Ethical approval 
Human tissue samples were provided by the UK Multiple Sclerosis Tissue Bank and the UK 
Parkinson’s Disease Society Tissue Bank at Imperial College London. Patients’ blood samples 
were provided by Dr A. Malaspina (North-East London and Essex MND Care and Research 
Centre. Ethics Committee: 09/H0703/27). Informed consent was obtained from all the 
individuals recruited. Blood samples and clinical information were collected following 
consent. The study has followed established standard of practice (SOPs) and the 
experiments were conformed to the principles set out in the World Medical Association 
Declaration of Helsinki. 
 
5.3.2 Selection of human post-mortem tissue 
Human post mortem samples were obtained from brains of cases of neuropathologically 
confirmed MS, PD and non-neurologic controls. Brains were selected according to the 
following criteria: 1) availability of full clinical history 2) no evidence of cancer at post-
mortem 3) negligible atherosclerosis of cerebral vasculature. Demographic data for the 
samples used are described in the Appendix (Table 10.4 and 10.5). 
 
5.3.3 Staining of human post-mortem tissue 
After collection, tissue was divided in specific regional and sub-regional areas, fixed in 10% 
PBS-buffered formalin and embedded in paraffin. From each paraffin block, 8 µm sections 
were cut and used for immunohistochemistry. Sections were deparaffinised in xylene and 
rehydrated in decreasing alcohols. Endogenous peroxidase activity was inhibited by 
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incubation in peroxidase inhibiting buffer for 30 minutes at room temperature. Sections 
were rinsed twice in TBS 1X and incubated for 1 h at room temperature in blocking solution 
to saturate non-specific binding. Then, sections were incubated overnight at 4°C with anti-
human ANXA1 primary antibody (Invitrogen, UK), rinsed twice in washing solution, 
incubated in biotinylated goat-anti rabbit secondary antibody (Vector Laboratories, UK) at 
the dilution of 1:100 for 2 hours at room temperature, rinsed twice with TBS 1X and 
incubated for 45 min in the avidin–biotin complex (ABC) conjugated with HRP in TBS (Vector 
Laboratories, UK). Following two washings in TBS 1X, the reaction was developed in 
developing solution for 5 minutes. Sections were rinsed twice in TBS 1X, counterstained with 
Ehrlich’s haematoxylin for 2 minutes, rinsed in tap water for 5 minutes, fast dip in acid 
alcohol and again rinsed in tap water twice (1 minute/wash). Sections needed to be 
dehydrated in 95% ethanol for 2 minutes, cleared in xylene for 10 seconds and mounted 
with DPX mountant for bright-field microscopic analysis. The staining was performed by Dr. 
S. McArthur. 
 
5.3.4 Light microscopy 
Brightfield photomicrographs were captured at room temperature using a Nikon Eclipse 
E800 microscope fitted with a 60X oil immersion objective lens (NA 1.4mm, WD 0.21mm), a 
CoolSNAP-Procf camera (Roper Scientific, UK) and Image ProPlus 4.5.1 software (Perkin-
Elmer, UK). Pictures were acquired by Dr. S. McArthur. 
 
5.3.5 Plasma anti-ANXA1 autoantibodies measurement via ELISA 
Human plasma samples from MS and healthy donors were used to measure ANXA1 content 
by ELISA as reported in the General methods (Chapter 3).  
Detection of serum autoantibodies directed towards human ANXA1 was performed by Dr. S. 
McArthur according to a published protocol (Goulding et al., 1989). Plastic ELISA 96-well 
plates (Nunc MaxiSorp, ThermoScientific, UK) were coated with 100 μl/well bicarbonate 
buffer, containing 10 μg/ml hrANXA1 at 4°C overnight; two wells were coated with only 
bicarbonate buffer and used as negative controls.  
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After 3 washes with bicarbonate buffer, wells were blocked with 100 μl/well 0.01M PBS (pH 
7.2) containing 1% FCS at 37°C for 1 hour. Control and patient serum samples were diluted 
1:20 in 0.01M PBS containing 1% FCS, loaded into the plate (100 μl/well) and incubated for 1 
hour at 37°C. Two wells were incubated without human serum to account for further 
unspecific secondary antibody binding. Plates were washed 7 times with wash buffer, and 
then incubated with HRP-conjugated goat-anti human IgG/IgM (1:1000; Sigma, UK) in 
antibody buffer for 1 hour at 37°C. After 7 washes with wash buffer, plates were incubated 
with 100 μl/well of commercial (eBioscience, UK) 3,3′,5,5′tetramethylbenzidine (TMB) HRP 
substrate and incubate at room temperature for 10 minutes until clear colour was 
developed. The reaction was finally stopped with 100 μl/well of stop reaction. Plates were 
read at 450 nm, with background correction at 570 nm.  
Results were expressed in ELISA units, which are defined as follows:  
ELISA	unit = 	
Absorbance	450	nm-570	nm × dilution	factor
reaction	volume
 
 
5.3.6 Testing plasma from MS patients effects on paracellular permeability 
On the basis of previous reports (Alexander et al., 2007; Minagar et al., 2003; Proia et al., 
2009), we decided to test the effects of plasma derived from patients affected by MS, in 
order to obtain more information about some of the findings described in this chapter. In 
particular, the investigation conducted by Alexander et al. (Alexander et al., 2007) was of 
special relevance, since they observed down-regulation of Annexin A1 of human brain 
endothelial cells after incubation with 10% serum from relapsing-remitting MS patients. 
hCMEC/D3 wild-type cells were cultured on transwell filters as described in the General 
methods chapters. When confluent, cell monolayers were incubated with EGM-2 MV 
medium complete with all the growth factors except for VEGF. After 3 days, fresh medium 
with all the growth factors (except for VEGF) and 20% plasma from a MS patient or a control 
patient was replaced for 24 hours. Paracellular permeability of 70kDa FITC-dextran was 
assessed over 60 minutes (Section 3.2.2.1.6).  
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After the experiment, cells were washed in DPBS without Ca2+ and Mg2+, quickly trypsinised 
and lysed in RIPA buffer as described in section 3.2.4.2.  
Total ANXA1 quantity was then measured via ELISA and normalized against total protein 
content, which was measured by BCA assay.  
Permeability coefficients (expressed as percentages of the permeability coefficients 
obtained in cells incubated with healthy control plasma samples) were then plotted against 
the normalized quantity of ANXA1 and correlation was defined through GraphPad Prism 5.  
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5.4 Results 
5.4.1 Expression of ANXA1 is selectively lost from the cerebral capillaries of 
MS post-mortem cases, but not with other neurodegenerative conditions 
Whilst examination of samples from PD cases revealed that expression of ANXA1 was 
maintained within the cerebral capillaries, ANXA1 was not detectable in those of post-
mortem subjects who had died with multiple sclerosis (Figure 5.2, Panel A). The loss of 
ANXA1 was moreover highly cell-specific, being limited to capillary endothelial cells of the 
BBB brain parenchyma, as both leukocytes and other vascular sites with strong ANXA1 
expression, such as the ependyma, choroid plexus and meningeal vessels, remained highly 
immunoreactive (Figure 5.2, Panel B).  
Since an old report linked the development of autoantibodies directed towards ANXA1 in 
patients with auto-immune disorders like systemic lupus erythematous (SLE), independently 
of the treatment the patients were receiving (Goulding et al., 1989), we decided to look for 
differences in autoantibodies in 10 healthy subjects and in 10 patients with MS, as this, if 
true, could have proved to be a potential explanation for the great differences in 
microvascular ANXA1 observed. 
The level of auto-antibodies was very low in controls and in MS patients (Figure 5.2, Panel C) 
and we did not observe any difference in terms of type of disease (relapsing/remitting 
compared to secondary progressive MS) or treatment received by the patients (data not 
shown). Therefore, this was not a plausible reason for the selective loss.  
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Figure 5.2 Expression of ANXA1 is selectively lost from the cerebral capillaries of subjects with 
multiple sclerosis, but not with other neurodegenerative conditions. A| Immunohistochemical 
analysis of ANXA1 expression within cortical capillaries of human male and female post mortem 
brains. Note in particular the strong expression of ANXA1 in circulating leukocytes of multiple 
sclerosis cases, but the absence of endothelial ANXA1 positivity (marked by asterisks). Typical images 
from cases described in Table 8.1, sections are 8µm thick, while scale bar is 10 µm. B| 
Immunohistochemical analysis of ANXA1 expression within the ependyma of the lateral ventricles, 
the choroid plexus and the meningeal blood vessels of aged controls and MS cases. Black arrow 
indicates the lack of expression of ANXA1 in parenchymal microvessel endothelial cells of MS cases, 
compared with the meningeal vessel endothelial cells (marked by asterisks); sections are 8 µm thick, 
scale bar is 20 µm. C| Detection of auto-antibodies in the plasma samples of MS patients (n=10) and 
healthy age- and sex-matched controls (n=10). Results are indicated in ELISA units, calculated as 
specified in the methods; data are presented as mean ± SEM. No statistical differences have been 
detected after Student t-test. Panels A, B and C were produced by Dr. S. McArthur.  
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5.4.2 Effect of MS plasma on endothelial ANXA1 content and permeability 
Having shown that the expression of auto-antibodies against ANXA1 is not responsible for 
the peculiar decrease in ANXA1 in BBB endothelium, we decided to investigate further by 
testing if plasma from patients affected with MS presented some factors that could 
negatively influence the expression of ANXA1 and consequently the paracellular 
permeability endothelial monolayers. Interestingly, MS patients showed a significant 
reduction in circulating ANXA1 in the plasma (Figure 5.3; Panel A), which could definitely 
have an important effect on paracellular permeability, aware of the exogenous ANXA1 role. 
Using the in vitro hCMEC/D3 model, we observed (Figure 5.3; Panel B) that exposure to MS 
patient plasma induced a significant increase in paracellular permeability, which closely 
correlated with a plasma-induced reduction in endothelial ANXA1 expression; this effect 
was not seen in cells exposed to plasma from healthy donors.  
 
Figure 5.3 Plasma from MS patients contains less ANXA1 and reduces ANXA1 content and 
paracellular permeability of endothelial cells. A| Plasma ANXA1 content from MS patients and 
healthy age- and sex-matched controls was calculated by ELISA; lines indicate mean values. Student 
t-test was performed between the two independent groups, with * indicating significant p <0.05 vs. 
control group. B| Paracellular permeability coefficient (expressed as percentage of the untreated 
control) of monolayers of human hCMEC/D3 cells following exposure for 24h to medium containing 
20% plasma from MS patients, correlated with total levels of ANXA1 in the same hCMEC/D3 cells 
following exposure; linear regression line and 95% confidence intervals are marked, coefficient of 
correlation is 0.38, p <0.05.  
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5.5 Discussion 
These results strongly support for a role of ANXA1 as a main player in the maintenance of 
BBB integrity, following and complementing the mechanistic evidence that has been 
described in Chapter 4.  
 
5.5.1 ANXA1 expression changes in MS: which implications?  
Our finding of a selective loss of ANXA1 expression in the cerebral capillary endothelium of 
MS subjects is particularly important. As mentioned in the introduction, tight junctions like 
occludin have been reported to be impaired in their expression and distribution within the 
microvascular endothelium of MS patients, clearly paralleling our findings in AnxA1-/- mice. 
One fundamental detail that should be mentioned is that the endothelial ANXA1 down-
regulation occurs also in normal appearing white matter (NAWM); several reports stated 
the presence of aberrant vascular properties in areas not (yet) affected by active lesions, 
therefore our findings may definitely confirm that and contribute to the debate concerning 
if changes in BBB permeability precede leukocyte extravasation, or represent a consequence 
of immune cell accumulation (Engelhardt and Coisne, 2011; Larochelle et al., 2011). In 
particular, our finding on ANXA1 down-regulation at sites distant from active lesions 
strongly suggests a pre-existing weakening of BBB integrity to the development of active 
demyelination. Despite increasing evidence strongly supports the fact that T lymphocytes 
normally enter the healthy and diseased brain by crossing the endothelium via transcytosis 
(Engelhardt and Sorokin 2009) leaving the tight junctions intact (Engelhardt and Wolburg 
2004), alterations at the level of the paracellular permeability are equally important and 
influent since they may lead to an even more intense cellular invasion or, if the impairment 
is considerable, it may represent a further way of invasion (Minagar and Alexander 2003; 
Grammas et al. 2011). 
Previous reports have suggested both beneficial (Huitinga et al., 1998) and detrimental 
(Paschalidis et al., 2009) roles for ANXA1 in the widely-used animal model EAE; another 
work reported the evidence for ANXA1 expression in various cell types populating disease 
plaques, without adding more about the implications that this protein could have in the 
course of the disorder (Probst-Cousin et al., 2002).  
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The discrepancy with some of our findings from human disease may be justified by the use 
of a controversial animal model (Friese et al., 2006), which however has given important 
information especially concerning the vasculature implications (Bennett et al., 2010; 
Engelhardt and Coisne, 2011). In support to our findings and hypothesis, we should note 
that our studies on the role of ANXA1 were undergone in a defined cell/tissue type by 
studying changes in paracellular permeability, rather than examining the multiple complex 
interacting systems that may be involved in a whole animal model of disease. Moreover, we 
have been the first ones to focus on the endothelium: this is an important source of 
externalized ANXA1, which can ideally target other cell types, like circulating leukocytes. To 
this regard, we have previously shown ANXA1 to limit leukocyte extravasation through 
binding of the α4β1 integrin VLA4, blocking leukocyte adhesion to the endothelium (Solito et 
al., 2000). It is important to remember that one of the most widely used treatments to limit 
MS symptoms is currently the monoclonal antibody Natalizumab (commercialized as Tysabri 
by Biogen Idec and Élan), which targets the same integrin as ANXA1. It is therefore easy to 
speculate that the down-regulation of ANXA1, occurring in the cerebral microvascular 
endothelium as well as in the blood of MS subjects, may represent the loss of an 
endogenous break aimed at limiting excessive leukocyte adhesion. 
Glucocorticoids are strong inducers of ANXA1 and are widely used as therapeutic agents in 
the treatment of MS thanks to their anti-inflammatory properties, a fact that suggest again 
the importance that ANXA1 may play in the disease.  Although we don’t have experimental 
proof of an effect of glucocorticoids-triggered ANXA1 in restoring BBB integrity in MS 
patients, we can strongly suppose it, especially if considering that glucocorticoids like 
dexamethasone can induce ANXA1 expression in hCMEC/D3 cell line (data not shown). 
 
5.5.2 Why ANXA1 expression is selectively lost from BBB endothelium in MS?  
The most intriguing, and complex, question that remains to be elucidated is to understand 
how and why ANXA1 expression decreases so massively and in such a selective way at the 
level of the microvasculature of MS cases. Other conditions like PD and AD (data not shown, 
very similar to PD and aged controls), also characterised with a degree of BBB breakdown 
and persistent neuroinflammation, do not show such a phenotype.  
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At present the reasons for these differences are unclear. Possibly, one of the determinants 
could be in the different nature of these neurological disorders: PD and AD have their 
source of degeneration and inflammation within the CNS, while MS seem to be determined 
more by the impact of inappropriate activation of the peripheral immune system (Hemmer 
et al., 2004). Growing evidence is confirming this last concept, indirectly supporting the fact 
that peripheral stimuli are extremely important, especially for MS; in literature, we can find 
evidence indicating that blood samples from MS patients can decrease TEER in vitro (Proia 
et al., 2009) and that can also induce a down-regulation in ANXA1 amongst other proteins 
within endothelial cells (Alexander et al., 2007). The typical elevation in cytokines (mainly 
TNF-α) and/or other soluble unknown molecules observed in MS patients, in particular 
those in relapsing/remitting phase where the disease is highly active (Alexander et al., 2007; 
Carrieri et al., 1998) may represent a possible explanation, especially in light of what 
happens to microvascular endothelial-specific ANXA1 under acute pro-inflammatory 
conditions (please refer to Chapter 6). Chronic contact with these pro-inflammatory 
cytokines are known to produce significant effects on brain barrier components, in 
particular on tight-junctions (Engelhardt and Sorokin, 2009), so it is very likely that this 
action may also be mediated by affecting modulating molecules like ANXA1. Our data 
confirms and extends these two studies (Alexander et al., 2007; Proia et al., 2009), plus it 
provides a clear rationale for a correlation between ANXA1 expression and changes in BBB 
permeability in MS, potentially opening a new avenue in the investigation of this disease.  
 
5.6   Limitations of the study and future work 
Clearly, these findings represent only initial observations which should be confirmed by a 
larger cohort of samples. In particular, it would be extremely interesting to differentiate MS 
patients according to disease classification (relapsing/remitting, secondary progressive, 
primary progressive, progressive relapsing), since some recent studies (Komori et al., 2012; 
Teunissen et al., 2011) have evidenced marked differences in certain pathophysiological 
factors. Nonetheless, the body of evidence strongly supports the histological results 
showing loss in specific ANXA1 expression as they were distinctly reproduced in every MS-
related tissue analysed (10 cases, regardless the MS subtype).  
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At present, we are liaising with clinicians to significantly extend the screening of MS plasma 
samples for ANXA1 concentration and the latest results are confirming the finding of a 
constitutively lower protein concentration linked to the disease. A new focus will be to 
analyse longitudinal samples, so that we could possibly understand if this specific decrease 
in the protein is linked to a peculiar phase of the disease or if it is present throughout the 
pathology. Several factors have been reported to be informative markers linked to new 
relapse phases or even potential predictors (Gurevich et al., 2009; Kalinowska-Lyszczarz et 
al., 2011) so it would be interesting to understand if ANXA1 may play a similar role. 
The disruptive effects shown by MS plasma on BMECs tightness and total protein content 
have to be confirmed with a larger cohort of samples, from which correlation studies would 
certainly benefit. It would be extremely interesting to identify the molecular culprit(s) for 
this effect, investigating first the most logical candidates (for example pro-inflammatory 
cytokines raised in the plasma, reactive species, endogenous toxins) and then eventually 
move to alternative ones. We may benefit from high-throughput tools like proteomics, 
which are able to assess numerous samples and to identify major differences, on which then 
we may want to focus more in details.  
 
5.7 Summary and conclusions 
Our results undoubtedly confirmed a role for ANXA1 in the vasculature; the specific drop in 
the microvessels represents a novel finding, while the drop in plasma certainly opens new 
avenues for exploitation as a biomarker, if we can further confirm the absence at early 
phase of disease. The interest in decoding the complex mechanism that regulates barrier 
properties is very high at the moment, in particular for the identification of endogenous 
molecules that can dynamically regulate and support the communication between 
periphery and brain, affecting the overall homeostasis of the CNS. Considering how common 
alterations in BBB for MS patients are, how highly specific is the loss of ANXA1 from MS 
capillaries and how strong is the relevance in terms of BBB physiology, we can definitely say 
that annexin A1 is one of the molecules, with great therapeutic potential and it may also 
constitute a novel highly specific biomarker for early disease detection (Alexander et al., 
2007).
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6.1 Overview and aim of the chapter 
Chapter 4 and 5 have described the important role of ANXA1 at BMECs level, maintaining 
physiological tight barrier properties as well as being implicated in conditions such as MS. 
Bearing in mind the ultimate aim of the project, i.e. to elucidate ANXA1 role in periphery-to-
brain communication, we complemented these findings by investigating the protein 
involvement at BBB level during peripheral inflammatory conditions. Since MS patients 
usually show a peculiar high pro-inflammatory profile in their blood, known to be 
responsible for the perpetuation of the disease, the findings presented have also strong 
clinical implications. Furthermore, since many central and peripheral inflammatory diseases 
are strongly biased by the sex of the patient, while ANXA1 is regulated by steroids (Solito et 
al., 1998; Solito et al., 2003b) and a steroid messenger at the same time, we expanded our 
experimental plan to investigate sex differences. 
 
6.2 The blood brain barrier as a signalling interface 
Until recently, the BBB was considered to be a passive, impermeable barrier to immune cells 
and diffusible factors produced in the periphery. However, the BBB dynamically senses and 
responds to what happens elsewhere in the body. Due to its peculiar location, the 
endothelium represents a common and accessible target for all the molecules circulating in 
the blood, such as physiological hormones, nutrients, signalling molecules, or pathological 
cardiovascular risk factors, mediators of oxidative stress happening somewhere else, 
molecular signals indicating tissue disorders. The endothelium of the BBB is at the forefront 
of the defensive system of the CNS and it is deeply affected by peripherally-originated 
factors and actively responds to them (Carvey et al., 2009). The polarized transporter and 
receptor system of the BBB is seen as the conveyer of a directional signalling on the BMECs: 
upon ligand binding, signals are generated and are transferred into brain parenchyma and 
vice versa.  
One of the main features modulated by systemic signals is barrier integrity, whose 
implications in physiology and pathology have been extensively described in the previous 
chapters.  
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In addition, directional release of substances is also another way to respond to certain 
stimuli; therefore, BMECs are not passive mediators in this type of communication, instead 
they actively participate in decoding what happens in the periphery and how the CNS should 
respond to that.  
 
6.2.1 How peripheral inflammation impacts at the BBB level 
In the previous chapter, I have described how factors produced in the CNS during 
neurological disorders impact on the homeostasis of the BBB, determining the implication in 
diseases like AD and PD (Coisne and Engelhardt, 2011). Similarly, there is now clear evidence 
that the CNS mounts a complex response to systemic inflammatory processes, through 
different pathways. One of these involves the BBB, either by impacting directly on BMECs or 
on astrocytes, pericytes and perivascular macrophages (Abbott, 2002; Guillemin and Brew, 
2004). Overall, BBB responds via regulation of endothelial cells tightness and specific gene 
transcription regulation (Nadeau and Rivest, 1999), which ultimately convey the signal to 
the CNS. Subtle changes in BBB function and basal permeability may certainly have long 
lasting effects on the overall CNS homeostasis or at least increase the susceptibility of the 
CNS to develop neurodegenerative conditions. For instance, increasing evidence describes 
the impact of developmental peripheral inflammatory events on the initiation of 
neurological conditions through a direct “imprinting” effect at the level of the brain 
vasculature (Stolp and Dziegielewska, 2009). Indeed, it is not scientifically accepted that 
peripheral signals are able to enter into the depth of the brain parenchyma to stimulate 
neurons and other resident cells. Other relevant findings report the impact of infection and 
related inflammation on the brain through the BBB: activation of microglial cells by 
peripheral stimuli has been shown to be dependent on specific receptors present at the 
BMECs level (Gosselin and Rivest, 2008), while the upregulation of adhesion molecules on 
endothelial cells triggered by inflammatory stimuli (both central and peripheral) is now 
widely accepted (Carvey et al., 2009).  
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6.2.1.1 The role of pathogen-associated molecules (PAMs) 
The main protagonists in defining the impact of inflammation on the BBB are inflammogens 
and pro-inflammatory mediators. Pathogen-related molecules such as LPS, a cell wall 
component of Gram-negative bacteria, are well known to modulate effects at the BBB level, 
not only when released in the brain parenchyma during CNS-related infections but 
especially when circulating in the blood, following systemic infections (McAllister and van de 
Water, 2009; Nagyoszi et al., 2010). Apparently, this happens either directly through an 
action on endothelial cells (Descamps et al., 2003) or indirectly through other BBB 
components, such as astrocytes (Abbott et al., 2006). There is no evidence for direct entry 
of PAMs in the brain parenchyma (Singh and Jiang, 2004; Banks and Robinson, 2010). 
Instead, these molecules signal through specific receptors, called Toll-like receptors (TLRs), a 
huge family of transmembrane proteins (in human there are 10 members) some of them 
abundantly expressed at the BMEC level (Nagyoszi et al., 2010). These receptors are able to 
recognize a great number of molecules sharing specific molecular patterns conserved 
among pathogens (the PAMPs). Also, there are some specialised TLRs, able to recognize 
molecules linked to the damaged tissue (the already mentioned DAMPs). These receptors 
are highly dynamic and respond quickly to the immunological state of the host; for example, 
in presence of infection, inflammation and oxidative stress are well known to up-regulate 
the expression of specific TLRs, augmenting their responsiveness.  
When circulating, LPS is bound to a soluble acute protein called LPS-binding protein (LBP); in 
this form they can bind to the receptorial complex for LPS on cells surface, which is formed 
by CD14, TLR-4 and the accessory protein MD-2 (Singh and Jiang, 2004), triggering complex 
intracellular signalling pathways, as depicted in Figure 6.1. The ultimate effects triggered by 
LPS on BBB are: increased paracellular permeability, by alteration of the junctional 
components, increased adsorptive endocytosis of substances, increased diapedesis of 
peripheral cells, both by augmented adhesion molecules and efficiency of the trans-cellular 
route of barrier crossing, alterations at the level of the transport system, secretion of 
several molecules (mainly pro- and anti-inflammatory cytokines, chemokines, reactive 
oxygen species) in a polarized fashion (Banks, 2006; Verma et al., 2006; Nagyoszi et al., 
2010).  
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Figure 6.1 Signalling triggered upon LPS binding. LPS is bound by LBP, and the complex is recognized 
by CD14, which is weakly associated to the cell membrane. This complex is able to activate TLR4, in 
turn signalling through the adaptor protein MyD88 and the serine kinase IRAK, responsible for the 
major molecular signalling pathways triggered downstream. The mechanism by which TLR4 is 
activated is not known and could be either direct or indirect. From Aderem and Ulevitch, 2000.  
 
6.2.1.2 The role of inflammatory mediators and cytokines 
It should be noted that, unless septicaemic conditions are reached, it is very difficult to 
obtain blood concentrations of pathogen-related molecules sufficient to be able to 
significantly affect the cerebral endothelium. More likely, the effects on BBB due to 
infections are triggered by the subsequent exponential release of inflammatory mediators. 
Interestingly, in areas of focal inflammation, infiltrating cells from the circulation, as well as 
activated resident cells like microglia, may create a milieu where the concentration of the 
cytokines reach much higher values than reported in the periphery and in circulation; such 
condition may therefore be enough to trigger substantial effects on the local 
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microvasculature (Wong et al., 1999). In addition, oxidative stress represents an important 
factor determining the direct damage to the BBB, affecting tight-junctions structure and 
homeostasis, with consequent disruption of BBB tightness (Lehner et al., 2011). Excitatory 
neurotransmitters (like glutamate and serotonin), histamine, arachidonic acid, endothelin-1, 
etc. also contribute to negatively affect the barrier functionality (Abbott, 2002). Enzymes 
like metalloproteases (MMPs) released by circulating or activated brain resident myeloid 
cells also play a primary role in disrupting cell junctions, basal lamina and overall the well-
being of the barrier (McColl et al., 2008; Stolp and Dziegielewska, 2009). However, the 
principal inflammatory messengers to readily affect the BBB are the pro-inflammatory 
cytokines, in particular TNF-α, IL-1β, IL-6 and interferons (IFNs), typically released during 
inflammatory reaction in response to infections or other insults; they show a strong 
influence on the BBB behaviour (Nadeau and Rivest, 1999; McAllister and van de Water, 
2009; Stolp and Dziegielewska, 2009), on BMECs (Lopez-Ramirez et al., 2012) and direct and 
indirect effects within the CNS, as reviewed in Figure 6.2.  
Most of the studies have focused on TNF-α, since it is considered to be the one most readily 
released during inflammation, initiating the so called acute phase reaction. It is clinically 
relevant, since it is implicated in several neurological disorders, mainly AD, PD and 
depression. Moreover, TNF-α is believed to play a key role within the pathological process of 
multiple sclerosis and its animal model of experimental autoimmune encephalomyelitis 
(EAE). In particular, not only it is produced by T lymphocytes invading the brain parenchyma, 
but it is also up-regulated in the serum of several patients before a relapse of active disease 
and it negatively affects the BBB and its peculiar tightness, while positively regulating the 
expression of adhesion molecules like ICAM-1 and VCAM-1, which represents a strong 
activation of the cerebrovascular endothelium (Minagar and Alexander, 2003; Silwedel and 
Forster, 2006).  
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Figure 6.2 The impact of pro-inflammatory cytokines on the endothelium of the BBB. Systemic 
inflammatory mediators can signal through the endothelium of the BBB and cause alterations of the 
tight junctions with a consequent increased permeability, increased expression of adhesion 
molecules, release of cytokines in the brain parenchyma and subsequent activation of the resting 
microglia, which can become over-activated and cause neuronal damage. As a consequence of these 
events, white blood cells may be able to move through BBB. Adapted from Stolp and Dziegielewska, 
2009.  
 
TNF-α is believed to stimulate the production of soluble mediators, such as prostaglandins 
and nitric oxide in the endothelium of brain capillaries as well as in the more accessible 
CVOs, which would represent the molecules to carry the signal into the brain parenchyma 
(Nadeau and Rivest, 1999). The BMECs highly express receptors for all the major 
inflammatory cytokines. In particular, TNF-α shows the ability to bind two receptors, 
respectively called TNF receptor type-1 (TNF-R1 or p55) and TNF receptor type-2 (TNF-R2 or 
p75), both of which present a death-domain in their cytosolic C-terminal portion. TNF-R1 
and TNF-R2 (in fewer amounts) are both expressed on BBB (Nadeau and Rivest, 1999; Pan 
and Kastin, 2002). They both bind soluble trimeric forms of TNF-α as well as membrane-
bound trimeric forms. Moreover, since the cytosolic domains are particularly different 
between the two receptors, it is believed that this may be linked to differential signalling 
triggers (Nadeau and Rivest, 1999).  
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In fact, p55 TNF-R1 is implicated in the upregulation of iNOS, COX enzymes, the adhesion 
molecules, the apoptotic pathway and the activation of NF-κB, while p75 TNF-R2 is more 
involved in cytokine production and integrin up-regulation.  
Several cytokines have been studied for their ability to cross the BBB and TNF-α is among 
these; interestingly, for TNF-α this occurs through the same TNF-α receptors, in a saturable 
and highly specific fashion, as shown by Pan & Kastin (Pan and Kastin, 2002). In pathological 
conditions, modelled by EAE, the transport of this relevant cytokine appears to be highly up-
regulated, with important clinical implications (Pan et al., 1996).  
 
6.2.1.2.1 Signalling pathways triggered by TNF-α and disruption of BBB 
We are now aware that cytokines can be actively transported through the barrier, so they 
are able to directly target CNS-resident cells (Nadeau and Rivest, 1999). However, being 
messenger molecules, TNF-α and other molecules main role is to take part in a signalling 
cascade involving a specific order of cells to be targeted and consequent amplification of the 
signal at each step to be achieved, in order to generate the appropriate response. Targeting 
BMECs is an essential step in the communication brought by pro-inflammatory cytokines. 
The signalling cascades triggered by cytokines are extremely complicated and ramified, as 
evident from the simplified cartoon on Figure 6.3, which exemplifies the TNF-α-triggered 
signalling. Not all of these pathways are activated upon binding of the ligand, since 
extensive cross-talk between them exists and usually one dominates over the others. For 
example, the nuclear factor-κB (NF-κB) negatively affects apoptosis signalling. Concurrent 
stimulation of other cytokines in the same cell (as happens during inflammation) can shift 
the balance towards a specific pathway and a specific functional response. In this way, a 
restricted number of signalling molecules can simultaneously trigger a vast array of 
responses on various cells with different roles, defining the appropriate inflammatory 
response.  
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Figure 6.3 Signalling pathways triggered by TNF-α. The cytokine can activate different pathways to 
induce apoptosis, cell survival or inflammation. In inflammation, TNF-α induces a strong activation of 
the stress-related JNK group, evokes the activation of p38-MAPK while it is responsible for minimal 
activation of the classical ERKs. Activation and nuclear translocation of NF-κB is another important 
pathway occurring in inflammation, which ultimately results in the NF-κB-driven transcription of 
some important inflammatory genes. Other signalling pathways, not depicted here, include 
phosphatidylinositol-3-kinase (PI3K)/Akt, which also promotes cell survival. Adapted from (Zhou et 
al., 2008; Wu and Zhou, 2010).  
 
At the level of BMECs, TNF-α results in increased leakiness and signalling through the 
BMECs, with the scope to communicate inflammation in the brain parenchyma. In addition, 
TNF-α can be highly cytotoxic: especially at high concentrations, it triggers the caspase-3/7 
pathway and apoptotic cell death program, as recently described in the same in vitro cell 
model we currently use (Lopez-Ramirez et al., 2012): understandably, cell death strongly 
contributes to the increase in permeability seen in inflammatory conditions. This cytokine is 
also able to trigger gene transcription through activation of NF-κB: in fact, blockade of this 
proved to be extremely protective towards the negative effects of inflammation on the 
endothelium (Zhou et al., 2008). Moreover, quick changes in endothelial cell morphology 
and permeability are also caused by mechanisms that have been proved to be linked to 
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activation of RhoA (Wojciak-Stothard et al., 1998; McKenzie and Ridley, 2007) and 
consequent changes in cortical F-actin, gap formation and negative effects on cell-cell 
junctions. Although the presence of this signalling pathway has not yet been proved at the 
level of BMECs, all the mentioned consequences of the cytokine-mediated inflammatory 
action have been identified by several investigators (Minagar and Alexander, 2003; Deli et 
al., 2005; Miller et al., 2005; Silwedel and Forster, 2006), confirming the negative impact of 
pro-inflammatory stimuli and the ultimate disruption of barrier properties. In detail, TNF-α 
(with or without other accessory cytokines) caused not only paracellular permeability 
augmentation, by negatively regulating gene transcription, functional localisation and 
expression of tight-junction proteins such as like occludin (Silwedel and Forster, 2006; 
Forster et al., 2008; Lopez-Ramirez et al., 2012), claudin-5 (Silwedel and Forster, 2006; 
Forster et al., 2008; McColl et al., 2008), ZO-1 (Aveleira et al., 2010; Lopez-Ramirez et al., 
2012) and JAM-A (Haarmann et al., 2010), and adherens junction proteins such as VE-
cadherin (Lopez-Ramirez et al., 2012), but also increased transcytosis (Miller et al., 2005), 
increased vesicular trafficking, adhesion molecule expression and leukocyte endothelial 
adhesion and migration (Minagar and Alexander, 2003). All the modifications appear to be 
triggered through JNK and apoptosis-independent caspase mechanisms, as described 
(Zehendner et al., 2011; Lopez-Ramirez et al., 2012). In order to perpetuate the 
inflammatory signal from the periphery into the brain parenchyma, BMECs are also able to 
synthesise cytokines (Frigerio et al., 1998) and easily-diffusible lipid mediators like 
prostaglandins (Ek et al., 2001) upon cytokines binding. All these responses strongly impact 
on the surrounding environment, on neurons but in particular on the highly reactive 
microglia cells.  
In summary, increasing evidence supports the existence of periphery-to-central cross-talk 
whose primary aim is to generate and assist the resolution of the events; endothelial cells of 
brain microvasculature are main protagonists in this phenomenon, contributing to the 
signalling between the two compartments. Inflammation-dependent BBB alterations may 
therefore result in immediate damage of the brain or in a subtle increase of the brain 
susceptibility to damage later on during life course, as in the case of developmental 
inflammation (Stolp and Dziegielewska, 2009).  
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6.3 Sex dimorphism and role of sex hormones 
Several disorders with an immune-inflammatory component present a sex (and age) bias in 
their presentation and pathophysiology. For example, rheumatic arthritis is more common 
and severe in women, as well as many other autoimmune diseases. Sex influences strongly 
characterise the brain, which has been correctly defined as sexually dimorphic: evidence of 
CNS developmental differences between males and females are becoming clearer and 
involve changes in synaptogenesis, population of the brain parenchyma by neuroglia and 
size of nuclei (Bale, 2009). However, the influence of sex hormones does not stop at the 
developmental level, but lasts throughout life, with different intensity, involving also other 
aspect of CNS physiology, like neuro-immunity and neuro-inflammation. Across a broad 
range of human CNS diseases, a significant difference between males and females in 
incidence, age of onset and severity can be seen. Neurological conditions such as attention 
deficit/hyperactivity disorder and schizophrenia (more common in males), 
neurodegenerative disorders like Alzheimer’s disease (male:female ratio around 1:3), 
Parkinson’s disease (male:female ratio almost 2:1), stroke, multiple sclerosis (Nilsson, 2007; 
Vegeto et al., 2008) show different incidence between males and females, at certain ages. 
Sex hormones are most likely involved, although the mechanisms are not fully clear. Most of 
them belong to the steroid hormone category, produced by the gonads or the adrenal 
glands; some other tissues also show the ability to synthesise them by conversion of other 
sex steroids. In this class of molecules we should mention androgens, like testosterone, 
estrogens, like estradiol, estriol and estrone, and progestogens, like progesterone.  
 
6.3.1 Estrogen hormones: a short overview 
Trying to summarize sex-linked endocrinology is a complex task, since this truly represents 
one of the widest scientific areas of interest, due to the numerous implications of sex 
hormones in several life actions: some have attempted this task and I address the interested 
reader to these authors' work (Brook, 1999; Gillies and McArthur, 2010a). Among all the sex 
hormones, estrogens (and particularly 17 β-estradiol, the most potent among the three, 
roughly 10 times more than estrone and 80 times more than estriol) represent the main 
regulatory female hormones plus offer an advantageous factor, since they provide 
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protection in diseases prevalent in men; the fact that most of such protection appears 
rapidly lost after menopause, with the concomitant decrease of these sexual hormones, 
supports such definition. However, the latest evidence on estrogens shows these hormones 
have extremely important roles also in men, since many tissues express the enzyme called 
aromatase, which is able to generate estrogen from circulating male hormone testosterone 
(Gillies and McArthur, 2010a). This is true particularly in the brain, where enzymatic activity 
has been detected to be quite strong at the level of different cell types such as astrocytes 
and neurons.  
As for all the steroidal hormones, estrogens derive from cholesterol through a complex 
series of synthetic reactions which involve several enzymes, most of which (including 
aromatase) are members of the huge cytochrome P450 superfamily. Stimulation of 
synthesis of estrogens in the female gonads (the ovaries) is triggered by a specific hormonal 
cascade which involves the gonadotropin releasing hormone (Gn-RH), followed by the 
folliculo-stimulating hormone (FSH) and the luteinizing hormone (LH). Interestingly, several 
non-reproductive tissues, like some brain resident cells, show the capability to synthetize 
estrogen from male hormones (BMECs, via aromatase) or from cholesterol (astrocytes) in a 
way independent of the gonadotropins (Krause et al., 2006).   
Estrogens can freely diffuse through cell membrane thanks to their amphipathic nature and 
they exert their functions through estrogen receptors, which are divided in two classes: the 
classic estrogen receptors, present in two isoforms, estrogen receptor α (ERα) and estrogen 
receptor β (ERβ) and the more recently discovered estrogen G-protein coupled receptor 
GPR30 (GPER) (Hazell et al., 2009).  
These hormones can mediate their actions through 2 different signalling pathways: the 
genomic and the non-genomic pathway. Classic ERs belong to the nuclear receptor 
superfamily and usually work as ligand-activated transcription factors, which are normally 
present in the cytosol but can dimerize and migrate into the nucleus upon ligand binding, 
where they can recognize and bind on estrogen responsive elements (EREs) present in the 
regulatory sequences of genes (Gillies and McArthur, 2010a). In this way, transcription of 
estrogen-responsive genes can be triggered or repressed (according to the mechanism 
adopted by the receptor and the type of co-activators or co-repressors that are recruited in 
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the site) and expression of the gene product modulated. It is possible that classic ERs can 
also work independently from ligand binding (ligand independent pathway), for example 
through phosphorylation triggered by other stimuli (Cenni and Picard, 1999). Moreover, 
regulation of genes which do not have EREs elements on their promoter, through 
interference with the binding of other transcription factors, was also shown (ERE-
independent pathway) (Kurebayashi et al., 1997; Harrington et al., 2003).  
The non-genomic pathway was discovered by observing estrogen-dependent effects too 
rapid to be a consequence of transcription-mediated effects; they usually involve increased 
intracellular Ca2+ by an action on intracellular stores or through an action on calcium 
channels, regulation of nucleoside (cAMP, cGMP) fluxes, transactivation of membrane 
receptors, and activation of various kinases involved in intracellular signalling perpetuation 
such as PKA, PI3K, MAPKs and ERKs. These effects were shown to be mediated either by 
membrane-associated classic ERs, apparently concentrated at specific cell membrane 
functional spots (caveolae) or by GPR30. These quick responses can either target specific 
molecules already existing within the cell by post-translationally modifying their action, or 
they can ultimately converge with the genomic pathway to affect gene transcription and 
protein synthesis in a more rapid way. These and other properties of the hormones, 
extensively reviewed in more comprehensive articles (Arnal et al., 2007), make estrogens an 
extremely interesting target of study. 
 
6.3.1.1 Regulation of ANXA1 by estrogens 
ANXA1 expression and action is intimately regulated by steroids like glucocorticoids (Solito 
et al., 2003b; Parente and Solito, 2004; Perretti and D'Acquisto, 2009; Perretti and Dalli, 
2009); this triggered growing interest to see if and how the molecule was affected by 
estrogens and in particular by the most potent 17β-estradiol. An early report indicated up-
regulation in synthesis and secretion of ANXA1 by 17β-estradiol (Castro-Caldas et al., 2001) 
in a human lymphoblast leukaemia cell line. Our group was the first to prove a direct 
transcriptional effect of estrogen at the level of ANXA1 human and mouse promoter (Solito 
et al., 2003a): as reviewed in Figure 6.4, we investigated the presence of putative ERE 
consensus sequences, according to the optimal binding sequence described by others 
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(Driscoll et al., 1998; Gruber et al., 2004) both in mouse and human promoters through a 
server for the prediction of known regulatory transcription elements (Farre et al., 2003). 
Overall, we were unable to detect palindromic ERE sequences in either promoters, but only 
regions with a reasonable similarity (within 85% similarity) to half of the consensus ERE for 
ERα and ERβ, while the mouse AnxA1 gene promoter showed also some other less similar 
putative elements upstream, indicating therefore a higher potential responsiveness. Other 
works confirmed our findings, for example by showing that ANXA1 was transcriptionally 
induced by estradiol in a model of breast cancer, mediating the anti-proliferative effect of 
the hormone (Ang et al., 2009), while Davies et al. (Davies et al., 2007) showed that 
ovariectomy in rodents negatively affected the expression of ANXA1 in the pituitary gland, 
while estradiol replacement restored it.  
More recently, estradiol was shown to swiftly modulate ANXA1 location on the membrane 
of human polymorphonuclear (PMN) leukocytes in a non-genomic fashion and to confer an 
anti-inflammatory profile upon inflammatory stimuli (Nadkarni et al., 2011) while in the 
brain microvasculature, ANXA1 has been shown to be mediator of the protective action of 
estradiol under inflammatory conditions, limiting the excessive adhesion of leukocytes on 
post-capillary venules (Hughes et al., 2012).  
Overall, despite the mechanisms of regulation being still not fully clear, increasing evidence 
is supporting the direct influence of estrogen on the expression and functional modulation 
of our molecule of interest.  
 
6.3.1.2 Impact of 17 β-estradiol in the CNS and brain microvasculature 
Several experimental and clinical studies have shown the influence of estradiol in the CNS, 
where it was proved to be involved in learning and memory mechanisms, mood definition 
and neurological development [for an extensive review refer to (Gillies and McArthur, 
2010b)]. On the clinical side, epidemiological studies comparing reproductive or senescent 
female and male patients have triggered great interest in estrogen-based treatments as a 
possible therapy for neurodegenerative and neuro-inflammatory disease, leading to the 
initiation of several clinical trials (Nilsson, 2007; Vegeto et al., 2008).  
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Figure 6.4 Comparative analysis of human and murine Annexin A1 promoter sequences. The figure 
reviews the finding reported in (Solito et al., 2003a). The human (Hu) and murine (Ms) promoter 
sequence comprised in the first 1000 bp upstream the beginning of the first region, the 5’ UTR, 
including the TATA box, were selected for human and murine Annexin A1 genes through UCSD 
Genome Browser and compared by BLAST® algorithm, identifying a stretch of around 200 bp with 
overall 82% identity. Through the PROMO ALGGEN server (Farre et al., 2003), a software for 
prediction of known transcription regulatory elements on DNA sequences, GRE and ERE putative 
sequences were identified within the sequence of interest, allowing for maximum 15% matrix 
dissimilarity between the query and the consensus. 
 
Initial studies have shown their protective action towards neurological disorders when 
presented in physiological concentrations/doses, in particular by triggering molecules with a 
neuro-trophic action, or with anti-apoptotic properties (Gillies et al., 2004), or stimulating 
the proliferation of stem cells helping regeneration (Maggi et al., 2004; Vegeto et al., 2008). 
Above these effects directly impacting on the affected neurons, estradiol is believed to 
possess strong immune-modulatory properties, which are exerted on the inflammatory 
reactions triggered in the CNS during neurodegenerative conditions. In particular, Vegeto’s 
group and others (Maggi et al., 2004; Krause et al., 2006; Vegeto et al., 2008) have elegantly 
shown the modulatory role on activated microglial cells, reducing pro-inflammatory 
cytokines and mediators release, their phagocytic phenotype, the production of ROS and 
nitric oxide via inducible NO synthase (iNOS), the activity of cyclo-oxigenases (COXs) which 
are all factors involved in the perpetuation of the disease.  
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Some evidence is arising concerning the ability of estradiol to reduce the expression of 
adhesion molecules on brain microvasculature, hampering the recruitment of more 
inflammatory molecules into the CNS. This has been observed in the case of AD and MS, 
offering new possibilities for therapeutic amelioration (Maggi et al., 2004; Vegeto et al., 
2008). Nitric oxide by endothelial NO synthase (eNOS) was also shown to be regulated in the 
endothelium (Nilsson, 2007), along with mitochondria functions [important for energy 
purposes, highly required in endothelium (Yang et al., 2005; Herson et al., 2009)]. Also, 
estradiol showed clinical impact on the outcome of vascular-related diseases such as stroke 
and consequent vasogenic oedema (Nilsson, 2007; Herson et al., 2009), indicating therefore 
direct implications on the brain vasculature. This also extends the discussion to the 
regulation of the integrity of the BBB and of barrier permeability, which is strongly affected 
by inflammation as explained earlier. Estradiol was shown to ameliorate the permeability of 
the BBB in vivo, since female mice appeared to possess a significantly less permeable barrier 
while experiments involving ovariectomy or animals in reproductive senescence showed 
that this advantage over males was eliminated (Bake and Sohrabji, 2004; Sohrabji and Bake, 
2006; Bake et al., 2009). Cell junctions like occludin were shown to be negatively modulated 
in absence of sex hormones, such a phenomenon being reversed by estradiol replacement 
(Kang et al., 2006). Also claudin-5 expression showed a similar phenotype in aged or 
ovariectomised animals (Bake and Sohrabji, 2004; Burek et al., 2010). These results justify 
aging-related BBB weakness and have been taken as partial explanation for the fact that 
several neurological disorders shown amelioration during pregnancy (when levels of 
estradiol are very high) and exacerbation in post-menopause or in the post-pregnancy 
period (Vegeto et al., 2008; Wilson et al., 2008). Supposedly, these actions are mediated via 
ERα at BMECs level, limiting the NFκB-mediated effects of inflammation (Galea et al., 2002; 
Krause et al., 2006; Nilsson, 2007; Vegeto et al., 2008). Only few scattered reports to our 
knowledge have attempted to investigate the protection offered by the steroid from the 
BBB integrity point of view. One (Galea et al., 2002) showed that pre-incubation with 
estradiol was able to limit the upregulation of adhesion molecules on endothelial 
membrane by blocking the inflammation-induced DNA binding by the transcriptional factor 
NFκB.  
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The most closely related study (Forster et al., 2008) indicates a protective effect on 
hCMEC/D3 cell line under TNF-α offered by the glucocorticoid hydrocortisone, which 
parallel the inductive effects shown by the synthetic glucocorticoid dexamethasone under 
non-inflammatory conditions (Romero et al., 2003). Therefore, knowing the impact that 
estradiol are believed to have on tightness properties of the brain barrier and with the 
evidence produced on estrogen modulation of ANXA1 promoter (Solito et al., 2003a), we 
hypothesised a protective role under inflammatory insults by this hormone, through the 
modulation of the molecule Annexin A1.  
 
6.3.1.3 Therapeutical exploitation of estradiol 
Many studies approaching the “bench-side” have been disappointing so far, partly due to a 
lack of knowledge about the molecular mechanisms and about the timing of action of 
estradiol, therefore triggering the need to clarify how and when this hormone becomes 
beneficial. Past and more recent evidence clearly supports a beneficial effect of estradiol 
but what years of studies on estrogen dosing for hormonal replacement therapies (HRTs) 
have taught, is that supplementation of hormones (estradiol and progesterone) needs to 
occur in a very controlled and tight fashion; in fact, the Women’s health initiative memory 
study (WHIMS) indicated an increased risk for dementia and cognitive impairment for 
women choosing HRT when already in menopause (Sohrabji and Bake, 2006). Also, recent 
evidence has demonstrated clearly that combinations of endogenous gonadal hormones, 
more than single ones, truly regulate the immunological status of the CNS (Sohrabji and 
Bake, 2006). This evidence was followed by findings of high hormonal doses resulting in 
detrimental effects like in the case of vascular-related diseases as stroke (Herson et al., 
2009) or in the modulation of important molecules like occludin (Ye et al., 2003), while 
replacement after a long period of low hypoestrogenicity did not produce protection in a 
model of aged animals (Bake and Sohrabji, 2004).  
The neuro- and vascular-related protection tightly depends on the clinical situation and 
experimental procedure. Beneficial effects of estrogen have been pre-clinically achieved 
only when given before the inflammatory burst, while it proved ineffective or even 
detrimental when provided after the initiation of the reaction (Vegeto et al., 2008).  
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It is clear, therefore, that timing of hormonal replacement in relation to the target, the stage 
of menopause and the initiation of the inflammatory challenge has a huge importance. 
Interestingly, some studies on murine models have evidenced how hormones normally not 
released by male gonads, like estradiol, could play a detrimental role in neurodegenerative 
conditions when administered in the male individuals (Gillies et al., 2004). This is one of the 
reasons why novel research has been looking for endogenous mediators of these hormones, 
which may modulate the mechanism of action in a less invasive fashion compared to that 
offered by exogenously given hormones and may suggest novel exploitable applications. 
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6.4 Methods 
Please refer to Chapter 3 for the description of general in vivo and in vitro procedures. Here 
I will provide details about certain technical aspects of procedures specifically used for the 
purpose of only this chapter. Please refer to the Appendix (Chapter 10) for solutions 
composition.  
 
6.4.1 In vivo techniques 
6.4.1.1 In vivo experimental plan 
In order to evaluate sex dimorphic responses to peripheral inflammation in terms of barrier 
permeability changes, we compared males and females C57Bl/6 mice over the time after 
challenging them i.p. with a single dose (3 mg/kg) of LPS, followed by i.v. Evans Blue 
circulation for 1 hour and subsequent evaluation of extravasation in the brain parenchyma 
as described (Section 3.2.1.3). LPS exposure time points analysed were: 4 hours (3 hours + 1 
hour Evans Blue circulation); 24 hours (23 hours + 1 hour Evans Blue circulation) and 7 days 
(7 days + 1 hour Evans Blue circulation). Section 10.9 (Figure 10.4; Panel A) in the Appendix 
describes the experimental plan.  
Since we detected significant differences between males and females after 4 hours LPS 
exposure (Figure 6.5), we decided to use this as end-point for the following experiment 
involving ovariectomy of female C57Bl/6 animals.  
 
6.4.1.2 Surgical rodent ovariectomy  
This procedure was performed by expert veterinary surgeons at Charles River Laboratories, 
according to the published guidelines (Burek et al., 2010). Comprehensive description is 
reported in the Appendix, Section 10.8.  
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6.4.2 In vitro techniques 
6.4.2.1 In vitro experimental plan 
For permeability studies, hCMEC/D3 were grown on transwell filters; when cells reached 
100% confluence, medium was changed to complete EGM-2MV without VEGF for 4 days 
(tightness incubation period) and stimuli were provided during this period of time. In detail, 
long incubation with 17β-estradiol (100 nM) or with the monoclonal antibody (or with the 
isotype control) occurred for 4 days, providing a repeated dose every 24 hours. Short 
incubations with the hormone occurred within the last 24 hours of the tightness incubation 
period. TNF-α and IFN-γ were both provided together at 10 ng/ml in the last 8 or 24 hours of 
the incubation period. For all the expression studies, cells were grown on tissue culture-
treated 24- or 12-well plates at a density that allowed becoming fully confluent and tight 
after 4 days of growth. This allowed us to perform long incubations with the stimuli (up to 4 
days). This choice was made to obtain conditions resulting in healthy growth and 
reproducible results in a setting close to what observed in functional permeability studies. In 
fact, we observed that non-polarized monolayers grown on surfaces other than transwell 
tend to overgrow and suffer once they reach 100% confluence, preventing us from keeping 
them in culture for long (4 days) incubations in such conditions. Figure 10.4, Panel B in the 
Appendix describes the experimental plan for in vitro experiments. 
 
6.4.2.2 Estrogen receptors agonists and antagonists 
In order to investigate which estrogen receptor(s) is involved in the modulation of ANXA1, 
we made use of highly specific agonising and antagonising molecules. The agonists chosen 
were: propylpryazole-triol (PPT) for ERα (used at EC50=200 pM); Diarylpropionitrile (DPN) for 
ERβ (used at EC50=850 pM); bromo-benzodioxol-tetrahydro-cyclopenta-quinolin-ethanone 
(G-1) for GPR30 (used at 20 nM). The antagonists were: Phenyl-trifluoro-methyl-pyrazolo-
pyrimidin-phenol (PHTPP) for ERβ (200 nM pre-incubation for 10 minutes, followed by 100 
nM β-estradiol); bromo-benzodioxol-cyclopenta-quinoline (G-15) for GPR30 (200 nM pre-
incubation for 10 minutes, followed by 100 nM β-estradiol). Total incubation time was 8 
hours (β-E peak of ANXA1 induction of either intracellular or extracellular ANXA1).  
Chapter 6 – Annexin A1 and peripheral inflammation at the BBB: sex-dependent differences 
 
Page | 178   Enrico Cristante – PhD degree thesis    
 
6.4.2.3 Quantitative reverse transcription (RT) PCR 
RNA from untreated and treated cells was extracted using Qiagen RNeasy Mini Kit (Qiagen, 
UK). 1 µg of RNA was reverse-transcribed for 2 h at 42°C using 30 International units (IU) of 
AMV retrotranscriptase (Promega Ltd, UK) according to manufacturer instructions, with 
oligo(dT)15 (Promega, UK) and RNAsin Ribonuclease inhibitor (Promega, UK). Negative 
controls were also included (a reaction without RNA). 5 µl of RNA solution were taken from 
each sample and used to create a mix solution. 100, 10 and 1 ng of reverse-transcribed RNA 
were analysed in triplicates by quantitative PCR according to manufacturer instructions 
(Quantitect SYBR green PCR kit; Qiagen, UK) and the following thermal cycle: initial 
denaturation - 15 mins, 95°C; 40 cycles comprising denaturation – 15 sec, 94°C, annealing – 
30 sec, 60°C, extension – 30 sec, 72°C. Data acquisition was performed during each 
extension cycle and melting curves were produced during the final ramping step up to 95°C.  
Each set of primers (specific for SYBR green quantitative PCR and purchased from Qiagen, 
UK; the sequence is undisclosed) was tested for optimal efficiency first.  
A linear standard curve was generated:  
threshold cycle (Ct) vs. log(reverse-transcribed	RNA	loaded	quantity) 
From this curve, the quantity of reverse-transcribed RNA giving a Ct around 22-26 (in the 
middle of the exponential phase of the reaction) was calculated and the slope of the curve 
was used to calculate the efficiency of the reaction as: 
E = 10
-
	
  
Efficiency values around 1.8/2.2 (representative of reactions where the number of products 
double at every cycle) were considered satisfying (Pfaffl, 2001; Bustin, 2010).  
Since we decided to use a highly expressed housekeeping gene, the ribosomal RNA 18S 
(rRNA18S), we chose to use Ct = 15 to calculate the quantity of reverse-transcribed RNA that 
needed to be analysed, because this value was in the middle of the exponential phase, 
therefore in the quantitative part of the whole reaction; moreover, the quantity of reverse-
transcribed RNA was, in this way, more similar to the ones that needed to be loaded for the 
other primers, therefore the role of normalization through the housekeeping gene was 
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more reliable. After all these considerations, a second reaction was set up: the amounts of 
reverse-transcribed RNA calculated for each set of primers were loaded in triplicates for all 
the samples to be assayed. The new mathematical model presented (Pfaffl, 2001) was 
applied in order to obtain a relative quantification of the target genes, normalized towards 
the reference housekeeping gene.  
The ratio “treated sample vs. control” was calculated as:  
Ratio = 	
(E	target	gene)	(

	–		)
(E	reference	gene)	(

	–		)
 
This mathematical model has been considered as the most precise one among those 
available so far, because it results in precisely describing if and how treated cells differ 
compared to the untreated controls, exploiting one (or more) reference genes as 
normalization means, in order to limit the effect of intra-assay variability; moreover, it does 
not assume a perfect reaction efficiency of 2 as other models do but it includes the 
efficiency value inside the final equation, so that these have their own weight. 
 
6.4.3 Immunofluorescent detection of FPR2 on hCMEC/D3 surface 
To evaluate the level of surface expression of FPR2, hCMEC/D3 cells were plated in collagen-
coated labtek chambers at low density to allow a more detailed microscopy analysis. Cells 
were treated or not with β-estradiol, TNF-α and IFNγ and at the end of the stimulation they 
were pre-labelled with anti-FPR2 monoclonal antibody diluted in DPBS with Ca2+/Mg2+ for 1 
h at 4°C, under agitation. Under these conditions, only receptors present on the cell surface 
bind the antibody, without internalizing. Cells were then washed and fixed for 10 minutes 
with 4% PFA. Fluorescent staining was performed by Alexa488-conjugated anti-Ms IgG and 
mounting with Prolong® anti-fade mountant (Invitrogen, UK) followed by confocal 
microscopy (Maderna et al., 2010).  
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6.4.4 Surface-bound ANXA1 retrieval 
In order to obtain ANXA1 molecules non-covalently bound on cell surface in a Ca2+ 
dependent manner, stimulated hCMEC/D3 were washed briefly with DPBS with Ca2+/Mg2+ 
and incubated for 20 minutes at 4°C under slow agitation with a small volume of 1 mM 
EDTA, 1 mM EGTA in DPBS without Ca2+/Mg2+. Subsequently the liquid was retrieved, briefly 
spun down to remove any detached cells and frozen for further assessment.  
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6.5 Results 
6.5.1 BBB-related sex differences towards peripheral inflammation  
Figure 6.5, Panel A shows a clear sex-dependent response of the BBB permeability to a 
single peripheral dose of LPS (3 mg/kg) in wild-type young adult (2 months old) mice: male 
animals responded with an increased Evans Blue extravasation after 4 hours from LPS i.p. 
administration, while female animals did not show such change. Basal tightness was 
restored in the following time points (24 hours and 7 days). In contrast, the same analysis in 
Anxa1 null mice (2 months) presented higher (10-fold) permeability values but loss of sex-
related response.  
To observe if such behaviour was linked to circulating sex hormones, we performed an in 
vivo barrier permeability assessment using reproductively senescent (15 months old) female 
wild-type animals, which were compared to young adult female counterparts and 
challenged i.p. with LPS for 24 hours. Interestingly, we detected (Figure 6.5; Panel B) a 
significant increase in dye extravasation in the aged-animals, supporting the growing 
evidence for the involvement of a female sex-hormone in the BBB. Interestingly, we did not 
detect basal differences in terms of dye extravasation between young and old female 
animals, which closely match other reports in literature (Sandoval and Witt, 2011).  
In order to investigate if 17 β-estradiol (17 βE) participates in protecting the brain barrier 
from opening under peripheral inflammatory insult, we performed ovariectomy on a set of 
young adult female wild-type animals, which were implanted with osmotic mini-pumps 
constantly releasing either 17 β-estradiol or the vehicle cyclic oligosaccharide β-cyclodextrin 
(Burek et al., 2010). As illustrated in Figure 6.5, Panel C, ovariectomy did not cause increase 
in the basal dye extravasation rate, while vehicle replacement impaired the female-
dependent protection towards peripheral inflammation (4 hours post LPS i.p. 
administration, the time point where sex differences where initially observed; Figure 6.5; 
Panel A) which was provided in intact young females. Replacement of 17 βE as the only sex 
hormone allowed restoration of the protective phenotype, indicating that at least partial 
involvement of the steroid.  
Chapter 6 – Annexin A1 and peripheral inflammation at the BBB: sex-dependent differences 
 
Page | 182   Enrico Cristante – PhD degree thesis    
 
Since we were ultimately interested in the role of ANXA1 as a BBB-specific modulator in the 
cross-talk between peripheral inflammatory events and CNS responses, we went to 
investigate Anxa1 expression at the level of brain microvessels, isolated as described in 
Chapter 4. To our surprise, we could detect basal differences in Anxa1 content in whole 
lysates between young adult females, old females and males, with the former showing the 
highest intensity of expression (Figure 6.5; Panel D). Under acute inflammatory challenge, 
Anxa1 expression increased in the young females, while the other two groups did not show 
any change, supporting our hypothesis of a direct female-related modulation of the Anxa1 
expression at the level of the brain barrier in presence of inflammation.  
 
Figure 6.5 Sex influences barrier responses to peripheral inflammation. A| Young adult (2 months 
old) wild-type (C57Bl/6) and Anxa1-/- mice (n=5) were pre-treated intraperitoneally with 3 mg/kg 
body weight of LPS (strain O111:B4) in saline for 3 hours, 23 hours and 7 days or with 100 µl saline 
(24 hours) as negative control. After the end of incubation time, they were intravenously injected 
with 100 µl 2% Evans blue in saline. Dye was allowed to circulate for 1 hour, before brain dye 
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content was assessed spectrophotometrically and normalized to plasma levels. Data are expressed 
as mean ± SEM. One-way ANOVAs were conducted to compare genotype- and sex-related 
differences. Tests were followed by Tukey’s range post-hoc test; *, ** and *** respectively indicate 
p<0.05, p<0.01 and p<0.001 vs. sex-related saline control. # indicates p<0.05 vs. sex-related saline 
control. B| Wild-type (C57Bl/6) young adult (2 months old) or reproductive senescent (15 months 
old) females were i.p. treated with either 3 mg/kg body weight of LPS (strain O111:B4) in saline for 
23 hours or with 100 µl saline and subsequently assessed for Evans blue extravasation as described 
for Panel A. Two-way ANOVA was performed (age and LPS administration as variables), followed by 
Tukey’s range post-hoc test. Interaction between age and treatment was detected. # indicates 
p<0.05 vs. age-related saline control and it was considered significant. C| Ovariectomised animals 
were implanted with minipumps constantly releasing either 17 β-estradiol (2 µg/kg/day) or vehicle 
for 14 days and then assessed by Evans Blue. Two-way ANOVA was performed (hormone 
replacement and LPS administration as variables), followed by Tukey’s range post-hoc test. 
Interaction between hormone replacement and treatment was detected. * indicates p<0.05 vs. 
saline-treated groups and the other LPS-treated groups. D| Total expression of Anxa1 was assessed 
on brain microvessels lysates from wild-type C57Bl/6 young, old females and young males by 
western blotting. Typical examples from n=3 mice per preparation are shown here. Panel A was 
produced with the help provided by Dr. S. McArthur. 
 
6.5.2 ANXA1 expression and release is regulated by 17 β-estradiol 
In vivo experiments proposed two important facts: β-estradiol was directly involved in sex-
dependent differences shown by the BBB in response to peripheral inflammation and 
annexin A1 showed a differential behaviour between genders, dependently on hormonal 
influence.  
Without excluding the involvement of other sex hormones towards ANXA1 expression, we 
decided to simplify our investigation by focusing primarily on ANXA1 modulation by the 
potent female sex hormone. To do that, we moved back to the in vitro model of human 
BMECs of choice, the hCMEC/D3 cell line.  
Figure 6.6 clearly shows the impact of 17 β-estradiol on ANXA1: Panels A and B indicate a 
dose-dependent effect for both ANXA1 release in cell medium and for ANXA1 cellular 
content. 100 nM was chosen as optimal dose for further experiments. Interestingly, 
released ANXA1 showed a fluctuating time-dependent behaviour over the period analysed, 
indicating a non-linear hormonal modulation; in parallel, we detected a positive effect of 
estradiol on cellular ANXA1 and a partial time-dependent fluctuating effect, more narrow 
and limited compared to Panel A.  
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This finding represents an important aspect to be considered with regard to the 
physiological oestrous cycle, where release of estradiol in the blood varies over time, with 
consequent changes from low to high concentrations, achieved by summation of different 
doses.  
In Panel E we studied the effect of β-estradiol from transcription point of view; we identified 
a quick and strong response on ANXA1 gene, FPR1 gene expression appeared to be inhibited 
by the hormone, while FPR2 gene transcription peaked at 4 hours and then decreased 
quickly under basal levels.  
Such findings, in particular those depicted in Figure 6.6 Panel E, are in accordance with 
previous evidence on the ANXA1 promoter responsiveness to hormonal challenges, as 
described in Figure 6.4. A quick prediction analysis of FPR1 and FPR2 human promoters 
identified (data not shown) in FPR1 promoter one ERE-like sequence close to the TATA box, 
while in FPR2 promoter we identified several ERE-like sequences scattered in the promoter 
sequence, indicating that also these genes, similarly to ANXA1, are directly modulated (as 
we have seen from the quantitative mRNA studies; Figure 6.6, Panel E) by the hormone. 
Therefore, ANXA1 behaviour appeared to be intensively modulated by estradiol in all its 
aspects, from gene transcription, to protein formation and externalisation.  
 
Chapter 6 – Annexin A1 and peripheral inflammation at the BBB: sex-dependent differences 
Enrico Cristante – PhD degree thesis                    Page | 185  
 
 
Figure 6.6 17 β-estradiol regulates release and expression of ANXA1 in hCMEC/D3. Dose-response 
study of ANXA1 A| release in cell medium and B| quantity in whole cell lysate, assessed by 
sandwich-ELISA. Exposure to different doses was performed for 8 hours. Data are representative of 
at least three independent experiments, performed in quadruplicate, expressed as mean ± SEM. 
One-way ANOVA was performed, followed by Tukey’s range post-hoc test; * and *** indicate p<0.05 
and p<0.001, respectively. Time-course study of ANXA1 C| release in cell medium and D| in whole 
cell lysate. Long-term administration (2, 3 and 4 days) was performed by repeating the dosing every 
24 hours. Chosen dose was 100 nM according to the dose-response study. Data are representative 
of at least three independent experiments, performed in quadruplicate, expressed as mean ± SEM. 
One-way ANOVA was performed, followed by Tukey’s range post-hoc test; * and *** indicate p<0.05 
and p<0.001 vs. untreated, respectively. E| Evaluation of transcription regulation of ANXA1, FPR1 
and FPR2 genes by effect of 17 β-estradiol. Quantitative PCR was performed on whole RNA cells 
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extracts after stimulation with the hormone for different time points, using highly specific qPCR 
primers as indicated in the methods. Data are representative of three independent experiments, 
performed in triplicate, expressed as mean ± SEM. One-way ANOVA was performed, followed by 
Tukey’s range post-hoc test; *, ** and *** indicate p<0.05, p<0.01 and p<0.001 vs. 0 hours, 
respectively.  
 
6.5.2.1 Estradiol differentially modulates ANXA1 synthesis and release 
In order to understand which estrogen receptor(s) is(are) involved in modulating ANXA1, we 
used specific agonists and antagonists directed towards the two classic ERs, ERα and ERβ, 
and the more recently discovered G-protein coupled receptor called GPR30. Doses were 
based on published findings (Harrington et al., 2003) while timing was preliminarily assessed 
through a time course study (not shown).  
Interestingly, hCMEC/D3 cell line possesses all the three forms of estrogen receptors, as 
illustrated in Figure 6.7, Panel A. Using a GPR30-selective agonist (G-1; 8 hours), we were 
able to reproduce the same effect of β-estradiol in terms of ANXA1 release in the cell 
medium, while using a GPR30-selective antagonist blocked the effect of estradiol. In terms 
of ANXA1 content in whole cell lysate, ERα-specific agonist PPT (8 hours) was able to mimic 
the effect of β-estradiol (p<0.07 vs. untreated), while ERβ-specific agonist DPN inhibited 
ANXA1 expression. Unfortunately, we cannot count on specific ERα antagonists, but only on 
ERβ ones, which blocked β-estradiol (Figure 6.7; Panel B).  
Overall, these data should indicate a complex interaction between the two classic estrogen 
receptors: if either one or the other is activated by specific agonists, the response is 
different if compared to what happens by concomitant activation by the pan-ligand 17β-
estradiol. Therefore, two distinct mechanisms seem to exist to achieve estradiol-dependent 
regulation of ANXA1: release into medium, which is a non-genomic phenomenon, is directly 
mediated by the action of the transmembrane receptor GPR30, while ANXA1 synthesis, 
most likely through transcription regulation, is affected by ERα and ERβ.  
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Figure 6.7 Estrogen receptors involvement in ANXA1 regulation. A| Representative flow cytometry 
profiles showing the expression of all three major β-estradiol receptors in untransfected hCMEC/D3 
cells. At least 10000 events were analysed after gating; histograms represent one of 3 independent 
experiments. B| Experiment looking at the effect of selective agonists of different estrogen 
receptors for ANXA1 release and ANXA1 expression regulation in whole cell lysate. Incubations with 
the different stimuli were performed for 8 hours. β-estradiol: 100 nM; PPT (ERα): 200 pM; DPN 
(ERβ): 850 pM; G-1 (GPR30): 20 nM; PHTPP (ERβ): 200 nM; G-15 (GPR30): 200 nM. Data are 
representative of at least three independent experiments, performed in triplicate, expressed as 
mean ± SEM. Two-ways ANOVAs were performed, followed by Tukey’s range post-hoc test; * 
indicate p<0.05 vs. untreated. Not all the groups are here presented (“antagonists alone” groups 
omitted, as they didn’t show any significant effect).  
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6.5.3 Estradiol protects the BMECs under inflammatory conditions 
Several reports indicated a protective effect of pre-incubation with steroid hormones as 
hydrocortisone or dexamethasone on BMECs, potentiating their tightness and limiting the 
effects caused by inflammation (Romero et al., 2003; Forster et al., 2008).   
We have proved that β-estradiol has important modulatory functions towards ANXA1, 
which is now known as an essential component of barrier integrity (Chapter 4 and 5). So, we 
moved to test possible links between the steroid and the anti-inflammatory molecule on cell 
monolayers challenged with inflammatory conditions. As representative pro-inflammatory 
molecules, we used TNF-α and IFNγ (10 ng/ml), which were exposed for 24 hours on the 
luminal side (i.e. blood side) of tight and confluent monolayers grown on transwell filters 
(Forster et al., 2008; Haarmann et al., 2010). Recently published evidence (Lopez-Ramirez et 
al., 2012) confirmed the expression of both TNF-α receptors (TNFR-1 and TNFR-2) and IFN-γ 
receptor on this human cell line, as it was already known for mammalian cerebrovascular 
endothelial cells (Okuda et al., 1999). Pre-exposure for 8 hours was able to produce a tighter 
monolayer (Figure 6.8; Panel A) and it was able to block the TNF-α/IFN-γ permeability 
increase (around 20%) compared to not hormone pre-treated cells.  
Similar results were obtained for long pre-exposure with β-estradiol: TEER measurements 
(Figure 6.8; Panel B) highlighted the decreasing effect of inflammation on the overall 
tightness. Similar results were also obtained by evaluating changes in paracellular 
permeability (Figure 6.8; Panel C). 
We believe this type of stimulation every 24 hours for 4 days resembles more closely what 
happens within the female organism, where the oestrous cycle is responsible for the 
constant presence of the hormone, present at high concentrations for most of the duration. 
Also, it has been shown that periodic repeated administration of β-estradiol helped reduce 
the effective amount of hormone necessary to obtain biological responses in vitro (Caulin-
Glaser et al., 1996). Since our ultimate aim was to mechanistically describe why young 
females showed protection towards peripheral inflammation, we focused only on long 
estrogenic pre-incubations for the following experiments.  
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Overall, these set of experiments highlighted the protective effect offered by estradiol, 
which was able to improve endothelium properties and to limit the inflammatory derived 
leakage. 
 
 
Figure 6.8 Short or long pre-incubation with 100 nM β-estradiol prevent inflammatory alterations 
of the barrier. A| Pre-incubation with 100 nM β-estradiol for 8 hours (short pre-incubation) 
contributes to a tighter endothelium and limits the expected permeability increase caused by pro-
inflammatory cytokines. Long-pre-incubation (4 days) with β-estradiol limits B| the decrease in TEER 
caused by pro-inflammatory cytokines and C| the increase in paracellular permeability. Data are 
representative of at least three independent experiments, performed in duplicate, expressed as 
mean ± SEM. Two-ways ANOVAs were performed, followed by Tukey’s range post-hoc test which 
indicated (in A| and B|) an overall effect of pre-incubation with estradiol. * indicates p<0.05 vs. 
untreated, # indicates p<0.05 vs. basal estradiol-treated, while $ indicates p<0.05 vs. estradiol-
untreated TNF-α/IFN-γ treated. NS indicates non-significant differences vs. untreated.  
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6.5.4 ANXA1 mediates the protective effect offered by β-estradiol 
Since β-estradiol showed a strong positive regulation of ANXA1 synthesis and release, both 
after a short time incubation (8 hours) and a long one (4 days), we investigated if this 
protein is somehow a mediator of estrogen anti-inflammatory effects on BMECs. 
First, we tested whether cells with a constitutive higher ANXA1 expression could present a 
similar protection. Full length (FL11) hCMEC/D3s showed tighter permeability in untreated 
conditions as already shown in Chapter 4.  
Incubation with pro-inflammatory cytokines TNF-α and IFN-γ caused, as expected, a great 
increase in permeability in wild-type cells. Interestingly, the effect was significantly limited 
in FL cells with higher expression of ANXA1 (Figure 6.9; Panel A), tightly resembling what 
happened in those monolayers pre-incubated with estradiol (Figure 6.8; Panel A). 
Subsequently, since estradiol showed great ability to up-regulate ANXA1 release, we 
investigated the role played by the externalised pool. To do that, we pre-incubated 
hCMEC/D3 monolayers with a daily dose of human recombinant ANXA1 for 4 days before 
cytokines challenge (during the last 24 hours). Interestingly, ANXA1 pre-exposure was able 
(Figure 6.9; Panel B) to stop the cytokine-induced increase in permeability, similarly to the 
protection offered by β-estradiol pre-exposure and by ANXA1 over-expression in FL 
hCMEC/D3 cells.  
To further test our hypothesis of ANXA1 as a mediator of estradiol action, we first used cells 
with a constitutive reduced expression of ANXA1 (AS hCMEC/D3). These cells showed a 
constitutively higher permeability due to lower ANXA1 (extensively described in Chapter 4) 
as described in Figure 6.9, Panel C; also, they did not show increased leakiness under 
inflammatory stimulation, which closely matched the results obtained in Anxa1 null mice 
challenged with LPS (Figure 6.5; Panel A). More importantly, while pre-exposure with β-
estradiol resulted in the abolishment of the cytokines-driven permeability increase in wild-
type cells, it failed to produce any effect on AS cells, as sex failed to impact on AnxA1 null 
mice.  
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Panels A, B and C of Figure 6.9 indicate the important role played by ANXA1 in presence of 
inflammatory mediators and suggests, along with the in vivo data, the requirement for this 
protein to obtain the β-estradiol-specific protection. To confirm this, further paracellular 
permeability assays were performed by stimulating cells with β-estradiol along with a 
neutralizing anti-ANXA1 antibody (introduced in Chapter 4). Both stimuli were added 
together every 24 hours, for 4 days, while mouse IgG2A isotype was used as negative 
control. Figure 6.9, Panel D shoes that by blocking the action of ANXA1 released in the cell 
medium, the overall protection offered by estradiol in presence of pro-inflammatory stimuli 
was completely lost, while no change was produced in presence of an unrelated mouse 
isotype antibody.  
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Figure 6.9 ANXA1 modulates the protective effect offered by estradiol. A| WT or FL11 hCMEC/D3 
cells were incubated with inflammatory stimuli for 24 hours and permeability was then assessed. B| 
WT hCMEC/D3 cells were pre-incubated with hrANXA1 for 4 days (repeating the dose every 24 
hours) and then with inflammatory stimuli for the last 24 hours, then assessing the permeability. C| 
WT or AS4 hCMEC/D3 cells were pre-incubated or not with β-estradiol (4 days, repeating the dose 
every 24 hours) and then with inflammatory stimuli for the last 24 hours and permeability was then 
assessed. Data are representative of at least three independent experiments, performed in 
duplicate, expressed as mean ± SEM. Two-ways ANOVAs were performed, followed by Tukey’s range 
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post-hoc test. In A| * indicates p<0.05 vs. untreated mock, $ p<0.05 vs. mock cytokines treated, 
while # indicates p<0.05 vs. FL ANXA1-untreated. In B| *** indicates p<0.001 vs. untreated mock-
transfected; $ p<0.05 vs. mock TNF-α/IFN-γ treated. D|and E| Testing the involvement of ANXA1 in 
β-estradiol protection by co-incubating cells with neutralizing monoclonal anti-ANXA1 (20 µg/ml) or 
mouse IgG2A isotype control (30 µg/ml) for 4 days (repeating the dose every 24 hours) along with 
100 nM β-estradiol and pro-inflammatory cytokines. Data are representative of at least three 
independent experiments, performed in duplicate, expressed as mean ± SEM. Three-ways ANOVA 
was performed (β-estradiol exposure, incubation with monoclonal anti-ANXA1, pro-inflammatory 
cytokines exposure as variables), followed by Tukey’s range post-hoc test, which identified 
interaction between the three conditions and between estradiol pre-exposure and pro-inflammatory 
cytokines (p<0.05). * and *** indicates p<0.05 and p<0.001 vs. untreated, respectively; $ p<0.05 vs. 
untreated TNF-α/IFN-γ treated; # indicates p<0.05 vs. β-estradiol treated TNF-α/IFN-γ.  
 
6.5.5 β-estradiol reverses cytokine-dependent negative effect on ANXA1 
release and FPR2 surface exposure 
Having demonstrated the direct involvement of ANXA1 in short and long estradiol pre-
exposure before pro-inflammatory cytokines challenge, we investigated how protein 
synthesis and release were modulated by either one of the two stimuli or by both, in order 
to gain more evidence for the interconnected relationship between ANXA1 and the 
hormone. Therefore, we exploited sandwich ANXA1 ELISA to measure differences in protein 
release as well as protein content in whole cell lysate, as depicted in Figure 6.10, Panel A 
and B. Interestingly, cytokines exposure produced a significant reduction in ANXA1 release, 
which could be directly taken as partial explanation of the effect caused by the two 
cytokines in terms of paracellular permeability. Pre-exposure with β-estradiol (100 nM; 4 
days, repeated every 24 hours) produced incremental release and most importantly was 
able to reverse the effect produced by cytokines, resulting in an increased release in ANXA1. 
As a consequence, by flow cytometric analysis we detected (Figure 6.10; Panel D) less 
ANXA1 bound on cells surface after cytokine stimulation, but again this could be prevented 
and actually reversed by β-estradiol exposure for 4 days. ANXA1 content in whole cell lysate 
was also found to be up-regulated in presence of one or both stimuli, indicating therefore 
that cells are prepared by estradiol as well as by cytokines to respond to the inflammatory 
event through increased synthesis of our protein of interest.  
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Figure 6.10 ANXA1 release and expression is altered by pro-inflammatory stimuli but rescued by β-
estradiol pre-exposure. A| and B| show ANXA1 content in cell medium and whole cell lysate, 
respectively, analysed by ANXA1 sandwich ELISA. Data are representative of 4 independent 
experiments, performed in quadruplicate, expressed as mean ± SEM. C|, D| and E| indicate surface 
expression of FPR1, ANXA1 and FPR2 on confluent monolayers under different conditions, analysed 
by flow cytometry. Data are representative of 4 independent experiments, performed in 
quadruplicate, expressed as mean ± SEM.  F| shows FPR2 surface expression on untreated and 
treated hCMEC/D3 cells. Nuclei are stained with DAPI (blue). Two-ways ANOVAs were performed 
followed by Tukey’s range post-hoc test, which identified an interaction between pro-inflammatory 
cytokines and estradiol pre-exposure in A| C|, D| and E| (p<0.05). * indicates p<0.05 vs. untreated, 
while p=0.071 is also vs. untreated; $ indicates p<0.05 vs. untreated TNF-α/IFN-γ treated.  
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As discussed in Chapter 1 and 4, the FPR receptors are important regulators for ANXA1 
action, their presence on cell surface being able to modulate how intense the action 
produced by the protein is going to be. We saw that the two main FPRs, FPR1 and FPR2, are 
transcriptionally regulated by β-estradiol (Figure 6.6; Panel E); in parallel, we detected a 
swift upregulation in FPR1 surface expression under cytokines stimulation, which was 
limited significantly in presence of estradiol pre-exposure; FPR2 surface expression, instead, 
was negatively regulated by TNF-α and IFN-γ, while a long pre-exposure with the sex 
hormones could produce an exactly opposite effect under the same inflammatory 
conditions, rendering BMECs more responsive to ANXA1. Figure 6.10, Panel F shows how 
receptor expression on cell surface decreased after 24 hours exposure to inflammatory 
challenge, while it strongly increased if cells were pre-exposed to estradiol before being 
challenged with cytokines.  
Overall, peripheral inflammatory stimuli appear to strongly limit the anti-inflammatory 
arsenal of BMECs by limiting ANXA1 release and reducing FPR2 expression on cell surface, 
therefore strongly reducing the potential of the autocrine/paracrine circuitry defined by 
these molecules. Chronic exposure to β-estradiol was able to prevent such phenomenon.  
 
6.5.5.1 β-estradiol and TNF-α regulate ANXA1 phosphorylation status 
To delineate a mechanism of action by which β-estradiol is able to counteract the negative 
effect on ANXA1 release by inflammatory stimuli, we looked at the phosphorylation state of 
released and membrane-bound ANXA1 under various combinations of stimuli. The N-
terminal of ANXA1 has potential sites for phosphorylation: it has been shown to be the 
substrate of a number of kinases, like the epidermal growth factor (EGF) receptor for 
tyrosine phosphorylation (de Coupade et al., 2000) or the protein kinase C (PKC), 
responsible for serine and threonine phosphorylation (Solito et al., 2006). Phosphorylation 
of the protein affects its structure and consequently its physiology.  
Strong evidence supports the observation that phosphorylation on the serine 27 residue is 
important for translocation from the cytosol to the cell surface (Solito et al., 2006) in a 
model of neuroendocrine cells, where ANXA1 plays an important role in controlling 
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hormonal release. Mutations of this or of other residues (serine 45) completely blocked 
ANXA1 externalisation. Similar results were also obtained in another cell model with strong 
exocytosis properties (McArthur et al., 2009).  
Following these studies, we decided to check for differences in ANXA1 phosphorylation rate. 
Since these were non-genomic modifications, happening very quickly (in the order of 
minutes) and lasting for a short time, but triggering a series of downstream events resulting 
in gross changes after several hours (i.e. significant increase in permeability), we chose to 
maintain the long pre-exposure with β-estradiol but to use a short incubation (20 minutes) 
with only TNF-α (to avoid overlapping between different cytokines’ signalling pathways). 
Since Figure 6.9 and Figure 6.10 showed β-estradiol, as well as pro-inflammatory stimuli, to 
modulate specifically the externalised ANXA1 pool, which then quickly binds cell targets in 
the vicinity, we first investigated differences in ANXA1 phosphorylation at the level of 
membrane-bound protein, detached through extensive EDTA/EGTA wash (see Section 
6.4.4). Figure 6.11, Panel A shows differences in terms of total ANXA1 (reproducing even 
more clearly the results described in Figure 6.10, Panel D); our assay did not detect Tyr21-
phosphorylated ANXA1 (both on the EDTA/EGTA wash and in the cell medium; data not 
shown), supporting the solely intracellular existence of this ANXA1 species. Interestingly, 
changes in total ANXA1 were also reflected in terms of Ser27-phosphorylated ANXA1: 
estradiol pre-exposure caused more ANXA1 to be membrane-associated but it also 
increased the percentage of the serine-phosphorylated species. Interestingly, a short 
incubation with TNF-α limited significantly the amount of total ANXA1 on cells surface, even 
reducing the one present on basal-untreated conditions; serine 27-phosphorylated form 
was also dramatically reduced compared to the control. The pre-incubation with β-estradiol 
rescued such phenotype, allowing a high quantity of total and ser27-phosphorylated protein 
to remain at the membrane, where it may be able to signal through the target cells.  
Therefore, β-estradiol was able to increase the amount of Ser27-phosphorylated ANXA1, 
which is thought to have a direct impact on the externalization of the protein and its 
consequent autocrine/paracrine action; also, this status seems important to tackle the 
effect that TNF-α showed towards ANXA1 release either in short or long exposure.  
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To get a preliminary confirmation of such a conclusion, we incubated cells with β-estradiol 
(4 days; 1 dose every 24 hours) after a short pre-incubation with the GPR30 specific 
antagonist called G-15 (exactly following the same posology), since this receptor seems to 
be the one able to generate prompt non-genomic responses. Through a modified version of 
ANXA1 sandwich ELISA, we observed (Figure 6.11, Panel B) that long-incubation with β-
estradiol was able to increase the Ser27-phoshorylated ANXA1 on the cell medium but this 
effect was blocked by pre-incubation with the GPR30 receptor-specific antagonist (G-15), 
suggesting the strong possibility of its involvement in this complex mechanism. Since 
phosphorylation is an event classically starting from within the cell, we extracted total cell 
lysate and probed for Serine27-phosphorylated ANXA1 in presence or absence of the 
different stimuli, including a short pre-incubation with G-15 before each dose of β-estradiol. 
We could detect a small increase in ANXA1 site specific phosphorylation under long 
estradiol incubation, which could be blocked by pre-incubation with G-15. Under other 
combinations of stimuli we could not detect significant differences at least at the 
intracellular level, indicating therefore that the action of TNF-α may affect other aspects on 
this pool, which will deserve more attention in the near future.  
Overall, here we detected phosphorylation on Serine27 residue of ANXA1 most likely 
(directly or indirectly) mediated by GPR30; this event appeared to be important for its 
externalisation and functional membrane association both under basal and inflammatory 
conditions, as confirmed by recent work (McArthur et al., 2009; Nadkarni et al., 2011). TNF-
α blocked phosphorylation at this precise residue, directly affecting the overall protein 
externalisation. Nonetheless, Serine27 seems to be essential for the estradiol-specific action 
on counteracting inflammation effects, rescuing ANXA1 correct release.  
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Figure 6.11 Phosphorylation of ANXA1 on Serine27 is mediated by the transmembrane estrogen 
receptor GPR30. A| EDTA/EGTA washes were analysed via immuno-blotting for ANXA1 
phosphorylation at different functionally relevant residues, namely Tyrosine21 and Serine27. Short 
TNF-α incubation was used to identify a quick post-translational modification. B| Since the 
concentration of phosphorylated-ANXA1 in cell medium may be too low for detection with immuno-
blotting, we adapted the ANXA1-specific ELISA to detect the Serine27-phosphorylated form. G-15 
was added 30 minutes before each daily dose of β-estradiol. C| Immuno-blot showing Serine27-
phosphorylated ANXA1 under various conditions. β-estradiol was administered every 24 hours for 4 
days; G-15 was also given every 24 hours for 4 days, 30 minutes before estradiol. TNF-α stimulation 
was performed for 20 minutes only, instead. Data are representative of 2 independent experiments; 
blots show representative results, while in B| data are expressed as mean ± SEM (n=2; statistics not 
performed).   
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6.5.6 Pro-inflammatory stimulation disrupts the actin cytoskeleton, which is 
protected by chronic pre-exposure with β-estradiol 
So far, we understood that pro-inflammatory stimuli (mainly conveyed by TNF-α) disrupted 
endothelial barrier tightness, with a significant increase in paracellular permeability; ANXA1 
significantly was affected by these conditions, its release from BMECs being significantly 
reduced.  
However, both events were prevented in cells pre-incubated with β-estradiol. To 
understand how the chronic pre-exposure to the sex hormone can block the effect of 
inflammation on the endothelium, we investigated one of the major target of the disruptive 
action produced by pro-inflammatory cytokines, as well as the major target of ANXA1 in 
these cells, i.e. the actin cytoskeleton. TNF-α and IFN-γ caused a significantly greater 
insoluble/soluble β-actin ratio (F/G actin; Figure 6.12, Panel A), which mirrors the increased 
formation of disorganised non-polarized stress fibres throughout the cytosol, as evidenced 
in Figure 6.12, Panel C. Chronic β-estradiol exposure was able to reinforce the cortical F-
actin ring under basal conditions; under inflammatory challenge, it also avoided the increase 
in impaired actin polymerisation, maintaining the correct cortical location of actin fibres and 
functional polarity of the cells forming the monolayer. Interestingly, these findings were also 
paralleled in primary capillaries extracted from young adult females, males or old females 
treated with peripheral inflammatory stimuli. In particular, old females showed a 
completely disorganised actin cytoskeleton (Figure 6.12, Panel C), in high contrast to what 
shown by young female capillaries, which maintained a continuous and more functional 
morphology closely similar to non-inflammatory conditions.  
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Figure 6.12 Pre-incubation with β-estradiol prevents the disruptive effect of pro-inflammatory 
cytokines on the actin cytoskeleton. A| Biochemical analysis of G (soluble) and F (insoluble) β-actin 
in hCMEC/D3 cells treated or not with TNF-α and IFN-γ after pre-exposure with β-estradiol. 
Histograms represent three independent experiments, performed in duplicate; data are presented 
as mean ± SEM. Two-ways ANOVA was performed, followed by Tukey’s range post-hoc test, which 
identified an effect of β-estradiol (p<0.05); ** indicates p<0.05 vs. untreated; $ indicates p<0.05. B| 
Primary capillaries were extracted from young adult females, male and old females, treated i.p. with 
saline or LPS, quickly fixed and stained with Alexa488-conjugated phalloidin and mounted in Prolong 
anti-fade mountant with DAPI (Blue; Invitrogen, UK). White arrows point to regions of particularly 
important actin cytoskeleton integrity or disruption. Scale bar: 10 µm. C| Confluent hCMEC/D3 cells 
pre-treated or not with β-estradiol for 4 days were treated (or not) with TNF-α and IFN-γ for 24 
hours. Subsequently, cells were fixed and permeabilized before staining with rhodamine-conjugated 
phalloidin. Images are representative of at least 3 different preparations. Scale bars: 30 µm (main 
image) and 10 µm (inset).  Panel B was produced thanks to help provided by Dr. S. McArthur. 
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6.5.7 Cell-cell junction components are protected by β-estradiol 
Estrogens have shown to have multiple effects on junctional proteins physiology, especially 
under non-inflammatory conditions (Nilsson, 2007; Burek et al., 2010), in which hormonal 
stimulation appears to be important to trigger the expression of some of these components 
(Kang et al., 2006). Having investigated the implications of 17 β-estradiol in rescuing the 
correct cytoskeleton structure and functional organisation, we checked if these events 
resulted also in protection of the major components of tight and adherens junctions. Pro-
inflammatory cytokines like TNF-α present a well-known disruptive action on these 
structures by affecting both their expression and their functional localisation, ultimately 
causing an increased permeability (Silwedel and Forster, 2006; McKenzie and Ridley, 2007; 
Aveleira et al., 2010). These findings were also confirmed in our model: 24 hours treatment 
of confluent cell monolayers with TNF-α and IFN-γ caused cell elongation/contraction and a 
significant decrease in the total expression levels of occludin and ZO-1 Figure 6.13; Panel A 
and D), which were paralleled by an almost complete loss of membrane-associated staining 
of these proteins (Figure 6.13; Panel B and E). These results were clearly paralleled on 
extracted brain capillaries: occludin staining of old female mice resulted deeply altered 
(Figure 6.13; Panel C) as a consequence of peripheral inflammatory stimulation. However, β-
estradiol pre-exposure was able to prevent such strong disruption, contributing to the 
maintenance of continuous staining over large areas of the treated monolayers.  
Another essential tight junction component, claudin-5, did not show alterations in total 
expression after inflammatory challenge (Figure 6.13; Panel F) but we did detect 
upregulation following chronic β-estradiol exposure, as already reported by others (Burek et 
al., 2010). Despite expression being unaltered, membranous functional expression of 
claudin-5 was disrupted (Figure 6.13; Panel G), with only few short punctuated cell-cell 
contact areas still positive for the protein.  
Also in this case, β-estradiol pre-treatment gave some sort of protection against the 
following inflammatory stimulation, with more contact areas presenting continuous 
staining. 
Finally, VE-cadherin, the main adherens junction component, appeared unaltered in terms 
of total expression (Figure 6.13; Panel H) as already shown in peripheral vasculature 
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(Hofmann et al., 2002), but resulted lost from cell membrane (Figure 6.13; Panel I) and 
almost completely internalized under inflammatory conditions. Pre-exposure with estradiol 
did not alter its basal localisation but it was able to prevent, at least in part, the disruptive 
effect shown under cytokines stimulation.  
To our knowledge, this evidence represents novel findings and well explains how the 
protective role of a long hormonal pre-exposure can potentiate the response given by 
BMECs against the disruptive role produced by inflammatory mediators. Taking into account 
β-estradiol modulatory effect on the actin cytoskeleton helps to understand the whole 
protective mechanism.  
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Figure 6.13 Estradiol pre-exposure prevents cytokine-dependent alterations in expression and 
functional localisation of cell junctions component. A|, D|, F| and H| show typical western blots of 
total content of occludin, zonula occludens-1 (ZO-1), claudin-5 and VE-cadherin alongside GAPDH 
loading controls in extracts from wild-type hCMEC/D3 treated in the specified conditions. n=3 
independent experiments, each performed in duplicate. Histograms show joined densitometric 
analysis of all the experiments, expressed as mean ± SEM. Two-ways ANOVA followed by Tukey’s 
post-hoc test was performed, * indicating p<0.05 vs. untreated, while $ indicates p<0.05 vs. 
untreated TNF-α/IFN-γ treated. B|, E|, G| and I| present confocal microscopy analysis of occludin, 
ZO-1, caludin-5 and VE-cadherin expression in confluent monolayers of hCMEC/D3 cells. Typical 
examples from n=3 experiments. Scale bar: 30 µm and 10 µm (inset). C| shows confocal analysis of 
occludin staining in primary vessels extracted from reproductively senescent female mice treated i.p. 
with either saline or 3 mg/kg LPS for 4 hours. Typical examples from n=3 experiments. Scale bar: 10 
µm. Panel C produced thanks to the help provided by Dr. S. McArthur.  
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6.6 Discussion 
This chapter described the latest findings on the involvement of ANXA1 in the response 
mounted by BMECs under peripheral inflammatory challenges, as well as a novel ANXA1-
dependent mechanism contributing to sex dimorphic responses at BBB level. These results 
support once more the new role of ANXA1 as one of the main protagonists of the regulatory 
system controlling paracellular permeability, but they also propose further functional 
implications in the protective mechanism triggered by circulating sex hormones. We believe 
to have provided convincing proof of concept as well as clearer details, compared to similar 
studies (Burek et al., 2010).  
 
6.6.1 ANXA1: a principal player in sex-dependent BBB response to peripheral 
inflammation  
Interestingly, young adult male mice showed a significant increase in Evans Blue brain 
content 4 hours after peripheral LPS administration, which subsided to basal levels 24 hours 
after. Females did not show any quantitative change, suggesting the presence of a 
protective mechanism.  
Our attention was drawn immediately by the potential effects that sex hormones may show 
on endothelial cells; in particular, 17 β-estradiol represented a strong candidate due to its 
prominent role both in physiology and in pathology. We confirmed its involvement by 
employing senescent animals; although murine senescence does not closely match what 
happens during human female menopause (Sohrabji and Bake, 2006; Vegeto et al., 2008), 
the circulating levels of female hormones decrease significantly (Parkening et al., 1978) 
limiting sex-dependent influences, which is what happened also in our model (Figure 6.5; 
Panel B). In addition, rescuing ovariectomised animals with β-estradiol provided a stronger 
confirmation of the involvement of the steroid (Figure 6.5; Panel C). Indeed, numerous 
reviews and articles reported the enormous effects of this steroid in the brain (Maggi et al., 
2004; Vegeto et al., 2008), with many stressing the impact shown on vasculature and 
endothelial cells (Sohrabji and Bake, 2006; Nilsson, 2007; Burek et al., 2010).  
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Recent investigations clearly showed that circulating estrogen does offer vascular protection 
[nicely reviewed by Nilsson, 2007 (Nilsson, 2007)]. In particular, the great interest on these 
vascular-related protective opportunities offered by estradiol and sex hormones is to 
attribute to several experimental and population-based studies, indicating that women are 
protected from stroke, many neurodegenerative disorders and cardiovascular diseases, an 
advantage which fades away with menopause. Our study started from this evidence and we 
believe it has contributed to add more mechanistic details, focusing specifically on the brain 
microvascular district. In particular, our findings have set Annexin A1 among the main 
effectors involved in protecting the BBB and the CNS itself from those signals produced by 
inflammatory events happening elsewhere in the body, as well as an important character in 
defining sex dimorphism. In fact, Anxa1 null mice failed to show sex-related differences 
(Figure 6.5): on one hand, this confirmed the important role of the protein; on the other, it 
opened several questions about why null mice failed to show both sex-dependent 
differences and significant increase under inflammatory conditions. Among possible 
explanations, one should account that the basal increased barrier permeability of knock-out 
mice (more than 10 times higher than wild-type) is so high that either a further increase is 
not permitted by some sort of compensatory mechanism [for example through up-
regulation of other permeability regulators; we hypothesised Anxa2 (Hannon et al., 2003)] 
or it is technically not detectable by the sensitivity limits of the assay chosen (Evans blue 
extravasation in the brain parenchyma). However, it is also possible that the lack of Anxa1 
prevents the expected barrier leakiness: in fact, we have shown that pro-inflammatory 
cytokines significantly block the release of the protein from BMECs, which we believe could 
represent a way to lead the expected response.    
 
6.6.2 ANXA1 physiology is regulated by β-estradiol 
6.6.2.1 Genomic pathways 
Figure 6.6 and Figure 6.10 show very clearly how the β-estradiol is able to modulate both 
transcription and release of the ANXA1, both through the classic estrogen receptors ERα 
and ERβ, as well as the new membrane-associated GPR30. Others already have shown β-
estradiol influence of ANXA1 expression (Davies et al., 2007; Ang et al., 2009). The steroid 
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was shown to activate cAMP-responsive element binding proteins (CREBs) and to induce 
transcriptional activity also through these factors (Wade and Dorsa, 2003); interestingly, 
Antonicelli et al. (Antonicelli et al., 2001) demonstrated the presence of a CRE element on 
ANXA1 promoter, while Ang et al. (Ang et al., 2009) showed the direct involvement of β-
estradiol-dependent action on ANXA1 transcriptional regulation, which was confirmed by us 
in a previous unpublished study (Solito et al., 2003a). Our group was the first to describe the 
ANXA1 promoter from estradiol point of view (Solito et al., 2003a), as seen in Figure 6.4. 
Putative ERE-like sequences were identified both on the human and murine sequences and 
we also showed the direct implications and impact of classical and non-classical estrogen 
receptors on ANXA1 behaviour. Aware of the results generated by using specific agonists 
and antagonists (Figure 6.7), we concluded that the genomic action of estradiol is mediated 
by both classical ERs: activation of ERβ resulted in a negative effect on ANXA1 basal 
expression, possibly through an ERE-independent action on other transcription factors 
(Gruber et al., 2004), while selective ERα activation with PPT resulted in ANXA1 up-
regulation. Blockade of ERβ and consequent stimulation with estradiol did not result in 
ANXA1 induction, indicating therefore that estradiol may need both receptors to be active. 
Receptor-specific agonists are highly specific molecules which bind exclusively to only one 
receptor and are able to trigger specific conformational changes that determine its 
activation at very low concentrations (850 pM for PPT, for example). Molecules like estradiol 
are able to bind several targets and therefore they may not be as good in activating a 
specific receptor as its specific agonist is; so this may be why we did not detect a raised 
ANXA1 expression in presence of the ERβ specific antagonist PHTPP.  
Importantly, ANXA1 receptor family also showed tight transcriptional regulation by β-
estradiol, reinforcing the strong impact of this hormone on this signalling platform. 
Apparently, these results clashed with a recent publication (Mou et al., 2012), which 
showed inflammogens up-regulating murine FPR2 transcription in a different BBB-like 
(bEND.3) in vitro model.  
The stimulus used is different from the ones we chose, plus only transcription of the 
receptor was quantified, which is not anymore considered a reliable way to understand how 
the functional expression of a protein is affected by certain stimuli.  
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Nonetheless, our results indicated a different regulation between the two FPR members 
under inflammation, which well fits with the latest theories indicating FPR1 to be a pro-
inflammatory effector, swiftly up-regulated during acute inflammation and able to interact 
with acute-phase protein like serum amyloid A (SAA), while FPR2 being more an anti-
inflammatory modulator, the principal mediator and conveyor of ANXA1 action (Perretti and 
Dalli, 2009; Dufton and Perretti, 2010). 
 
6.6.2.2 Non-genomic pathway 
Regulation of ANXA1 gene transcription was an important effect shown by estradiol; 
however, the most prominent action was the GPR30-induced ANXA1 release, which also 
held important implications under inflammatory conditions. The mechanism(s) by which 
ANXA1 is externalised of the cytoplasm is poorly understood, although it appeared to be 
independent from the classical endoplasmic reticulum/Golgi pathway of exocytosis (Philip et 
al., 1998). However, it seems to require the activation of kinases as PKC, which ultimately 
lead to ANXA1 serine-phosphorylation (Solito et al., 2003b; Yazid et al., 2009). Other limited 
studies also proposed the involvement of the ATP-binding cassette (ABC) transporter 
proteins (Parente and Solito, 2004; Solito et al., 2006), which are in some cases involved in 
physiological molecules release. In our model, we did identify an estradiol-dependent 
increase in Serine27-specific phosphorylation, which was prevented by blocking GPR30 with 
its specific antagonist G-15 (Figure 6.11). This effect was detected both in the intracellular 
pool of ANXA1 and in the one released in the cell medium, directly affecting, we believe, the 
total amount of ANXA1 that is released under estrogenic stimulation and that is able to bind 
to the cell surface. Although the definition of the signalling pathways triggered by this 
relatively novel receptor is still far from  complete as well as the novel evidence concerning 
the classical ERs being membrane associated and triggering non-genomic effects, we now 
know that GPR30 is able to stimulate the activation of PKC, at least in a sub-population of 
neurons injured in a model of hyperalgesia (Kuhn et al., 2008).  
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Moreover, the estradiol-specific GPCR is also able to trigger the activation of the 
phosphatidylinositol 3-kinase (PI3K) (Prossnitz et al., 2007), which we have shown to play a 
key role in activating PKC in the neuroendocrine system (Solito et al., 2003b). Taking this 
into account, it seems plausible to hypothesize GPR30 as receptors able to trigger ANXA1 
phosphorylation for ANXA1 release and surface translocation.  
We did not investigate estradiol-related effects on the shedding of microparticles bearing 
ANXA1. Such response is gaining increasing interest in the scientific community, since these 
submicrometre-sized vesicles represent an alternative way of releasing factors as well as a 
suitable potential bio-markers (Angelillo-Scherrer, 2012). One study linked the level of 
circulating estradiol with the amount of pro-inflammatory and pro-coagulant microparticles 
in the blood (Jayachandran et al., 2009). More recently, another report indicated the quick 
non-genomic effect of estrogenic pre-incubation of PMN cells before a pro-inflammatory 
stimulus in limiting the release of pro-inflammatory microparticles presenting ANXA1 on 
their surface (Nadkarni et al., 2011). Although this study analysed a different experiment 
asset, it indicated the potential involvement of sex hormones like estradiol in novel 
pathways, which should be definitely investigated considering the importance of 
endothelial-derived microparticles (Grammas et al., 2011). 
 
6.6.2.3 Circulating versus central estrogen 
Knowing that β-estradiol is able to modulate ANXA1 expression, which is linked with the 
endothelium integrity, it may be argued that male individuals should present higher 
physiological levels of permeability (Figure 6.5) but this is not the case. As already 
mentioned in the Section 6.3, gonads are the primary but not the only source of sex 
steroids: both males and females present many non-reproductive tissues expressing 
aromatase P450, the enzyme able to convert testosterone (and other steroids) to 17 β-
estradiol. Astrocytes are among those cells with high enzymatic activity, suggesting that 
cerebrovascular concentration of estrogen may be different from circulating levels.  
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Therefore, estrogenic influences on basal expression of ANXA1 among male and female 
individuals could be similar, contributing to the comparable levels of basal permeability. 
Under inflammatory conditions, what really seems to make a difference is the circulating 
estrogen, absent from male and reproductively senescent female animals, those unable to 
counteract the barrier leakage (Figure 6.5).  
 
6.6.3 ANXA1 as a principal mediator of estradiol protective action 
In the present chapter, we identified a close relationship between BBB-specific estradiol 
action and ANXA1 under peripheral challenges. We modelled these conditions through the 
potent inflammatory cytokine TNF-α, which takes part to the initial stages of amplification 
of the inflammatory reaction, induces a strong activation of two main pathways, the first 
one represented by the mitogen-activated protein kinases (MAPK), which activate specific 
transcription factors, while the other one represented by activation and nuclear 
translocation of NF-κB, usually through degradation of its inhibitory proteins (i.e. IκB), 
ultimately resulting in inflammatory genes transcription (Maggi et al., 2004). In the present 
report, we did not detect any difference in terms of classically activated signalling pathways 
(as reviewed in Figure 10.5; Appendix). 30 minutes exposure to TNF-α [as well as 24 hours 
(not shown; comparable to 30 minutes)] caused augmented p65 nuclear translocation, not 
prevented by estradiol pre-exposure. Similarly, TNF-α exposure triggered intensive 
phosphorylation of several MAPK (p38; ERKs; SAPK-JNK) and IκB and estradiol did not 
prevent/limit the activation of these pathways. Another signalling pathway analysed was 
phosphatidylinositol-3-kinase (PI3K)/Akt, which seemed to be only minimally activated; as 
expected by its limited involvement.  
Although these findings apparently confute earlier reports (Galea et al., 2002; 
Sumanasekera et al., 2007), we should take into account the possibility that differences in 
NFκB nuclear action occurred in a different time frame than the one we used (10-30 
minutes) or perhaps the monomer p65 was not the one to investigate (since NFκB is formed 
by combinations of different monomers, among which p50, p52, p65, p100, etc.). Notably, 
we did not investigate the c-fos-mediated transcription pathway, which is another 
mechanism by which TNF-α controls genes expression.  
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On the other hand, these findings support and strengthen the presence of a novel non-
conventional anti-inflammatory mechanism of estradiol based on ANXA1. In our model, 
estradiol directly counteracted the effects caused by inflammation by blocking the 
cytokines-dependent negative impact on ANXA1 release and FPR2 surface exposure (Figure 
6.10), restoring and potentiating this pathway. We currently ignore the full mechanism 
through which the normal protein release is limited by pro-inflammatory cytokines, 
although we obtained clear evidence for the involvement of post-translational 
phosphorylation at crucial sites of the protein [see Figure 6.11 and (Solito et al., 2003b)]. 
This does certainly represent a strong base for future investigation. Overall, the fact that 
estradiol was shown to play its role towards peripheral inflammation principally by rescuing 
the ANXA1-FPR2 circuitry gives a huge importance and add a novel central role to it not only 
considering the implications played on a healthy endothelium (as detailed in Chapter 4) but 
especially those here described under phlogistic conditions.  
 
6.6.4 ANXA1 anti-inflammatory action on the BBB: possible implications 
In this chapter, we identified a new negative action of pro-inflammatory stimuli on ANXA1 
release, which certainly contributes to cause increased permeability, but we also observed 
how estradiol was able to block this effect and actually to increase the amount of protein 
externalized; this certainly strengthened ANXA1 action and counteracted the effects 
provoked by inflammation. To this regard, we should not forget that certain ways, through 
which pro-inflammatory cytokines like TNF-α and IFN-γ produce disruptive consequences on 
endothelium, include the activation of highly disruptive pathways like the RhoA- (Wojciak-
Stothard et al., 1998) and the PLA2-dependent ones (Heller and Kronke, 1994). We (Chapter 
4) and others (Hannon et al., 2003; Parente and Solito, 2004) have clearly shown both of 
these mechanisms to be strongly targeted by ANXA1. Long-term effects on tightness-related 
proteins, like occludin and adherens-junctions, were also described for TNF-α (McKenzie and 
Ridley, 2007); it is not too speculative to propose ANXA1 to counteract and rescue these 
events, as we have been able to observe in highly disrupted endothelial monolayers 
(Chapter 4). In a recent report, TNF-α and IFN-γ were shown to trigger caspases dependent 
pathways in the same in vitro model (hCMEC/D3 line); dependently on the concentration 
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used, these were either leading to cell death or to specific disruption of cell-cell junctions 
and loss of barrier tightness (Lopez-Ramirez et al., 2012). Interestingly, Annexin A1 is known 
to regulate caspase 3 activity (Solito et al., 2001) and in a model of spinal cord injury it was 
shown to play a neuroprotective role by limiting the activation of this intracellular signalling 
pathway (Liu et al., 2007). This evidence, although not tested in our model, may provide a 
novel explanation for ANXA1 central protection and anti-inflammatory role.  
 
6.7 Limitations of the study 
In this section of the study, we tried to combine in vivo evidence with in vitro mechanistic 
investigation to support the strong implications of annexin A1 in inflammatory pathways 
mediated by cytokines like TNF-α; also, we showed the involvement of the protein in the 
protection offered by chronic exposure to a female sex-hormone like β-estradiol. To model 
peripheral inflammation, we did not use LPS to test permeability changes in vitro, despite 
this has been widely used (Descamps et al., 2003; Mou et al., 2012). Despite these cells do 
express (Figure 10.6; Appendix) the receptors (TLR-2 and TLR-4) and the accessory proteins 
(MD2 and CD14) necessary to respond to the inflammogen, the LPS binding protein (LBP), 
whose role appears to be essential to trigger an effect, is absent from the medium. Also, 
permeability increase caused by the inflammogen was much less pronounced than the one 
provoked by TNF-α and IFN-γ, which could have limited the definition of a sensitive assay 
where treatment-specific effects could be detected. Most importantly, LPS would have 
represented a model of septicaemia, not a proper way to mimic peripheral inflammation: 
pro-inflammatory cytokines circulating in the blood are the real mediators of peripheral 
immune events and those truly impacting on the brain interfaces. 
Estradiol is a potent gonadal female hormone, which has several implications in numerous 
cellular functions; specifically for the brain microvasculature, it was shown (Krause et al., 
2006) to affect not only paracellular permeability, but also other functions, some of which 
have been reported to be affected by ANXA1 action, for example mitochondrial efficiency, 
blocking free radicals production and COXs activity, cytokines-related apoptosis as well as 
cytokines-triggered increase in adhesion molecules (Nilsson, 2007).  
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Since we were particularly interested in the role of ANXA1 on paracellular permeability and 
cytoskeleton regulation, we left out these additional areas of interest, but we believe they 
may conceal other mechanisms of action helpful to explain the results.  
Notably, gonadal estradiol represents only a piece of that complex puzzle that is the sex-
related endocrine system. Several other players are released, defining a complex network of 
molecules, whose concentration varies during the oestrous cycle and at different 
combinations of hormones and doses correspond different actions on the cerebrovascular 
system (Kang et al., 2006; Krause et al., 2006). Although we have shown in vivo that 17 β-
estradiol is directly involved in protecting females (ovariectomy experiment; Figure 6.4), we 
should take into account possible synergistic effects with other sex hormones like 
progesterone, which has been proposed to have joint effects with estradiol on ANXA1 
modulation as introduced by Nadkarni et al. (Nadkarni et al., 2011), and testosterone, which 
can be converted in estradiol (Krause et al., 2006).  
Although it is absolutely relevant to consider that cerebral concentrations of estradiol are 
very similar between male and female individuals thanks to the aromatase-specific activity, 
we decided to focus on stimulations that mimic the effect of circulating estradiol 
synthetized in female gonads, since we initially detected a specific female protection, which 
was absent in male mice.  
In terms of peripheral inflammatory model, apparently we could not find any difference in 
the numerous signalling steps triggered by a short incubation with pro-inflammatory 
cytokine; confirmation of these results will be extremely important and will have to focus on 
longer incubation times. In this way, we hopefully will be able to increase the strength of 
these findings and will support the central role of ANXA1. In our experiments, we focused 
on the incubation with two pro-inflammatory cytokines, TNF-α and IFN-γ, with important 
clinical implications [in MS; (Carrieri et al., 1998; Proia et al., 2009)] recently validated as an 
optimal model for barrier increases in permeability (Lopez-Ramirez et al., 2012). Despite 
that, these cytokines have also been shown to be directly transported within the brain 
(Nagyoszi et al., 2010) or to undergo non-specific diffusion within the brain parenchyma 
after augmented permeability, which is an aspect we did not have the chance to investigate. 
More interestingly, peripheral signals are widely sensed by endothelial cells, triggering 
Chapter 6 – Annexin A1 and peripheral inflammation at the BBB: sex-dependent differences 
 
Page | 214   Enrico Cristante – PhD degree thesis    
 
numerous molecular responses, like further unidirectional release of cytokines and 
mediators (arachidonic acid, prostaglandins, nucleotides, etc.) in the brain parenchyma 
(Banks, 2006). Although we failed to detect, in our in vitro model, any significant change in 
cytokines release under the various stimuli (not shown), whose nature is still debated, 
future attention will be required on these aspects.  
 
6.8 Future work 
With all this in mind, future research should be focused on the molecular dynamics involved 
in ANXA1 release, both in presence of pro-inflammatory stimuli and estradiol. Our initial 
results (Figure 6.11) seem to have paved the way towards the right direction: future studies 
of other known sites of post-translational modifications are required, though; for example, 
investigating if Tyrosine21-phosphorylation could offer direct explanation for the retaining 
effects caused by pro-inflammatory cytokines. 
We feel it will be important to generate a better understanding of routes of periphery-brain 
communication through the BBB, keeping a special eye on the new dynamic role of annexin 
A1. In particular, we should not forget the fundamental role played by other important 
sensors forming the BBB, i.e. the perivascular macrophages, pericytes and astrocytes 
(Thomas, 1999; Serrats et al., 2010), which latest evidence depicted as extremely valuable in 
generating a response.  
Brain barriers age as the rest of the organism and respond less well to certain treatments 
like the hormonal ones (Sohrabji and Bake, 2006); since these studies will be mostly relevant 
for applications dedicated for aged people with neurological conditions, it will be important 
to consider the differences that characterised the aged BBB. Unfortunately, literature leaves 
big gaps in this area, which need to be filled soon.  
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6.9 Summary and conclusions 
In this chapter, we gained strong confirmation for a protective role of estradiol on cerebral 
endothelium; to this, we added novel evidence for ANXA1 involvement in this mechanism. 
Estradiol pre-exposure resulted in actions that closely resembled those played 
physiologically by ANXA1 on the BBB: regulation of actin cytoskeleton, stabilization of cell-
cell junctions between adjacent cells and protection of the barrier tightness; we think that 
these events are able to tackle the disruptive role brought by uncontrolled inflammation. 
Therefore, estradiol pre-exposure may be able to “prime” the endothelium to respond to 
possible disruptive stimuli by modulating the readily available pool of ANXA1.   
Overall, these findings lead us to define a new potential mechanism (described in Figure 
6.14) of action for 17 β-estradiol anti-inflammatory/rescuing effect on BMECs, which, if 
confirmed, may offer novel ideas for further exploitation. Despite some aspects of this 
complex network still need to be confirmed, such findings could easily be taken into account 
to justify the strong evidence gathered around the protective role of estradiol on brain 
microvasculature (Bake and Sohrabji, 2004; Sohrabji and Bake, 2006; Bake et al., 2009) as 
well as to decipher the numerous contrasting results given by hormonal replacement 
therapies under inflammatory and neurological conditions (Krause et al., 2006; Li et al., 
2011). If translated to the human, these results may therefore suggest ANXA1 as a new 
endogenous player in the complex action offered by estrogen and represent the basis for a 
new wave of research on endogenous mediators which may modulate the ultimate 
hormonal effect in a less invasive fashion. 
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Figure 6.14 Mechanism of action of β-estradiol in BMECs and involvement of ANXA1 as mediator 
of the steroid. The cartoon illustrates the hypothesized pathways that are triggered by estradiol to 
limit subsequent increase in brain endothelial permeability under inflammatory conditions. Both 
genomic and non-genomic actions result in increased ANXA1 expression and release, counteracting 
the negative influence of pro-inflammatory mediators. ANXA1 exerts its numerous functions both 
from within the cells (Chapter 4) and from outside, where it is able to trigger a complex 
autocrine/paracrine mechanism through FPR2. Overall, this counteracts the negative effects that are 
triggered by pro-inflammatory cytokines like TNFα, which involve activation of RhoA, PLA2 (both of 
which are negatively regulated by ANXA1) as well as caspase-3 (regulated by ANXA1), -7 and -9 with 
consequent apoptosis-dependent or independent actions, direct negative effects on tight junctions 
(which are rescued, when disrupted, by ANXA1) and induction of other pro-inflammatory mediators 
with a negative impact on brain endothelium. Through this complex involvement of signalling 
pathways, triggers and breaks, chronic exposure to estradiol seem to be able to make the 
cerebrovascular endothelium more resilient to peripheral inflammatory stimuli. 
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7.1 Overview and aim of the chapter 
In the previous chapter we have reported the involvement of Annexin A1 at the level of the 
BMECs, which represents the interface between the peripheral immune system and the 
CNS. With the knowledge of how inflammatory events happening elsewhere in the body 
signal and impact the CNS, our subsequent step was to investigate the behaviour of ANXA1 
within the brain, both intact and injured. Therefore, we first studied which brain cells 
normally express the protein and how such expression was modulated by signals coming 
from outside the brain. As shown in Chapter 2 (Figure 2.1 and Figure 2.2) there is a unique 
expression pattern of Anxa1 in a distinct region of the midbrain, the substantia nigra pars 
compacta (SNpc), which is clinically important as containing the dopaminergic neurones that 
degenerate in Parkinson’s disease. In particular, our preliminary study detected both Anxa1 
gene promoter activity (β-galactosidase staining) and protein expression at the level of a 
sub-population of dopaminergic neurons and at level of microglia-like cells. In addition, a 
peculiar modulation in Anxa1 gene promoter activity was evident under systemic 
inflammatory conditions, indicating that this protein was most likely modulated by 
peripherally-derived stimuli.  
Part of our latest findings on the role of ANXA1 on microglia behaviour have already been 
published and will only be briefly described for the specific purposes of the chapter. For an 
exhaustive description, we refer the reader to the relevant publication (McArthur et al., 
2010).  
 
7.2 The impact of peripheral inflammation within the brain 
As exhaustively considered in the Introduction (Section 1.3), the concept of a brain largely 
unaffected by peripheral inflammatory events is essentially wrong; CNS is deeply affected by 
what happens in the rest of the body and responds to it accordingly. Cellular, humoral or 
neural pathways are in charge of mediating the communication between the two 
compartments and we demonstrated how Annexin A1 takes part to the regulation of part of 
this process. Animal and human studies support the primary importance of peripherally-
originated inflammatory molecules in mediating sickness-related behaviour.  
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Once inflammatory messengers have entered the brain, or have been synthesised within the 
brain (by astrocytes, endothelial cells and perivascular macrophages at the level of the CVOs 
and  neurovascular unit; by other myeloid brain resident cells, as a consequence of the 
peripherally-triggered signalling), they are able to influence the peculiar nervous system 
components, primarily the neurons, the ultimate goal being a coordinated response towards 
the cause of inflammation (Dantzer, 2004). The resident immune cells of the CNS, microglia, 
are able to promptly sense and respond to the first signs of peripheral signals (Lucas et al., 
2006): by releasing pro-inflammatory factors like cytokines, reactive species and lipid 
metabolites, microglia take part in the amplification of the reaction by sending alert 
messages throughout the brain, triggering various neuronal structures to mount autonomic 
and neuro-endocrine defensive actions.  
Since the CNS represents a very delicate structure, this series of reactions is supposed to 
occur in a timely fashion, tightly regulated by specialised anti-inflammatory/resolutive 
mechanisms, which still need to be fully elucidated (Yong and Marks, 2010). No long-term 
consequences should be left behind; however, clinical and experimental evidence indicates 
that inflammatory reactions may not always subside adequately, keeping microglia and 
other surveillance resident cells persistently in an activated state. Such a situation seems to 
happen according to the duration and the intensity of the initial inflammatory stimulus, on 
concurrent or recurrent stimulation and/or on failure of the anti-inflammatory mechanisms. 
In this scenario, a constant status of stress and damage negatively affects the general 
homeostasis of the intact brain. Several studies have reported intense and prolonged 
changes in the brain as a response to peripheral infections and/or inflammation. These 
include activated microglia phenotype and recruitment of neutrophils and monocytes into 
the brain (Jeong et al., 2010), leading to long term loss of discrete neuronal populations  
(Qin et al., 2007) as well as consequent alterations of neurological functions, such as 
disruptions to psychomotor coordination (Brydon et al., 2008). Understandably, the impact 
of peripheral inflammatory events may result in the establishment of a constant neuro-
inflammatory cycle, which represents one of the most powerful risk factors for many 
neurological disorders, as well as one of the major mechanisms contributing to the 
occurrence, recurrence and the persistence of neurodegenerative disorders.  
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7.2.1 Impact of peripheral inflammation in aging and pathology 
Several reports have shown the strong influence of systemic inflammation in patients with 
on-going neurological conditions, such as AD (Perry, 2010; Murray et al., 2011). In fact, 
under existing pathological conditions or in the aged brain, the impact of inflammation 
results in an even more complex set of responses, which are linked to a particular microglia 
phenotype called “primed”: chronic neurodegenerative diseases and aging represent a 
constant ensemble of subtle, slow, chronic inflammatory stimuli, which bring microglia to 
adapt into a particular sub-activated status, characterised by proliferation, structural 
changes towards the activated morphology, increased expression of several cell-surface 
antigens and transcription of inflammatory genes, but supressed secretion of inflammatory 
molecules. Microglia represents a group of long-lived cells that retain memory of all the 
events that occurred in their microenvironment. Therefore, their behaviour is affected in 
the long term by neurodegeneration, which is characterised by the loss of structure and 
function of neurons and a constant release of molecules and cellular components into the 
surrounding environment (Godbout et al., 2005; Tansey et al., 2007). The primed phenotype 
can be viewed as the result of an adaptation towards subtle constant stimulation, a 
protective response that avoids over-activation to the same repeated type of trigger. Some 
have defined it as “alternatively anti-inflammatory” (Perry, 2004) since increasing evidence 
is reporting low pro-inflammatory cytokines (IL-1, IL-6, TNF-α, IFN-γ) and increased anti-
inflammatory ones (TGF-β1) in brains affected from chronic neurodegenerative disorders 
(Perry, 2010). Some others have defined it as “dystrophic” or partially activated after the 
observation that diseased or senescent microglia are functionally impaired in their ability to 
produce neurotrophic factors or to eliminate toxins and dead cells, while showing increased 
neurotoxicity and reduced anti-oxidant activity (Holmes and Butchart, 2011; L'Episcopo et 
al., 2011). Regardless of the truth behind its nature, evidence supports that in a 
neurodegenerating or aged brain different types of stimuli may evoke exaggerated 
inflammatory responses through this type of microglia, which appear to have a primary 
impact on disease progression and to contribute towards neuronal loss (Cunningham et al., 
2005; Godbout et al., 2005; Couch et al., 2011; Murray et al., 2011).  
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We should not forget that the primary role of microglia is to contribute to neuroprotection, 
for example by releasing neurotrophic and survival factors (Gao and Hong, 2008); however, 
the balance between the positive and negative effects offered by neuroinflammation on its 
own is very fine: uncontrolled microglial over-activation can become destructive with the 
consequent damage of healthy or already injured brain regions.  
 
7.2.1.1 Impact of peripheral inflammation in chronic neurodegeneration 
We are now aware of the clinical relevance played by neuroinflammation in several 
neurodegenerative diseases like AD, MS and PD; the fact that BBB is often impaired in these 
pathologies facilitates the impact of several environmental factors, like infection-driven 
inflammatory mediators, on creating a vicious self-propagating cycle contributing to the 
progression of the disease (Perry, 2004, 2010) as depicted in Figure 7.1; in addition, the fact 
that most of these pathologies (AD and PD) show an increasing risk of developing or 
exacerbating with age, could be seen as chronic exposure to systemic inflammation. For 
example, it has been shown that systemic infections of the respiratory tract are tightly 
associated with one-third of MS relapses, while systemic challenge with bacterial-derived 
inflammogens or cytokines exacerbated the clinical symptoms of the animal model EAE 
(Schiffenbauer et al., 1993). Animal and human studies showed increased cognitive decline 
and exaggerated sickness behaviour in response to systemic inflammation in AD patients 
and animal models (Holmes and Butchart, 2011); moreover, a strong correlation between 
elevated peripheral inflammatory indicators and new pathology development or existing 
pathology exacerbation has been observed, which may be used as prognostic markers.  
 
7.2.1.2 Increase in microglia population under pathological conditions 
The parenchymal microglial cells represent a long-lived and stable population derived from 
the infiltrating phase occurring during gestation. Physiologically, a small number of 
leukocytes crosses the BBB and enters the CNS; at the same extent, resident microglia is 
only partially maintained by peripherally circulating cells (i.e. monocytes) (Chan et al., 2007; 
von Bernhardi et al., 2010).  
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Figure 7.1 Mechanisms and triggers that initiate the vicious cycle of neuroinflammation. Various 
stimuli can result in activation of microglia, microgliosis and consequent release of toxic substances 
which negatively target neurons. Alternatively, a healthy neuron may become dysfunctional as a 
result of built-up oxidative stress or genetic factors, and become a primary stimulus for microglia 
activation. Adapted from Tansey et al., 2007. 
 
However, the situation changes dramatically under pathological conditions; studies 
employing chimeric animals or allogenic transplantation clearly showed cells of monocytic 
nature differentiating into microglia (Djukic et al., 2006; Hanisch and Kettenmann, 2007; 
D'Mello et al., 2009; Ajami et al., 2011; Mizutani et al., 2012) in support of an on-going 
inflammatory reaction. Although the molecular mechanism of recruitment is not fully clear, 
it is evident that haematopoietic cells are an important source for the CNS even when the 
brain does not show gross signs of acute inflammation but more a subtle chronic 
inflammatory milieu, characteristic for example of aging (von Bernhardi et al., 2010).  
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Notably, in a model of meningitis (Djukic et al., 2006), conversion of blood monocytes into 
microglia did not occur during the acute phase of the disease but during the post-infection 
period; since this is a crucial phase for the post-infection recovery, the role of these cells is 
to restore tissue homeostasis. However, the recruitment of monocytes in a non-regulated 
fashion may become hazardous and potentially exacerbate existing conditions. Interestingly, 
a recent report (D'Mello et al., 2009) demonstrated how peripheral inflammation is able to 
indirectly stimulate circulating cell recruitment into the CNS, supporting the huge impact 
that even low-grade immune reaction may generate. These novel findings opened up new 
avenues in understanding the pathophysiology of many conditions, as well as offering a new 
potential delivery strategy of therapeutic molecules (in the form of coding DNA sequences) 
to the CNS through peripheral haematopoietic cells (Djukic et al., 2006). 
  
7.2.1.2.1 Parkinson’s disease: generalities 
Although less extensively studied than Alzheimer’s disease, today we know that Parkinson’s 
disease can also be profoundly affected by peripheral inflammatory events (Machado et al., 
2011). Being the second most common neurodegenerative disorder of aging, and the most 
common movement disorder, the burden of disability from PD is considerable.  
In a nutshell, PD is characterised by degeneration of dopaminergic (DA) neurons mainly at 
the level of the SNpc; this is a midbrain nucleus included in the basal ganglia system, and the 
major source of dopamine of the brain. The DA neurons of the SNpc project into the 
striatum (forming the nigrostriatal dopaminergic pathway, NSDA) and the output signals 
govern the locomotor behaviour (Brydon et al., 2008). As a consequence of the extensive 
loss of DA neurons (more than 70% of them have degenerated/died at the time of the first 
overt pathological signs), clinical signs include motor symptoms such as rigidity, 
bradykinesia, tremor at rest, gait and balance problems, and non-motor symptoms 
contributing to deterioration of the life style, including mild cognitive impairment, 
depression, sleep disorders, olfactory deficits, dementia and increased mortality (Hindle, 
2010). Unfortunately there is no yet successful treatment for PD patients to date and this 
links to the fact that the diagnosis usually occurs when substantial damage has already 
occurred (Glass et al., 2010).  
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The aetiology of PD remains still not clear. Once regarded as a purely sporadic disease, 
nowadays its multifactorial nature is clearly explained by the influence of genetic and 
environmental factors contributing to the development of the disease along with aging, 
which still represents the largest single risk factor (Hindle, 2010; Schapira and Jenner, 2011). 
Environmental risks for PD include exposure to pesticides, heavy metals and solvents, rural 
environment and some types of jobs with toxins high exposure. Although there are forms of 
PD that are considered to be purely familial, they account for less than 5% of the total cases 
(Yang et al., 2009); in many cases, genetic alterations or polymorphisms on certain 
molecular pathways (mitochondria functions, proteasome and autophagy) represent 
important susceptibility factors.  
In post-mortem studies, altered levels of inflammatory cytokines have been detected, along 
with the typical features of activated microglia. In addition, some recent studies have 
identified a role for pro-inflammatory CD4+ T helper class-1 (TH1) lymphocytes, which may 
contribute to DA neurons toxicity (Glass et al., 2010). These clinical signs stress the impact 
offered by neuroinflammation in the disease, although we don’t know whether this 
constitutes a primary cause of the DA neurons death or a response triggered towards 
neuronal loss. Both options may be equally involved in the pathology (Schapira and Jenner, 
2011). PD progression strongly depends on a chronic inflammatory milieu, with cytokines 
and nitric oxide being extremely important as amplifiers of the initiating neuro-
inflammatory event (McGeer and McGeer, 2004; Glass et al., 2010). Evidence that 
inflammatory responses are able to trigger loss of dopaminergic neurons is provided by 
endotoxin-mediated neurotoxicity (Kim et al., 2000).  
 
7.2.1.2.1.1 Impact of systemic inflammation in Parkinson’s disease 
Being so strongly influenced by neuroinflammation, PD is also intensively affected by 
peripheral inflammatory events, which can exacerbate the course of the pathology. Today, 
systemic inflammatory insults are considered risk factors in the PD aetiology and in the 
exacerbation of existing pathology (Ferrari and Tarelli, 2011). Qin et al. (Qin et al., 2007) 
showed that peripheral administration of the inflammogen LPS is able to cause long lasting 
subtle neuroinflammation at the level of the SNpc (levels of pro-inflammatory cytokines 
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elevated for 10 months), which results in delayed loss of DA neurons. Instead, Jeong et al. 
(Jeong et al., 2010) did not report chronic loss of neurons after LPS administration, but 
focused more on the acute response of the microglia populating this region, which promptly 
developed an activated morphology and cytokine profile. Recruitment of peripheral 
monocytes has also been reported and it represents a factor that increases the susceptibility 
of the SNpc (Jeong et al., 2010). Interestingly, one report (Reale et al., 2009) identified a 
higher pro-inflammatory profile for peripheral blood mononuclear cells (PBMC; which 
include monocytes and lymphocytes) in PD patients, which exacerbated in presence of 
inflammatory stimulation (LPS); this could suggest a cross-talk periphery-brain occurring in 
both directions as well as the definition of a chronic self-propelling detrimental cycle which 
contributes to the disease progression.  
 
7.2.1.2.1.2 Peculiar features of the SNpc 
PD represents an excellent model to advance the current understanding of 
neurodegeneration: in fact, the pathological event is well defined and consist in the specific 
loss of the DA neurons of the SNpc (Schapira and Jenner, 2011), which has been reported to 
present the highest density of microglia in the whole brain (Kim et al., 2000). Also, DA 
neurons of the SNpc present a higher intracellular oxidative state due to a high glycolytic 
regime (Tansey et al., 2007) but mostly because of the synthetic process of dopamine, 
which requires a series of oxidative reactions and produces high amounts of neuromelanin, 
known to trigger oxidative reactions. In addition to that, they also show less anti-oxidative 
defence (Glass et al., 2010). Overall, it is easy to understand how a significant increase in 
pro-inflammatory reactions involving ROS and RNS, for example in response to systemic 
inflammation, represent a really serious danger for such a delicate brain area, maximizing 
the importance of such studies.  
 
7.2.1.2.2 How to model Parkinson’s disease 
In order to study in detail the pathogenesis of Parkinson’s disease, as well as all the factors 
that may influence the outcome, either positively (potential therapies) or negatively 
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(environmental triggers, genetic susceptibility, etc.), we need to be able to model the 
pathology accurately; that is why several animal models of the disease are currently chosen 
and used according to the specific needs of the investigation.  
The neurotoxin 6-hydroxydopamine model (6-OHDA) in rodents is the traditional model, 
especially useful for studies investigating the behavioural deficits and motor dysfunctions of 
the disease. 6-OHDA is a structural analogue of catecholamines (of which dopamine is one 
of the members) and it is able to exert its toxic effects on catecholaminergic neurons, 
accessible through the dopamine (DAT) or the noradrenaline (NAT) membrane transporters 
(Simola et al., 2007). Being unable to cross the BBB, this molecule has to be directly injected 
in the area of interest through stereotaxic surgery, along with NAT blockers (like 
desipramine), which impedes targetting noradrenergic neurons. 6-OHDA causes DA 
neuronal death by triggering an intense oxidative stress (Simola et al., 2007). The toxin can 
also alter mitochondrial function, by impairing the activity of complex I of the respiratory 
chain. All these events result in the consequent generation of ROS, which quickly trigger 
neuronal damage and demise. Importantly, the toxin can be injected on only one side of the 
animal brain, with the opposite side serving as an intra-animal control. This injection 
produces DA neuron loss on the injected side while sparing the contralateral DA neurons. 
There is no evidence of Lewy bodies in this model and the progression of the disease is 
acute instead of chronic.  
The 1-methyl-4-phenyltetrahydropyridine (MPTP) model is currently considered the PD 
model of choice in mice while rats are very insensitive to this toxin. After intraperitoneal 
injection, the molecule can easily access the brain thanks to its lipid-soluble/amphiphilic 
nature and it does not show toxicity in the original form but it can be metabolized in the 
toxic 1-methyl-4-phenylpiridinium (MPP+) by astrocytic oxidases and in this form it shows 
preferential toxicity for the DA striatal nerve terminals as well as for DA neurons of the 
SNpc. The toxin seems to target the mitochondria respiratory chain (complex I), resulting in 
increased oxidative stress and in a lower energy production. Also, the selectivity of the toxin 
is not as precise, since the active MPP+ can target also other neurons and brain cells due to 
its high penetration and reactivity (Blandini and Armentero, 2012).  
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More recent models, like the rotenone systemic injection (Blandini and Armentero, 2012) or 
the intranigral injection of lactacystin (Ahn and Jeon, 2006) target important pathways 
impaired in the human disease, namely mitochondrial respiratory activity and proteasome, 
resulting in physiopathological manifestations very similar to those seen in PD (e.g. the 
accumulation and aggregation of α-synuclein and ubiquitin, the progressive oxidative 
damage, and neuronal apoptosis). The intracerebral injection of inflammogen such LPS has 
been also explored (Ahn and Jeon, 2006; Liu and Bing, 2011); although it produces selective 
loss of DA neurons in the SNpc, it does not resemble the main features of PD and it only 
proves useful to study the impact of inflammation in triggering/progressing the disease. 
 
7.2.1.3 Controlling and limiting the impact of peripheral inflammation 
Controlling neuroinflammation is still a major challenge from a therapeutic point of view; 
therefore, a huge effort has been produced in studying means to control microglia over-
activation in all its facets. Several anti-inflammatory and anti-oxidant molecules and 
therapies have been tested including non-steroidal anti-inflammatory drugs (NSAIDs), iNOS 
inhibitors, steroids like glucocorticoids (dexamethasone) and immunosuppressants as 
cyclosporine A (Tansey et al., 2007). The results produced were controversial: while NSAIDs 
chronic use was reported to reduce the risk of developing PD by about 45% (Chen et al., 
2003; McGeer and McGeer, 2004; Tansey et al., 2007) and proved to be useful in animal 
models of PD (L'Episcopo et al., 2011), most of aforementioned compounds did not show 
significant improvements during their translation in humans (Allan and Rothwell, 2001), 
either for their strong side-effects or because the human disease proved to be more 
complex to treat. Several clinical trials have in fact failed in the past, mainly due to the 
advanced pathology of the patients enrolled in the studies or because the dosing and timing 
regimes were wrong. Noteworthy, these drugs are not truly anti-inflammatory, since they 
do not stimulate the anti-inflammatory/resolution pathway and restoration of the 
homeostasis, but they rather halt the on-going inflammatory response. For this reason, 
recent studies are beginning to focus more smartly on endogenous molecules, which could 
be exploited in a more “natural” way, promoting the resolution of a persistent, dysregulated 
and detrimental neuroinflammatory reaction. Several counter-regulating mechanisms 
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(called Off signals) have been recently identified as constantly in place. For example, the 
immunoglobulin family member CD200 (OX-2) normally expressed on neurons binds a 
ligand on microglia (CD200 receptor) and limits its reactivity; similarly, the chemokine 
CX3CL1 (more familiarly known as fractalkine) is highly expressed and released 
constitutively by neurons, binds the microglial receptor CX3CR1 and in its absence 
neuroinflammatory reactions are exacerbated (Cardona et al., 2006; Biber et al., 2007).  
Overall, this evidence indicates that neurons are active regulators of microglia behaviour, 
and are not simply passive targets of microglial over-activation; neurodegeneration results 
in a loss of neurons, but also in a considerable loss of endogenous anti-inflammatory 
mechanisms, which could contribute to the consequent microglia activation (de Haas et al., 
2007).  
Certain regulatory mechanisms also exist at the level of glia cells, like the nuclear receptor 
Nurr1 which is able to limit the NF-κB-mediated transcription of pro-inflammatory genes; 
Nurr1 has been shown to provide protection in animal PD models by reducing the 
production of neurotoxic mediators by microglia and astrocytes (Saijo et al., 2009; Glass et 
al., 2010). 
 
7.2.1.3.1 Annexin A1 as a potential counter-regulator of neuroinflammation 
Annexin A1 relevance as a modulator of several anti-inflammatory molecules, along with the 
ability to prevent the activation of reactive enzymes like COXs, iNOS and cPLA2 (Minghetti et 
al., 1999), to limit the production of cytokines classically shown to be up-regulated in PD (IL-
6 and IL-8) (Mogi et al., 1994) and other positive correlations with cerebral ischemia models 
(Relton et al., 1991; Black et al., 1992; Rothwell and Relton, 1993; Gavins et al., 2007) gave 
this molecule huge expectations as a neuro-inflammatory modulator. We recently 
demonstrated ANXA1 to be important for microglia-driven non-inflammatory clearance of 
apoptotic neurons (McArthur et al., 2010), which is an essential requirement to avoid 
secondary necrosis and perpetuation of central inflammation. 
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7.3 Methods 
Please refer to Chapter 3 for the description of general in vivo and immunostaining 
procedures and to McArthur et al. 2010 (McArthur et al., 2010) for details relative to that 
publication. Here description about certain technical aspects and the experimental plan 
specifically used for the purpose of this chapter is provided. Please refer to the Appendix 
(Chapter 10) for the solution composition.  
 
7.3.1.1 In vivo experimental plan 
In order to evaluate brain-resident cell responses to peripheral inflammation in terms of 
dopaminergic neuron survival and specific expression of Anxa1, we compared male wild-
type C57Bl/6 or Anxa1 null mice (n=4-6/group; 2-3 months old) over the time after 
challenging them i.p. with a single dose (3 mg/kg) of LPS. Animals were culled by anaesthetic 
overdose, perfused with saline and blood and brains were collected at 2 hours, 24 hours and 
7 days after administration of LPS. 
To investigate genotype-related differences in DA neurons survival under 
neurodegenerative conditions, we performed 6-OHDA unilateral intrastriatal infusion (see 
below) in male wild-type C57Bl/6 or Anxa1 null mice (n=4-6/group) and culled them after 24 
hours, 1 week, 2 weeks or 4 weeks post-lesioning. Vehicle infusion (1 µl) served as baseline 
control and was assessed after 24 hours.  
To evaluate for a potential synergistic/exacerbating effect of systemic inflammation on on-
going neurodegeneration of the SNpc DA neurons, male wild-type C57Bl/6 or Anxa1 null 
mice (n=4-6/group) received 6-OHDA lesions and after 1 week (established as a good time-
point where number of dopaminergic neurons was significantly decreased) were challenged 
i.p. with a single dose (3 mg/kg) of LPS. After 1 week mice were placed under terminal 
anaesthesia for collection of brains.  Figure 10.7 visually describes the experimental plan 
and it has been assigned to the Appendix for space constraints.   
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7.3.2 Cytokine quantification by ELISA  
Blood samples obtained by cardiac puncture were taken from animals that had received i.p. 
administration of LPS for various time frames. The samples were left to clot at 37°C for 10 
minutes and then centrifuged at 4000 RPM (~ 1200xg) for 20 minutes at 4°C; the 
supernatant (serum) was collected in a fresh tube, taking care to prevent carry-over of red 
blood cells. Brain lysates were instead obtained as described in (Puntener et al., 2012). 
Briefly, half brains were homogenised by sonication (2 cycles; 10 seconds/cycle on ice) in 
TRIS buffer containing a protease inhibitor cocktail (1ml/100 mg tissue). Samples were 
centrifuged for 30 minutes at 13000 RPM and supernatants assayed for total protein using 
the BCA protein assay described in the general Methods.  
Serum samples were analysed for TNF-α and IL-6 content while brain lysates were analysed 
for IL-10 content using ELISA kits (eBioscience, UK) according to manufacturer’s instructions. 
Samples were run in triplicates; serum samples and brain lysates were diluted 1:10 using the 
provided assay diluent in order to avoid values outside the sensibility range of the kit. 
Detection of the colorimetric reaction was performed by reading the plates at 450 nm and 
correcting for unspecific absorbance by subtracting the reading at 570 nm. Brain lysates 
contents were normalized on total protein content, giving values as ng cytokine/mg protein. 
 
7.3.3 6-Hydroxydopamine (6-OHDA) lesioning of the NSDA pathway  
Intracerebral injection of 6-OHDA into the left striatum of mouse brain has previously been 
shown to induce lesions in the striatum itself (loss of striatal DA) and SNpc [loss of tyrosine 
hydroxylase immunoreactive, TH-IR, neurons (Callio et al., 2005)]. Dr. S. McArthur provided 
extensive help and technical advice. Half an hour prior to lesioning, animals were injected 
i.p. with 20 mg/kg of desipramine, an inhibitor of the noradrenalin re-uptake transporter, in 
order to prevent the access of the toxin to noradrenergic or adrenergic neurons. Animals 
were then anesthetised by intraperitoneal injection of a mixture of hypnorm/hypnovel 
(1:1:2; respectively, hypnorm:hypnovel:water). The fur along the snout and on the forehead 
of the animal was shaved and the area was disinfected by application of 100% ethanol. The 
animal was then fitted into a stereotactic frame and an incision was made running from 
midway between the eyes to midway between the ears.  
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The membranous coating of the skull was then removed to reveal the bregma, which was 
accentuated by marking with a dissection pin. Using this as starting point, the injection 
needle was moved 2 mm left and 1 mm towards the tail to sit above the striatum (Callio et 
al., 2005). This point was marked on the surface of the skull and a hole of approximately 1 
mm diameter was drilled using a hand-held dental drill. The meninges were cleared from 
the surface and the injection needle was lowered 3 mm into the brain. Over a period of 2 
minutes 1 μl of 6-OHDA solution or 1 μl of vehicle was injected. The injection needle was 
then left in place for a further 3 minutes to allow diffusion of the neurotoxin from the lesion 
site. The animals received 80 μl buprenorphine analgesics (Vetergesic) subcutaneously and 
were removed from the stereotactic frame. The head incision was sealed with three sutures 
and the animal was monitored until it had recovered from anaesthesia. Toxin exposure was 
for 24 hours, 1, 2 and 4 weeks, after which animals were deeply anesthetised, perfused and 
the brain was collected and fixed. Brains from vehicle-treated animals were collected after 
24 hours only, since longer time-points did not show any difference in loss of DA neurons 
(Jeon et al., 1995). 
Previous studies (Gillies et al., 2004) confirmed that placement of 6-OHDA or vehicle 
injections on the left side had no significant effect on the dopaminergic populations on the 
right side; therefore, results of DA neurons remaining in the lesioned side were expressed as 
percentage of DA neurons in the contralateral side, as extensively done in the past 
(Schwarting and Huston, 1996).  
 
7.3.4 Fluorescence microscopy for quantification 
Brain tissue sections prepared as described in the General methods (Chapter 3), were 
viewed with a Nikon eclipse i50 microscope using Lumen200 fluorescent illumination system 
(Prior Scientific, USA) with filter sets to detect 488nm (green), 546nm (red) and 310nm 
(DAPI) excitation wavelength. Images were captured with a QIACAM digital camera 
(QImaging Inc., Canada) and using Image Pro Plus software 7.0 (Media Cybernetics Inc., UK) 
to control an OASIS turbo scan system that could create tiled images of whole sections or 
area of interest. Images were saved with spatial reference information settings for each 
objective based on calibration images. 
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7.3.4.1 Quantification of DA neurons and microglia cells on tissue sections 
DA neurons were identified as the tyrosine hydroxylase positive (TH+) cells, which 
represents one of the rate limiting enzyme in DA synthesis (Kaufman, 1995). To identify 
microglia, we chose to stain for ionized calcium binding adaptor molecule 1 (Iba1), a 
cytoplasmic calcium-binding protein thought to play a role in activation of phagocytic 
myeloid cells. It clearly stains microglia cells, as well as monocytes and resident 
macrophages in a lesser extent. For double-staining constraints, certain labelling 
experiments were performed by using integrin-α M (Cd11b), another molecule expressed 
under basal conditions on cells of a myeloid origin, in particular resident ones. In the brain, 
these molecules have been shown to be present on resident microglia and to be up-
regulated when these cells undergo activation (Ransohoff and Brown, 2012).  
TH+ cells, Iba1+ and Annexin A1 positive (Anxa1+) cells within the SNpc and ventral tegmental 
area (VTA) were counted using an image analysis software package (Image ProPlus 7.0, 
Media Cybernetics, UK). Images were projected onto a PC monitor and the sections were 
analysed by manually single blinded-counting all of the TH+ cells and Iba1+ located within 
the two nuclei (whose boundaries were delineated by following the profile described by the 
TH+ cells). Definition of the SNpc and VTA boundaries was accomplished along nuclei 
defined by TH positive cells, following published visual guidelines (Ikemoto, 2007), reviewed 
in Figure 10.8 (Appendix). In each animal, the total number of positive cells in at least four 
sections, representative of the whole extent of both nuclei, was counted; sections were 
labelled as rostral or caudal according to their location relative to the brain area of interest. 
Average of cell counts per rostral/caudal region was calculated for each group and 
comparison was made as absolute numbers or percentages of vehicle treated groups to 
evaluate significant changes in the numbers. This profile-based counting technique for serial 
reconstruction has proven the most appropriate method when cell numbers are relatively 
low (Huerta-Ocampo et al., 2005). This two-dimensional method, employed previously 
(Gillies et al., 2004; Huerta-Ocampo et al., 2005), enables counting of all cells across the 
whole of the coronal plane of the SNpc and VTA, where TH+ immunohistochemistry 
completely delineates nuclear margins. This provides a large sampling window, enabling 
highly accurate assessment in the (x, y) plane, which compares favourably with three 
dimensional counting methods (Benes and Lange, 2001). 
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7.3.5 Nitrite content measurement 
Nitrite (NO2
-) levels are good indicators of nitric oxide (NO) production by NO synthase 
enzymes present in cells or tissues; since NO is a highly reactive molecule, it undergoes a 
series of reactions with several molecules present in biological fluids and is eventually 
metabolized to nitrite and nitrate (NO3
-), the latter being converted to the former almost 
totally (Rakesh, 2007). Nitrite levels can be measured using the Griess reaction (Green et al., 
1982). A total of 50 μl/total brain lysate (generated as described for cytokine extraction) was 
incubated with 100 μl of Griess reagent (see Appendix) for 15 min. Nitrite production was 
determined by comparing the absorbance at 540 nm with a standard curve generated by 
NaNO2, and minimum sensitivity was 3 μM. Nitrite contents were normalized on total 
protein content. 
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7.4 Results 
7.4.1 Comparison between wild-type and Anxa1 null mice in terms of DA 
neurons and Iba1
+
 cells 
Immunofluorescence studies on wild-type and on Anxa1 null mouse (Chapter 2; Figure 2.1 
and 2.2) showed Anxa1 to be expressed in several regions of the brain and in a wide range 
of cell types, including putative neurons and microglia. Bright Anxa1 immunoreactivity in 
wild-type animals and β-gal staining in Anxa1 null mice were present in a small set of cells in 
the SNpc; double immunofluorescence staining confirmed that these cells were DA neurons, 
as typified by the positivity to TH specific staining. We characterised these results in more 
detail, and we observed that a small sub-population of DA neurons (around 15% of total TH+ 
neurons) were positive for Anxa1 in untreated conditions  (Figure 7.2; Panel A) while only a 
few scattered DA neurons of the neighbouring region VTA (functionally and 
developmentally distinct) were positive for the protein. We confirmed the intense 
expression of Anxa1 in the sub-population by confocal microscopy (Figure 7.2; Panel C), 
which identified the strong presence of the protein within the cell body, although the 
protein was also present at the level of the axonal fibres as evident from Figure 7.2, Panel A 
(magnification).  
ANXA1 was also expressed in a small portion of TH+ dopaminergic neurons of the human 
SNpc, paralleling the observations made on the mouse model (Figure 7.2; Panel E). 
Comparing wild-type and Anxa1 null mice in terms of total number of DA neurons either in 
the SNpc or in the VTA, we did not detect any significant difference under basal conditions 
(Figure 7.2: Panel D).  
We then characterised genotype-related differences in terms of microglia cells. 
Interestingly, we detected great differences in the density of microglia cells at the level of 
the basal mesencephalic basal ganglia: Anxa1 null mice showed a higher values of Iba1+ cells 
both in the SNpc and in the VTA (Figure 7.3; Panel A and B) compared to the wild-type age- 
and sex-matched animals. Wild-type animals showed densities comparable with reported 
values (Kim et al., 2000), which were increased significantly in the KO animals. Interestingly, 
we were able to detect morphological differences throughout the brain parenchyma, as 
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depicted in Figure 7.3, Panel F, which shows a representative example taken from the 
thalamus: wild-type Iba1+ microglia cells showed thin, complex ramifications covering large 
micro-areas of the tissue, while cells stained on sections derived from the Anxa1 null mice 
appeared with short and limited ramifications. From a functional point of view, Anxa1-/- 
brain tissue showed increased basal expression of two inflammatory enzymes usually 
expressed only during immune reactions, iNOS and COX-2. These changes suggested the 
constitutive presence of an immunologically active state.  
We then examined the expression of Anxa1 in resident microglia cells from wild-type 
animals. Although staining in the Anxa1 null mice for the reporter gene, β-galactosidase, 
indicated diffuse expression in small microglia-like cells, double immunofluorescence 
staining for Anxa1 and Cd11b detected only a very low signal, specifically localized in limited 
regions of the cell body and cell membrane, as evident from Figure 7.3, Panel C. However, 
we were able to detect a more cell body and ramifications-diffused ANXA1 positivity of 
several microglia cells in human brain post-mortem samples, as represented in Figure 7.3, 
Panel D (see Section 5.3.3 for tissue processing and staining methods).  
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Figure 7.2 Characterisation of Anxa1 expression and Anxa1 gene activity in mouse and human 
mesencephalon. A| Anxa1 (green) and tyrosine-hydroxylase (TH; red) immunofluorescent positivity 
are visualised in a section representative of the SNpc and VTA in wild-type C57Bl/6 male mice. 
Typical examples from n=3 experiments. Scale bars: 250 µm.  B| β-galactosidase (green) and 
tyrosine-hydroxylase (TH; red) immunofluorescent positivity are visualised in a section 
representative of the SNpc and VTA in wild-type C57Bl/6 male mice. Typical examples from n=3 
experiments. Scale bars: 250 µm and 125 µm (inset). C| presents confocal microscopic analysis of 
Anxa1 (green) and TH (red) expression in a magnified area of the SNpc. Typical example from n=3 
experiments. Scale bar: 10 µm. D| Quantification of DA TH+ neurons in the SNpc and VTA of wild-
type and Anxa1-/- animals. Histograms show results from n=6 animals/genotype and are expressed as 
mean ± SEM (total n° cells/region of interest). Student t-test between the genotypes showed non-
significant (NS) differences. E| Immunohistochemistry analysis of human substantia nigra from a 
patient affected by a non-relevant pathology. TH+ neurons were stained in pink, while ANXA1 in 
brown using horseradish peroxidase- and alkaline phosphatase-conjugated antibody and Vector kits 
(Vector Laboratories, UK) to develop colorimetric reactions. Panels C and E were produced by Dr. S 
McArthur. 
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Figure 7.3 Genotype-related differences in the number and morphology of Iba1
+
 cells populating 
the SNpc and the VTA. A| Iba1+ (green) immunofluorescent positivity is visualised in a section 
representative of the SNpc and VTA in wild-type and Anxa1 null male mice (2-3 months old). 
Anatomical regions boundaries were defined through double-staining for TH (not shown). Typical 
examples from n=3 animals. Scale bars: 250 µm. B| Quantification of Iba+ cells density in the SNpc 
and VTA of wild-type and Anxa1-/- animals. Histograms show results from n=6 animals/genotype and 
are expressed as mean ± SEM (n cells/mm2). Student t-test between the genotypes was performed, 
with * and ** indicating p<0.05 and p<0.01 vs. wild-type, respectively. C| Confocal microscopic 
analysis of Cd11b (green), used as a marker for resident microglia and Anxa1 (red) in a magnified 
area of the SNpc of wild-type male mice (2-3 months old). Typical example from n=3 experiments. 
Scale bar: 10 µm. D| Representative immunohistochemistry analysis of ANXA1 expression in 
microglia resident in the cortex derived from a human healthy donor. ANXA1 was stained in brown 
using HRP-avidin-biotin complex (ABC) Vector kit (Vector Laboratories, UK) and DAB to develop 
based colorimetric reaction. Scale bar: 10 µm.  E| Representative Immuno-blots show differences in 
expression of iNOS and COX-2 between genotypes in whole brain extracts; α-tubulin was used as 
loading control. 50 µg of total protein were loaded per lane. F| Representative 
immunohistochemistry analysis of Iba1+ expression chosen as marker for microglia resident; images 
shown were taken from the thalamus of either untreated wild-type or Anxa1 null male mice (2-3 
months old). Iba1 was stained in brown using HRP-avidin-biotin complex (ABC) Vector kit (Vector 
Laboratories, UK) and DAB to develop the colorimetric reaction; sections were counterstained with 
hematoxylin (see Section 5.3.3. for tissue processing and staining methods). Scale bar: 20 µm.           
Panel D and F were produced by Dr. S McArthur. 
 
7.4.2 Impact of peripheral inflammation upon the midbrain 
7.4.2.1 Specific temporal pattern of Anxa1 expression in the SNpc under 
peripheral inflammatory challenge 
The finding that only a small percentage of the DA neurons of the murine and human SNpc 
express Annexin A1 raised interest on the modulation of the protein under inflammatory 
and neurodegenerative conditions. Due to the peculiar localisation of Anxa1 in such an 
important region, we decided to focus on this area, using the neighbouring VTA, rich in 
dopaminergic neurones functionally distinct, as an internal control to compare the 
specificity of the possible changes. Only few studies have looked, to our knowledge (Qin et 
al., 2007; Jeong et al., 2010), beyond the acute phase of the impact of peripheral LPS in the 
brain (24 hours), when pro-inflammatory cytokines production seems to peak; our initial 
data (Figure 2.2) demonstrated the importance of looking beyond this phase.  
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Interestingly, a single dose of LPS (3 mg/kg) administered i.p. was able to induce an increase 
in the number of Anxa1 positive DA neurons, which started after 24 hours and became 
statistically significant after 7 days, as shown in Figure 7.4, Panel A and B.  
No significant changes occurred in the percentage of Anxa1+ DA neurons of the VTA, which 
remained particularly low. This dose of LPS has been widely used to define a moderate non-
lethal peripheral immune reaction, which normally resolves within 24-36 hours (Figure 7.6; 
Panel A and B) from administration; despite their increased endotoxin-related vulnerability 
(Damazo et al., 2005), Anxa1 null mice have been extensively tested to be able to undergo 
such a challenge (Roviezzo et al., 2002). 
More in detail, we observed an increase in the number of neurons present along a well-
defined strip of DA neurons. Importantly, this phenomenon occurred with a different time-
course when compared to the expression of peripheral inflammatory markers (Figure 7.6; 
Panel A and B). As already reported in other studies (Roviezzo et al., 2002; Damazo et al., 
2005), Anxa1 null mice show a basal level of pro-inflammatory cytokines higher than wild-
type, which was also reproduced during peripheral inflammatory challenges with a more 
intense and prolonged pro-inflammatory status as testified by TNF-α (Panel A) and partially 
by IL-6 (Figure 7.6; Panel B).  
Interestingly, while we did not detect any significant difference in terms of numbers of TH-
immunoreactive (TH-IR) cells of the SNpc in the wild-type during the peripheral 
inflammatory challenge, we observed a significant decrease in the number of TH-IR neurons 
of the Anxa1 null mice after 24 hours from LPS i.p. administration, which was restored after 
7 days (Figure 7.4; Panel C). This may strongly indicate more the transient loss of 
dopaminergic phenotype than the actual loss of the neurons, since both loss and restoration 
appeared to occur swiftly and may well suggest the establishment of particularly challenging 
conditions within the midbrain microenvironment. The number of TH-IR neurons in the VTA 
did not show any significant change for both genotypes.  
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Figure 7.4 Effects of systemic LPS challenge on Anxa1 expression on SNpc DA neurons of wild-type 
and Anxa1
-/-
 brains. A| Anxa1 expression was monitored by immunofluorescence (Anxa1: green;  
TH: red) in the midbrain regions SNpc and VTA after challenging the animals with one i.p. dose 3 
mg/kg of LPS or 100 µl saline (as a negative control) for 2 hours, 24 hours or 7 days. Images are 
representative examples of one half of the midbrain. Each treatment group included 4-6 animals. 
Scar bar: 500µm B| Quantification of the percentage of Anxa1+ TH+ cells out of the total of TH+ 
neurons of either SNpc or VTA under the different challenging conditions. 24 hours saline is shown 
as negative control, omitting the other time points studied since they did not show any significant 
difference among themselves or towards the untreated control. Data are presented as mean ± SEM 
(n=4-6 animals/group). One-way ANOVA was performed for each genotype study, followed by 
Bonferroni post-hoc test between the different data sets. * indicates p<0.05 compared to the 
correspondent saline and untreated control.     C| and D| show the quantification of TH+ neurons 
either in SNpc or in VTA, respectively. Results are expressed as relative percentage of total TH+ 
neurons compared to the time-related saline control and are presented as mean ± SEM. For each 
genotype, one-way ANOVA was performed, followed by Bonferroni post-hoc test between the 
different data sets. * indicates p<0.05 compared to the correspondent saline control.  
 
7.4.2.2 Microglia recruitment under peripheral inflammatory conditions 
Microglia cells are extremely sensitive to what happens in the periphery (Czeh et al., 2011), 
so we investigated the effect of peripheral LPS on Iba1+ cell density in both genotypes. We 
detected an increase in Anxa1 null mice already after 24 hours, accompanied by increased 
intensity of staining and a less ramified morphology (Figure 7.5; Panel A and D); the number 
of recruited microglia cells remained increased after 7 days. WT animals showed slower 
kinetics, with a significant increase in microglia density only after 7 days (Figure 7.5; Panel A 
and C), despite the peripheral inflammatory reaction being already resolved (Figure 7.6; 
Panel A and B). The number of cells/mm2 of Anxa1 null animals remained higher than the 
wild-type at every time point studied. The VTA showed no significant change in cell density 
at any of the points studied (Figure 7.5; Panel B). In both genotypes, a substantial part of the 
newly recruited microglia appeared to come from the neighbouring area, the SNpr, as we 
detected in another set of experiments (see below). 
In the AnxA1 null mouse, the morphology of β-galactosidase positive cells changed in the SN 
over the course of a week following LPS administration, and notably the VTA began to 
present cells positive for β-galactosidase activity (Chapter 2; Figure 2.2). We checked this in 
wild-type animals: peripheral inflammation was neither able to induce an increase in Anxa1 
expression in VTA resident microglia nor a general visible change in protein localisation 
(Figure 7.5; Panel B and E).  
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Figure 7.5 Characterisation of the effect of systemic inflammation on microglia recruitment in the 
SNpc and VTA and changes in expression of microglia-associated Anxa1. A| and B| show the 
results of the quantification of Iba+ cell density in the SNpc and VTA of wild-type and Anxa1-/- animals 
challenged with 3 mg/kg dose of LPS i.p. The category graphs show results from n=6 
animals/genotype and are expressed as mean ± SEM (n° cells/mm2). Two-way ANOVA was 
performed (time of LPS exposure and genotype as variables) and identified a significant effect of 
genotype and LPS treatment (p<0.001); the analysis was followed by Bonferroni post-hoc test. # 
indicates p<0.05 vs. wild-type correspondent treatment, while * indicates p<0.05 vs. 24h saline 
treated genotype-matched group. C| and D| show representative magnifications of the SNpc of 
saline-treated or LPS-treated wild-type and Anxa1-/- animals stained for Iba1. Scale bar: 100 µm. E| 
Representative images from confocal microscopy performed on SNpc sections from saline- or LPS-
treated wild-type animals. Anxa1 (red) and Cd11b (green) co-localisation is visualized. 2 hours LPS, 7 
days LPS and other saline-treated controls have been omitted because comparable to the 24h saline 
treated sample here shown. Arrows indicate points of Anxa1 staining within Cd11b+ cells. Scale bar: 
5 µm. Panel E produced together with Dr. S McArthur. 
 
Annexin A1 has been reported to be positively linked to IL-10 release in a macrophage cell 
line (Ferlazzo et al., 2003). Interestingly, we detected a significant genotype-related 
difference, both basally and under peripheral inflammatory challenge, in terms of brain IL-
10 content: while wild-type animals showed a basal level of around 0.6 ng/mg protein, 
which increased as a direct consequence of the peripheral inflammatory challenge 24 hours 
after LPS administration, Anxa1 null mice showed a very low concentration of the cytokine, 
which did not change significantly under inflammatory challenges.  
Annexin A1-induced IL-10 release has also been described to be an iNOS (an enzyme mainly 
expressed in the brain by microglia and astrocytes, especially after injury) expression 
modulator (Ferlazzo et al., 2003). Since we detected basal expression of iNOS in the Anxa1 
null mouse compared to the wild-type counterpart, we measured the content of nitrite in 
brain lysates, as an indication of the gaseous product NO: basally, null mice showed an 
overall higher content, which significantly increased under peripheral challenge (Figure 7.6; 
Panel D).  
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Figure 7.6 Temporal profile of pro-inflammatory cytokines in the serum and brain homogenates 
and of nitrite brain content from treated wild-type and Anxa1 null mice challenged with i.p. LPS. 
A| and B| Serum samples from LPS treated and saline treated controls were obtained and analysed 
for cytokines levels (TNF-α and IL-6) using ELISA commercial kits and following manufacturer’s 
instructions. Results are from n=4-6 animals and were normalized to the saline-treated counterpart 
to remove any effect due to saline treatment; data are presented as mean ± SEM (ng/ml). Two-way 
ANOVA was performed (time of LPS exposure and genotype), which indicated a significant effect of 
genotype and time of LPS treatment (p<0.001) as well as an interaction between the two (p<0.01) 
for TNF-α; the analysis was followed by Bonferroni post-hoc test, $ and $$ indicating p<0.05 and 
p<0.01 vs. wild-type correspondent treatment, while *** indicates p<0.001 vs. 24h saline treated 
genotype-matched group. C| shows differences in IL-10 whole brain concent between wild-type and 
Anxa1 null mice, either saline or LPS-treated for 24 hours. Two-way ANOVA was performed (type of 
stimulation and genotype), which indicated a significant effect of genotype and type of treatment 
(p<0.001) as well as an interaction between the two (p<0.01); the analysis was followed by 
Bonferroni post-hoc test, $ indicating p<0.05 vs. wild-type saline-treated group, while *** indicates 
p<0.001 vs. genotype-matched group. Results are from n=3-5 animals and are presented as mean ± 
SEM (ng/mg protein). D| shows normalized nitrite whole brain content between wild-type and 
Anxa1 null mice, either saline or LPS-treated for 24 hours. Results are from n=3-5 animals and are 
presented as mean ± SEM (µM/mg protein). Two-way ANOVA was performed (type of stimulation 
and genotype), indicating a significant effect of genotype (p<0.01).  
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7.4.3 Impact of neurodegeneration in the midbrain 
7.4.3.1 Genotype-related differences in TH positive neuronal loss in the SNpc 
The expression of Annexin A1 in DA neurons of the SNpc raised further questions, linked to 
the potential role as an anti-inflammatory protein under physiological conditions as well as 
under neurodegenerative conditions (Parkinson’s disease). Therefore, we used our well-
established model of experimental PD, the intrastriatal administration of 6-OHDA, to 
investigate potential differences in terms of DA neuronal loss between wild-type C57Bl/6 
mice and Anxa1 null mice. We chose a sub-maximal dose (2 µg 6-OHDA), shown to cause a 
gradual loss of DA neurons over the time, plus we treated only the left striatum, in order to 
have an internal negative control (the contralateral right side) for comparison (Bowenkamp 
et al., 1996; Schwarting and Huston, 1996). 
As evident from Figure 7.7, Panel A, we were able to establish both in wild-type and in 
Anxa1 null animals a progressive and specific TH+ neuronal loss in the SNpc, which did not 
affect significantly the neighbouring region VTA (Figure 7.7; Panel B). In wild-type, loss of TH 
phenotype started already 24 hours after intrastriatal toxin injection, and progressively 
continued over the 4 weeks of investigation. By performing TH and Anxa1 double staining 
on wild-type lesioned animals, we noticed that a considerable percentage of the 
dopaminergic neurons surviving over the time was Anxa1 positive (Figure 7.7; Panel C): the 
percentage of Anxa1 positive TH cells increased over the time, which was not due to an 
increase in the absolute number of Anxa1 expressing neurons (data not shown), but rather 
to the preferential survival of these cells during the neurodegenerative event. Such 
phenomenon appeared to be SNpc-specific, since we did not detect any difference in the 
number of the scattered Anxa1+ TH+ cells of the VTA (Figure 7.7; Panel D). Interestingly, 
Anxa1 null mice showed a different phenotype: after an intense loss of TH positivity after 1 
day, we were unable to detect further significant changes in the number of remaining 
neurons; this event caused a significant difference between genotypes at 4 weeks post-toxin 
administration, therefore indicating slower distinct kinetics in the model when applied to 
the Anxa1 null animals.  
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Figure 7.7 Temporal loss of dopaminergic neurons in the midbrain of wild-type and Anxa1 null 
mice following intrastriatal injection of 6-OHDA. Temporal specific loss of TH positive neurons from 
the SNpc (A|) and VTA (B|) of lesioned wild-type and Anxa1 null mice. Each group was formed of 
n=4-6 young males (2-3 months old). Results are presented as mean ± SEM. As negative control we 
only performed saline intrastriatal injection and exposure for 24 hours. Two-way ANOVA was 
performed (time of toxin exposure and genotype as variables) and identified a significant effect of 
toxin exposure and an interaction between the two variables (p<0.01 and p<0.001, respectively); the 
analysis was followed by Bonferroni post-hoc test. *** and ** indicates p<0.001 and p<0.01 vs. the 
genotype related saline-treated control, respectively. # indicates p<0.05 vs. 1 week, 2 weeks and 4 
weeks-treated groups. $ indicates p<0.05 vs. 4 weeks treated wild-type group. C| and D| quantify 
the number of Anxa1 positive TH positive neurons of either lesioned or non-lesioned sides of the 
SNpc and VTA, respectively, in wild-type animals. Values are presented as mean ± SEM (each group 
included n=4-6 animals). Two-way ANOVA (area and time of toxin exposure) was performed and 
identified a significant effect of toxin exposure (p<0.01), of the area analyzed (p<0.001) and an 
interaction between the two (p<0.001). The analysis was followed by Bonferroni post-hoc test; * and 
*** indicate p<0.05 and p<0.001 vs. saline-treated correspondent area control, while $ indicates 
p<0.05 vs. correspondent time-related non-lesioned area. Panels A-D produced by Dr. S McArthur. 
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7.4.3.2 Microglia recruitment in the injured site 
Intrastriatal injection of 6-OHDA retrogradely targets the SNpc, through the projections that 
nigral DA neurons send to the striatum. The consequent specific neurodegeneration of the 
neurons of the SNpc normally triggers the activation of the numerous resident microglia 
cells and further recruitment from neighbouring regions (Schwarting and Huston, 1996). 
This phenomenon was also reproduced in our hands (Figure 7.8; Panel A and B) and showed 
different kinetics and intensity between the analysed genotypes. In the wild-type animals, 
the number of Iba1+ cells promptly peaked shortly after initiation of the lesion (24 hours 
post 6-OHDA administration) but steadily and slowly decreased afterwards, returning to the 
initial density after 4 weeks post-toxin injection. We noticed an increased intensity of 
microglia-related staining at the level of the SN pars reticulata, as well as the directional 
migration of cells from this region towards the SNpc, which led us hypothesise that the swift 
increase in cell number could be at least partially linked to this neighbouring region (Figure 
7.8; Panel D).  The Anxa1 null mice, on the other hand, showed a slower kinetics; the cell 
density peaked after 1 week from lesioning onset and remained significantly higher 
throughout the study, only partially decreasing over time. Absolute density values were 
constantly higher in the Anxa1 null animals and morphology maintained the characteristic 
features we found in this genotype, regardless of the treatment (Figure 7.8; Panel C).   
No significant differences were noted in the VTA throughout the treatment, either for wild-
type or null mice (Figure 7.8; Panel B).   
Rapid microglia number increase and activation was not only evident in the SNpc but also in 
the striatum, which is the area from where the neurodegenerative event started. As evident 
from Figure 7.9, Panel A, rapid increase in Iba1+ cell number in the lesioned striatum of wild-
type animals occurred after 24 hours of toxin exposure, and swiftly subsided thereafter. 
Similarly to SNpc, the kinetics in the Anxa1 null mice was also slower, while cell density and 
intensity of Iba1 staining remained persistently high during the time-course (not shown). 
Since we wanted to assess if the rapid changes in microglia density were also accompanied 
by changes in Anxa1 expression or if the protein levels remained unchanged, similarly to 
what we observed under peripheral inflammatory challenges, we checked (Figure 7.9; Panel 
B) its expression in CD11b-positive cells in the striatum.  
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CD11b was chosen both because it allowed us to perform co-staining along with Anxa1 or 
because it is one of the most extensively-used markers (Larson and Springer, 1990) for cells 
of myeloid origin (like microglia, resident macrophages, circulating monocytes, natural killer 
cells). We were able to identify, only in the lesioned striatum of wild-type animals, 
numerous cells with an intense Anxa1 positivity (pointed by the white arrow in Figure 7.9, 
Panel B): these cells were positive for Cd11b but showed a completely different morphology 
compared to the small, ramified cell body of microglia cells, either resting or activated (see 
previous figures for comparison). These cells showed a globular shape with no apparent 
ramification. Only a few of these cells were evident in the non-lesioned side of the brain, 
while many were instead identified in the striatum of the lesioned side, 24 hours after the 
onset of the neurodegenerative reaction. After that time point, we failed to identify such a 
huge number of this specific type of cells, which could represent recruited monocytes from 
circulation.  
As specified before, this phenomenon happened in the striatum; myeloid cells in the 
lesioned SNpc did not show any evident increase in Anxa1 or changes in morphology.  
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Figure 7.8 Temporal microglia recruitment in the lesioned midbrain. A| and B| show lesioning-
related changes over time in Iba1+ cell density from the SNpc and VTA of wild-type and Anxa1 null 
mice, respectively. Each group was formed of n=4-6 young males (2-3 months old). Results are 
presented as mean ± SEM (percentage of non-lesioned side). As negative control we only performed 
saline intrastriatal injection and exposure for 24 hours, since longer time points did not result in 
significant changes. Two-way ANOVA was performed (time of toxin exposure and genotype as 
variables) and identified a significant effect of toxin exposure (p<0.001), of genotype (p<0.05) and an 
interaction between the two variables (p<0.001); the analysis was followed by Bonferroni post-hoc 
test. ***, ** and ** indicate p<0.001, p<0.01 and p<0.05 vs. the genotype related saline-treated 
control, respectively. $$ and $ indicate p<0.01 and p<0.05 vs. the correspondent wild-type treated 
group. C| shows representative magnifications of the lesioned SNpc of wild-type and Anxa1-/- 
treated-animals at different time points, stained for Iba1. Scale bar: 100 µm. D| Images are referred 
to an injured wild-type brain 24 hours after 6-OHDA administration. SNpc was delimited by following 
the boundaries set by TH positive neurons. SNpr: substantia nigra pars reticulata. Scale bar: 150 µm.  
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Figure 7.9 Microglia markers-positive cells in the injured striatum. A| shows representative 
examples of striatal sections from 6-OHDA treated wild-type animals, stained for Iba1. Internal 
comparison between lesioned and non-lesioned striatum was performed. 2 and 4 weeks treated 
groups are not reported because results are similar to 1 week-treated group. Inset represents nigral 
microglia cells magnification. Scale bar 150 µm; inset 75 µm. B| Lesioned and non-lesioned striatal 
regions (24h post-toxin infusion) were compared for Anxa1 expression differences in CD11-stained 
cells. Arrows indicate cells which showed an intense Anxa1 specific staining, while the squares 
indicate the region magnified in the pictures in the last row. Images are representative examples. 
Scale bars: 10 µm (first and second row); 5 µm (last row). Panel A produced by Dr. S McArthur.  
 
7.4.4 How peripheral inflammation impacts the injured substantia nigra 
7.4.4.1 Exacerbation in DA neuronal loss 
Having characterised the response of the wild-type and Anxa1 null SNpc under separate 
peripheral inflammatory and neurodegenerative challenges we proceeded to test the most 
important hypothesis of this section, that is, the impact of systemic inflammatory reactions 
on on-going neurodegeneration of the NSDA pathway both in the presence and in the 
absence of Annexin A1. We decided to use 7 days post-6OHDA administration as lesioning 
end-point because we detected a significant loss of TH+ cells both in wild-type and in Anxa1 
null mice, followed by 7 days of peripheral inflammatory challenge, since we observed 
significant changes in terms of microglia recruitment (for both genotypes) and Anxa1 
expression (in wild-type animals) at the same dose and time frame.  
First, we assessed changes in the numbers of DA neurons: both genotypes developed 
significant loss (around 20% if compared to the contralateral non-injured side) of TH+ cells 
after 2 weeks post-toxin intrastriatal injection (Figure 7.10; Panel A), as already seen in the 
previous experimental set (Figure 7.7; Panel A). Challenging lesioned animals with a 
peripheral dose of LPS (3 mg/kg) produced a further decrease in the lesion side of only 
Anxa1 null mice (around 14% in relation to the 6OHDA/saline genotype matched group), 
which did not reach statistical significance (p<0.1). No significant changes were detected in 
the functionally unrelated VTA region (Figure 7.10; Panel B).  
By performing TH and Anxa1 double staining on wild-type lesioned animals, we noticed a 
significant increase in the number of Anxa1+ TH+ neurons, while we observed again that a 
considerable percentage of the dopaminergic neurons surviving over the time were Anxa1 
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positive (Figure 7.10; Panel C); despite the fact that the treatment caused a considerable 
loss of TH+ neurons, the percentage of those Anxa1 increased over the time. Interestingly, 
we were not able to detect such phenomenon in the Anxa1 null mouse by co-staining β-
galactosidase with TH: we detected a decreased number of β-gal+ neurons along with the 
decrease in the number of TH+ cells, which underlines the importance of Anxa1 in giving a 
preferential survival to those cells expressing it within the wild-type lesioned brains.  
 
Figure 7.10 Loss of dopaminergic neurons in the midbrain of wild-type and Anxa1 null mice 
following intrastriatal injection of 6-OHDA and subsequent peripheral inflammatory challenge. A| 
and B| show the temporal specific loss of TH positive neurons from the SNpc and VTA, respectively, 
from lesioned wild-type and Anxa1 null mice further challenged by single i.p. administration of LPS. 
Results expressed as percentage of the unlesioned side and are mean ± SEM. Three-way ANOVA was 
performed (genotype, toxin exposure and LPS exposure as variables) and in the lesioned side it 
identified a significant effect of toxin exposure (p<0.001); the analysis was followed by Tukey’s post-
hoc test. ***, ** and * indicate p<0.001, p<0.01 and p<0.05 vs. the genotype related saline/saline-
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treated control, respectively. $ indicates p=0.1 vs. Anxa1 null-related 6OHDA/saline-treated group 
and wild-type 6OHDA/LPS-treated group. C| quantifies the number of Anxa1 positive TH positive 
neurons of the intrastriatally injected side of SNpc and VTA, while D| quantifies the number of β-gal 
positive TH positive neurons. Values are expressed as % of double-positive cells among total TH+ cells 
and are presented as mean ± SEM (each group included n=4-6 animals). Two-way ANOVA (toxin 
exposure and LPS exposure) was performed and identified significant effects of toxin and LPS 
exposure (p<0.05) in the wild-types, and for the toxin exposure (p<0.05) in the Anxa1 null mice. The 
analysis was followed by Tukey’s post-hoc test; * and ** indicate p<0.05 and p<0.01 vs. saline/saline-
treated correspondent area control. 
 
7.4.4.2 Augmented recruitment of microglia in the injured area 
The intrastriatal injection of 6-OHDA was able to cause a swift activation of recruitment of 
microglia (Section 7.4.3.2). Current evidence suggests that in the presence of on-going 
neurodegenerative processes, these guarding cells are able to enter a primed state where 
they are not fully activated but they are hyper-responsive to additional stimuli, which in that 
case can cause exaggerated and prolonged production of neurotoxic inflammatory 
mediators (Perry, 2010). Such phenomenon strongly indicates that the normal resolution 
processes may be compromised; therefore we wanted to understand if Anxa1, whose lack 
was linked to the increased loss of neurons after peripheral inflammatory challenge, could 
be involved in the mechanisms controlling exaggerated activation, proliferation and 
recruitment of myeloid cells to the site of injury.  
Quantifying Iba1+ cells both in lesioned and non-lesioned sides of wild-type and Anxa1 null 
LPS-treated mice (Figure 7.11), we observed that Anxa1 null animals (Panel A and D) showed 
a significantly higher number of microglia (as shown previously in untreated and treated 
conditions), as well as an intense increase in the number of cells populating the lesioned 
SNpc: we were able to detect a further significant increase in the lesioned side after further 
challenge with peripheral LPS (p<0.05). Wild-type animals, on the other hand, responded 
(Panel A and C) in every condition with an increase in lesioned SNpc microglia density, but 
did not show any significant increase in presence of both lesioning and peripheral challenge. 
We did not detect any change in the response of the non-lesioned side, except the higher 
microglia density in the Anxa1 null mice and the increase induced, in both genotypes, 1 
week after peripheral LPS administration. No significant differences were noted in the VTA 
throughout the treatment, either for wild-type or null mice (Figure 7.8; Panel B). 
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Figure 7.11 Microglia recruitment in the lesioned and peripherally challenged midbrain. A| and B| 
show changes in Iba1+ cell density respectively from the lesioned and non-lesioned SNpc of wild-type 
and Anxa1 null mice. Each group was formed of n=4-6 young males (2-3 months old). Results are 
presented as mean ± SEM (cell density; cells/mm2). Three-way ANOVA was performed (toxin 
exposure, LPS exposure, genotype as variables) and in the lesion side it detected a significant effect 
for toxin exposure, LPS exposure, genotype and interaction between genotype and toxin exposure, 
as well as between the three variables (p<0.0001). The analysis was followed by Tukey’s post-hoc 
test. ** and * indicate p<0.01 and p<0.05 vs. the genotype related saline/saline-treated control, 
respectively. $ indicate p<0.05 vs. the Anxa1 null saline/LPS and 6OHDA/saline-treated groups. C| 
and D| show representative magnifications of the lesioned SNpc of wild-type and Anxa1-/- treated-
animals, respectively, at the different conditions, stained for Iba1. Scale bar: 100 µm. 
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7.5 Discussion 
The main scope of this chapter was to understand if annexin A1 participates in helping the 
brain to control its inflammatory response under peripheral inflammation and 
neurodegenerative insults. These data report novel evidence on how annexin A1 expression 
is modulated by peripheral inflammation specifically at the level of a small sub-population of 
dopaminergic neurons of the SNpc. Lack of annexin A1 appeared to be crucial in negatively 
affecting neuronal loss while, most of all, positively affecting microglia density.  
 
7.5.1 The substantia nigra is a peculiar region of annexin A1 expression 
Initial findings (Chapter 2) clearly showed that annexin A1 might play a peculiar role in the 
substantia nigra. In particular, it was evident that Anxa1 was present in two morphologically 
distinct cellular species, whose behaviour in terms of expression of the protein seemed 
tightly modulated by peripheral stimuli. We were able to confirm that these cells were a 
small (less than 20%) population of nigral TH positive dopaminergic neurons (Figure 7.2), 
along with microglia cells (Figure 7.3), which densely populate this area of the brain (Kim et 
al., 2000). These findings were not only confined to the rodent brain, but were found to be 
true also in the human cerebral tissue. In our murine model, both cell types showed to 
respond differently to injury and inflammation dependent on the presence of Anxa1, 
suggesting an important intracerebral /protective regulatory role for it.  
 
7.5.1.1 Basal differences in the Anxa1
 
null mouse  
We did not detect any genotype-linked difference in the total number of DA neurons of the 
areas of interest (SNpc and VTA, as shown in Figure 7.2), indicating that the lack of annexin 
A1 is not linked with basal changes in the architecture of these neuronal regions. On the 
other hand, Anxa1 null mice presented a higher microglia cell density under resting 
conditions (Figure 7.3), along with differences in morphology and intensity of Iba1+ marker 
(reported to increase during cell activation), basal expression of phlogistic enzymes that 
usually are only expressed under inflammatory conditions (iNOS and COX-2) as reported 
(Wong et al., 1996).  
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Overall, the impression is that in the absence of Anxa1, the cerebral milieu presents 
inflammation-prone features, which make it more reactive and vulnerable under certain 
stimuli. It is unclear why Anxa1 null mice showed higher nigral microglial density under basal 
conditions but this may be due to various events happening during development and/or 
adulthood. The basal loss of vascular tightness, which we clearly showed to characterise the 
Anxa1 null mice (Chapter 4), could have facilitated the access of the brain parenchyma 
during development, when the barrier is particularly immature and leaky, or after 
developmental colonisation. In particular, Morgan et al. (Morgan et al., 2010) suggested 
that aberrant infiltration of microglia precursors during development may be triggered by 
genetic alterations affecting the innate immune system and/or by excessive early neuron 
generation or the altered development of neuronal connectivity. The lack of Anxa1 gene 
may represent a strong genetic influence for the central innate immune system 
development, as it has been suggested for the peripheral one (Hannon et al., 2003). 
Notably, some preliminary evidence (data not shown) found no gross permeability 
differences between wild-type and Anxa1 null mice until post-natal day 17 (P17), most 
probably indicating that the gross difference noted in adulthood arose only when the barrier 
reached maturity. Therefore, other events may have contributed to the noted differences; 
for instance, increased rate of proliferation could also explain why we detected higher cell 
density in the Anxa1 null mouse, which could be speculatively seen in light of the anti-
proliferative and pro-apoptotic role of endogenous Annexin A1 reported in other models 
(Solito et al., 2001; Lim and Pervaiz, 2007; Ang et al., 2009). Also, peripheral monocytes can 
access the brain when BBB is opened as a result of cytokines, chemokines and other 
inflammatory mediators (D'Mello et al., 2009; Ransohoff and Perry, 2009; Morgan et al., 
2010): this supports such a possibility under non-pathological conditions for the Anxa1 null 
mouse, characterised by an altered, higher pro-inflammatory cytokines profile.   
We also detected clear alterations on Anxa1 null microglia morphology, especially in terms 
of reduction of process number and cell soma enlargement (Figure 7.3; Panel A and E). 
Although morphological analysis of these cells is not a wholly reliable way to determine 
their activity status (Ransohoff and Perry, 2009; Perry, 2010), these changes are at least 
indicative of altered microglial activity. 
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Overall, this may suggest that under unchallenged conditions cells are not in a normal 
resting state but rather bear a basally-activated behaviour, since they lack Annexin A1, 
thought to be a potent activity brake. 
 
7.5.1.2 Genotype-related differences on the impact of peripheral 
inflammation 
Under peripheral inflammation, different temporal responses of microglia were detected 
between the genotypes. Anxa1 null microglia cells seemed to become hyper-sensitive and 
hyper-responsive despite the absence of real tissue injury and this numerical increase could 
be attributed to either intense proliferation following extensive activation, or to cell 
recruitment from close regions (Figure 7.8; Panel D); in addition, the existence of an intense 
feedback mechanism involving peripherally circulating monocytes has been already shown 
in wild-type mice by several groups (D'Mello et al., 2009).  
In support of the stimulatory action of peripheral inflammation, microglia cells showed clear 
changes in their morphology (enlargement of the cell body, reduction in cell processes), 
which have been already reported in the brain of a mouse model of hepatic inflammation 
(D'Mello et al., 2009) but appeared to be particularly enhanced in the Anxa1 null mice. In 
both genotypes, this behaviour resulted to be SNpc-specific, which enriches the relevance 
and the peculiarity of these findings. Moreover, we detected a significant increase in nitrite 
concentration in the Anxa1 null mouse, both under basal conditions but especially after 
peripheral challenge, while the presence of anti-inflammatory molecule IL-10 appeared 
strongly limited, reinforcing the tight link previously shown between ANXA1 and this 
cytokine (Ferlazzo et al., 2003).  
Interestingly, we detected a significant temporary decrease in nigral TH+ neurons 24 hours 
after LPS administration, which was restored to saline treated control levels after 7 days 
(Figure 7.4). The only available evidence showing similar results (in wild-type mice) reported 
progressive neuronal loss after 7 months after a single administration of LPS (5 mg/kg, a 
dose very similar to what we used) (Qin et al., 2007).  
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In our case it is unlikely that after an initial quick cellular loss the brain is able to rapidly 
regenerate neurons, for two important reasons: first, it is well known that the regenerative 
potential of the nervous system (Gage, 2003) and in particular of the substantia nigra 
(Mitsumoto et al., 1998) is limited; second, periphery-brain communication is able to 
generate a chronic inflammatory environment, which seems to be maintained for a long 
time despite the systemic reaction being subdued within a short temporal frame (Qin et al., 
2007), and probably act against repair and regeneration of the injured tissue. Most likely, 
we observed a temporary loss of dopaminergic phenotype, characterised by loss in TH 
positivity (Kaufman, 1995). This event has been reported under conditions of particular 
stress of nigral neurons (Bowenkamp et al., 1996), which tend to lose their peculiar 
dopaminergic ability due to the highly inimical environment (oxidative stress, activation of 
the brain innate immune system). This finding could be the result of a highly challenging 
milieu in the substantia nigra of Anxa1 null mice as a consequence of peripheral 
inflammation. Indeed, the massive numerical increase in the highly populated microglia pool 
might represent a source of challenge for the vulnerable TH+ neurons, possibly through 
increased levels of NO, as observed in the challenged Anxa1 null mice; this gaseous 
molecule shows neurotoxicity when produced in high quantities (Rakesh, 2007). This and 
other factors might have contributed to the pro-inflammatory milieu that seems to 
characterise the nervous tissue of null mice and caused the temporary loss of TH phenotype 
until rescuing mechanisms, like those offered by astroglia (Lin et al., 1993; Bowenkamp et 
al., 1996) through neurotrophic/neuroprotective factors, support the endangered cells. 
To our knowledge, only one group (Qin et al., 2007) was able to show a direct effect on DA 
neurons by only peripheral administration of LPS; therefore, our findings of a quick (24 
hours) increased vulnerability of DA neurons in presence of peripheral inflammation and in 
absence of annexin A1 are therefore novel and stress the important role played by this 
protein in preventing an excessive inflammatory environment building in the brain.  
In presence of peripheral inflammation, resident wild-type Cd11b positive cells did not show 
evident quantitative or qualitative changes in Anxa1 expression, which was maintained in 
association to the cell membrane at basal levels (Figure 7.5; Panel E), nor we observed a 
numerical increase in Anxa1 positive microglia cells, as expected from what it was obtained 
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from the Anxa1 null mouse (X-gal staining; Chapter 2, Figure 2.2). In a related in vitro model 
based on BV2 cells, a murine microglia cell line (McArthur et al., 2010), we observed 
increased externalisation/release of Anxa1 under inflammatory conditions (Figure 10.9: 
Panel C). Despite the results here presented, we endorse the theory of microglia being able 
to respond to a pro-inflammatory environment through modulation of annexin A1 (Solito et 
al., 2008). The fact that stimulation in vitro might generate a different type of response 
should be taken into account; nonetheless, we strongly believe that the regulation of this 
protein in myeloid cells occurs in terms of release/mobilisation of the protein (Figure 10.9; 
Panel C), which only in vitro/ex vivo studies are able to test. 
 
7.5.1.3 Genotype-related differences on the response to neurodegeneration 
The establishment of neurodegeneration represents a direct injurious stimulus within the 
brain, able to bring direct consequences on the entire surrounding environment, including 
microglia and their activity (Glass et al., 2010; Ransohoff and Brown, 2012). Choosing to 
model nigral neuronal loss through 6-OHDA intrastriatal administration, we guaranteed 
both a direct toxic effect on SNpc TH+ dopaminergic neurons but also the consequent 
activation of surrounding microglia, which is particularly abundant in this area (Kim et al., 
2000). In our hands, this was observed in lesioned wild-type animals (Figure 7.8; Panel A), 
which responded to dopaminergic-specific neuronal damage by quick (24 hours) and intense 
(2-fold) microglial recruitment and density increase, which subsided immediately after, 
suggesting the existence of a tight control system, able to encourage the beneficial role of 
microglia (mainly removal of dead neurons to avoid them becoming signals perpetuating 
inflammation) but to prevent prolonged microglia activity.  
Anxa1 null mice showed a different, slower kinetics of microglia recruitment in the lesioned 
side of the brain, which peaked only after 1 week from toxin injection and remained high 
without subsiding. This particular behaviour suggests important aspects: first, annexin A1 
may be required for microglia activation and recruitment under these conditions, so its 
absence slowed a prompt reaction; secondly, the absence of Annexin A1 again seem to 
represent the loss of an important “safety brake”, a signal for homeostasis restoration, since 
the reaction mounted by microglia in the injured site did not decrease over time.  
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Although the lesion size did not differ between genotypes, we noticed that many of the 
surviving dopaminergic neurons expressed Anxa1, which opened a new broad scenario for a 
potential neuroprotective role. In support of that, Knott et al. (Knott et al., 2000) suggested 
annexin A1 as a rescue signal to damaged neurons in a model of PD.  
Anxa1 null mice differed also in this case from wild-types in terms of TH positive neuronal 
loss: despite the lesioned substantia nigra being more populated by microglia cells, which 
did not decrease throughout the time window analysed, the typical chronicity of the 
neuronal loss surprisingly stopped after an initial decreasing phase (Figure 7.7; Panel A). This 
result could easily refute the hypothetical neuroprotective role for Annexin A1 proposed 
according to the wild-type results, but alternatively it could be justified by considering the 
inability of Anxa1-/- microglia to phagocytose apoptotic cells (Figure 10.9; Panel A). We 
(McArthur et al., 2010) and others (Blume et al., 2009; Blume et al., 2012) have shown 
Annexin A1 to be an important signal for the removal of apoptotic cells, which are peculiar 
of neurodegenerative diseases and models, like the 6-OHDA (Gomez-Lazaro et al., 2008).  
When apoptotic neurons are not efficiently removed by phagocytes, they may occur in 
secondary necrosis, which still presents the expression of characteristic antigens as it has 
been observed for TH positive DA neurons (Alavian et al., 2009), so they can ideally be still 
visualized and counted.  Secondary necrotic neurons can eventually become deleterious, 
since they can trigger an actively pro-inflammatory microglial phenotype, which is 
neurotoxic (Pais et al., 2008) and annexin A1 is at the forefront in limiting such response to 
the failure in apoptotic neurons clearance (Blume et al., 2009; Blume et al., 2012). 
Therefore, we think that the results obtained in the Anxa1 null mouse in terms of DA 
neurons survival are strongly influenced by the proven inability of Anxa1 null microglia to 
efficiently remove dead neurons. Moreover, the constantly higher microglia density 
observed during the lesioning experiment may also depend on the chronic pro-
inflammatory environment generated by the inefficient clearance of the apoptotic neurons.  
Also, we should not forget that inflammation and its players are originally meant to provide 
a protective/resolutive/supportive role during injury. This concept is also valid for the brain 
during neurodegenerative diseases (Ransohoff and Perry, 2009; Wee Yong, 2010; Czeh et 
al., 2011; Ransohoff and Brown, 2012) and for microglia, which is often referred, too 
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simplistically, as the bad immune cells (Mena and Garcia de Yebenes, 2008); indeed, 
microglia is able to release neurotrophic factors against LPS-induced DA neurons damage, at 
least during its acute response to injury (Sawada et al., 2008). In our case, a longer time 
course of investigation for the 6-OHDA model of DA neuronal degeneration in Anxa1 null 
mice would certainly provide more clarity on the real scenario of the model, explaining 
better the quantitative data obtained. 
In an unique way, the lesioned striatum of wild-type animals showed a rapid increase of 
Anxa1 in Cd11b positive cells (Figure 7.9; Panel B), which could either represent resident 
microglial cells or derived from adjacent regions, activated by degeneration of surrounding 
neurons or peripheral monocytes recruited by the injury. The limited specificity of the 
marker used does not help discriminating between the two hypotheses, although various 
works support either the first [ANXA1 upregulation in microglia (Knott et al., 2000)] or the 
second [peripheral recruitment of monocytes (Whitton, 2007; Reale et al., 2009)]. Against 
the second option, though, it seems that recruitment of monocytes from the periphery may 
not happen so rapidly (Hanisch and Kettenmann, 2007; Jin et al., 2010) to justify our results. 
Notably, the analysis of the morphology has never represented a reliable and exhaustive 
way to define the nature of a cell and its activity status (Aloisi, 2001; Perry et al., 2010), 
supporting more the use of a combination of cell markers.  
Importantly, the rapid increase in Anxa1 expression was not generalized in every striatal 
Cd11b positive cell and its restoration to basal conditions was very rapid (Figure 7.9), 
possibly suggesting that this may depend on a tight regulation by specific micro-
environmental factors (either inhibitory or stimulatory), as shown in MS patients (Elderfield 
et al., 1992). We were not able to obtain a similar correlation between Anxa1 expression 
and Cd11b in the injured SNpc; one possible explanation is that we missed the right time 
point when these events may have happened.  
Overall, these findings described an altered immune-toxic response of Anxa1 null mice to 
intracerebral 6-OHDA toxin administration, characterised by a delayed but persistent 
increase in microglia density not followed by chronic loss of dopaminergic neurons.  
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7.5.1.4 Impact of peripheral inflammation on the injured brain  
Under the conditions we employed, we detected no significant effects on the existing 
lesioning event in wild-type animals (Figure 7.10), while we did find increased loss of TH 
positive neurons in the challenged Anxa1 null mouse. Along with this, we detected an effect 
more than either alone but less than additive between lesioning and peripheral 
inflammatory impact in terms of microglia density within the injured area only in the null 
mice, while wild-types responded to the two consequent stimuli in a more tightly controlled 
fashion (Figure 7.11).  
It is becoming clear that additional stimuli on a brain already challenged may result in the 
exacerbation of the symptoms and acceleration of the disease course, the main cause being 
the hyper-responsiveness of microglia, which during neurodegeneration acquires a peculiar 
not-fully activated primed phenotype (Perry, 2010). This concept is now receiving great 
attention because it carries many implications for disease progression and deterioration of 
quality of life of patients with neurodegenerative disorders; however, still conflicting 
evidence arise in literature in terms of which phenotype is triggered under 
neurodegenerative conditions. Typical pro-inflammatory cytokines like TNF-α, IL-1β, IL-6 
have been reported to be up-regulated in the 6-OHDA-lesioned SNpc and in striatum (Mogi 
et al., 1999; Nagatsu and Sawada, 2006) and a fully-activated phenotype of microglia (Gao 
and Hong, 2008). By contrast, Depino et al. (Depino et al., 2003) reported an atypical 
cytokine response to sub-acute 6-OHDA injection into the striatum, characterised by high 
cytokines transcription but limited production (the primed phenotype), because 6-OHDA-
triggered apoptosis was not sufficient to induce secretion of pro-inflammatory mediators. 
The results obtained in our last experiment did not shed more clarity on these open 
questions, which will require more investigation to be properly answered. These results, 
together with those from the previous experimental settings, may strongly suggest an 
important immuno-modulatory role for Annexin A1: in fact, while Anxa1 null microglia 
suffered the synergistic effects of existing neurodegeneration and the strong impact of 
peripheral inflammation by further increasing their number, wild-type microglia did not 
show such influence, therefore presenting a tighter control of exaggerated responses 
otherwise caused by intense stimuli.  
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7.5.2 The Anxa1 null mouse provides new details on the central role of Anxa1 
Anxa1 null microglia appeared to react excessively to peripheral inflammation, while 
displaying a peculiar response to 6-OHDA driven neurodegeneration and an exaggerated 
reactivity when both conditions were present. Overall, all the findings indicate that the lack 
of Anxa1 may promote a pro-inflammatory/classically activated phenotype, similar to the 
“M1” status extensively described for resident tissue macrophages, characterised by intense 
release of toxic effectors and not by efficient tissue clearance, repair and resolution (Czeh et 
al., 2011). Hyper-responsiveness due to the loss of an endogenous immune-brake may help 
to explain why Anxa1 null mice suffer the synergistic effect between central and peripheral 
challenges, resulting in the increased loss of neurons.  
Along with the peculiar Anxa1 null microglia basal morphology (Figure 7.3), we could link 
these observations to aged microglia features: a sensitised phenotype can be produced 
through all the subtle stimuli received during life-span, characterised by a sensible reduction 
in all the beneficial actions offered by these cells, for example the clearance of dead cell 
debris and toxins from the cerebral environment (Czeh et al., 2011). In addition to this, 
alterations in Annexin A1 functions have been linked to aging (Strijbos et al., 1993), which 
classically is also characterised by an increased microglia density in unchallenged conditions 
(Godbout et al., 2005; L'Episcopo et al., 2011).  
The hypothesised Anxa1 role in regulating the phenotype of microglia and in negatively 
limiting the complexity of the response is becoming clearer. We have already described the 
mechanism contributing to the non-inflammatory/pro-resolutive phagocytosis of apoptotic 
cells (McArthur et al., 2010) while negatively regulating the aggressive phenotype that 
microglia can acquire under pro-inflammatory stimuli, characterised by ineffective and 
detrimental phagocytosis of non-apoptotic/non-injured cells (reviewed in Figure 10.9; Panel 
B). Our evidence among others (Wu et al., 1995; Minghetti et al., 1999; Knott et al., 2000) 
that annexin A1 is able to inhibit iNOS and COX enzymes expression along with the 
production of certain pro-inflammatory precursors and mediators such as arachidonic acid, 
IL-1β, IL-6 and TNF-α, all found to be up-regulated in certain conditions, clearly supports our 
(Solito et al., 2008) idea of a mechanism to control innate immunity over-activation lead by 
Annexin A1, both in the intact or in the challenged-injured brain.  
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7.5.3 ANXA1 in the neurons: an Off signal for microglia?  
One of the most significant results obtained in this section was to describe the modulatory 
nature of neuronal Anxa1: peripheral inflammation was able to increase the percentage of 
DA neurons expressing ANXA1 in the SNpc. Under neurodegenerative conditions, instead, 
these neurons showed the tendency to preferentially survive, while those in the Anxa1 null 
mouse died regardless of their positivity for the replacing gene reporter β-galactosidase.  
The presence of Annexin A1 in neurons has been already reported in literature: Young et al. 
(Young et al., 1999) showed it to be expressed in cerebellar neurons, Knott et al. (Knott et 
al., 2000) detected it in intact and lesioned SNpc DA neurons in PD patients, while others 
(Strijbos et al., 1991; Eberhard et al., 1994) showed Anxa1 positivity in hippocampal 
neurons. However, none has reported changes in expression and in the number of Anxa1 
positive neurons, which certainly opens up a new scenario for this molecule.   
The central response to systemic inflammation is unique and independent when compared 
to the quick dynamics of the parallel peripheral response, which peaks at 2 hours following 
LPS injection and subsides back to baseline at 24 hours. Previous reports (Singh and Jiang, 
2004; Qin et al., 2007) showed how quickly single LPS injections induced alterations in the 
brain, especially de novo synthesis and release of pro-inflammatory factors (TNF-α, IL-1, NF-
κB, NO) by microglia and brain endothelial cells but to our knowledge no information about 
the effects on neurons exists. Peripheral immune reactions are sensed in the brain as an 
alarm for potential danger, triggering central responses aimed to help tackling the cause of 
inflammation. In particular, microglia cells can sense peripheral endotoxins and 
inflammation (i.e. cytokines), by undertaking a pro-inflammatory profile (Cunningham et al., 
2005; Perry et al., 2007). The line existing between advantages and disadvantages of such 
responses is very fine; evolution may have developed a feed-back system centred on 
specific neurons, able to control the surrounding abundant microglia population from 
becoming dangerous. Relevantly, it is nowadays clear that neurons are seen not anymore as 
simple passive targets of the strong potential of microglial cells, but may also control their 
activity, mainly restricting the intensity of their reactivity under inflammatory conditions 
(Biber et al., 2007; Zhang et al., 2011).  
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This is accomplished through a series of physiological molecules, normally expressed and 
released at the level of neurons [the most indicative examples are CX3CL1 (fractalkine) and 
CD200-ligand]. Annexin A1 may be certainly included among these Off molecules of 
neuronal origin, especially in light of its innate ability to be secreted and to act in the 
surrounding environment by targeting neighbouring cells, as seen in other models 
(Buckingham et al., 2003; McArthur et al., 2009). 
Taking into account all these considerations, it appears clearer why neurons expressing 
Annexin A1 are those surviving longer within the degenerating substantia nigra: the possible 
scenario indicates the ability to define an anti-inflammatory/modulatory microenvironment 
around these cells where constant increased release Annexin A1 maintains the surrounding 
activated microglia less reactive and neurotoxic, therefore halting/delaying their demise. 
The loss of these neurons, along with these endogenous regulatory molecules, normally 
coincides with an increased reactivity of microglia, as we have in part seen in the Anxa1 null 
mouse and others have proved in different models (Biber et al., 2007). 
For completion, Annexin A1 may also be considered as an On signal, since it is a factor 
promoting phagocytosis of apoptotic cells, one of the typical actions provided by the 
beneficial microglia phenotype during neuronal damage, as well as a chemoattractant 
signal, as recently reported (Blume et al., 2012; Dalli et al., 2012) in other tissue.  
 
7.6 Limitations of the study 
The results presented in this chapter do represent an enormous effort to depict cell types, 
mediators and signals in such a complex physiopathological system. We must not forget that 
most of the results presented were obtained by manual counting of positive stained cells on 
brain sections, which required a large amount of time but provided clear quantitative 
observations. We were able to detect some very informative differences between 
genotypes, which nicely described a new face for the central role played by this protein and 
will fuel the ground for future research. 
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A way to improve this descriptive study would be to perform a parallel staining for a generic 
neuronal marker (for example nuclear neuronal antigen NeuN) to confirm that the 
diminution in the TH+ neurons does actually represent loss of DA neurons and not only the 
loss of the dopaminergic phenotype. However, the long-standing experience on this model 
in our laboratory has already confirmed this (Murray et al., 2003; Gillies et al., 2004).  
β-galactosidase immunostaining did not replicate quantitatively the results obtained with 
Anxa1: fewer TH+ neurons stained positively for this gene reporter, which proved to be a 
protein quite difficult to visualize with classic immunofluorescence techniques (Figure 7.2; 
Panel B) at least in brain tissue fixed under these conditions. The limitations faced during 
the staining and the fact that this protein does not represent a functionally relevant 
substitute but only an indicator of cells where the Anxa1 promoter is active, brought us to 
avoid using it as an useful marker for our functional purposes. However, its comparison 
reinforced the protective role offered by neuronal Anxa1 in wild-type animals under 
neurodegeneration.  
We benefited from the use of Iba1 and Cd11b, among the most used markers for microglia 
cells, although not fully informative of the activation state of the cells; this represents a very 
complex topic and recent studies have indicated the need to stain cells with several specific 
markers in order to discern their particular phenotype. However, this would be complex to 
do on tissue sections; primary isolation of microglia cells would certainly represent a useful 
solution. Despite the lack of immune-phenotyping, we detected some clear differences in 
terms of morphology and cell density, both in untreated and treated conditions.  
In terms of annexin A1 expression at microglia level, we confirmed previous results 
(McKanna, 1993), but we detected only few Anxa1+ microglia in the unchallenged wild-type 
mouse, and the staining was very localised, as opposed to the results achieved on human 
tissue. Low immunostaining efficiency may be among the principal causes, as already 
detected elsewhere (McKanna, 1993; McArthur et al., 2010): annexin A1 is notoriously 
difficult to identify on brain sections, mainly since the antigen is particularly sensitive to 
fixation conditions, with several protocols unable to preserve a sufficient immunoreactivity. 
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7.7 Future work 
Overall, in this part of the project we prioritized the description of the complex processes, 
before focusing on mechanistic details. Simplified in vitro experiments with primary 
microglia from Anxa1 null mice will help understanding more in detail every aspect in which 
Anxa1 is involved. In particular, it will be extremely useful to detect Anxa1-dependent 
differences in those pro-inflammatory mediators (cytokines, iNOS, NADPH oxidase and COX 
enzymes expression) that have been linked to the progression of various disorders (Glass et 
al., 2010), although some evidence already exists (Wu et al., 1995; Minghetti et al., 1999). 
These results will certainly clarify the hypothesis of a chronically inflamed brain in absence 
of Annexin A1, both in presence or absence of various inflammatory stimuli. This will also 
help to understand if Anxa1 null microglia is a sort of primed microglia or if it becomes fully 
activated under neurodegenerative conditions. Early studies evidenced marked differences 
in NO/nitrite between genotypes, as well as in iNOS basal expression, which represent an 
index of inflammation; it would be interesting to deepen this area as well as investigating 
other quickly-responding (Czapski et al., 2007; Argaw et al., 2012) NO-producing enzymes as 
endothelial NOS (eNOS) or neuronal NOS (nNOS).  
Since there is growing evidence supporting the existence of a dichotomy of functional 
phenotypes for microglia as it exists for macrophages [M1 versus M2; see (Czeh et al., 
2011)], it will be interesting to investigate if ANXA1 represents a marker for the alternatively 
activated/beneficial phenotype or if it is a strong inducer of it.  
Co-culture experimental settings, using primary mesencephalic mixed neurons and glia 
cultures from wild-type and Anxa1 null mouse or microglia (BV2) and neuron-like (PC12) cell 
lines [a model already established by us in previous studies (McArthur et al., 2010)], will 
immensely contribute to study the role of neuronal Anxa1 as a modulator of microglia 
activation, as well as the role of microglial Anxa1 as an endogenous immunological brake. 
Speculatively, we don’t think Annexin A1 may represent a direct survival signal for neurons 
challenged with a specific toxin, although some have proposed a specific transcriptional role 
for this protein in neurons (Knott et al., 2000); we think instead this protein, when 
expressed within the neurons, is able to control and limit over-activation of microglia.  
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A simple experiment with 6-OHDA incubation of midbrain neurons from wild-type or Anxa1 
null mouse will certainly help unravelling the question. In parallel, another important aspect 
to be investigated in the future is the role of peripherally recruited cells within the SNpc 
(D'Mello et al., 2009). The next experiments will try to shed more light on this topic, giving 
more indications on the extent of circulating cell recruitment in respect to resident cell 
proliferation under these stimuli.  
 
7.8 Summary and conclusions 
In this chapter, we provided details about the genotype-related differences shown in 
presence or absence of Annexin A1 in the intact brain, but also in response to peripheral, 
central challenges or both.  
The protein appeared to be strongly modulated in presence of these stimuli, suggesting its 
direct involvement in the complex regulatory machinery constantly protecting the CNS 
against excessive detrimental responses. Neurodegeneration in wild-type animals triggered 
a rapid microglia activation and recruitment in the lesioned site, along with a quick increase 
in Anxa1 expression, but both events subsided in a relatively short period of time, which 
could represent, in our opinion, the proof of concept for the regulative role of Anxa1 in 
central inflammation. On the other hand, the response generated to peripheral 
inflammatory reactions could be classified by looking at Annexin A1 as one of the key 
mediators of the central responses to peripheral challenges, with a novel modulatory role 
play from neurons. 
The mechanism of action of annexin A1 is multi-faceted, intervening at different levels as 
evident in Figure 7.12, sketched according to our latest data and published evidence. 
Therefore, this molecule may become a new smart target and may represent a novel 
solution to control detrimental loops and adverse microglia phenotypes (Hanisch and 
Kettenmann, 2007) especially in the already injured brain, where it has been shown to 
present a beneficial impact against exaggerated responses.  
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Figure 7.12 Potential mechanisms of Annexin A1 action in presence of peripheral inflammatory 
conditions, neurodegeneration and the synergistic action of the two. Our recent evidence, along 
with some previous findings (Young et al., 1999; Knott et al., 2000), has confirmed the expression of 
annexin A1 on various groups of neurons, like the dopaminergic neurons of the substantia nigra pars 
compacta. We believe that this molecule acts as an endogenous off signal: it is able to keep microglia 
under tight control in basal conditions, while the upregulation observed during systemic challenges 
may represent the ability to prevent microglial excessive activation. In addition to that, Annexin A1 is 
also expressed by microglia itself, where it functions as an immune-modulatory effector towards a 
pro-resolutive/beneficial phenotype, similarly to its role in the periphery (Parente and Solito, 2004).  
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8.1 Overview 
The findings reported in this thesis identified a new, complex role for ANXA1 in mediating 
and regulating the intricate interlink between periphery and CNS. By exploiting the highly 
informative Anxa1 null mouse, along with established cell lines and primary cell cultures, we 
have been able to unravel new mechanisms of action and new cellular targets for ANXA1 
and its physiological and pathological implications. The major findings and conclusions 
drawn for each part of the study are summarized separately below.   
 
8.2 Annexin A1 physiological role at the blood brain barrier level 
In the ideal journey unravelling the role of Annexin A1 in regulating the central impact of 
peripheral inflammation, we first explored its implications at the level of BBB, in particular 
the brain microvascular endothelial cells, representing the real interface between the brain 
and the rest of the body and participating to decode all the signals circulating in the blood.  
In order to fully understand the role(s) of Annexin A1 in the impact of inflammation on the 
BBB, we had to first investigate the physiological implications of the protein at such level. 
We first detected a characteristic increase in basal leakiness to Evans Blue in Anxa1 null 
mice. This evidence was further confirmed by immunohistological detection of IgG 
extravasation, as well as through gadolinium leakage on dynamic contrast MRI (Figure 4.7), 
while successful rescue of the altered phenotype was also obtained in vivo using human 
recombinant ANXA1 protein. The main gross differences between Anxa1 null mice and wild-
type microvasculature were detected at endothelial level, excluding any significant 
morphological alteration in other important cellular and molecular components of the BBB 
(Figure 4.8). In particular, major differences at the level of the physical barrier were evident, 
represented by the disruption in the physiological expression and organisation of occludin 
and VE-cadherin, extremely important for a functional barrier. As already observed in other 
tissues (Hannon et al., 2003), Anxa1 null mouse presented a partial compensatory response 
at the level of the brain microvasculature, offered by another member of the Annexins 
family, namely Annexin A2, shown to be a junctional peripheral protein (Lee et al., 2004) 
and cytoskeleton modulatory effector (Morel et al., 2009). In order to investigate the 
cellular and molecular implications of Annexin A1, we confirmed in vitro that Anxa1-/- 
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monolayers of primary murine BMECs presented increased paracellular permeability 
compared to wild-type ones, supporting the endothelium-specific role of ANXA1. Then, we 
chose to use a more manageable model, represented by a well-established and intensively 
used cell line of BMECs, the hCMEC/D3 cell line (Weksler et al., 2005); we successfully 
modified its endogenous level of ANXA1 expression by antisense technology or stable full 
length ANXA1 sequence transfection and we were able to show a direct correlation 
between the degree of protein expression and the level of tightness, as reviewed in Figure 
4.11. Annexin A1 was visualized at level of tight cell-cell contacts, in particular in electro-
dense areas, where tight junctions usually form; we were only able to detect partial 
molecular interactions between ANXA1 and VE-cadherin, leaving the question around a role 
of ANXA1 as a junctional protein still open.  
Looking for the true molecular involvement of Annexin A1 in endothelial tightness, we 
observed major ANXA1-dependent differences in the structural organisation of the actin 
cytoskeleton and we were able to clearly prove, by multiple approaches, the direct 
interactions occurring between ANXA1 and the major component of the actin cytoskeleton, 
i.e. β-actin (Figure 4.12). Low levels of ANXA1 produced structural disruption of the cortical 
F-actin rim, along with the formation of numerous dysfunctional stress-fibres, known to 
cause loss of tightness in the endothelium (Beckers et al., 2010). Higher levels of ANXA1 
were able, instead, to move the shift towards cortical actin cytoskeleton, which truly 
represents the scaffolding structure necessary for junctions formation and maintenance 
(Prasain and Stevens, 2009).  
Since Annexin A1 was present in cells both in an endogenous and in a released form, we 
depicted two contributions participating in junctional structure stabilization. The 
endogenous pool of protein was shown to act as an actin binding protein; the externalised 
pool, instead, participated in regulating the small Rho GTP-ases pathway, which holds 
important significance in the regulation of the actin cytoskeleton (Figure 4.13 and 4.17).  
With such findings we have been the first to clearly show a new structural role of ANXA1 in 
contributing to brain microvasculature tightness both in vivo and at cellular/molecular level, 
producing strong implications for the potential utilisation of Annexin A1 as a therapeutic 
tool. 
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8.2.1 Future perspectives 
In our opinion, the results presented have contributed to advance the knowledge on BBB 
tightness, cytoskeleton and cellular junctions regulation in the healthy barrier, which 
certainly presents important implications for non-physiological conditions and aging. 
Interestingly, these findings propose several potential applications which may benefit from 
this novel role of Annexin A1. First, we have demonstrated the possibility to improve basal 
tightness properties of the BBB endothelium by up-regulating ANXA1 expression or through 
the treatment with recombinant protein. Several attempts have been made to develop 
interventions able to support the BBB, not only with the aim to target those pathologies 
where its peculiar properties tend to fade away, but also to provide a preventative 
protective treatment before the onset of an insulting stimulus, be it a systemic treatment 
[for example, the negative effect of chemotherapics (Kannarkat et al., 2007)] or a potent 
infection, since BBB dysfunction can also be a causative phenomenon, not only a factor 
propagating an existing condition. Some promising data in the potentiation of BBB have 
been achieved by using glucocorticoids, able to modulate the cortical actin cytoskeleton and 
cellular junctions formation (Hoheisel et al., 1998; Romero et al., 2003; Cucullo et al., 2004; 
Bauer et al., 2005; Forster et al., 2005). Many analogies with the action of ANXA1 can be 
found, which could possibly explained through the widely-accepted role of this protein as a 
primary messenger and mediator of glucocorticoid action (Solito et al., 1998); this is true for 
the classic immune-modulatory action of this class of steroids, but it can easily be true also 
at this new level of brain microvascular endothelium. In addition, the use of steroids present 
several side-effects which may undermine the effectiveness of the treatment, therefore the 
focus of the research has been switched towards endogenous anti-inflammatory mediators 
able to replicate the effect of these drugs with a lower impact on the whole body; 
glycerophosphoinositol [GPI; (Cucullo et al., 2004)] is one of these natural compounds and 
we think ANXA1 will generate novel alternative interest.  
Secondly, we were able to reduce tightness either temporarily, by targeting the protein 
through a neutralizing antibody (Figure 4.13), or constitutively, by down-regulating the 
expression of the ANXA1 gene. Increasing interest has been generated by new therapeutic 
paradigms aiming at transitional barrier opening to improve the administration of 
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therapeutic molecules into the brain otherwise unable to reach effective concentrations. 
This new idea requires to be developed very carefully and requires a tight temporal and 
structural control of the opening to limit noxious side-effects (for instance, the formation of 
oedema or the extravasation of reactive molecules into the brain). Annexin A1 may 
represent a potential useful regulator and could guarantee flexibility of action.  
Thirdly, rescuing potential is offered by using recombinant human protein, shown to 
improve the phenotype of the impaired Anxa1 null mouse, as well as of the antisense 
hCMEC/D3 line (Figure 4.13). Previous reports (Relton et al., 1991) also suggested the 
therapeutic potential offered by this molecule in reducing the severity of vascular-related 
pathologies, facilitating the recovery.  
Overall, we think to have opened a new pathway in the understanding of the physiological 
regulation of brain microvasculature extraordinary tightness, offering new options for 
different applications and a novel in vivo platform of constitutive leaky barrier (the Anxa1 
null mouse), which may be useful to investigate new mechanisms and test new treatments.  
 
8.3 Annexin A1 implications on the BBB under pathological conditions 
With the significant impact of these novel findings in mind, we were intrigued by the 
observations we obtained from samples derived from MS patients. This disorder is 
particularly atypical, since it does not seem to have a classical central origin, like AD or PD, 
but instead it appears to arise from several factors which may start playing their impact 
from the periphery; also, blood flow and vasculature seem to play an important part. These 
considerations, along with the results presented, certainly confirm the importance of 
Annexin A1 at the interface between brain and rest of the body.  
Loss of ANXA1 expression was detected in brain capillaries of MS cases (Figure 5.2), a result 
which appeared extremely tissue-specific as confirmed by the maintenance of expression in 
other vascular-related sites like the ependyma, the meningeal vessels and the choroid 
plexus, as well as bigger vessels.  
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In addition, we were able to detect a significant reduction in plasma ANXA1 content of MS 
patients as well as a specific permeability-increasing effect on hCMEC/D3 monolayers 
incubated with the same plasma samples, which was linked to a decreased total level of 
ANXA1 (Figure 5.3).  
 
8.3.1 Future perspectives 
The molecular mechanisms leading to BBB breakdown in MS are not well understood, 
therefore we think these new findings, together with the new role of Annexin A1, may offer 
novel hints for future research. It is interesting that one of the most widely and successfully 
used treatment, namely recombinant interferon β-1-α, is able to indirectly preserve ANXA1 
expression in endothelial cells treated with MS patients serum [in an experimental set-up 
similar to ours; (Alexander et al., 2007)]. This anti-inflammatory cytokine is thought to work 
by preserving BBB integrity [although this evidence has only be confirmed in vitro (Muller et 
al., 2012; Kraus et al., 2008)]. Annexin A1 could be a mediator of interferon β action and 
may contribute to explain its efficacy on BBB. Also, interferon β contribute to down-regulate 
circulating factors (pro-inflammatory cytokines) that have a negative effect (Chapter 5) on 
the protein expression, in this way limiting the systemic impact of the disease.  
The main questions posed by our descriptive study are: why is the expression of Annexin A1 
selectively lost from plasma and brain capillaries from multiple sclerosis patients? What 
factor(s) contribute(s) to that? Ideally, we should start by focusing on alterations in the 
inflammatory status of MS patients, checking for significant differences in cytokines, 
chemokines and factors, which are known to negatively affect endothelium. Notably, 
several reports have already described alterations in fluids towards a pro-inflammatory 
profile (Carrieri et al., 1998; Minagar et al., 2003). The correlation between peripheral 
factors and ANXA1 expression will also confirm, once again, the central role played by this 
protein in the communication between periphery to CNS. The decrease of Annexin A1 from 
MS brain capillaries and from serum may represent an early phenomenon during the course 
of the disease, which could therefore be translated into diagnostic exploitation. Possibly, it 
may reflect an early weakening of the capillaries, with consequent altered exchanges with 
the brain and the resulting activation of the surrounding areas of the CNS. This event could 
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also prepare for the augmented entry of circulating leukocytes, which contributes to the 
progression of the disease. Not randomly, ANXA1 shares the same target (i.e. α4β1 integrin) 
of another widely used treatment for MS, the antibody Natalizumab (Tubridy et al., 1999). 
Finally, we should not forget that ANXA1 is the key mediator of the peripheral and central 
action of glucocorticoids, another therapeutic choice for MS. All this represents another 
confirmation of how this endogenous natural molecule may prove useful therapeutically in 
future studies. In our opinion, further studies on blood and tissue samples are definitely 
required to understand if and how lack of protein may alter the leukocytes transmigration 
across the BBB in MS, which is the major trigger for disease escalation. The current view 
supports the brain entry of peripheral blood cells mainly through extravasation at the level 
of post-capillary venules, where the hemodynamic shear forces are more limited. However, 
there is great focus on the interactions, particularly adhesion, occurring at the level of the 
capillaries (Steiner et al., 2011); our studies on a human cell line will certainly impact on the 
current interest.  
 
8.4 Annexin A1 and peripheral inflammation at the BBB: sex-dependent 
differences 
As ANXA1 is an anti-inflammatory protein in the peripheral immune system, the following 
step was to investigate in details the consequences of peripheral inflammation on BMECs 
and the involvement of ANXA1. Evans blue in vivo brain extravasation under inflammatory 
conditions (modelled by i.p. administration of LPS) showed two important aspects: first, 
peripheral inflammation caused a transient increase in BBB permeability; second, there is a 
clear sex-related bias which was lost in Anxa1 null mice (Figure 6.5). By performing similar 
experiments on aged and ovariectomised animals, we then were able to confirm that this 
dimorphic response was linked to sex hormones, most likely 17 β-estradiol. Significantly, we 
observed a sex-dependent modulation of Anxa1 under inflammatory stimulation.  
In order to depict the molecular mechanism behind these results, we moved to our 
established in vitro model of BMECs, the hCMEC/D3 cell line. Here, we confirmed 
modulation of ANXA1 expression by physiological concentrations of 17 β-estradiol, in a time 
and dose-dependent manner (Figure 6.6) as well as post-translational modifications (Figure 
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6.12). Interestingly, also ANXA1-specific receptors appeared to be modulated upon 
exposure to the hormone. More in detail, the effect of the hormone was evident both at the 
level of the externalised pool of ANXA1, as well as the cellular one, therefore indicating the 
potential presence of two distinct mechanisms; indeed, we saw that ANXA1 release was 
mediated through GPR30, the transmembrane receptor for estradiol, while the effect on the 
whole cell content was probably a combination of both the classic estrogen receptors, ER-α 
and ER-β action (Figure 6.7).  
To shed some light on the sex-dependent results, we decided to focus on long pre-
incubations with 17 β-estradiol, so that we could mimic the chronic exposure to hormones 
occurring in vivo. Paralleling the results obtained in the animals, our pre-conditioning 
protocol was able to protect endothelial monolayers from the disruptive effect caused by 
pro-inflammatory cytokines (Figure 6.8), both in terms of FITC-dextran paracellular 
permeability and TEER. Interestingly, we were not able to detect any β-estradiol-dependent 
alterations in the classical signalling pathways triggered by TNF-α (Appendix; Figure 10.5), as 
it had been detected in other BBB-related and non-related models (Galea et al., 2002; 
Ghisletti et al., 2005), instead we saw the important involvement of ANXA1 in mediating the 
protective effect offered by β-estradiol towards inflammatory stimulation, which indeed 
could be prevented by blocking estradiol-induced ANXA1 action (Figure 6.10). This 
phenomenon could be explained in terms of ANXA1 release and autocrine/paracrine 
pathway, which tended to be limited/blocked by inflammation but protected through 
chronic estradiol action (Figure 6.11). This result was also accompanied by a similar 
behaviour for surface-expressed FPR2, which appeared to be negatively modulated by pro-
inflammatory cytokines but this effect was completely reverted by pre-incubation with the 
female hormone. These results may suggest two important novel mechanisms: a new 
ANXA1-dependent way through which phlogistic mediators disrupt brain barrier properties 
and a novel explanation for the protective role of 17 β-estradiol on brain microvasculature 
under inflammatory challenges.  
Importantly, these findings were replicated at functional levels: in fact, we were able to see 
the protective effect conveyed by hormonal pre-incubation being translated into rescuing 
actin cytoskeleton disruption, tight- and adherens-junctions localisation, which historically 
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have been known as primary targets of inflammatory mediators as well as ultimate results 
of the novel role of ANXA1 (Figure 6.13 and Figure 6.14). Overall, these findings confirm 
ANXA1 as intimately linked to the response generated by microvascular 17 β-estradiol, 
which has a long standing candidacy as protective effector for the brain vasculature in a 
number of inflammatory and pathological conditions (Maggi et al., 2004; Vegeto et al., 
2008).  
 
8.4.1 Future perspectives 
All the results presented in this section confirmed, once more, how central annexin A1 
appears to be in many mechanisms and responses. They also provide a good example of 
potentiation of an endangered barrier, supporting future studies on therapeutic 
implications on this endogenous mediator. This new avenue could prove valuable to solve 
many disease-related complications and to avoid the typical side-effects, which 
unfortunately accompany hormonal treatments (Ye et al., 2003; Sohrabji and Bake, 2006). 
More importantly, these findings contribute to the on-going debate on some current 
research focuses: high and persistent levels of pro-inflammatory cytokines both in the CNS 
and in the peripheral circulatory system play a key role in neurological disorders with 
vascular components, such as multiple sclerosis (Silwedel and Forster, 2006; Bennett et al., 
2010; Coisne and Engelhardt, 2011). Therefore, one may ask if such temporary increase in 
permeability (as we have detected in male wild-type mice) play a beneficial or detrimental 
effect. ANXA1-mediated effect of estradiol results to be protective and to limit the course of 
the inflammatory response, which undoubtedly has advantageous functional roles. 
Communication between peripheral and central system is undoubtedly necessary and 
numerous mechanisms exist to ensure prompt signalling and consequently quick central 
response: endothelial cells are primarily involved in these mechanisms, being able to sense 
messengers like inflammogens and cytokines and triggering an amplification phase (Banks, 
2006; Banks and Robinson, 2010). Therefore, signalling is normally preferred as a way to 
communicate what it is happening elsewhere in the body; however, in certain conditions, it 
may be beneficial to induce a modest and reversible barrier opening to permit a quicker and 
stronger communication and a more rapid and drastic response. Indeed, plasma brings 
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numerous factors with trophic relevance, which could help normal repair processes in an 
injured brain; in addition, this may allow “sampling” of the blood by neurons and immune-
surveillance brain resident cells (microglia and astrocytes too), in order to remain informed 
about the peripheral status. Provided that such transient opening events occur in a tightly 
regulated manner, we should understand that a momentary increase in permeability may 
be part of the physiological function of cytokines and inflammogens (like LPS) response; the 
behaviour shown by wild-type male mice in Figure 6.5 represents a good example, since the 
physiological basal permeability was autonomously restored within 24 hours after LPS 
administration. Consequences of a prolonged BBB leakage are highly negative and can result 
in immediate damage of the brain as well as in an increase in brain susceptibility to damage 
later in life (Stolp and Dziegielewska, 2009): the consequences may be the extravasation of 
circulating molecules (and potentially cells) that strongly activates the central immune 
system (Lucas et al., 2006) and exacerbate any existing disease (McColl et al., 2008). 
Annexin A1, by regulating and limiting permeability changes in presence of harmful stimuli, 
should therefore be regarded as a protective effector. Losing the ability to regulate its 
expression and activity could result in exaggerated responses, as shown in the old female 
animals, whose barrier responded with a prolonged increase in permeability.  
 
8.5 Central Annexin A1 under peripheral inflammation and 
neurodegeneration 
ANXA1 mapping showed a clear SNpc-specific expression on glia-like and a small population 
of neuron-like cells, which was further modulated by peripheral inflammatory events (Figure 
2.2). Such events are responsible for worsening neurodegenerative conditions, so we 
investigated the protein involvement within the CNS, both under peripheral inflammatory 
and neurodegenerative conditions. Interestingly, Anxa1 null mouse showed basal microglia 
density much higher than in wild-type male counterparts (Figure 7.3).  
In addition, Anxa1-/- Iba1+ cells presented some evident differences in their soma shape and 
ramifications, possibly suggesting a differential status in absence of the Anxa1, an 
hypothesis further supported by Anxa1 null whole brain lysates showing increased basal 
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expression of two inducible enzymes usually expressed by microglia under inflammatory 
challenge, iNOS and COX-2. This indicated a basal reactivity of the Anxa1 null CNS.  
By challenging wild-type and Anxa1 null animals with a single dose of LPS i.p., we generated 
an exacerbated peripheral inflammatory reaction in the knock-out mouse model [as already 
reported (Damazo et al., 2005)]. Significant increment in the number of Anxa1+ TH+ neurons 
within the SNpc indicated a long-term effect of inflammation in the brain, well after the 
acute peripheral reaction has subsided; we interpreted this result as a response mounted by 
delicate neurons to cope with the peripheral challenge. In the Anxa1 null mouse, we 
observed a temporary (24 hours after i.p. LPS administration, restored at normal levels 6 
days after) decrease in the total number of nigral TH+ neurons, which may indicate the 
establishment of a particularly challenging environment (Figure 7.4). As an explanation, we 
could consider the exceptionally high increment of Anxa1 null microglia density, 
accompanied by increased NO production and a reduced efficiency of the anti-inflammatory 
machinery (IL-10). These results suggest that the absence of Annexin A1 represent the lack 
of an important immunological brake.  
Having verified that peripheral stimulation has a great impact within the SNpc, in particular 
in the Anxa1 null mouse, we moved to a neurodegeneration model, the 6-OHDA intrastriatal 
infusion, known to lead to a gradual lesion of the SNpc. Genotype-related differences were 
detected in terms of microglia recruitment: wild-type animals responded with a quick short-
lived increase in cell density in the lesioned SNpc, while the Anxa1 null mice instead 
displayed a slower kinetics, which peaked at 1 week post-lesioning start and did not seem to 
resolve completely (Figure 7.8). These findings support for an impaired nature of Anxa1 null 
microglia cells, which seemed to be less sensitive to neuronal cell damage compared to 
peripheral inflammation. Surprisingly, we did not detect a negative impact of Anxa1 lack in 
terms of TH neuronal survival (Figure 7.7); instead, lesioning in null mice showed a different 
dynamic of cell loss compared to the typically chronic one showed by wild-types. The 
current knowledge could not fully justify these results, which may be linked to the impaired 
ability of Anxa1 null microglia to clear apoptotic neurons; however, further investigations 
will try to shed more light on this topic. Still importantly, those TH+ neurons expressing 
Anxa1 (in the wild-type animals) showed a preferential survival rate compared to the 
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surrounding Anxa1, indirectly supporting the immune-modulatory nature of the protein 
towards the surrounding reactive microenvironment.  
Finally, in order to investigate the impact of peripheral inflammation on on-going 
neurodegeneration and to understand if the presence of Annexin A1 could play some sort of 
beneficial/modulatory role, we first induced significant lesioning of the SNpc and then we 
challenged the animal peripherally with LPS. Wild-type mice did not show differences linked 
to the subsequent peripheral stimulation, while Anxa1 null mice did show exacerbated loss 
of TH+ neurons, which was paralleled by an exaggerated higher microglia cell density in the 
lesioned side, indicating an additive effect between the two stimuli. Overall, Annexin A1 
appeared to be important in controlling the inflammatory impact, possibly helping to limit 
DA neuronal loss and neurodegenerative progression. 
 
8.5.1 Future perspectives 
We believe that these results will stimulate novel interest on the central role of ANXA1 in 
the periphery-to-brain communication. Malfunctions in the communication pathway may 
represent a detrimental process common to several neurodegenerative disorders, and 
ANXA1 may be implicated. In addition, our results contributed to add more information 
about the peculiar features characterizing the SNpc and to the relevant impact inflammation 
can have, not only when originated within the brain, but especially when derived from the 
periphery.  
Despite some novel theories sustaining that boosting inflammation and the immune system 
may represent a new way to obtain beneficial effects on the injured brain (Rivest, 2009; 
Wee Yong, 2010), medicine has historically reached more successes in inhibiting the 
immune reaction rather than activating it, the only exception being represented by vaccines 
(Lucin and Wyss-Coray, 2009).  
A clearer knowledge of the mechanisms implicated in immune-central communication and 
those involved in microglia activation to an aggressive phenotype will certainly indicate a 
better understanding on how all these events can be controlled. We believe to have started 
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this contribution by proposing Annexin A1, as well as its small peptides, as a molecule tightly 
involved in these processes.  
Having described the potential role of ANXA1 in limiting the central effects of systemic 
inflammation opens numerous implications: nowadays, treatments for PD patients are 
aimed at controlling and limiting symptoms, rather than targeting disease causes and 
homeostasis restoration, since these are difficult goals to achieve when diagnosis occurs 
late. In particular, steroidal and non-steroidal anti-inflammatory drugs have been used with 
mixed success to inhibit excessive microglial activation (in particular the antibiotic 
minocycline) and the production of pro-inflammatory/toxic cytokines and reactive species 
(ROS/NOS), which negatively impact on damaged or intact neurons (Chen et al., 2003; 
Whitton, 2007). These numerous evidences support the potential use of anti-inflammatory 
drugs to limit the progression of existing neurological disorders, but also to halt the negative 
impact of reactions transferred from the periphery, which should now be considered strong 
CNS influencing factors (Chen et al., 2003; Lucin and Wyss-Coray, 2009). However, these 
drugs bear numerous side effects when given over a long period of time. This is why the 
attention is now progressively switching into studying endogenous mediators shown to play 
a role in the anti-inflammatory/pro-resolution action of the drugs, but possibly more gentle 
in terms of toxic impact on the body. Such approach is now considered a smarter solution by 
many and will soon produce some new exciting advances in the field, successfully 
controlling the chronic neuroinflammatory environment, the real perpetuating agent. 
ANXA1 should be considered one of these endogenous anti-inflammatory molecules (the 
resolvins) that present a strong candidacy and a valuable potential (Relton et al., 1991; 
Strijbos et al., 1991; Black et al., 1992; Rothwell and Relton, 1993; Knott et al., 2000). We 
have been among the first ones to provide some clear mechanistic explanation on some of 
the beneficial roles of ANXA1 in the brain (McArthur et al., 2010) and this study closely 
follows by adding novel evidence and broadening the meaning of this molecule.  
Our latest observation may produce strong implications for novel ANXA1-based strategies to 
combat those neurological disorders that show microglia over-activation as a fundamental 
contributor to the disease, possibly reversing its detrimental state towards a more beneficial 
one.  
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8.6 A novel role for ANXA1 in the central impact of peripheral inflammation  
There is a growing awareness that systemic inflammation transmits to the brain and, unless 
the consequent neuroinflammatory response is controlled, it has a huge impact on the CNS. 
Our work has helped to establish Annexin A1 as a key endogenous molecule involved into 
periphery-to-brain communication: by limiting the propagation of inflammation, preventing 
an exaggerated production of inflammatory mediators throughout the body and by 
triggering the complex resolution process, ANXA1 already contributes to limit the impact 
that daily inflammatory events can have on the rest of the body and on the CNS. These are 
already known as the classical array of actions for which ANXA1 has been extensively 
studied in the last 30 years (Parente and Solito, 2004; Perretti and D'Acquisto, 2009). Here, 
we showed novel interventions at other fundamental sites along the immune-nervous axis, 
controlling and regulating the transfer of systemic inflammatory stimuli to the brain, as well 
as resolving/limiting the central inflammatory responses generated. Annexin A1 plays an 
important role in maintaining tight and protective the BBB endothelium, a role which is 
modulated according to the type of stimuli received, so that a correspondent response can 
be consequently generated. Circulating pro-inflammatory cytokines, which are extremely 
important messengers, are able to modulate the expression and localisation of ANXA1 with 
a consequent but transient barrier permeability increase, believed to be beneficial when 
tightly controlled (Abbott, 2002). In such way, certain informative stimuli may enter the 
brain and communicate with some of the resident cellular types, like neurons and microglia 
cells. Within specific brain regions, like SNpc, ANXA1 is expressed according to a peculiar 
pattern of expression and our evidence strongly supports for a modulatory role both under 
basal conditions but especially under peripheral stimulation, i.e. controlling the 
neuroinflammatory response generated as a consequence of the signalling cascade 
triggered through the BBB and limiting excessive activation. We think, therefore, that our 
recent work greatly support from a molecular, cellular and structural level the working 
hypothesis of the entire project, depicted in Figure 8.1 and described in (Solito et al., 2008).  
Notably, having had the possibility to study a complex phenomenon in an in vivo set-up 
allowed us not only to describe a novel endothelium-specific role for ANXA1, but especially 
to appreciate the tight relationship existing between the various structures of interest and 
the responses generated by one when another resulted impaired.  
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We believe Anxa1 null mouse will still prove to be a useful model to deepen our knowledge 
on the molecular periphery-to-brain communication, which is still at its infancy. In parallel, 
in vitro experiments between microvascular endothelium, neurons and microglia will 
confirm molecularly the role of central ANXA1 as a protective communicator.  
 
8.7 Closing comments 
Nowadays, we live longer mainly thanks to an improved quality of life and control of 
diseases but the central impact of infections and of certain diseases (like chronic kidney 
disease and heart failure) still represents a huge threat. It has been recently reported that a 
significant part of the next 5 years NHS budget will be spent in treating people with 
secondary cognitive dysfunction; therefore, future work in this field cannot stop, but should 
focus on unravelling the mechanisms of interaction between periphery and brain, together 
with deciphering how we can exploit the novel discoveries therapeutically. Consequently, 
we will generate new ways able to halt and resolve the detrimental effects brought by 
inflammation, not simply by temporarily stopping them. Therefore, it is important that 
research funding into this area does not stop as well as novel approaches and original ideas, 
which thankfully seems not to lack (Ajami et al., 2011; Hatherell et al., 2011; Abbott et al., 
2012; Lippmann et al., 2012; Patabendige et al., 2012).  
Our results strongly indicate ANXA1 as a target that should be taken into further research in 
the next future, so that the novelty of these findings won’t wear out too quickly. The 
multifaceted array of actions shown by this molecule will certainly turn to be an advantage, 
so that targeting disorders like PD will result practicable and effective and in a novel 
paradigm of treatments not aiming anymore at limiting the impact of the symptoms but 
instead at resolving the causes and the aggravating circumstances.  
We think that our latest results will generate new enthusiasm around Annexin A1, an old 
molecule not only since it has been studied for over 30 years, but also because the ancestor 
gene is around 400 millions years old. The therapeutic potential is in front of everyone’s 
eyes, as well as the possibility to use it as a novel early diagnosis biomarker, which will 
represent an enormous step forward into more effective therapies and better quality of life.  
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Figure 8.1 Working hypothesis modified with evidence produced. This figure represents the 
working hypothesis, which generated the entire project and was preliminarily presented in Solito et 
al. 2008. 1| Peripheral infection and inflammation cause the release of pro-inflammatory mediators, 
including cytokines, arachidonic acid, prostaglandins and nitric oxide. Annexin A1 is triggered as part 
of the anti-inflammatory/resolution process and it counteracts the action of these mediators, 
especially in terms of release of the mediators themselves and extravasation of leukocytes through 
the activated endothelium. 2| ANXA1 plays a fundamental role in the brain microvascular 
endothelium, by contributing to maintenance of the peculiar tightness. Under inflammatory 
stimulation, ANXA1 is modulated and ultimately is able to counteract the effects of the pro-
inflammatory stimuli. 3| The brain also mounts an inflammatory response to systemic inflammation, 
4| as well as to local injury (trauma, stroke, neurodegeneration, etc.), which is characterised by 
microglia cells quickly responding and activating, with consequent release of great amounts of pro-
inflammatory mediators. ANXA1 may represent one of the mediators of the tight immune-related 
control that characterise the brain, supporting beneficial microglia phenotypes, like 5| the 
phagocytising one which beneficially clears up apoptotic cell bodies, limiting further damage and 
amplification of the stimulation (McArthur et al., 2010).  
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10.1 Composition of solutions 
Where not stated within brackets, reagents have been bought from Sigma-Aldrich, UK. 
 
10.1.1 Solutions for general usage 
 
Phosphate buffered saline PBS (0.01M)                Final concentration 
NaCl                     0.138M 
KCl                    0.0027M 
Distilled H2O                    100% (v/v)  
pH 7.4 
 
Saline solution                   Final concentration 
NaCl                     0.9% (w/v) 
Distilled H2O                    100% (v/v)  
pH 7.4 
 
Tris buffered saline (TBS) 1X                 Final concentration 
Tris.HCl                    25 mM 
NaCl                     150 mM 
KCl                     2 mM 
pH 7.4 
 
10.1.2 Solutions for in-vivo usage 
 
Sucrose solution for cryo-preservation                Final concentration 
Sucrose                    30% (w/v) 
PBS 0.01 M                            100% (v/v)  
pH 7.4 
 
Evan’s Blue solution                               Final concentration 
Evan’s Blue                    2% (w/v) 
PBS 0.01 M                            100% (v/v)  
pH 7.4 
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6-Hydroxydopamine (6-OHDA) lesioning solution                            Final concentration 
6-OHDA                                2 mg/ml  
NaCl                     0.9% (w/v) 
Ascorbic acid                    0.1% (w/v) 
Saline                    100% (v/v)  
pH 7.4 
 
10.1.3 Cell culture 
 
Dulbecco’ modified eagle medium          500 ml                     Final concentration 
(DMEM; Lonza, CH) 
Heat inactivated fetal calf serum (FCS; Lonza, CH)              10% 
Gentamycin (Invitrogen, UK)                 50 µg/ml 
Non-essential amminoacids (NEAA 100X; Invitrogen, UK)             100 µM 
 
Endothelial cell growth medium      500 ml             Final concentration 
(EGM-2 MV; Lonza, CH)     
Heath inactivated fetal calf serum (FCS; Lonza, CH)              2.5% 
VEGF                     half provided vial 
IGF-1                     half provided vial 
EGF                     half provided vial 
Basic FGF                    half provided vial 
Hydrocortisone                   whole provided vial 
Ascorbic acid                   whole provided vial 
Gentamycin                   whole provided vial 
 
Dulbecco’s phosphate buffered saline w/o Ca
2+
/Mg
2+
       500 ml              Final concentration 
(DPBS w/o Ca
2+
/Mg
2+
; Lonza, CH) 
KCl                    200 mg/ml 
KH2PO4                   200 mg/ml 
NaCl                    0.8% (w/v) 
MgCl2 ·6H2O                    100 mg/l 
CaCl                     100 mg/ml 
NaH2PO4                    1.15 g/l 
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Henk’s balanced salt solution w/o Ca
2+
/Mg
2+              500 ml                      Final concentration 
(HBSS w/o Ca
2+
/Mg
2+
; Lonza, CH) 
KCl                   400 mg/l 
KH2PO4                   60 mg/l 
NaCl                    8 g/l  
NaHCO3                   350 mg/ml 
NaH2PO4·7 H2O                 90 mg/l 
 
Coating solution for routine passaging of hCMEC/D3             Final concentration 
Thin rat tail collagen type I (BD Biosciences, UK)              150 µg/ml 
Double distilled H2O or DPBS without Ca
2+/Mg2+                        100% (v/v) 
pH 7.4 
 
Trypsin solution                   Final concentration 
Trypsin (Lonza; CH)                  0.25% (w/v) 
EDTA                    0.38% (w/v) 
 
Freezing medium                   Final concentration 
Dimethylsulfoxide (DMSO)                  10% (v/v) 
FCS (Lonza, CH)                  90% (v/v) 
 
Stable integration selecting solution                Final concentration 
G418® (Invitrogen; UK)                             200 – 400 µg/ml 
Cell growth medium                   100% (v/v) 
 
Fibronectin for transwell coating                 Final concentration 
Fibronectin from bovine plasma in 0.5 M NaCl, 0.05 M Tris, pH 7.5            10 µg/ml 
DPBS without Ca2+/Mg2+                 100% (v/v) 
pH 7.4 
 
Collagen for Transwell coating                     Final concentration        
Collagen from calf skin in 0.1 M acetic acid               50 µg/ml 
DPBS without Ca2+/Mg2+                 100% (v/v) 
pH 7.4 
 
17 β-estradiol stock solution                               Final concentration 
17 β-estradiol                   100 µM  
Ethanol                    100% (v/v) 
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Propylpryazole-triol (PPT) stock solution                                  Final concentration 
PPT (Tocris Bioscience, UK)                     100 mM  
Ethanol                    100% (v/v) 
 
Diarylpropionitrile (DPN) stock solution                               Final concentration 
DPN (Tocris Bioscience, UK)                             100 mM  
Ethanol                    100% (v/v) 
 
G-1 stock solution                                                                      Final concentration 
G-1 (Tocris Bioscience, UK)                                       100 mM  
Ethanol                    100% (v/v) 
 
Phenyl-trifluoromethyl-pyrazolo-phenol (PHTPP) stock solution              Final concentration 
PHTPP (Tocris Bioscience, UK)                                      100 mM  
Ethanol                   100% (v/v) 
 
G-15 stock solution                                                                      Final concentration 
G-15 (Tocris Bioscience, UK)                                       100 mM  
Ethanol                    100% (v/v) 
 
TNF-α stock solution                  Final concentration 
TNF-α (R&D Systems, UK)                             100 µg/ml  
BSA                    0.1% (w/v) 
DPBS with Ca2+/Mg2+                   1X 
 
IFN-γ stock solution                   Final concentration 
IFN-γ (R&D Systems, UK)                  100 µg/ml 
BSA                    0.1% (w/v) 
DPBS with Ca2+/Mg2+                   1X 
 
Lipopolisaccharide (LPS) stock solution                Final concentration 
LPS (Clone 0111:B4; Sigma, UK)                 1 mg/ml 
NaCl                     0.9% (w/v) 
Saline                     100% (v/v)  
 
Griess reagent                    Final concentration 
Sulfanilamide                    1% (w/v) 
Naphthylethylenediamine dihydrochloride                0.1% (w/v) 
Phosphoric acid solution                  5% (v/v) 
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10.1.4 Solutions for ex-vivo usage 
 
Trichloroacetic acid (TCA) solution                 Final concentration 
Trichloroacetic acid                               60% (w/v) 
Distilled H2O                   100% (v/v) 
 
Proteinase K stock solution                              Final concentration 
Proteinase K                   10 mg/ml 
Distilled H2O                   100% (v/v) 
 
Lysis buffer for genotyping                 Final concentration 
Tris.HCl                    250 mM 
EDTA                     25 mM 
NaCl                     500 mM 
SDS                     2.5% (w/v) 
 
10.1.5 Primary murine cerebrovascular endothelial cells isolation 
 
Wash buffer            100 ml                  Final concentration 
HEPES buffer                    10 mM 
BSA                     0.1% (w/v) 
HBSS without Ca2+/Mg2+                 1X 
pH 7.4 
 
BSA stock solution                   Final concentration 
BSA                     30% (w/v) 
HBSS without Ca2+/Mg2+                  1X 
 
Density centrifugation solution                 Final concentration 
BSA                     25% (w/v) 
Wash buffer  
 
Enzyme cocktail                                10 ml/prep                           Final concentration 
Collagenase/Dispase (Roche, UK)                 2 mg/ml 
DNase I                    20 IU/ml 
Tosylysine Chloromethyl Ketone Hydrochloride (TLCK)             0.147 µg/ml  
 
Rat tail type I collagen                  Final concentration 
Filter sterile rat tail type I collagen (home-made)              0.33 mg/ml 
Distilled H2O                    100% (v/v) 
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Cell growth medium                               Final concentration 
FBS (Lonza, CH)                                                                                                      20% (v/v) 
Heparin (Cinitial = 50 mM)                80 µg/ml 
Gentamicin                  50 μg/ml 
Selenium, Insulin, Transferrin (SIT) supplement             1X 
Endothelium supplement (Cinitial = 7.5 mg/ml)             75 µg/ml 
Vitamin C (Cinitial = 170 mM)                   75 µM 
Puromycin (Cinitial = 1 mg/ml)*               4 µg/ml 
DMEM (low glucose, 1000 mg/l; Invitrogen, UK) 
*for the first three days only 
 
10.1.6 Protein extraction for cells and tissue samples 
 
RIPA extraction buffer                      Final concentration 
Tris.HCl pH 7.4                   50 mM  
NaCl                     150 mM 
EDTA                     1mM 
Sodium deoxycholate                              1% (w/v) 
Triton X-100                    1% (w/v) 
SDS                     0.1% (w/v) 
Protease/phosphatase inhibitors cocktail 
 
Soluble proteins extraction buffer                 Final concentration 
HEPES                     25 mM 
NaCl                     150 mM 
EDTA                     4 mM 
EGTA                     10 mM 
Triton X-100                    1% (v/v) 
pH 7.5 
Protease/phosphatase inhibitors cocktail 
 
Insoluble proteins extraction buffer                Final concentration 
HEPES                     25 mM 
NaCl                     150 mM 
EDTA                     4 mM 
EGTA                     10 mM 
Triton X-100                    1% (v/v) 
SDS                     1% (w/v) 
pH 7.5 
Protease/phosphatase inhibitors cocktail 
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Soluble β-actin extraction buffer                             Final concentration 
DPBS with Ca2+/Mg2+                                                        1X 
Triton X-100                   1% (v/v) 
Unlabelled phalloidin                  1 µg/ml 
Protease/phosphatase inhibitors cocktail 
 
Insoluble β-actin extraction buffer                Final concentration  
DPBS with Ca2+/Mg2+                  1X 
Triton X-100                   1% (v/v) 
SDS                    2% (w/v) 
Protease/phosphatase inhibitors cocktail 
 
Protein extraction buffer for brain cytokines               Final concentration 
NaCl                     150 mM 
Tris.HCl pH 7.4                   25 mM 
EDTA                     1mM 
Protease/phosphatase inhibitors cocktail 
 
Protease and phosphatase inhibitors mix                Final concentration 
PMSF                                         1mM 
Aprotinin                                                                 10 µg/ml 
NaF                                                         25 mM 
Na3VO3                   1mM 
 
10.1.7 Co-immunoprecipitation 
 
RIPA buffer without SDS                  Final concentration 
Tris.HCl                    50 mM 
EDTA                                 10 mM 
NaCl                     150 mM 
NP-40 (Nonidet P-40)                   1% (v/v) 
Sodium deoxycholate                  1% (w/v) 
 
Low salt buffer                                                           Final concentration 
Tris.HCl                   10 mM  
NaCl                    150 mM 
EDTA                    2 mM 
NP-40                    0.2% (v/v) 
pH 7.4 
 
Chapter 10 – Appendix 
Page | 328   Enrico Cristante – PhD degree thesis    
 
High salt buffer                                                           Final concentration 
Tris.HCl                   10 mM 
NaCl                    500 mM 
EDTA                    2 mM 
NP-40                    0.2% (v/v) 
pH 7.4  
 
Beads resuspension buffer                  Final concentration 
Tris.HCl                    10 mM  
pH 7.4 
 
10.1.8 SDS-PAGE and Immunoblotting 
 
Resolving acrylamide gel                 Final concentration 
40% Acrylamide/Bis-Acrylamide mixture (37.5:1 ratio)             8%-15% 
(Biorad, UK) 
Tris.HCl pH 8.8                   0.375M 
20% (w/v) sodium dodecyl sulphate solution              0.1% (w/v) 
Tetramethylethylenediamine (TEMED)               1:1000 
Ammonium persulfate (APS)                 0.05% (w/v) 
Distilled H2O 
 
Stacking acrylamide gel                 Final concentration 
40% Acrylamide/Bis-Acrylamide mixture (37.5:1 ratio)             4% 
Tris.HCl pH 6.8                   0.126M 
20% (w/v) sodium dodecyl sulfate solution               0.1% (w/v) 
Tetramethylethylenediamine (TEMED)               1:1000 
Ammonium persulfate (APS)                 0.05% (w/v) 
Distilled H2O 
 
Loading buffer 3X                   Final concentration 
Tris.HCl pH 6.8                   0.2M  
Glycerol                    30% (v/v) 
β-mercaptoethanol                   15% (w/v) 
SDS                     6% (w/v) 
Bromophenol blue                   few grains 
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Running buffer 1X                              Final concentration  
Tris.HCl                    25 mM 
Glycine                    192 mM 
SDS                     0.1% (w/v) 
pH 8.3 
 
Transfer buffer 1X                               Final concentration 
Tris.HCl                    25 mM 
Glycine                    192 mM 
Methanol                   10% (v/v) 
 
Blocking solution                   Final concentration 
BSA                     3% (w/v) 
TBS                     1X 
Tween-20                    0.05% (v/v) 
 
TBS-T                     Final concentration 
TBS                                 1X 
Tween-20                    0.05% (v/v) 
 
10.1.9 DNA transfection, amplification and DNA gel electrophoresis 
 
Tris acetate EDTA (TAE) buffer                 Final concentration 
Tris-Acetate (50X; Invitrogen, UK)                40 mM 
EDTA                    1 mM 
 
Agarose gel for DNA analysis                 Final concentration 
Agarose (Invitrogen, UK)                  0.8-2% 
TAE buffer                               1X 
Ethidium Bromide                   0.8 ng/μl 
 
Gel loading buffer 10X                  Final concentration 
Glycerol                    30% (v/v)  
Bromophenol blue                   0.25% (w/v) 
Distilled H2O                    100% (v/v) 
 
Ampicillin stock solution                  Final concentration 
Ampicillin                    1 mg/ml 
Distilled H2O                    100% (v/v) 
Filter sterilised 
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Luria Bertani (LB) broth                  Final concentration 
Bacto tryptone (Invitrogen, UK)                1% (w/v) 
Bacto-yeast extract (Invitrogen, UK)                 0.5% (w/v) 
NaCl                                                   1% 
 
LB Bacto-agar                   Final concentration 
(All reagents from Invitrogen, UK) 
Bacto tryptone                  1% 
Bacto-yeast extract                  0.5%  
NaCl                    1% 
Agar                     1.5% 
 
Non-selective SOC medium                  Final concentration 
(All reagents from Invitrogen, UK) 
Bacto-tryptone                   2% (w/v) 
Yeast extracts                    0.5% (w/v) 
NaCl                     8.6 mM 
KCl                     2.5 mM 
MgSO4                    20 mM 
Glucose                    20 mM 
pH 7.0 
 
CaCl2 solution for HEK293FT transfection                Final concentration 
CaCl2                     2M 
Distilled H2O                    100% (v/v) 
 
2X Hank’s Balanced Salts (HBS) solution                     Final concentration 
HEPES                     50 mM 
NaCl                     281 mM 
Na2HPO4                    1.5 mM 
pH 7.08-7.1 
Filter sterilized 
 
Sodium butyrate stock solution                 Final concentration 
Sodium butyrate                   1 M 
PBS                     0.01 M 
Freshly prepared before use 
 
Tris-EDTA (TE) buffer                  Final concentration 
Tris.HCl pH 8                    10 mM 
EDTA                     1 mM 
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10.1.10 Enzyme-linked immunosorbent assay (ELISA)  
 
Bicarbonate buffer                   Final concentration 
NaHCO3                   25 mM 
Na2CO3                   25 mM 
Distilled H2O                    100% (v/v) 
pH 9.6 
 
Blocking buffer                   Final concentration 
BSA                     1% (w/v) 
DPBS without Ca2+/Mg2+                  1X 
Distilled H2O                    100% (v/v) 
 
Assay diluent                    Final concentration 
PBS                     0.01 M    
Tween-20                    0.05% (v/v) 
 
Wash buffer                    Final concentration 
NaCl                     0.9% (w/v) 
Tween-20                    0.05% (v/v) 
Distilled H2O                    100% (v/v) 
 
Wash buffer (auto-antibody protocol)                         Final concentration 
PBS                    0.01 M 
Tween-20                    0.05% (v/v) 
Distilled H2O                    100% (v/v) 
 
Stop reaction                               Final concentration 
H2SO4                     2M 
Distilled H2O                    100% (v/v) 
 
Antibody buffer (auto-antibody protocol)                Final concentration 
EDTA                     1 mM 
Tween-20                    0.05% (v/v) 
FCS                                 1% (v/v) 
PBS                    0.01M 
pH 7.5 
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10.1.11 Histochemistry and immunophenotyping on cells and tissue 
 
Anti-freeze solution                   Final concentration 
NaH2PO4·H2O                    11.53 mM 
Na2HPO4                    38.5 mM 
NaCl                     150 mM 
Polyvinylpyrrolidone                   1% (w/v) 
Sodium Azide                    0.02% (w/v) 
Ethanediol                    50% (v/v) 
 
Sudan Black                    Final concentration 
Sudan Black                    0.5% (w/v) 
Ethanol                                            70% (v/v) 
Distilled H2O                    30% (v/v) 
 
Permeabilization buffer                  Final concentration 
TBS                     1X 
Triton X-100                    0.2-0.5% (v/v) 
 
Blocking solution                   Final concentration 
Normal goat serum (NGS)                              10% (v/v) 
BSA                     1% (w/v) 
TBS                     1X 
Triton X-100                    0.1% (v/v) 
 
Blocking solution (for human tissue)               Final concentration 
BSA                     10% (w/v) 
TBS                     1X 
Triton X-100                    0.5% (v/v) 
Peroxidase inhibiting buffer (for human tissue)                           Final concentration 
H2O2                     0.3% (v/v) 
PBS                     0.01 M 
 
Washing solution (for human tissue)               Final concentration 
TBS                     1X 
Triton X-100                    0.05% (v/v) 
 
Developing solution (for human tissue)                Final concentration 
Diaminobenzidine                   0.025% (v/v) 
H2O2                     0.01% (v/v) 
TBS                    1X 
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Antibody buffer                               Final concentration 
TBS                     1X 
NGS                     1% (v/v) 
BSA                     0.1% (w/v) 
Triton X-100                    0.1% (v/v) 
 
Paraformaldehyde (PFA) for tissue and cell fixation             Final concentration 
PFA (VWR International, UK)                  4% (w/v) 
PBS pH 7.4; filtered                  0.01 M 
 
Mowiol                    Final concentration 
Mowiol (Calbiochem; UK)                 10% (w/v) 
Glycerol                   25% (v/v) 
Distilled H2O                    25% (v/v)  
Sodium Azide                    0.02% (w/v) 
Tris.HCl pH 8.5                   50% (v/v) 
 
Eosin Y counterstain                   Final concentration 
Eosin Y                    0.1% (w/v) 
Ethanol                    80% (v/v) 
Glacial acetic acid                   0.44% (v/v) 
Distilled H2O                    20% (v/v) 
 
Staining solution for β-galactosidase activity               Final concentration 
K4Fe(CN)6·3H2O                   30 mM 
K3Fe(CN)6                    30 mM 
MgCl2                                              2 mM  
Na-deoxycholate                   0.01% (w/v) 
Triton X-100                    0.02% (v/v) 
X-gal                     2 mg/ml  
PBS                     0.01M 
 
Rinse buffer for β-galactosidase activity                Final concentration 
NaH2PO4.2H2O                   100mM 
Na2HPO4.12H2O                   100mM 
Triton X-100                    0.1% (v/v) 
Distilled H2O                    100% (v/v) 
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Harris Hematoxylin solution                  Final concentration 
Alcoholic hematoxylin solution                 0.5% (v/v) 
HgO                     0.25% (w/v) 
KAl(SO4)2                    10% (w/v) 
Glacial acetic acid                   2% (v/v) 
Distilled H2O                                                                                                            100% (v/v) 
 
10.1.12 Flow cytometry  
 
Blocking solution                   Final concentration 
DPBS with Ca2+/Mg2+                  1X 
BSA                     3% (w/v) 
with or without saponin 10% (w/v)                 0.025-0.1% (w/v) 
 
Wash buffer                    Final concentration 
NGS                     1% (v/v) 
BSA                     0.1% (w/v) 
DPBS with Ca2+/Mg2+                             1X 
with or without saponin 10% (w/v)                 0.025-0.1% (w/v) 
 
Antibody buffer                   Final concentration 
DPBS with Ca2+/Mg2+                  1X 
BSA                     0.1% (w/v) 
with or without saponin 10% (w/v)                 0.025-0.1% (w/v) 
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10.2 Antibodies 
Antibodies used throughout the project are listed here, along with their source, the final 
concentration/dilution factor used and which application they have been optimised for. 
 
10.2.1 Primary antibodies 
 
Anti-ANXA1 Ms Not commercial Solito et al. , 2000 50 ng/ml FC; E
Anti-ANXA1 Rb Life Technologies 71-3400 1:1000 IF; FC; E
Anti-ANXA1 Rb Not commercial Solito et al. , 1998a 1:1000 IF; WB; FC
Anti-Aκt Rb Cell signaling 4685 1:1000 WB
Anti-Cd11b Rt Abcam ab6332 1:300 IF
Anti-CD31 Rb Novus Biologicals NB100-92205 1:100 IF
Anti-Cdc42 Ms Cell Biolabs 240201 1:200 WB
Anti-claudin 5 Ms Life Technologies 35-2500 1:100 IF; WB
Anti-claudin 5 Rb Santa Cruz Biotech sc-28670 1:50; 1:500 IF; WB
Anti-COX2 Rb Cayman Chemical 160106 1:500 WB
Anti-ERα Ms Santa Cruz Biotech sc-130072 1:1000 FC
Anti-ERβ Ms Santa Cruz Biotech sc-133554 1:150 FC
Anti-FPR1 Ms R&D systems MAB3744 1:100 IF; FC
Anti-FPR2 Ms R&D systems MAB3749 1:100 IF; FC
Anti-GAPDH Rb Abcam ab9483 1:5000 WB
Anti-GPR30 Ms R&D systems AF5534 1:500 FC
Anti-Histone H3 Rb Cell signaling 9717 1:1000 WB
Anti-Iba1 Rb Wako 019-19741 1:2000 IF
Anti-iNOS Rb Sigma-Aldrich N7782 1:500 WB
Anti-IκB Rb Cell signaling 4812 1:1000 WB
Anti-Laminin Rb Sigma-Aldrich L9393 1:500 IF
Anti-MDR1 Rb Santa Cruz Biotech sc-1517R 1:100 WB
Anti-occludin Ms Life Technologies 33-1500 1:100 IF; WB
Anti-p38 MAPK Rb Cell signaling 9212 1:1000 WB
ApplicationAntibody Species Company Cat. Number
Dilution 
Factor/Final 
concentration
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Table 10.1 Primary antibodies used throughout the study. Detailed information about primary 
antibodies is here reported. Abbreviations: Dk=donkey; Gt=goat; Ms=mouse; Rb=rabbit; Rt=rat. 
IF=immunofluorescence; FC=flow cytometry; WB=western blotting; E=ELISA.  
Anti-p44/42 MAPK 
(ERK1/2)
Rb Cell signaling 4695 1:1000 WB
Anti-p65 Rb Cell signaling 4764 1:1000 WB
Anti-PDGFR 
(CD140b)
Rat eBioscience 14-1402-82 1:250 IF
Anti-Perlecan Rb Sigma-Aldrich HPA018892 1:3000 IF
Anti-phospho Aκt Rb Cell signaling 4056 1:1000 WB
Anti-phospho IκB Ms Cell signaling 9246 1:1000 WB
Anti-phospho p38 
MAPK
Rb Cell signaling 9215 1:200 WB
Anti-phospho p44/42 
MAPK (ERK1/2)
Rb Cell signaling 8544 1:1000 WB
Anti-phospho 
SAPK/JNK
Rb Cell signaling 4668 1:1000 WB
Anti-Phospho Ser 
ANXA1
Rb Not commercial Solito et al. , 2003b 1:500 WB
Anti-Phospho Tyr 
ANXA1
Rb Not commercial Solito et al. , 2003b 1:500 WB
Anti-Rac1 Ms Cell Biolabs 240106 1:200 WB
Anti-RhoA Ms Santa Cruz Biotech sc-179 1:250 WB
Anti-SAPK/JNK Rb Cell signaling 9258 1:1000 WB
Anti-Tyrosine 
Hydroxylase (TH)
Ms Millipore MAB318 1:4000 IF
Anti-VE Cadherin Rb Santa Cruz Biotech sc-28644 1:80; 1:250 IF; WB
Anti-ZO1 Rb Life Technologies 40-2200 1:80; 1:100 IF; WB
Anti-β actin Rb Abcam ab6276 1:5000 WB
Anti-β Galactosidase Rb MP Biomedicals 55976 1:100 IF
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10.2.2 Secondary antibodies and fluorescently conjugated phalloidins 
 
Table 10.2 Secondary antibodies and fluorescently conjugated phalloidin used throughout the 
study. Detailed information about secondary antibodies is here reported. Abbreviations: Dk=donkey; 
Gt=goat; Ms=mouse; Rb=rabbit; Rt=rat. IF=immunofluorescence; FC=flow cytometry; WB=western 
blotting; E=ELISA.  
 
 
 
AF488-Phalloidin N.A. Life Technologies A-12379 1:40 IF
Rhodamine-
Phalloidin
N.A. Life Technologies R-415 1:40 IF
Anti-mouse IgG 
AF488 conj.
Gt Life Technologies A-11029 1:500 IF; FC 
Anti-mouse IgG 
AF594 conj.
Gt Life Technologies A-11005 1:500 IF; FC 
Anti-mouse IgG HRP 
conjugated
Gt Sigma-Aldrich A-5906 1:15000 WB
Anti-rabbit IgG 
AF488 conj.
Gt Life Technologies A-11034 1:500 IF; FC 
Anti-rabbit IgG 
AF594 conj.
Gt Life Technologies A-11012 1:500 IF; FC 
Anti-rabbit IgG AP 
conjugated
Gt Sigma-Aldrich A-8025 1:10000 IF
Anti-rabbit IgG HRP 
conjugated
Gt AbD Serotec STAR54 1:10000 WB
Anti-rat IgG FITC 
conj.
Dk Beckman - Coulter 732978 1:500 IF; FC 
Anti-rat IgG FITC 
conj.
Dk Beckman - Coulter 732978 1:500 IF; FC 
Anti-rat IgG FITC 
conj.
Dk Beckman - Coulter 732978 1:500 IF; FC 
ApplicationAntibody Species Company Cat. Number
Dilution 
Factor/Final 
concentration
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10.3 Primers sequences 
 
Table 10.3 List of primers used throughout the study. General information about primers used in 
this study is reported here.  
 
 
 
Primer name Sequence (5’ - 3’) Annealing temperature
gcaacctttgaaactcaagcc
tactgtcgtcgtcccctcaaactg
Human TLR4 R
LacZ F
55°C
55°C
58°C
58°C
58°C
58°C
ANXA1 exon 3 F gccttgcacaaagctatcatgg
gcattggtcctcttggttaagaatg
gttgcaccacagatgaaacgc
aaggtgaaggtcggagtcaacg
ggcagagatgatgacccttttggc
cccctgcgtgtgct
caggattgtcagacagg
ctgcaactcatccgatgcaag
cagtctctcctttcagagctctgc
ggcttctctgtcttgtgacc
gggcttgaaccaggaagacg
tgtattcaaggtctggctgg
LacZ R
GAPDH F
GAPDH R
Human CD14 F
Human CD14 R
Human MD2 F
Human MD2 R
Human TLR2 F
Human TLR2 R
Human TLR4 F
gcggcggatccatggcaatggtatcagaattcctc
gcgaggatggattgaaggtaggataggggctca
ANXA1 exon 4 R
ANXA1 F
ANXA1 R
50°C
50°C
55°C
55°C
60°C
60°C
56°C
56°C
56°C
56°C
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10.4 Lentiviral particles production 
10.4.1 Plasmid maps  
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Figure 10.1 Maps of the plasmids that are used for production of lentiviral particles. A| The TRC2-
pLKO-puro vectors are used for transient or stable transfection of shRNA sequences as well as 
production of lentiviral particles. Usually length is around 7500 bp and it contains various elements. 
The Woodchuck Hepatitis Post-Transcriptional Regulatory Element (WPRE) allows for enhanced 
expression of the transgene delivered by lentiviruses. A strong ubiquitous promoter (hPGK) 
guarantees strong expression of a puromycin selectable marker (puroR) allowing for positively 
selection of only those that stably acquired the viral genome into their genomic sequence. Self-
inactivating replication incompetent viral particles can be produced in packaging cells (HEK293T) by 
co-transfection with compatible packaging plasmids (see General methods for the details). B| 
Modified pLENTI 7.3 vector used for cloning the human cDNA of ANXA1 in order to produce viral 
particles for ANXA1 over-expression. It contains several components: two Inverted terminal repeats 
(ITRs), the cytomegalovirus promoter (CMV), a multiple cloning site (MCS) where to insert the 
desired sequence to be over-expressed, the WPRE and the central Polypurine Tract (cPPT) sequence 
from the HIV-1 integrase gene, which promotes at least 4-fold increase in protein expression 
compared to vectors lacking this element. Restriction enzymes used for the cloning strategy (PstI 
and ApaI) are indicated in blue squares.  
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10.4.2 Lentiviral particles production 
10.4.2.1 Molecular cloning  
In order to produce lentiviral particles bearing short hairpin RNA (shRNA) sequences 
directed against human Annexin A1 (NCBI accession number NM_000700) transcriptional 
products (messenger RNA, mRNA), we obtained a kind gift from Dr. M. de Graauw (Leiden 
University, NL) consisting on 5 plasmids (commercially available from Sigma-Aldrich, UK), 
each of those consisting on modified lentiviral genomic sequences containing validated 
shRNA directed against human Annexin A1 (TRC2.0 Mission® shRNA vectors; Sigma-Aldrich, 
UK). Due to their long catalogue number, these plasmids were identified by abbreviated 
numbers: 1257, 1258, 1259, 1260 and 1261; Figure 10.1, Panel A, shows the general 
features of this type of vectors. Since they did not need any molecular modification, they 
were simply amplified by transformation and MaxiPrep procedure.  
In order to produce lentiviral particles containing the coding sequence (cDNA) for ANXA1, 
molecular cloning had to be performed on a plasmid encoding for the viral genome. This 
plasmid was originally modified by Dr. E. Pazarentzos and is based on the vector pLENTI 7.3, 
which is a standard plasmid to produce high titres of recombinant lentiviral particles (from 
Invitrogen, UK). Briefly, as shown in Figure 10.1, Panel B, the vector contains two ITR 
sequences, among which the cytomegalovirus (CMV) promoter is present and the transgene 
should be placed within the multiple cloning site (MCS). The cloning strategy adopted was 
the following: human coding sequence for ANXA1 was obtained by co-digestion of 1 µg of 
the plasmid pRCMV-ANXA1 (Solito et al., 1998) with 10 international units (IU) of the 
restriction enzyme ApaI (Fermentas, Thermo Scientific, UK) and 10 IU of PstI (Fermentas, 
Thermo Scientific, UK) following manufacturer instructions. The modified vector pLENTI 7.3 
was linearized following the same cloning strategy. Digestion products were purified 
QIAQuick Gel extraction purification kit (Qiagen, UK) and ligation was performed overnight 
at 16°C, using T4 DNA ligase (Invitrogen, UK) and a molecular ratio backbone:insert of 1:3 
(sticky-sticky ends ligation, as suggested by several molecular biology manuals (Sambrook, 
1989) and by the enzyme datasheet); a negative control (absence of the insert) has been 
included to help interpretation of the results. Finally, 10 µl of the ligation were used to 
transform heat-competent bacteria DH5α (Invitrogen, UK) through heat-shock protocol, 
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which briefly involves: incubation of 100 µl of bacteria suspension and DNA on ice for 30 
minutes to allow the latter to stick to the bacterial wall surface; 45 sec heat shock at 42°C; 1 
hour recovery at 37°C with vigorous shaking in presence of non-selective SOC-medium 
(Invitrogen, UK). 100/200 μl of suspension were pleated on LB-agar plates containing the 
selective antibiotic for those plasmids (Ampicillin; Sigma-Aldrich) and incubated at 37°C 
overnight. Resistant colonies were picked-up and grown overnight at 37°C in selective LB 
broth. Plasmid DNA was checked for identity by sequencing (ANXA1 F and ANXA1 R: Section 
10.3) through gene sequencing core facilities at Hammersmith Campus (Imperial College 
London, UK) and by restriction reactions using ApaI, PstI and KpnI (Fermentas, Thermo 
Scientific, UK). 
 
10.4.2.2 Lentiviral particles production  
Virulent media was produced in HEK293FT cells (Invitrogen, UK), routinely cultured in 
Dulbecco Modified Eagle medium (DMEM; Lonza, CH) supplemented with 1X non-essential 
amino acids (Lonza, CH) and 10% FCS. Plasmids encoding Vesicular Stomatitis Virus 
Glycoprotein (pVSV-G; encoding for the G-protein of the viral envelope), group antigen and 
reverse transcriptase (pGag.Pol) and mRNA export helper protein (pRev; containing the 
minimal set of lentiviral genes required to generate the virion structural proteins and 
packaging functions) were used for transfection. Two hours prior to transfection, the 
medium was replaced with fresh DMEM 10% FCS. 5.4 µg of the pVSV-G, 3.8 µg of the pRev, 
7.8 µg of the pGag.Pol, 9 µg of the pAdVantage and 20 µg of the lentiviral transgene plasmid 
were mixed. CaCl2 solution was added (final concentration 250 mM; final volume 500 µl), 
mixed thoroughly and incubated for 5 minutes. Meanwhile, 500 µl of 2X HBS solution was 
prepared in a 15 ml conical tube. After 5 minutes incubation, the DNA/CaCl2 mixture was 
added drop by drop into 15 ml conical tube while vigorously shaking the tube on a vortex 
machine. The mix was immediately added to the dish drop by drop. After 16 hours 
transfection, medium was aspirated and replaced with fresh warm medium containing 
sodium butyrate (1 mM) as enhancing transcriptional agent. After 3 days post transfection, 
the supernatant was harvested and centrifuged (500xg, 10 minutes, RT) to remove cells and 
large debris, then passed through a 0.45 µm sterile filter (Millipore, UK).   
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10.5 Characterisation of hCMEC/D3 cells with modified ANXA1 expression 
 
 
Figure 10.2 Immunophenotyping of stable hCMEC/D3 clones. Flow cytometric analysis of ANXA1 
and tight- (occludin, claudin-5) and adherens- (VE-cadherin) junctions expression in stably 
transfected hCMEC/D3 cells that have been chosen to conduct the majority of the functional studies 
described in the thesis. These clones were chosen as the best ones since they showed the best 
ANXA1 expression modification. At least 10000 events were analysed per profile, and histograms 
represent one of at least n=3 independent experiments. 
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10.6 Assessment of endocytosis on hCMEC/D3 monolayers 
 
 
Figure 10.3 Evaluation of hCMEC/D3 endocytosis of 70 kDa FITC-dextran. Representative confocal 
microscopic analysis on confluent monolayers of hCMEC/D3 cells incubated for various time points 
with a 3 mg/ml solution of 70kDa FITC-Dextran. Z-stack profiles were recorded with a confocal 
microscope and analyzed for presence of endocytotic cytoplasmic vesicles. No evident sign of 
significant endocytosis was detected at any time point, indicating that the movement of fluorescent 
molecules from apical to baso-lateral regions is occurring mainly through the paracellular pathway. 
Pictures are representative of n=3 samples/time point; scale bar is 5 µm. 
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10.7 Demographic data from human post-mortem brains and plasma samples 
 
 
Table 10.4 Human tissue demographic data. General information about age and disease of the post-
mortem brain tissue analysed in the study. 
 
 
Table 10.5 Human plasma demographic data. Information about the patients, who donated blood 
samples for further plasma isolation. R/R: relapsing remitting; SP: secondary progressive; PP: 
primary progressive. Treatments: REBIF & AVONEX are interferon-β, COPAXONE is glatiramer 
acetate. All patients are of Caucasian ethnic origin; control plasma samples used for the study are 
from 9 disease-free, age- and sex-matched donors. 
  
Disease duration 
(years)
Disease
Multiple Sclerosis
Gender ratio (M:F)
11 63.2 (43-81) 30 (14-50) 4:7
Parkinson's disease
Non-neurologic 
controls
Post-mortem  delay 
(hours)
9-27
7 73.7 (62-87) 13 (5-27) 5:2 7-26
6 83.6 (81-88) n/a 3:3 7-47
Number of cases
Mean age (range), 
years
Patient Age Gender MS type Treatment
BUH00115 49 M R/R NONE
BUH00116 45 F R/R NONE
BUH00117 49 M R/R COPAXONE
BUH00118 64 F PP AVONEX
BUH00119 65 F R/R NONE
BUH00121 44 F R/R REBIF
BUH00122 51 F R/R REBIF
BUH00123 60 F SP REBIF
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10.8 Surgical rodent ovariectomy  
Briefly, 3 months old female C57BL/6 mice (Charles River, UK) were deeply anaesthetised 
with a mixture of hypnorm/hypnovel (1:1:2; respectively, hypnorm:hypnovel:water) and 
sham operated or ovariectomised according to standard procedures. Briefly, dorsal midline 
incisions inferior to palpated rib cage and each kidney were performed to expose the 
ovaries, which were then removed. Micro-osmotic pumps (Alzet model 2002; 0.5 ± 0.1µl/hr 
rate of release for 2 weeks; DURECT Co., USA) filled with either vehicle (23 mg/ml 2-
Hydroxypropyl-β-cyclodextrin solution) or β-cyclodextrin-encapsulated 17β-estradiol (4.2 
µg/ml sterile water solution) were implanted subcutaneously in the ovariectomized (OVX) 
animals. Minipumps guaranteed the release of 2 µg/kg/day of 17β-estradiol per animal for 
14 days; this dose was chosen to ensure a response to estradiol close to physiological levels 
(Andersson et al., 2005). After 2 weeks from surgery and implantation, each group 
(OVX+vehicle; OVX+estradiol; sham operated) was divided in two sub-groups (n=5): one 
group was treated with 3 mg/kg LPS i.p. while the second one with 100 µl 0.9% NaCl 
solution. 3 hours later, all the animals underwent intravenous administration of Evans Blue 
and extravasation was assessed as described in the General methods. 
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10.9 Experimental plan for Chapter 6 
 
Figure 10.4 Experimental time plan for in vivo and in vitro experiments. In vivo and in vitro 
stimulation time points for the experiments described in Chapter 6. 17-βE is 17β-estradiol.  
Chapter 10 – Appendix 
Page | 348   Enrico Cristante – PhD degree thesis    
 
10.10 TNF-α cell signalling pathways are not modulated by β-estradiol 
 
 
Figure 10.5 TNF-α activates numerous cell signalling pathways which are not modulated by pre-
exposure with β-estradiol. A| Sub-confluent cells grown on labtek devices were (or not) pre-
exposed to estradiol and then stimulated (or not) with TNF-α for 30 minutes. Immediately washed 
and fixed for 10 minutes, cells were permeabilized and stained for p65 (one subunit of the most 
common forms of NF-κB). Semi quantitative analysis of nuclear p65 was conducted as described 
(Maggi et al., 2004) by counting 50 cells/coverslip and expressing the results as percentage of total 
counted cells. Data are presented as mean ± SEM. The experiments were performed in duplicate and 
cells were counted in a blind manner. Two-ways ANOVA was performed; * indicates p<0.05 vs. 
untreated and 4 days 17 β-estradiol treated. Similar results (i.e. no effects of the steroid on the 
inflammatory response) were obtained after a longer incubation with the cytokine (24 hours). B| 
Representative Immuno-blots show the main signalling pathways activated by TNF-α (10 minutes 
incubation) and absence of estradiol-dependent influence. Typical examples are reported.  
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10.11 hCMEC/D3 respond to LPS less well than pro-inflammatory cytokines 
 
 
Figure 10.6 hCMEC/D3 cell line responds to LPS. A| RT-PCR was performed to assess the actual 
expression of TLR2, TLR4, MD2 and CD14 by unstimulated hCMEC/D3 cells; this suggested their 
ability to detect, and possibly respond, to exogenous inflammogens like LPS. 10 µl of PCR reaction 
volume were loaded, while 5 µl were loaded for the highly expressed ANXA1 and GAPDH and 
negative control (that is, a PCR reaction run with GAPDH primers and nuclease-free water as 
template). Length of the expected bands: TLR2: 292 bp; TLR4: 438 bp; MD-2: 293 bp; CD14: 236 bp; 
ANXA1: 1100 bp; GAPDH: 350 bp. 100 bp marker was also run in parallel (lane M). B| Validation of 
hCMEC/D3 cells as a model to assess the effect of pro-inflammatory stimuli on endothelial 
paracellular permeability was accomplished by comparing the effects of 24 hours incubation with 10 
ng/ml TNFα and 10 ng/ml IFNγ [as reported by others (Haarmann et al., 2010; Lopez-Ramirez et al., 
2012)] with that caused by overnight incubation with LPS [10 ng/ml; (Descamps et al., 2003)].            
70 kDa-FITC-conjugated dextran was used. Results indicate 3 independent experiments, each of 
them performed in duplicate, and are presented as mean ± SEM. Student t-test was performed; *** 
indicates p < 0.001 vs. untreated, * p < 0.05 while $ indicates p < 0.05 vs. TNFα-IFNγ treated samples.  
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10.12 Experimental plan for Chapter 7 
 
Figure 10.7 Experimental time plan for in vivo experiments. In vivo stimulation time points for the 
experiments described in Chapter 7. 6-OHDA is 6-hydroxydopaamine. 
Chapter 10 – Appendix 
Enrico Cristante – PhD degree thesis                    Page | 351  
 
10.13 Schematic representation of substantia nigra pars compacta and 
ventral tegmental area throughout the midbrain 
 
 
Figure 10.8 Definition of area boundaries for the substantia nigra pars compacta and the ventral 
tegmental area. Figures represent schematic examples of unilateral mesencephalic region, focusing 
on the shape and distribution of the SNpc and VTA from the initial rostral part (A) until the final 
caudal part (D). Coordinates are meant from the bregma. Based on Ikemoto, 2007 and modified with 
permission of Dr Simon McArthur.  
  
A B
C D
VTA
SNpc
VTA VTA
SNpc
VTA
-4.8mm to -5.2mm -5.2mm to -5.3mm
-5.3mm to -5.5mm -5.5mm to -5.9mm
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10.14 Annexin A1 role in central regulation of apoptotic cells phagocytosis 
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Figure 10.9 Most relevant results concerning the role of Annexin A1 in regulating phlogistic and 
non-phlogistic phagocytosis of apoptotic cells. This figure reports the most significant results 
presented in McArthur et al., 2010 and correlated to the scopes of Chapter 7. A| Microglia cells 
isolated from Anxa1 null mice show impaired phagocytosis of apoptotic PC12 cell line (rat 
pheochromocytoma cell line from adrenal medulla; used as a model of apoptotic cells since they 
selectively die if treated overnight with 6-OHDA toxin). Data are presented as percentage of 
microglia cells with PC12 incorporated (phagocytized) and are indicated as mean ± SEM, n = 3). Two-
way ANOVA and Bonferroni post-hoc test were performed. * indicates p<0.05. B| BV2 murine cell 
line was chosen as a model of microglia cells (Blasi et al., 1990). These cells express typical microglial 
cell surface markers and exhibit the characteristic effector functions of native microglia, therefore 
representing a good model for investigating microglial regulation. 500 nM human recombinant 
ANXA1 was administered to LPS-activated (10 ng/ml; overnight incubation) BV2 cells co-incubated 
with non-apoptotic PC12. The inflammogen was shown to cause indiscriminate phagocytosis of 
alive/non-target cells, but this effect could be reverted by incubation with the anti-inflammatory 
molecule. Data are mean ± SEM, n=3 experiments. Two-way ANOVA and Bonferroni post-hoc test 
were performed. * indicates p < 0.05 versus untreated BV2 cells, while $ indicates p<0.05 versus LPS-
treated BV2 cells. C| Dose-response analysis of BV2 Anxa1 medium release under LPS stimulation 
(overnight incubation). One-way ANOVA and Bonferroni post-hoc test were performed. * indicates 
p<0.05 vs. vehicle treated (0 ng/ml LPS) group. D| Schematic representation of the proposed ANXA1 
role in controlling microglial phagocytosis. Microglia cells constitutively produce and release ANXA1, 
which enables non-phlogistic phagocytosis through binding to PS externalized on the apoptotic 
neurone surface. The phospholipid binding induces a conformational change in the ANXA1 molecule, 
allowing presentation of the N-terminal domain to the receptor Fpr2 on microglia surface, triggering 
the engulfment of the cell body. In inflammatory conditions, modelled by LPS stimulation in vitro, 
microglia is activated and aberrantly phagocytises non-apoptotic cells, an effect which cannot be 
reversed by endogenous levels of ANXA1. The addition of exogenous recombinant ANXA1, however, 
reverses the activation of the microglia and promotes their non-inflammatory phagocytic 
phenotype. 
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Meetings attendance 
 
- London Vascular Biology forum. December 2011, London. Abstract selected for 
poster presentation.  
"Sex dimorphism in inflammation: a role for Annexin A1 in mediating the effects of 
estrogen on the blood brain barrier" 
 
- 1st Early career symposium on blood brain barriers. November 2011, Milton Keynes 
(UK). Abstract selected for oral communication. 
"Sex dimorphism in inflammation: a role for Annexin A1 in mediating the effects of 
estrogen on the blood brain barrier" 
 
- 14th Symposium on signal transduction in the blood brain barriers. September 2011, 
Istanbul. Abstract selected for oral communication.  
"Sex dimorphism in inflammation: a role for Annexin A1 in mediating the effects of 
estrogen on the blood brain barrier" 
 
- 6th International Conference on Annexins. August 2011, Barcelona. Abstract selected 
for oral communication.  
"Characterisation of formyl peptide receptor 1 (FPR1) and FPRL-1 interactions: 
team-working is better than individualism"  
 
- Neuroscience 2010. November 2010, San Diego. Abstract selected for poster 
presentation.  
"Role of Annexin A1 at the blood brain barrier level in mediating the brain 
response to inflammation" 
 
- WorldPharma 2010. July 2010, Copenhagen. Abstract selected for oral 
communication.  
"Role of Annexin A1 at the blood brain barrier level in mediating the brain 
response to inflammation" 
 
- London Vascular Biology forum. December 2009, London. Abstract selected for 
poster presentation.  
"A role for Annexin A1 in mediating the effects of estrogen on the blood brain 
barrier in normal and inflammatory conditions" 
 
- 5th International Conference on Annexins. September 2009, Bordeaux. Abstracted 
selected for poster presentation.  
"The impact of peripheral inflammation in the brain: a new role for the systemic 
anti-inflammatory molecule Annexin A1" 
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Awards 
 
- Best oral communication prize, 14th Symposium on signal transduction in the blood 
brain barriers (Sept 2011) 
 
- Travel grant from “British Society for Neuroendocrinology” to participate to the 14th 
Symposium on Signal transduction in the blood brain barriers (Sept 2011) 
 
- Travel grant from “Guarantors of Brain” to participate to Neuroscience 2010                   
(July 2010) 
 
- Travel grant from “British Pharmacological Society” to participate to WorldPharma 
2010 (July 2010) 
 Enrico Cristante – PhD degree thesis                    Page | 357  
 
 
